#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Adolescent cannabis use and brain systems supporting adult working memory encoding, maintenance, and retrieval
#Text=Given prior reports of adverse effects of cannabis use on working memory, an executive function with a protracted developmental course during adolescence, we examined associations between developmental patterns of cannabis use and adult working memory (WM) processes.
1-1	0-10	Adolescent	_	
1-2	11-19	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[1]	
1-3	20-23	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[1]	
1-4	24-27	and	_	
1-5	28-33	brain	_	
1-6	34-41	systems	_	
1-7	42-52	supporting	_	
1-8	53-58	adult	_	
1-9	59-66	working	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask[2]	
1-10	67-73	memory	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask[2]	
1-11	74-82	encoding	_	
1-12	82-83	,	_	
1-13	84-95	maintenance	_	
1-14	95-96	,	_	
1-15	97-100	and	_	
1-16	101-110	retrieval	_	
1-17	111-116	Given	_	
1-18	117-122	prior	_	
1-19	123-130	reports	_	
1-20	131-133	of	_	
1-21	134-141	adverse	_	
1-22	142-149	effects	_	
1-23	150-152	of	_	
1-24	153-161	cannabis	_	
1-25	162-165	use	_	
1-26	166-168	on	_	
1-27	169-176	working	_	
1-28	177-183	memory	_	
1-29	183-184	,	_	
1-30	185-187	an	_	
1-31	188-197	executive	_	
1-32	198-206	function	_	
1-33	207-211	with	_	
1-34	212-213	a	_	
1-35	214-224	protracted	_	
1-36	225-238	developmental	_	
1-37	239-245	course	_	
1-38	246-252	during	_	
1-39	253-264	adolescence	_	
1-40	264-265	,	_	
1-41	266-268	we	_	
1-42	269-277	examined	_	
1-43	278-290	associations	_	
1-44	291-298	between	_	
1-45	299-312	developmental	_	
1-46	313-321	patterns	_	
1-47	322-324	of	_	
1-48	325-333	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[3]	
1-49	334-337	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[3]	
1-50	338-341	and	_	
1-51	342-347	adult	_	
1-52	348-355	working	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask[4]	
1-53	356-362	memory	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask[4]	
1-54	363-364	(	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask[4]	
1-55	364-366	WM	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask[4]	
1-56	366-367	)	http://maven.renci.org/NeuroBridge/neurobridge#WorkingMemoryTask[4]	
1-57	368-377	processes	_	
1-58	377-378	.	_	

#Text=Seventy-five adults with longitudinal assessments of cannabis use (60 with reported use, 15 with no reported use) and prenatal drug exposure assessment completed a spatial WM task during fMRI at age 28.
2-1	379-391	Seventy-five	_	
2-2	392-398	adults	_	
2-3	399-403	with	_	
2-4	404-416	longitudinal	_	
2-5	417-428	assessments	_	
2-6	429-431	of	_	
2-7	432-440	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[5]	
2-8	441-444	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[5]	
2-9	445-446	(	_	
2-10	446-448	60	_	
2-11	449-453	with	_	
2-12	454-462	reported	_	
2-13	463-466	use	_	
2-14	466-467	,	_	
2-15	468-470	15	_	
2-16	471-475	with	_	
2-17	476-478	no	_	
2-18	479-487	reported	_	
2-19	488-491	use	_	
2-20	491-492	)	_	
2-21	493-496	and	_	
2-22	497-505	prenatal	_	
2-23	506-510	drug	_	
2-24	511-519	exposure	_	
2-25	520-530	assessment	_	
2-26	531-540	completed	_	
2-27	541-542	a	_	
2-28	543-550	spatial	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
2-29	551-553	WM	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
2-30	554-558	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
2-31	559-565	during	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
2-32	566-570	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[7]	
2-33	571-573	at	_	
2-34	574-577	age	_	
2-35	578-580	28	_	
2-36	580-581	.	_	

#Text=All subjects passed a multi-drug urine screen on the day of testing and denied recreational drug use in the past week.
3-1	582-585	All	_	
3-2	586-594	subjects	_	
3-3	595-601	passed	_	
3-4	602-603	a	_	
3-5	604-614	multi-drug	_	
3-6	615-620	urine	_	
3-7	621-627	screen	_	
3-8	628-630	on	_	
3-9	631-634	the	_	
3-10	635-638	day	_	
3-11	639-641	of	_	
3-12	642-649	testing	_	
3-13	650-653	and	_	
3-14	654-660	denied	_	
3-15	661-673	recreational	_	
3-16	674-678	drug	_	
3-17	679-682	use	_	
3-18	683-685	in	_	
3-19	686-689	the	_	
3-20	690-694	past	_	
3-21	695-699	week	_	
3-22	699-700	.	_	

#Text=A fast event-related design with partial trials was used to separate the BOLD response associated with encoding, maintenance, and retrieval periods of the WM task.
4-1	701-702	A	_	
4-2	703-707	fast	_	
4-3	708-721	event-related	_	
4-4	722-728	design	_	
4-5	729-733	with	_	
4-6	734-741	partial	_	
4-7	742-748	trials	_	
4-8	749-752	was	_	
4-9	753-757	used	_	
4-10	758-760	to	_	
4-11	761-769	separate	_	
4-12	770-773	the	_	
4-13	774-778	BOLD	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-14	779-787	response	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-15	788-798	associated	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-16	799-803	with	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-17	804-812	encoding	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-18	812-813	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-19	814-825	maintenance	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-20	825-826	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-21	827-830	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-22	831-840	retrieval	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-23	841-848	periods	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-24	849-851	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-25	852-855	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-26	856-858	WM	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-27	859-863	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[8]	
4-28	863-864	.	_	

#Text=Behavioral results showed that subjects who began using cannabis earlier in adolescence had longer reaction times (RT) than those with later initiation.
5-1	865-875	Behavioral	_	
5-2	876-883	results	_	
5-3	884-890	showed	_	
5-4	891-895	that	_	
5-5	896-904	subjects	_	
5-6	905-908	who	_	
5-7	909-914	began	_	
5-8	915-920	using	_	
5-9	921-929	cannabis	_	
5-10	930-937	earlier	_	
5-11	938-940	in	_	
5-12	941-952	adolescence	_	
5-13	953-956	had	_	
5-14	957-963	longer	_	
5-15	964-972	reaction	_	
5-16	973-978	times	_	
5-17	979-980	(	_	
5-18	980-982	RT	_	
5-19	982-983	)	_	
5-20	984-988	than	_	
5-21	989-994	those	_	
5-22	995-999	with	_	
5-23	1000-1005	later	_	
5-24	1006-1016	initiation	_	
5-25	1016-1017	.	_	

#Text=Cannabis age of onset was further associated with reduced posterior parietal cortex (PPC) encoding BOLD activation, which significantly mediated age of onset WM RT associations.
6-1	1018-1026	Cannabis	_	
6-2	1027-1030	age	_	
6-3	1031-1033	of	_	
6-4	1034-1039	onset	_	
6-5	1040-1043	was	_	
6-6	1044-1051	further	_	
6-7	1052-1062	associated	_	
6-8	1063-1067	with	_	
6-9	1068-1075	reduced	_	
6-10	1076-1085	posterior	_	
6-11	1086-1094	parietal	_	
6-12	1095-1101	cortex	_	
6-13	1102-1103	(	_	
6-14	1103-1106	PPC	_	
6-15	1106-1107	)	_	
6-16	1108-1116	encoding	_	
6-17	1117-1121	BOLD	_	
6-18	1122-1132	activation	_	
6-19	1132-1133	,	_	
6-20	1134-1139	which	_	
6-21	1140-1153	significantly	_	
6-22	1154-1162	mediated	_	
6-23	1163-1166	age	_	
6-24	1167-1169	of	_	
6-25	1170-1175	onset	_	
6-26	1176-1178	WM	_	
6-27	1179-1181	RT	_	
6-28	1182-1194	associations	_	
6-29	1194-1195	.	_	

#Text=However, cannabis age of onset brain-behavior associations did not differ between groups with a single reported use and those with repeated use, suggesting age of onset effects may reflect substance use risk characteristics rather than a developmentally-timed cannabis exposure effect.
7-1	1196-1203	However	_	
7-2	1203-1204	,	_	
7-3	1205-1213	cannabis	_	
7-4	1214-1217	age	_	
7-5	1218-1220	of	_	
7-6	1221-1226	onset	_	
7-7	1227-1241	brain-behavior	_	
7-8	1242-1254	associations	_	
7-9	1255-1258	did	_	
7-10	1259-1262	not	_	
7-11	1263-1269	differ	_	
7-12	1270-1277	between	_	
7-13	1278-1284	groups	_	
7-14	1285-1289	with	_	
7-15	1290-1291	a	_	
7-16	1292-1298	single	_	
7-17	1299-1307	reported	_	
7-18	1308-1311	use	_	
7-19	1312-1315	and	_	
7-20	1316-1321	those	_	
7-21	1322-1326	with	_	
7-22	1327-1335	repeated	_	
7-23	1336-1339	use	_	
7-24	1339-1340	,	_	
7-25	1341-1351	suggesting	_	
7-26	1352-1355	age	_	
7-27	1356-1358	of	_	
7-28	1359-1364	onset	_	
7-29	1365-1372	effects	_	
7-30	1373-1376	may	_	
7-31	1377-1384	reflect	_	
7-32	1385-1394	substance	_	
7-33	1395-1398	use	_	
7-34	1399-1403	risk	_	
7-35	1404-1419	characteristics	_	
7-36	1420-1426	rather	_	
7-37	1427-1431	than	_	
7-38	1432-1433	a	_	
7-39	1434-1455	developmentally-timed	_	
7-40	1456-1464	cannabis	_	
7-41	1465-1473	exposure	_	
7-42	1474-1480	effect	_	
7-43	1480-1481	.	_	

#Text=Within repeated cannabis users, greater levels of total cannabis use were associated with performance-related increases in dorsolateral prefrontal cortex (DLPFC) activation during maintenance.
8-1	1482-1488	Within	_	
8-2	1489-1497	repeated	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[9]	
8-3	1498-1506	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[9]	
8-4	1507-1512	users	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[9]	
8-5	1512-1513	,	_	
8-6	1514-1521	greater	_	
8-7	1522-1528	levels	_	
8-8	1529-1531	of	_	
8-9	1532-1537	total	_	
8-10	1538-1546	cannabis	_	
8-11	1547-1550	use	_	
8-12	1551-1555	were	_	
8-13	1556-1566	associated	_	
8-14	1567-1571	with	_	
8-15	1572-1591	performance-related	_	
8-16	1592-1601	increases	_	
8-17	1602-1604	in	_	
8-18	1605-1617	dorsolateral	_	
8-19	1618-1628	prefrontal	_	
8-20	1629-1635	cortex	_	
8-21	1636-1637	(	_	
8-22	1637-1642	DLPFC	_	
8-23	1642-1643	)	_	
8-24	1644-1654	activation	_	
8-25	1655-1661	during	_	
8-26	1662-1673	maintenance	_	
8-27	1673-1674	.	_	

#Text=This pattern of significant results remained unchanged with inclusion of demographic and prenatal measures as covariates.
9-1	1675-1679	This	_	
9-2	1680-1687	pattern	_	
9-3	1688-1690	of	_	
9-4	1691-1702	significant	_	
9-5	1703-1710	results	_	
9-6	1711-1719	remained	_	
9-7	1720-1729	unchanged	_	
9-8	1730-1734	with	_	
9-9	1735-1744	inclusion	_	
9-10	1745-1747	of	_	
9-11	1748-1759	demographic	_	
9-12	1760-1763	and	_	
9-13	1764-1772	prenatal	_	
9-14	1773-1781	measures	_	
9-15	1782-1784	as	_	
9-16	1785-1795	covariates	_	
9-17	1795-1796	.	_	

#Text=Surprisingly, however, at the group level, cannabis users generally performed better than participants who reported never using cannabis (faster RT, higher accuracy).
10-1	1797-1809	Surprisingly	_	
10-2	1809-1810	,	_	
10-3	1811-1818	however	_	
10-4	1818-1819	,	_	
10-5	1820-1822	at	_	
10-6	1823-1826	the	_	
10-7	1827-1832	group	_	
10-8	1833-1838	level	_	
10-9	1838-1839	,	_	
10-10	1840-1848	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[10]	
10-11	1849-1854	users	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[10]	
10-12	1855-1864	generally	_	
10-13	1865-1874	performed	_	
10-14	1875-1881	better	_	
10-15	1882-1886	than	_	
10-16	1887-1899	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
10-17	1900-1903	who	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
10-18	1904-1912	reported	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
10-19	1913-1918	never	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
10-20	1919-1924	using	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
10-21	1925-1933	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[11]	
10-22	1934-1935	(	_	
10-23	1935-1941	faster	_	
10-24	1942-1944	RT	_	
10-25	1944-1945	,	_	
10-26	1946-1952	higher	_	
10-27	1953-1961	accuracy	_	
10-28	1961-1962	)	_	
10-29	1962-1963	.	_	

#Text=We extend previous investigations by identifying that WM associations with cannabis age of onset may be primary to PPC stimulus encoding activity, while the amount of cannabis use is associated with DLPFC maintenance processes.
11-1	1964-1966	We	_	
11-2	1967-1973	extend	_	
11-3	1974-1982	previous	_	
11-4	1983-1997	investigations	_	
11-5	1998-2000	by	_	
11-6	2001-2012	identifying	_	
11-7	2013-2017	that	_	
11-8	2018-2020	WM	_	
11-9	2021-2033	associations	_	
11-10	2034-2038	with	_	
11-11	2039-2047	cannabis	_	
11-12	2048-2051	age	_	
11-13	2052-2054	of	_	
11-14	2055-2060	onset	_	
11-15	2061-2064	may	_	
11-16	2065-2067	be	_	
11-17	2068-2075	primary	_	
11-18	2076-2078	to	_	
11-19	2079-2082	PPC	_	
11-20	2083-2091	stimulus	_	
11-21	2092-2100	encoding	_	
11-22	2101-2109	activity	_	
11-23	2109-2110	,	_	
11-24	2111-2116	while	_	
11-25	2117-2120	the	_	
11-26	2121-2127	amount	_	
11-27	2128-2130	of	_	
11-28	2131-2139	cannabis	_	
11-29	2140-2143	use	_	
11-30	2144-2146	is	_	
11-31	2147-2157	associated	_	
11-32	2158-2162	with	_	
11-33	2163-2168	DLPFC	_	
11-34	2169-2180	maintenance	_	
11-35	2181-2190	processes	_	
11-36	2190-2191	.	_	

#Text=Poorer performance of participants who reported never using cannabis and the consistency of cannabis age of onset associations across single and repeated users limit interpretation of direct developmental effects of cannabis on WM in adulthood.
12-1	2192-2198	Poorer	_	
12-2	2199-2210	performance	_	
12-3	2211-2213	of	_	
12-4	2214-2226	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
12-5	2227-2230	who	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
12-6	2231-2239	reported	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
12-7	2240-2245	never	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
12-8	2246-2251	using	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
12-9	2252-2260	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[12]	
12-10	2261-2264	and	_	
12-11	2265-2268	the	_	
12-12	2269-2280	consistency	_	
12-13	2281-2283	of	_	
12-14	2284-2292	cannabis	_	
12-15	2293-2296	age	_	
12-16	2297-2299	of	_	
12-17	2300-2305	onset	_	
12-18	2306-2318	associations	_	
12-19	2319-2325	across	_	
12-20	2326-2332	single	_	
12-21	2333-2336	and	_	
12-22	2337-2345	repeated	_	
12-23	2346-2351	users	_	
12-24	2352-2357	limit	_	
12-25	2358-2372	interpretation	_	
12-26	2373-2375	of	_	
12-27	2376-2382	direct	_	
12-28	2383-2396	developmental	_	
12-29	2397-2404	effects	_	
12-30	2405-2407	of	_	
12-31	2408-2416	cannabis	_	
12-32	2417-2419	on	_	
12-33	2420-2422	WM	_	
12-34	2423-2425	in	_	
12-35	2426-2435	adulthood	_	
12-36	2435-2436	.	_	

#Text=Introduction
#Text=Marijuana and other forms of cannabis are the most widely used illicit drugs in the United States.
13-1	2437-2449	Introduction	_	
13-2	2450-2459	Marijuana	_	
13-3	2460-2463	and	_	
13-4	2464-2469	other	_	
13-5	2470-2475	forms	_	
13-6	2476-2478	of	_	
13-7	2479-2487	cannabis	_	
13-8	2488-2491	are	_	
13-9	2492-2495	the	_	
13-10	2496-2500	most	_	
13-11	2501-2507	widely	_	
13-12	2508-2512	used	_	
13-13	2513-2520	illicit	_	
13-14	2521-2526	drugs	_	
13-15	2527-2529	in	_	
13-16	2530-2533	the	_	
13-17	2534-2540	United	_	
13-18	2541-2547	States	_	
13-19	2547-2548	.	_	

#Text=The first onset of cannabis use is typically during adolescence, a period of normative functional brain development and the refinement of cognitive functions.
14-1	2549-2552	The	_	
14-2	2553-2558	first	_	
14-3	2559-2564	onset	_	
14-4	2565-2567	of	_	
14-5	2568-2576	cannabis	_	
14-6	2577-2580	use	_	
14-7	2581-2583	is	_	
14-8	2584-2593	typically	_	
14-9	2594-2600	during	_	
14-10	2601-2612	adolescence	_	
14-11	2612-2613	,	_	
14-12	2614-2615	a	_	
14-13	2616-2622	period	_	
14-14	2623-2625	of	_	
14-15	2626-2635	normative	_	
14-16	2636-2646	functional	_	
14-17	2647-2652	brain	_	
14-18	2653-2664	development	_	
14-19	2665-2668	and	_	
14-20	2669-2672	the	_	
14-21	2673-2683	refinement	_	
14-22	2684-2686	of	_	
14-23	2687-2696	cognitive	_	
14-24	2697-2706	functions	_	
14-25	2706-2707	.	_	

#Text=However, the impact of adolescent cannabis exposure on brain systems supporting adult cognitive functioning remains largely unknown.
15-1	2708-2715	However	_	
15-2	2715-2716	,	_	
15-3	2717-2720	the	_	
15-4	2721-2727	impact	_	
15-5	2728-2730	of	_	
15-6	2731-2741	adolescent	_	
15-7	2742-2750	cannabis	_	
15-8	2751-2759	exposure	_	
15-9	2760-2762	on	_	
15-10	2763-2768	brain	_	
15-11	2769-2776	systems	_	
15-12	2777-2787	supporting	_	
15-13	2788-2793	adult	_	
15-14	2794-2803	cognitive	_	
15-15	2804-2815	functioning	_	
15-16	2816-2823	remains	_	
15-17	2824-2831	largely	_	
15-18	2832-2839	unknown	_	
15-19	2839-2840	.	_	

#Text=Cannabis use has been associated with deficits in working memory (WM), a core component of executive function that continues to develop through adolescence into adulthood.
16-1	2841-2849	Cannabis	_	
16-2	2850-2853	use	_	
16-3	2854-2857	has	_	
16-4	2858-2862	been	_	
16-5	2863-2873	associated	_	
16-6	2874-2878	with	_	
16-7	2879-2887	deficits	_	
16-8	2888-2890	in	_	
16-9	2891-2898	working	_	
16-10	2899-2905	memory	_	
16-11	2906-2907	(	_	
16-12	2907-2909	WM	_	
16-13	2909-2910	)	_	
16-14	2910-2911	,	_	
16-15	2912-2913	a	_	
16-16	2914-2918	core	_	
16-17	2919-2928	component	_	
16-18	2929-2931	of	_	
16-19	2932-2941	executive	_	
16-20	2942-2950	function	_	
16-21	2951-2955	that	_	
16-22	2956-2965	continues	_	
16-23	2966-2968	to	_	
16-24	2969-2976	develop	_	
16-25	2977-2984	through	_	
16-26	2985-2996	adolescence	_	
16-27	2997-3001	into	_	
16-28	3002-3011	adulthood	_	
16-29	3011-3012	.	_	

#Text=Dose-dependent effects of acute cannabis exposure have been associated with accuracy in delayed match to sample tasks and regular cannabis users have been shown to make more spatial WM errors than non-regular users in the Cambridge Neuropsychological Test Automated Battery (CANTAB).
17-1	3013-3027	Dose-dependent	_	
17-2	3028-3035	effects	_	
17-3	3036-3038	of	_	
17-4	3039-3044	acute	_	
17-5	3045-3053	cannabis	_	
17-6	3054-3062	exposure	_	
17-7	3063-3067	have	_	
17-8	3068-3072	been	_	
17-9	3073-3083	associated	_	
17-10	3084-3088	with	_	
17-11	3089-3097	accuracy	_	
17-12	3098-3100	in	_	
17-13	3101-3108	delayed	_	
17-14	3109-3114	match	_	
17-15	3115-3117	to	_	
17-16	3118-3124	sample	_	
17-17	3125-3130	tasks	_	
17-18	3131-3134	and	_	
17-19	3135-3142	regular	_	
17-20	3143-3151	cannabis	_	
17-21	3152-3157	users	_	
17-22	3158-3162	have	_	
17-23	3163-3167	been	_	
17-24	3168-3173	shown	_	
17-25	3174-3176	to	_	
17-26	3177-3181	make	_	
17-27	3182-3186	more	_	
17-28	3187-3194	spatial	_	
17-29	3195-3197	WM	_	
17-30	3198-3204	errors	_	
17-31	3205-3209	than	_	
17-32	3210-3221	non-regular	_	
17-33	3222-3227	users	_	
17-34	3228-3230	in	_	
17-35	3231-3234	the	_	
17-36	3235-3244	Cambridge	_	
17-37	3245-3263	Neuropsychological	_	
17-38	3264-3268	Test	_	
17-39	3269-3278	Automated	_	
17-40	3279-3286	Battery	_	
17-41	3287-3288	(	_	
17-42	3288-3294	CANTAB	_	
17-43	3294-3295	)	_	
17-44	3295-3296	.	_	

#Text=While the exact mechanisms of cannabis-induced cognitive impairment are still unknown, behavioral pharmacology indicates Δ9 THC (tetrahydrocannabinol), the primary psychoactive component of cannabis, induces memory impairments.
18-1	3297-3302	While	_	
18-2	3303-3306	the	_	
18-3	3307-3312	exact	_	
18-4	3313-3323	mechanisms	_	
18-5	3324-3326	of	_	
18-6	3327-3343	cannabis-induced	_	
18-7	3344-3353	cognitive	_	
18-8	3354-3364	impairment	_	
18-9	3365-3368	are	_	
18-10	3369-3374	still	_	
18-11	3375-3382	unknown	_	
18-12	3382-3383	,	_	
18-13	3384-3394	behavioral	_	
18-14	3395-3407	pharmacology	_	
18-15	3408-3417	indicates	_	
18-16	3418-3420	Δ9	_	
18-17	3421-3424	THC	_	
18-18	3425-3426	(	_	
18-19	3426-3446	tetrahydrocannabinol	_	
18-20	3446-3447	)	_	
18-21	3447-3448	,	_	
18-22	3449-3452	the	_	
18-23	3453-3460	primary	_	
18-24	3461-3473	psychoactive	_	
18-25	3474-3483	component	_	
18-26	3484-3486	of	_	
18-27	3487-3495	cannabis	_	
18-28	3495-3496	,	_	
18-29	3497-3504	induces	_	
18-30	3505-3511	memory	_	
18-31	3512-3523	impairments	_	
18-32	3523-3524	.	_	

#Text=THC is a partial CB1 receptor agonist and THC-induced memory impairments are reversed by CB1 receptor antagonists.
19-1	3525-3528	THC	_	
19-2	3529-3531	is	_	
19-3	3532-3533	a	_	
19-4	3534-3541	partial	_	
19-5	3542-3545	CB1	_	
19-6	3546-3554	receptor	_	
19-7	3555-3562	agonist	_	
19-8	3563-3566	and	_	
19-9	3567-3578	THC-induced	_	
19-10	3579-3585	memory	_	
19-11	3586-3597	impairments	_	
19-12	3598-3601	are	_	
19-13	3602-3610	reversed	_	
19-14	3611-3613	by	_	
19-15	3614-3617	CB1	_	
19-16	3618-3626	receptor	_	
19-17	3627-3638	antagonists	_	
19-18	3638-3639	.	_	

#Text=CB1 receptors are highly expressed in several subcortical brain regions, including the cerebellum and basal ganglia, as well as cortical association areas.
20-1	3640-3643	CB1	_	
20-2	3644-3653	receptors	_	
20-3	3654-3657	are	_	
20-4	3658-3664	highly	_	
20-5	3665-3674	expressed	_	
20-6	3675-3677	in	_	
20-7	3678-3685	several	_	
20-8	3686-3697	subcortical	_	
20-9	3698-3703	brain	_	
20-10	3704-3711	regions	_	
20-11	3711-3712	,	_	
20-12	3713-3722	including	_	
20-13	3723-3726	the	_	
20-14	3727-3737	cerebellum	_	
20-15	3738-3741	and	_	
20-16	3742-3747	basal	_	
20-17	3748-3755	ganglia	_	
20-18	3755-3756	,	_	
20-19	3757-3759	as	_	
20-20	3760-3764	well	_	
20-21	3765-3767	as	_	
20-22	3768-3776	cortical	_	
20-23	3777-3788	association	_	
20-24	3789-3794	areas	_	
20-25	3794-3795	.	_	

#Text=Importantly, subcortical regions and lateral prefrontal and posterior parietal cortices (PPC) undergo significant maturation during adolescence.
21-1	3796-3807	Importantly	_	
21-2	3807-3808	,	_	
21-3	3809-3820	subcortical	_	
21-4	3821-3828	regions	_	
21-5	3829-3832	and	_	
21-6	3833-3840	lateral	_	
21-7	3841-3851	prefrontal	_	
21-8	3852-3855	and	_	
21-9	3856-3865	posterior	_	
21-10	3866-3874	parietal	_	
21-11	3875-3883	cortices	_	
21-12	3884-3885	(	_	
21-13	3885-3888	PPC	_	
21-14	3888-3889	)	_	
21-15	3890-3897	undergo	_	
21-16	3898-3909	significant	_	
21-17	3910-3920	maturation	_	
21-18	3921-3927	during	_	
21-19	3928-3939	adolescence	_	
21-20	3939-3940	.	_	

#Text=Recent work has also shown CB1 levels in primate dorsolateral prefrontal cortex (DLPFC) continue to mature through adolescence.
22-1	3941-3947	Recent	_	
22-2	3948-3952	work	_	
22-3	3953-3956	has	_	
22-4	3957-3961	also	_	
22-5	3962-3967	shown	_	
22-6	3968-3971	CB1	_	
22-7	3972-3978	levels	_	
22-8	3979-3981	in	_	
22-9	3982-3989	primate	_	
22-10	3990-4002	dorsolateral	_	
22-11	4003-4013	prefrontal	_	
22-12	4014-4020	cortex	_	
22-13	4021-4022	(	_	
22-14	4022-4027	DLPFC	_	
22-15	4027-4028	)	_	
22-16	4029-4037	continue	_	
22-17	4038-4040	to	_	
22-18	4041-4047	mature	_	
22-19	4048-4055	through	_	
22-20	4056-4067	adolescence	_	
22-21	4067-4068	.	_	

#Text=Given changes in the endocannabinoid system in developmentally sensitive regions, including the DLPFC and PPC, adolescents may be particularly sensitive to the effects of cannabis on WM and/or other executive functions that rely on WM.
23-1	4069-4074	Given	_	
23-2	4075-4082	changes	_	
23-3	4083-4085	in	_	
23-4	4086-4089	the	_	
23-5	4090-4105	endocannabinoid	_	
23-6	4106-4112	system	_	
23-7	4113-4115	in	_	
23-8	4116-4131	developmentally	_	
23-9	4132-4141	sensitive	_	
23-10	4142-4149	regions	_	
23-11	4149-4150	,	_	
23-12	4151-4160	including	_	
23-13	4161-4164	the	_	
23-14	4165-4170	DLPFC	_	
23-15	4171-4174	and	_	
23-16	4175-4178	PPC	_	
23-17	4178-4179	,	_	
23-18	4180-4191	adolescents	_	
23-19	4192-4195	may	_	
23-20	4196-4198	be	_	
23-21	4199-4211	particularly	_	
23-22	4212-4221	sensitive	_	
23-23	4222-4224	to	_	
23-24	4225-4228	the	_	
23-25	4229-4236	effects	_	
23-26	4237-4239	of	_	
23-27	4240-4248	cannabis	_	
23-28	4249-4251	on	_	
23-29	4252-4254	WM	_	
23-30	4255-4258	and	_	
23-31	4258-4259	/	_	
23-32	4259-4261	or	_	
23-33	4262-4267	other	_	
23-34	4268-4277	executive	_	
23-35	4278-4287	functions	_	
23-36	4288-4292	that	_	
23-37	4293-4297	rely	_	
23-38	4298-4300	on	_	
23-39	4301-4303	WM	_	
23-40	4303-4304	.	_	

#Text=To this end, initial research has provided support for an association between early cannabis initiation and later cognitive differences, with studies demonstrating both domaingeneral (e.g., IQ) and domain-specific (e.g., visual attention) effects.
24-1	4305-4307	To	_	
24-2	4308-4312	this	_	
24-3	4313-4316	end	_	
24-4	4316-4317	,	_	
24-5	4318-4325	initial	_	
24-6	4326-4334	research	_	
24-7	4335-4338	has	_	
24-8	4339-4347	provided	_	
24-9	4348-4355	support	_	
24-10	4356-4359	for	_	
24-11	4360-4362	an	_	
24-12	4363-4374	association	_	
24-13	4375-4382	between	_	
24-14	4383-4388	early	_	
24-15	4389-4397	cannabis	_	
24-16	4398-4408	initiation	_	
24-17	4409-4412	and	_	
24-18	4413-4418	later	_	
24-19	4419-4428	cognitive	_	
24-20	4429-4440	differences	_	
24-21	4440-4441	,	_	
24-22	4442-4446	with	_	
24-23	4447-4454	studies	_	
24-24	4455-4468	demonstrating	_	
24-25	4469-4473	both	_	
24-26	4474-4487	domaingeneral	_	
24-27	4488-4489	(	_	
24-28	4489-4492	e.g	_	
24-29	4492-4493	.	_	
24-30	4493-4494	,	_	
24-31	4495-4497	IQ	_	
24-32	4497-4498	)	_	
24-33	4499-4502	and	_	
24-34	4503-4518	domain-specific	_	
24-35	4519-4520	(	_	
24-36	4520-4523	e.g	_	
24-37	4523-4524	.	_	
24-38	4524-4525	,	_	
24-39	4526-4532	visual	_	
24-40	4533-4542	attention	_	
24-41	4542-4543	)	_	
24-42	4544-4551	effects	_	
24-43	4551-4552	.	_	

#Text=For example, early cannabis initiation (e.g., prior to 17-years-old), as well as persistent cannabis use in adolescence, has been associated with lower adult IQ.
25-1	4553-4556	For	_	
25-2	4557-4564	example	_	
25-3	4564-4565	,	_	
25-4	4566-4571	early	_	
25-5	4572-4580	cannabis	_	
25-6	4581-4591	initiation	_	
25-7	4592-4593	(	_	
25-8	4593-4596	e.g	_	
25-9	4596-4597	.	_	
25-10	4597-4598	,	_	
25-11	4599-4604	prior	_	
25-12	4605-4607	to	_	
25-13	4608-4610	17	_	
25-14	4610-4611	-	_	
25-15	4611-4620	years-old	_	
25-16	4620-4621	)	_	
25-17	4621-4622	,	_	
25-18	4623-4625	as	_	
25-19	4626-4630	well	_	
25-20	4631-4633	as	_	
25-21	4634-4644	persistent	_	
25-22	4645-4653	cannabis	_	
25-23	4654-4657	use	_	
25-24	4658-4660	in	_	
25-25	4661-4672	adolescence	_	
25-26	4672-4673	,	_	
25-27	4674-4677	has	_	
25-28	4678-4682	been	_	
25-29	4683-4693	associated	_	
25-30	4694-4698	with	_	
25-31	4699-4704	lower	_	
25-32	4705-4710	adult	_	
25-33	4711-4713	IQ	_	
25-34	4713-4714	.	_	

#Text=However, other work suggests the effect of cannabis age of onset, as a continuous variable, or when comparing those who initiated prior to and following 16-years-old, may be specific to increased response times but not accuracy measures in executive function tasks.
26-1	4715-4722	However	_	
26-2	4722-4723	,	_	
26-3	4724-4729	other	_	
26-4	4730-4734	work	_	
26-5	4735-4743	suggests	_	
26-6	4744-4747	the	_	
26-7	4748-4754	effect	_	
26-8	4755-4757	of	_	
26-9	4758-4766	cannabis	_	
26-10	4767-4770	age	_	
26-11	4771-4773	of	_	
26-12	4774-4779	onset	_	
26-13	4779-4780	,	_	
26-14	4781-4783	as	_	
26-15	4784-4785	a	_	
26-16	4786-4796	continuous	_	
26-17	4797-4805	variable	_	
26-18	4805-4806	,	_	
26-19	4807-4809	or	_	
26-20	4810-4814	when	_	
26-21	4815-4824	comparing	_	
26-22	4825-4830	those	_	
26-23	4831-4834	who	_	
26-24	4835-4844	initiated	_	
26-25	4845-4850	prior	_	
26-26	4851-4853	to	_	
26-27	4854-4857	and	_	
26-28	4858-4867	following	_	
26-29	4868-4870	16	_	
26-30	4870-4871	-	_	
26-31	4871-4880	years-old	_	
26-32	4880-4881	,	_	
26-33	4882-4885	may	_	
26-34	4886-4888	be	_	
26-35	4889-4897	specific	_	
26-36	4898-4900	to	_	
26-37	4901-4910	increased	_	
26-38	4911-4919	response	_	
26-39	4920-4925	times	_	
26-40	4926-4929	but	_	
26-41	4930-4933	not	_	
26-42	4934-4942	accuracy	_	
26-43	4943-4951	measures	_	
26-44	4952-4954	in	_	
26-45	4955-4964	executive	_	
26-46	4965-4973	function	_	
26-47	4974-4979	tasks	_	
26-48	4979-4980	.	_	

#Text=Increased response times may be due to primary differences in cognitive processing speed or visual attention that are associated with adolescent cannabis onset.
27-1	4981-4990	Increased	_	
27-2	4991-4999	response	_	
27-3	5000-5005	times	_	
27-4	5006-5009	may	_	
27-5	5010-5012	be	_	
27-6	5013-5016	due	_	
27-7	5017-5019	to	_	
27-8	5020-5027	primary	_	
27-9	5028-5039	differences	_	
27-10	5040-5042	in	_	
27-11	5043-5052	cognitive	_	
27-12	5053-5063	processing	_	
27-13	5064-5069	speed	_	
27-14	5070-5072	or	_	
27-15	5073-5079	visual	_	
27-16	5080-5089	attention	_	
27-17	5090-5094	that	_	
27-18	5095-5098	are	_	
27-19	5099-5109	associated	_	
27-20	5110-5114	with	_	
27-21	5115-5125	adolescent	_	
27-22	5126-5134	cannabis	_	
27-23	5135-5140	onset	_	
27-24	5140-5141	.	_	

#Text=Previous fMRI studies have shown associations between early cannabis onset and BOLD activation in key regions of executive function and WM, including DLPFC, PPC, and anterior cingulate cortex.
28-1	5142-5150	Previous	_	
28-2	5151-5155	fMRI	_	
28-3	5156-5163	studies	_	
28-4	5164-5168	have	_	
28-5	5169-5174	shown	_	
28-6	5175-5187	associations	_	
28-7	5188-5195	between	_	
28-8	5196-5201	early	_	
28-9	5202-5210	cannabis	_	
28-10	5211-5216	onset	_	
28-11	5217-5220	and	_	
28-12	5221-5225	BOLD	_	
28-13	5226-5236	activation	_	
28-14	5237-5239	in	_	
28-15	5240-5243	key	_	
28-16	5244-5251	regions	_	
28-17	5252-5254	of	_	
28-18	5255-5264	executive	_	
28-19	5265-5273	function	_	
28-20	5274-5277	and	_	
28-21	5278-5280	WM	_	
28-22	5280-5281	,	_	
28-23	5282-5291	including	_	
28-24	5292-5297	DLPFC	_	
28-25	5297-5298	,	_	
28-26	5299-5302	PPC	_	
28-27	5302-5303	,	_	
28-28	5304-5307	and	_	
28-29	5308-5316	anterior	_	
28-30	5317-5326	cingulate	_	
28-31	5327-5333	cortex	_	
28-32	5333-5334	.	_	

#Text=However, previous investigations have examined cannabis associations in the context of a general-process WM activation, where the BOLD signal is not specific to different periods of the task (cue, delay, response) and therefore not representative of subprocesses of WM (encoding, maintenance, retrieval).
29-1	5335-5342	However	_	
29-2	5342-5343	,	_	
29-3	5344-5352	previous	_	
29-4	5353-5367	investigations	_	
29-5	5368-5372	have	_	
29-6	5373-5381	examined	_	
29-7	5382-5390	cannabis	_	
29-8	5391-5403	associations	_	
29-9	5404-5406	in	_	
29-10	5407-5410	the	_	
29-11	5411-5418	context	_	
29-12	5419-5421	of	_	
29-13	5422-5423	a	_	
29-14	5424-5439	general-process	_	
29-15	5440-5442	WM	_	
29-16	5443-5453	activation	_	
29-17	5453-5454	,	_	
29-18	5455-5460	where	_	
29-19	5461-5464	the	_	
29-20	5465-5469	BOLD	_	
29-21	5470-5476	signal	_	
29-22	5477-5479	is	_	
29-23	5480-5483	not	_	
29-24	5484-5492	specific	_	
29-25	5493-5495	to	_	
29-26	5496-5505	different	_	
29-27	5506-5513	periods	_	
29-28	5514-5516	of	_	
29-29	5517-5520	the	_	
29-30	5521-5525	task	_	
29-31	5526-5527	(	_	
29-32	5527-5530	cue	_	
29-33	5530-5531	,	_	
29-34	5532-5537	delay	_	
29-35	5537-5538	,	_	
29-36	5539-5547	response	_	
29-37	5547-5548	)	_	
29-38	5549-5552	and	_	
29-39	5553-5562	therefore	_	
29-40	5563-5566	not	_	
29-41	5567-5581	representative	_	
29-42	5582-5584	of	_	
29-43	5585-5597	subprocesses	_	
29-44	5598-5600	of	_	
29-45	5601-5603	WM	_	
29-46	5604-5605	(	_	
29-47	5605-5613	encoding	_	
29-48	5613-5614	,	_	
29-49	5615-5626	maintenance	_	
29-50	5626-5627	,	_	
29-51	5628-5637	retrieval	_	
29-52	5637-5638	)	_	
29-53	5638-5639	.	_	

#Text=Moreover, no studies have examined brain-behavior relationships in the context of cannabis age of onset BOLD activation differences.
30-1	5640-5648	Moreover	_	
30-2	5648-5649	,	_	
30-3	5650-5652	no	_	
30-4	5653-5660	studies	_	
30-5	5661-5665	have	_	
30-6	5666-5674	examined	_	
30-7	5675-5689	brain-behavior	_	
30-8	5690-5703	relationships	_	
30-9	5704-5706	in	_	
30-10	5707-5710	the	_	
30-11	5711-5718	context	_	
30-12	5719-5721	of	_	
30-13	5722-5730	cannabis	_	
30-14	5731-5734	age	_	
30-15	5735-5737	of	_	
30-16	5738-5743	onset	_	
30-17	5744-5748	BOLD	_	
30-18	5749-5759	activation	_	
30-19	5760-5771	differences	_	
30-20	5771-5772	.	_	

#Text=Together, these limitations make it difficult to assess whether observed BOLD differences support domain-general or domain-specific age of onset cognitive associations and whether reported BOLD activation differences are relevant to behavior.
31-1	5773-5781	Together	_	
31-2	5781-5782	,	_	
31-3	5783-5788	these	_	
31-4	5789-5800	limitations	_	
31-5	5801-5805	make	_	
31-6	5806-5808	it	_	
31-7	5809-5818	difficult	_	
31-8	5819-5821	to	_	
31-9	5822-5828	assess	_	
31-10	5829-5836	whether	_	
31-11	5837-5845	observed	_	
31-12	5846-5850	BOLD	_	
31-13	5851-5862	differences	_	
31-14	5863-5870	support	_	
31-15	5871-5885	domain-general	_	
31-16	5886-5888	or	_	
31-17	5889-5904	domain-specific	_	
31-18	5905-5908	age	_	
31-19	5909-5911	of	_	
31-20	5912-5917	onset	_	
31-21	5918-5927	cognitive	_	
31-22	5928-5940	associations	_	
31-23	5941-5944	and	_	
31-24	5945-5952	whether	_	
31-25	5953-5961	reported	_	
31-26	5962-5966	BOLD	_	
31-27	5967-5977	activation	_	
31-28	5978-5989	differences	_	
31-29	5990-5993	are	_	
31-30	5994-6002	relevant	_	
31-31	6003-6005	to	_	
31-32	6006-6014	behavior	_	
31-33	6014-6015	.	_	

#Text=An additional complexity of examining cannabis age of onset effects arises from the association between age of onset and cumulative cannabis exposure, where those with early initiation accumulate greater total cannabis use (cf.,).
32-1	6016-6018	An	_	
32-2	6019-6029	additional	_	
32-3	6030-6040	complexity	_	
32-4	6041-6043	of	_	
32-5	6044-6053	examining	_	
32-6	6054-6062	cannabis	_	
32-7	6063-6066	age	_	
32-8	6067-6069	of	_	
32-9	6070-6075	onset	_	
32-10	6076-6083	effects	_	
32-11	6084-6090	arises	_	
32-12	6091-6095	from	_	
32-13	6096-6099	the	_	
32-14	6100-6111	association	_	
32-15	6112-6119	between	_	
32-16	6120-6123	age	_	
32-17	6124-6126	of	_	
32-18	6127-6132	onset	_	
32-19	6133-6136	and	_	
32-20	6137-6147	cumulative	_	
32-21	6148-6156	cannabis	_	
32-22	6157-6165	exposure	_	
32-23	6165-6166	,	_	
32-24	6167-6172	where	_	
32-25	6173-6178	those	_	
32-26	6179-6183	with	_	
32-27	6184-6189	early	_	
32-28	6190-6200	initiation	_	
32-29	6201-6211	accumulate	_	
32-30	6212-6219	greater	_	
32-31	6220-6225	total	_	
32-32	6226-6234	cannabis	_	
32-33	6235-6238	use	_	
32-34	6239-6240	(	_	
32-35	6240-6242	cf	_	
32-36	6242-6243	.	_	
32-37	6243-6244	,	_	
32-38	6244-6245	)	_	
32-39	6245-6246	.	_	

#Text=Total cannabis use has been shown to predict cognitive performance and may thus partially explain previously reported cannabis age of onset WM associations.
33-1	6247-6252	Total	_	
33-2	6253-6261	cannabis	_	
33-3	6262-6265	use	_	
33-4	6266-6269	has	_	
33-5	6270-6274	been	_	
33-6	6275-6280	shown	_	
33-7	6281-6283	to	_	
33-8	6284-6291	predict	_	
33-9	6292-6301	cognitive	_	
33-10	6302-6313	performance	_	
33-11	6314-6317	and	_	
33-12	6318-6321	may	_	
33-13	6322-6326	thus	_	
33-14	6327-6336	partially	_	
33-15	6337-6344	explain	_	
33-16	6345-6355	previously	_	
33-17	6356-6364	reported	_	
33-18	6365-6373	cannabis	_	
33-19	6374-6377	age	_	
33-20	6378-6380	of	_	
33-21	6381-6386	onset	_	
33-22	6387-6389	WM	_	
33-23	6390-6402	associations	_	
33-24	6402-6403	.	_	

#Text=However, an exposure effect of early cannabis use predicts cannabis age of onset associations to be dose-dependent, where any lasting effect of early use would be larger for those adolescents who consume greater amounts of cannabis.
34-1	6404-6411	However	_	
34-2	6411-6412	,	_	
34-3	6413-6415	an	_	
34-4	6416-6424	exposure	_	
34-5	6425-6431	effect	_	
34-6	6432-6434	of	_	
34-7	6435-6440	early	_	
34-8	6441-6449	cannabis	_	
34-9	6450-6453	use	_	
34-10	6454-6462	predicts	_	
34-11	6463-6471	cannabis	_	
34-12	6472-6475	age	_	
34-13	6476-6478	of	_	
34-14	6479-6484	onset	_	
34-15	6485-6497	associations	_	
34-16	6498-6500	to	_	
34-17	6501-6503	be	_	
34-18	6504-6518	dose-dependent	_	
34-19	6518-6519	,	_	
34-20	6520-6525	where	_	
34-21	6526-6529	any	_	
34-22	6530-6537	lasting	_	
34-23	6538-6544	effect	_	
34-24	6545-6547	of	_	
34-25	6548-6553	early	_	
34-26	6554-6557	use	_	
34-27	6558-6563	would	_	
34-28	6564-6566	be	_	
34-29	6567-6573	larger	_	
34-30	6574-6577	for	_	
34-31	6578-6583	those	_	
34-32	6584-6595	adolescents	_	
34-33	6596-6599	who	_	
34-34	6600-6607	consume	_	
34-35	6608-6615	greater	_	
34-36	6616-6623	amounts	_	
34-37	6624-6626	of	_	
34-38	6627-6635	cannabis	_	
34-39	6635-6636	.	_	

#Text=The absence of dose-dependent age of onset effects might suggest differences attributed to early cannabis use are driven by baseline differences in neurocognitive function (cf.,).
35-1	6637-6640	The	_	
35-2	6641-6648	absence	_	
35-3	6649-6651	of	_	
35-4	6652-6666	dose-dependent	_	
35-5	6667-6670	age	_	
35-6	6671-6673	of	_	
35-7	6674-6679	onset	_	
35-8	6680-6687	effects	_	
35-9	6688-6693	might	_	
35-10	6694-6701	suggest	_	
35-11	6702-6713	differences	_	
35-12	6714-6724	attributed	_	
35-13	6725-6727	to	_	
35-14	6728-6733	early	_	
35-15	6734-6742	cannabis	_	
35-16	6743-6746	use	_	
35-17	6747-6750	are	_	
35-18	6751-6757	driven	_	
35-19	6758-6760	by	_	
35-20	6761-6769	baseline	_	
35-21	6770-6781	differences	_	
35-22	6782-6784	in	_	
35-23	6785-6799	neurocognitive	_	
35-24	6800-6808	function	_	
35-25	6809-6810	(	_	
35-26	6810-6812	cf	_	
35-27	6812-6813	.	_	
35-28	6813-6814	,	_	
35-29	6814-6815	)	_	
35-30	6815-6816	.	_	

#Text=The primary aim of the present study was to characterize the association between adolescent cannabis use and brain systems supporting WM in adulthood.
36-1	6817-6820	The	_	
36-2	6821-6828	primary	_	
36-3	6829-6832	aim	_	
36-4	6833-6835	of	_	
36-5	6836-6839	the	_	
36-6	6840-6847	present	_	
36-7	6848-6853	study	_	
36-8	6854-6857	was	_	
36-9	6858-6860	to	_	
36-10	6861-6873	characterize	_	
36-11	6874-6877	the	_	
36-12	6878-6889	association	_	
36-13	6890-6897	between	_	
36-14	6898-6908	adolescent	_	
36-15	6909-6917	cannabis	_	
36-16	6918-6921	use	_	
36-17	6922-6925	and	_	
36-18	6926-6931	brain	_	
36-19	6932-6939	systems	_	
36-20	6940-6950	supporting	_	
36-21	6951-6953	WM	_	
36-22	6954-6956	in	_	
36-23	6957-6966	adulthood	_	
36-24	6966-6967	.	_	

#Text=Importantly, utilizing a sample with longitudinal cannabis use assessments, we examined associations of cannabis age of onset and total cannabis usage with WM performance and investigated how these are associated with distinct patterns of cortical engagement during WM encoding, maintenance, and retrieval.
37-1	6968-6979	Importantly	_	
37-2	6979-6980	,	_	
37-3	6981-6990	utilizing	_	
37-4	6991-6992	a	_	
37-5	6993-6999	sample	_	
37-6	7000-7004	with	_	
37-7	7005-7017	longitudinal	_	
37-8	7018-7026	cannabis	_	
37-9	7027-7030	use	_	
37-10	7031-7042	assessments	_	
37-11	7042-7043	,	_	
37-12	7044-7046	we	_	
37-13	7047-7055	examined	_	
37-14	7056-7068	associations	_	
37-15	7069-7071	of	_	
37-16	7072-7080	cannabis	_	
37-17	7081-7084	age	_	
37-18	7085-7087	of	_	
37-19	7088-7093	onset	_	
37-20	7094-7097	and	_	
37-21	7098-7103	total	_	
37-22	7104-7112	cannabis	_	
37-23	7113-7118	usage	_	
37-24	7119-7123	with	_	
37-25	7124-7126	WM	_	
37-26	7127-7138	performance	_	
37-27	7139-7142	and	_	
37-28	7143-7155	investigated	_	
37-29	7156-7159	how	_	
37-30	7160-7165	these	_	
37-31	7166-7169	are	_	
37-32	7170-7180	associated	_	
37-33	7181-7185	with	_	
37-34	7186-7194	distinct	_	
37-35	7195-7203	patterns	_	
37-36	7204-7206	of	_	
37-37	7207-7215	cortical	_	
37-38	7216-7226	engagement	_	
37-39	7227-7233	during	_	
37-40	7234-7236	WM	_	
37-41	7237-7245	encoding	_	
37-42	7245-7246	,	_	
37-43	7247-7258	maintenance	_	
37-44	7258-7259	,	_	
37-45	7260-7263	and	_	
37-46	7264-7273	retrieval	_	
37-47	7273-7274	.	_	

#Text=Further, through comparisons with non-users we examined the extent to which observed cannabis associations supported poorer neurocognitive outcomes in adulthood.
38-1	7275-7282	Further	_	
38-2	7282-7283	,	_	
38-3	7284-7291	through	_	
38-4	7292-7303	comparisons	_	
38-5	7304-7308	with	_	
38-6	7309-7318	non-users	_	
38-7	7319-7321	we	_	
38-8	7322-7330	examined	_	
38-9	7331-7334	the	_	
38-10	7335-7341	extent	_	
38-11	7342-7344	to	_	
38-12	7345-7350	which	_	
38-13	7351-7359	observed	_	
38-14	7360-7368	cannabis	_	
38-15	7369-7381	associations	_	
38-16	7382-7391	supported	_	
38-17	7392-7398	poorer	_	
38-18	7399-7413	neurocognitive	_	
38-19	7414-7422	outcomes	_	
38-20	7423-7425	in	_	
38-21	7426-7435	adulthood	_	
38-22	7435-7436	.	_	

#Text=Consistent with the reviewed literature (cf.,), we hypothesized cannabis age of onset would be associated with WM reaction time, while total cannabis use would be associated with a more general decrease in WM performance.
39-1	7437-7447	Consistent	_	
39-2	7448-7452	with	_	
39-3	7453-7456	the	_	
39-4	7457-7465	reviewed	_	
39-5	7466-7476	literature	_	
39-6	7477-7478	(	_	
39-7	7478-7480	cf	_	
39-8	7480-7481	.	_	
39-9	7481-7482	,	_	
39-10	7482-7483	)	_	
39-11	7483-7484	,	_	
39-12	7485-7487	we	_	
39-13	7488-7500	hypothesized	_	
39-14	7501-7509	cannabis	_	
39-15	7510-7513	age	_	
39-16	7514-7516	of	_	
39-17	7517-7522	onset	_	
39-18	7523-7528	would	_	
39-19	7529-7531	be	_	
39-20	7532-7542	associated	_	
39-21	7543-7547	with	_	
39-22	7548-7550	WM	_	
39-23	7551-7559	reaction	_	
39-24	7560-7564	time	_	
39-25	7564-7565	,	_	
39-26	7566-7571	while	_	
39-27	7572-7577	total	_	
39-28	7578-7586	cannabis	_	
39-29	7587-7590	use	_	
39-30	7591-7596	would	_	
39-31	7597-7599	be	_	
39-32	7600-7610	associated	_	
39-33	7611-7615	with	_	
39-34	7616-7617	a	_	
39-35	7618-7622	more	_	
39-36	7623-7630	general	_	
39-37	7631-7639	decrease	_	
39-38	7640-7642	in	_	
39-39	7643-7645	WM	_	
39-40	7646-7657	performance	_	
39-41	7657-7658	.	_	

#Text=We also hypothesized cannabis effects would be observed in developmentally sensitive, DLPFC and PPC regions associated with WM performance.
40-1	7659-7661	We	_	
40-2	7662-7666	also	_	
40-3	7667-7679	hypothesized	_	
40-4	7680-7688	cannabis	_	
40-5	7689-7696	effects	_	
40-6	7697-7702	would	_	
40-7	7703-7705	be	_	
40-8	7706-7714	observed	_	
40-9	7715-7717	in	_	
40-10	7718-7733	developmentally	_	
40-11	7734-7743	sensitive	_	
40-12	7743-7744	,	_	
40-13	7745-7750	DLPFC	_	
40-14	7751-7754	and	_	
40-15	7755-7758	PPC	_	
40-16	7759-7766	regions	_	
40-17	7767-7777	associated	_	
40-18	7778-7782	with	_	
40-19	7783-7785	WM	_	
40-20	7786-7797	performance	_	
40-21	7797-7798	.	_	

#Text=However, to fully characterize cannabis use associations and WM brain- behavior relationships, we performed full-brain analyses.
41-1	7799-7806	However	_	
41-2	7806-7807	,	_	
41-3	7808-7810	to	_	
41-4	7811-7816	fully	_	
41-5	7817-7829	characterize	_	
41-6	7830-7838	cannabis	_	
41-7	7839-7842	use	_	
41-8	7843-7855	associations	_	
41-9	7856-7859	and	_	
41-10	7860-7862	WM	_	
41-11	7863-7868	brain	_	
41-12	7868-7869	-	_	
41-13	7870-7878	behavior	_	
41-14	7879-7892	relationships	_	
41-15	7892-7893	,	_	
41-16	7894-7896	we	_	
41-17	7897-7906	performed	_	
41-18	7907-7917	full-brain	_	
41-19	7918-7926	analyses	_	
41-20	7926-7927	.	_	

#Text=Methods and materials
#Text=Participants
#Text=Participants were drawn from the Maternal Health Practices and Child Development Project (MHPCD), a longitudinal, prospective cohort study of the effects of prenatal drug exposure on children from low-income families in Pittsburgh, PA (cf.,).
42-1	7928-7935	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[13]	
42-2	7936-7939	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[13]	
42-3	7940-7949	materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[13]	
42-4	7950-7962	Participants	_	
42-5	7963-7975	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-6	7976-7980	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-7	7981-7986	drawn	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-8	7987-7991	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-9	7992-7995	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-10	7996-8004	Maternal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-11	8005-8011	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-12	8012-8021	Practices	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-13	8022-8025	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-14	8026-8031	Child	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-15	8032-8043	Development	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-16	8044-8051	Project	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-17	8052-8053	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-18	8053-8058	MHPCD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-19	8058-8059	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-20	8059-8060	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-21	8061-8062	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-22	8063-8075	longitudinal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-23	8075-8076	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-24	8077-8088	prospective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-25	8089-8095	cohort	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-26	8096-8101	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-27	8102-8104	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-28	8105-8108	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-29	8109-8116	effects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-30	8117-8119	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-31	8120-8128	prenatal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-32	8129-8133	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-33	8134-8142	exposure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-34	8143-8145	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-35	8146-8154	children	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-36	8155-8159	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-37	8160-8170	low-income	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-38	8171-8179	families	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-39	8180-8182	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-40	8183-8193	Pittsburgh	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-41	8193-8194	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-42	8195-8197	PA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-43	8198-8199	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-44	8199-8201	cf	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-45	8201-8202	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-46	8202-8203	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-47	8203-8204	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	
42-48	8204-8205	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[14]	

#Text=From this larger cohort, 86 subjects were eligible based upon exclusion criteria and consented (see below) and 75 subjects successfully completed neuroimaging protocols at age 28.
43-1	8206-8210	From	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-2	8211-8215	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-3	8216-8222	larger	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-4	8223-8229	cohort	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-5	8229-8230	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-6	8231-8233	86	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-7	8234-8242	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-8	8243-8247	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-9	8248-8256	eligible	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-10	8257-8262	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-11	8263-8267	upon	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-12	8268-8277	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-13	8278-8286	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-14	8287-8290	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-15	8291-8300	consented	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-16	8301-8302	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-17	8302-8305	see	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-18	8306-8311	below	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-19	8311-8312	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-20	8313-8316	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-21	8317-8319	75	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-22	8320-8328	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-23	8329-8341	successfully	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-24	8342-8351	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-25	8352-8364	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[16]	
43-26	8365-8374	protocols	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[16]	
43-27	8375-8377	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-28	8378-8381	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-29	8382-8384	28	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
43-30	8384-8385	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	

#Text=Reasons for unsuccessful neuroimaging protocols were claustrophobia during acquisition (n = 3), follow-up report of metal in the body (n = 1), positive pregnancy test (n = 1), THC positive urine screen on the day of neuroimaging (n = 2), current psychiatric medication (n = 2), and non-compliance (n = 2).
44-1	8386-8393	Reasons	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-2	8394-8397	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-3	8398-8410	unsuccessful	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-4	8411-8423	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-5	8424-8433	protocols	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-6	8434-8438	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-7	8439-8453	claustrophobia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-8	8454-8460	during	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-9	8461-8472	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-10	8473-8474	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-11	8474-8475	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-12	8476-8477	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-13	8478-8479	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-14	8479-8480	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-15	8480-8481	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-16	8482-8491	follow-up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-17	8492-8498	report	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-18	8499-8501	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-19	8502-8507	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-20	8508-8510	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-21	8511-8514	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-22	8515-8519	body	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-23	8520-8521	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-24	8521-8522	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-25	8523-8524	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-26	8525-8526	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-27	8526-8527	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-28	8527-8528	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-29	8529-8537	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-30	8538-8547	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-31	8548-8552	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-32	8553-8554	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-33	8554-8555	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-34	8556-8557	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-35	8558-8559	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-36	8559-8560	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-37	8560-8561	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-38	8562-8565	THC	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-39	8566-8574	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-40	8575-8580	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-41	8581-8587	screen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-42	8588-8590	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-43	8591-8594	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-44	8595-8598	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-45	8599-8601	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-46	8602-8614	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-47	8615-8616	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-48	8616-8617	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-49	8618-8619	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-50	8620-8621	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-51	8621-8622	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-52	8622-8623	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-53	8624-8631	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-54	8632-8643	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-55	8644-8654	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-56	8655-8656	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-57	8656-8657	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-58	8658-8659	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-59	8660-8661	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-60	8661-8662	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-61	8662-8663	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-62	8664-8667	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-63	8668-8682	non-compliance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-64	8683-8684	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-65	8684-8685	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-66	8686-8687	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-67	8688-8689	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-68	8689-8690	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
44-69	8690-8691	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=Study exclusion criteria included childhood (age 10) IQ scores below 80, current psychiatric disorder (assessed with the Mini International Neuropsychiatric Interview) or current psychiatric medication, past head injury with loss of consciousness, and MRI contraindications, including pregnancy, claustrophobia, and non-removable metal in the body.
45-1	8692-8697	Study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-2	8698-8707	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-3	8708-8716	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-4	8717-8725	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-5	8726-8735	childhood	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-6	8736-8737	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-7	8737-8740	age	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-8	8741-8743	10	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-9	8743-8744	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-10	8745-8747	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-11	8748-8754	scores	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-12	8755-8760	below	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-13	8761-8763	80	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-14	8763-8764	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-15	8765-8772	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-16	8773-8784	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-17	8785-8793	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-18	8794-8795	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-19	8795-8803	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-20	8804-8808	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-21	8809-8812	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-22	8813-8817	Mini	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[19]	
45-23	8818-8831	International	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[19]	
45-24	8832-8848	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[19]	
45-25	8849-8858	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MentalHealthDiagnosisScale[19]	
45-26	8858-8859	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-27	8860-8862	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-28	8863-8870	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-29	8871-8882	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-30	8883-8893	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-31	8893-8894	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-32	8895-8899	past	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-33	8900-8904	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-34	8905-8911	injury	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-35	8912-8916	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-36	8917-8921	loss	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-37	8922-8924	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-38	8925-8938	consciousness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-39	8938-8939	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-40	8940-8943	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-41	8944-8947	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[20]	
45-42	8948-8965	contraindications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-43	8965-8966	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-44	8967-8976	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-45	8977-8986	pregnancy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-46	8986-8987	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-47	8988-9002	claustrophobia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-48	9002-9003	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-49	9004-9007	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-50	9008-9021	non-removable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-51	9022-9027	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-52	9028-9030	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-53	9031-9034	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-54	9035-9039	body	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
45-55	9039-9040	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=One subject only completed three of four fMRI runs and was consequently excluded from fMRI analysis.
46-1	9041-9044	One	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-2	9045-9052	subject	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-3	9053-9057	only	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-4	9058-9067	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-5	9068-9073	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-6	9074-9076	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-7	9077-9081	four	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-8	9082-9086	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[22]	
46-9	9087-9091	runs	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-10	9092-9095	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-11	9096-9099	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-12	9100-9112	consequently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-13	9113-9121	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-14	9122-9126	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-15	9127-9131	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[23]	
46-16	9132-9140	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
46-17	9140-9141	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	

#Text=The Institutional Review Board at the University of Pittsburgh approved this study.
47-1	9142-9145	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
47-2	9146-9159	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
47-3	9160-9166	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
47-4	9167-9172	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
47-5	9173-9175	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
47-6	9176-9179	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
47-7	9180-9190	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
47-8	9191-9193	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
47-9	9194-9204	Pittsburgh	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
47-10	9205-9213	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
47-11	9214-9218	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
47-12	9219-9224	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	
47-13	9224-9225	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[24]	

#Text=Measures
#Text=Cannabis use
#Text=The MHCPD substance use assessment procedure (detailed in) was designed to maximize honest and accurate substance use self-report.
48-1	9226-9234	Measures	_	
48-2	9235-9243	Cannabis	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[25]	
48-3	9244-9247	use	http://maven.renci.org/NeuroBridge/neurobridge#CannabisAbuse[25]	
48-4	9248-9251	The	_	
48-5	9252-9257	MHCPD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[26]	
48-6	9258-9267	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[26]	
48-7	9268-9271	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[26]	
48-8	9272-9282	assessment	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[26]	
48-9	9283-9292	procedure	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[26]	
48-10	9293-9294	(	_	
48-11	9294-9302	detailed	_	
48-12	9303-9305	in	_	
48-13	9305-9306	)	_	
48-14	9307-9310	was	_	
48-15	9311-9319	designed	_	
48-16	9320-9322	to	_	
48-17	9323-9331	maximize	_	
48-18	9332-9338	honest	_	
48-19	9339-9342	and	_	
48-20	9343-9351	accurate	_	
48-21	9352-9361	substance	_	
48-22	9362-9365	use	_	
48-23	9366-9377	self-report	_	
48-24	9377-9378	.	_	

#Text=Cannabis use was assessed at previous assessment phases at 14-, 16-, and 22-years-old, and at the time of testing (28-years-old).
49-1	9379-9387	Cannabis	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[27]	
49-2	9388-9391	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[27]	
49-3	9392-9395	was	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[27]	
49-4	9396-9404	assessed	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[27]	
49-5	9405-9407	at	_	
49-6	9408-9416	previous	_	
49-7	9417-9427	assessment	_	
49-8	9428-9434	phases	_	
49-9	9435-9437	at	_	
49-10	9438-9440	14	_	
49-11	9440-9441	-	_	
49-12	9441-9442	,	_	
49-13	9443-9445	16	_	
49-14	9445-9446	-	_	
49-15	9446-9447	,	_	
49-16	9448-9451	and	_	
49-17	9452-9454	22	_	
49-18	9454-9455	-	_	
49-19	9455-9464	years-old	_	
49-20	9464-9465	,	_	
49-21	9466-9469	and	_	
49-22	9470-9472	at	_	
49-23	9473-9476	the	_	
49-24	9477-9481	time	_	
49-25	9482-9484	of	_	
49-26	9485-9492	testing	_	
49-27	9493-9494	(	_	
49-28	9494-9496	28	_	
49-29	9496-9497	-	_	
49-30	9497-9506	years-old	_	
49-31	9506-9507	)	_	
49-32	9507-9508	.	_	

#Text=At each visit, cannabis age of onset was obtained (“How old were you when you first tried marijuana?”).
50-1	9509-9511	At	_	
50-2	9512-9516	each	_	
50-3	9517-9522	visit	_	
50-4	9522-9523	,	_	
50-5	9524-9532	cannabis	_	
50-6	9533-9536	age	_	
50-7	9537-9539	of	_	
50-8	9540-9545	onset	_	
50-9	9546-9549	was	_	
50-10	9550-9558	obtained	_	
50-11	9559-9560	(	_	
50-12	9560-9561	“	_	
50-13	9561-9564	How	_	
50-14	9565-9568	old	_	
50-15	9569-9573	were	_	
50-16	9574-9577	you	_	
50-17	9578-9582	when	_	
50-18	9583-9586	you	_	
50-19	9587-9592	first	_	
50-20	9593-9598	tried	_	
50-21	9599-9608	marijuana	_	
50-22	9608-9609	?	_	
50-23	9609-9610	”	_	
50-24	9610-9611	)	_	
50-25	9611-9612	.	_	

#Text=Quantity of cannabis use was assessed through self-report of the usual dose over the past year at each assessment phase.
51-1	9613-9621	Quantity	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[28]	
51-2	9622-9624	of	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[28]	
51-3	9625-9633	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[28]	
51-4	9634-9637	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[28]	
51-5	9638-9641	was	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[28]	
51-6	9642-9650	assessed	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[28]	
51-7	9651-9658	through	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[28]	
51-8	9659-9670	self-report	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[28]	
51-9	9671-9673	of	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[28]	
51-10	9674-9677	the	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[28]	
51-11	9678-9683	usual	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[28]	
51-12	9684-9688	dose	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[28]	
51-13	9689-9693	over	_	
51-14	9694-9697	the	_	
51-15	9698-9702	past	_	
51-16	9703-9707	year	_	
51-17	9708-9710	at	_	
51-18	9711-9715	each	_	
51-19	9716-9726	assessment	_	
51-20	9727-9732	phase	_	
51-21	9732-9733	.	_	

#Text=As in previous work from the MHCPD, all consumption was converted to a dose of marijuana joints based on THC estimates from previous literature.
52-1	9734-9736	As	_	
52-2	9737-9739	in	_	
52-3	9740-9748	previous	_	
52-4	9749-9753	work	_	
52-5	9754-9758	from	_	
52-6	9759-9762	the	_	
52-7	9763-9768	MHCPD	_	
52-8	9768-9769	,	_	
52-9	9770-9773	all	_	
52-10	9774-9785	consumption	_	
52-11	9786-9789	was	_	
52-12	9790-9799	converted	_	
52-13	9800-9802	to	_	
52-14	9803-9804	a	_	
52-15	9805-9809	dose	_	
52-16	9810-9812	of	_	
52-17	9813-9822	marijuana	_	
52-18	9823-9829	joints	_	
52-19	9830-9835	based	_	
52-20	9836-9838	on	_	
52-21	9839-9842	THC	_	
52-22	9843-9852	estimates	_	
52-23	9853-9857	from	_	
52-24	9858-9866	previous	_	
52-25	9867-9877	literature	_	
52-26	9877-9878	.	_	

#Text=For example, reported hashish dose was counted as equivalent to three joints of marijuana; a blunt of was counted as four joints.
53-1	9879-9882	For	_	
53-2	9883-9890	example	_	
53-3	9890-9891	,	_	
53-4	9892-9900	reported	_	
53-5	9901-9908	hashish	_	
53-6	9909-9913	dose	_	
53-7	9914-9917	was	_	
53-8	9918-9925	counted	_	
53-9	9926-9928	as	_	
53-10	9929-9939	equivalent	_	
53-11	9940-9942	to	_	
53-12	9943-9948	three	_	
53-13	9949-9955	joints	_	
53-14	9956-9958	of	_	
53-15	9959-9968	marijuana	_	
53-16	9968-9969	;	_	
53-17	9970-9971	a	_	
53-18	9972-9977	blunt	_	
53-19	9978-9980	of	_	
53-20	9981-9984	was	_	
53-21	9985-9992	counted	_	
53-22	9993-9995	as	_	
53-23	9996-10000	four	_	
53-24	10001-10007	joints	_	
53-25	10007-10008	.	_	

#Text=Frequency of the usual quantity of use was also obtained over the past year at each assessment phase (every day, 3–4 times per week, 1–2 times per week, once per month, 6–11 times per year, 1–5 times per year, no use).
54-1	10009-10018	Frequency	_	
54-2	10019-10021	of	_	
54-3	10022-10025	the	_	
54-4	10026-10031	usual	_	
54-5	10032-10040	quantity	_	
54-6	10041-10043	of	_	
54-7	10044-10047	use	_	
54-8	10048-10051	was	_	
54-9	10052-10056	also	_	
54-10	10057-10065	obtained	_	
54-11	10066-10070	over	_	
54-12	10071-10074	the	_	
54-13	10075-10079	past	_	
54-14	10080-10084	year	_	
54-15	10085-10087	at	_	
54-16	10088-10092	each	_	
54-17	10093-10103	assessment	_	
54-18	10104-10109	phase	_	
54-19	10110-10111	(	_	
54-20	10111-10116	every	_	
54-21	10117-10120	day	_	
54-22	10120-10121	,	_	
54-23	10122-10123	3	_	
54-24	10123-10124	–	_	
54-25	10124-10125	4	_	
54-26	10126-10131	times	_	
54-27	10132-10135	per	_	
54-28	10136-10140	week	_	
54-29	10140-10141	,	_	
54-30	10142-10143	1	_	
54-31	10143-10144	–	_	
54-32	10144-10145	2	_	
54-33	10146-10151	times	_	
54-34	10152-10155	per	_	
54-35	10156-10160	week	_	
54-36	10160-10161	,	_	
54-37	10162-10166	once	_	
54-38	10167-10170	per	_	
54-39	10171-10176	month	_	
54-40	10176-10177	,	_	
54-41	10178-10179	6	_	
54-42	10179-10180	–	_	
54-43	10180-10182	11	_	
54-44	10183-10188	times	_	
54-45	10189-10192	per	_	
54-46	10193-10197	year	_	
54-47	10197-10198	,	_	
54-48	10199-10200	1	_	
54-49	10200-10201	–	_	
54-50	10201-10202	5	_	
54-51	10203-10208	times	_	
54-52	10209-10212	per	_	
54-53	10213-10217	year	_	
54-54	10217-10218	,	_	
54-55	10219-10221	no	_	
54-56	10222-10225	use	_	
54-57	10225-10226	)	_	
54-58	10226-10227	.	_	

#Text=As in previous work from the MHCPD, our primary dosage estimate combined frequency and quantity measures (the product of average frequency and quantity) to create an average daily dose of cannabis (joints per day) for each assessment period.
55-1	10228-10230	As	_	
55-2	10231-10233	in	_	
55-3	10234-10242	previous	_	
55-4	10243-10247	work	_	
55-5	10248-10252	from	_	
55-6	10253-10256	the	_	
55-7	10257-10262	MHCPD	_	
55-8	10262-10263	,	_	
55-9	10264-10267	our	_	
55-10	10268-10275	primary	_	
55-11	10276-10282	dosage	_	
55-12	10283-10291	estimate	_	
55-13	10292-10300	combined	_	
55-14	10301-10310	frequency	_	
55-15	10311-10314	and	_	
55-16	10315-10323	quantity	_	
55-17	10324-10332	measures	_	
55-18	10333-10334	(	_	
55-19	10334-10337	the	_	
55-20	10338-10345	product	_	
55-21	10346-10348	of	_	
55-22	10349-10356	average	_	
55-23	10357-10366	frequency	_	
55-24	10367-10370	and	_	
55-25	10371-10379	quantity	_	
55-26	10379-10380	)	_	
55-27	10381-10383	to	_	
55-28	10384-10390	create	_	
55-29	10391-10393	an	_	
55-30	10394-10401	average	_	
55-31	10402-10407	daily	_	
55-32	10408-10412	dose	_	
55-33	10413-10415	of	_	
55-34	10416-10424	cannabis	_	
55-35	10425-10426	(	_	
55-36	10426-10432	joints	_	
55-37	10433-10436	per	_	
55-38	10437-10440	day	_	
55-39	10440-10441	)	_	
55-40	10442-10445	for	_	
55-41	10446-10450	each	_	
55-42	10451-10461	assessment	_	
55-43	10462-10468	period	_	
55-44	10468-10469	.	_	

#Text=Based on age of onset and total cannabis use measures, subjects were distributed across three groups (Table 1): non-users (NU, n = 15), those who did not report cannabis use at any time point, cannabis experimenters (EXP, n = 14), those who reported an age of cannabis initiation but no other cannabis use, and repeated cannabis users (REP, n = 46), those who reported initiation and any additional cannabis use.
56-1	10470-10475	Based	_	
56-2	10476-10478	on	_	
56-3	10479-10482	age	_	
56-4	10483-10485	of	_	
56-5	10486-10491	onset	_	
56-6	10492-10495	and	_	
56-7	10496-10501	total	_	
56-8	10502-10510	cannabis	_	
56-9	10511-10514	use	_	
56-10	10515-10523	measures	_	
56-11	10523-10524	,	_	
56-12	10525-10533	subjects	_	
56-13	10534-10538	were	_	
56-14	10539-10550	distributed	_	
56-15	10551-10557	across	_	
56-16	10558-10563	three	_	
56-17	10564-10570	groups	_	
56-18	10571-10572	(	_	
56-19	10572-10577	Table	_	
56-20	10578-10579	1	_	
56-21	10579-10580	)	_	
56-22	10580-10581	:	_	
56-23	10582-10591	non-users	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	
56-24	10592-10593	(	_	
56-25	10593-10595	NU	_	
56-26	10595-10596	,	_	
56-27	10597-10598	n	_	
56-28	10599-10600	=	_	
56-29	10601-10603	15	_	
56-30	10603-10604	)	_	
56-31	10604-10605	,	_	
56-32	10606-10611	those	_	
56-33	10612-10615	who	_	
56-34	10616-10619	did	_	
56-35	10620-10623	not	_	
56-36	10624-10630	report	_	
56-37	10631-10639	cannabis	_	
56-38	10640-10643	use	_	
56-39	10644-10646	at	_	
56-40	10647-10650	any	_	
56-41	10651-10655	time	_	
56-42	10656-10661	point	_	
56-43	10661-10662	,	_	
56-44	10663-10671	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#NondependentCannabisAbuse[29]	
56-45	10672-10685	experimenters	http://maven.renci.org/NeuroBridge/neurobridge#NondependentCannabisAbuse[29]	
56-46	10686-10687	(	_	
56-47	10687-10690	EXP	_	
56-48	10690-10691	,	_	
56-49	10692-10693	n	_	
56-50	10694-10695	=	_	
56-51	10696-10698	14	_	
56-52	10698-10699	)	_	
56-53	10699-10700	,	_	
56-54	10701-10706	those	_	
56-55	10707-10710	who	_	
56-56	10711-10719	reported	_	
56-57	10720-10722	an	_	
56-58	10723-10726	age	_	
56-59	10727-10729	of	_	
56-60	10730-10738	cannabis	_	
56-61	10739-10749	initiation	_	
56-62	10750-10753	but	_	
56-63	10754-10756	no	_	
56-64	10757-10762	other	_	
56-65	10763-10771	cannabis	_	
56-66	10772-10775	use	_	
56-67	10775-10776	,	_	
56-68	10777-10780	and	_	
56-69	10781-10789	repeated	http://maven.renci.org/NeuroBridge/neurobridge#NondependentCannabisAbuse[30]	
56-70	10790-10798	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#NondependentCannabisAbuse[30]	
56-71	10799-10804	users	http://maven.renci.org/NeuroBridge/neurobridge#NondependentCannabisAbuse[30]	
56-72	10805-10806	(	_	
56-73	10806-10809	REP	_	
56-74	10809-10810	,	_	
56-75	10811-10812	n	_	
56-76	10813-10814	=	_	
56-77	10815-10817	46	_	
56-78	10817-10818	)	_	
56-79	10818-10819	,	_	
56-80	10820-10825	those	_	
56-81	10826-10829	who	_	
56-82	10830-10838	reported	_	
56-83	10839-10849	initiation	_	
56-84	10850-10853	and	_	
56-85	10854-10857	any	_	
56-86	10858-10868	additional	_	
56-87	10869-10877	cannabis	_	
56-88	10878-10881	use	_	
56-89	10881-10882	.	_	

#Text=No subjects reported use without age of initiation.
57-1	10883-10885	No	_	
57-2	10886-10894	subjects	_	
57-3	10895-10903	reported	_	
57-4	10904-10907	use	_	
57-5	10908-10915	without	_	
57-6	10916-10919	age	_	
57-7	10920-10922	of	_	
57-8	10923-10933	initiation	_	
57-9	10933-10934	.	_	

#Text=If subject report of cannabis age of onset differed between assessment periods, the cannabis age of onset from the earliest assessment period was used, as it was more proximal to the onset time.
58-1	10935-10937	If	_	
58-2	10938-10945	subject	_	
58-3	10946-10952	report	_	
58-4	10953-10955	of	_	
58-5	10956-10964	cannabis	_	
58-6	10965-10968	age	_	
58-7	10969-10971	of	_	
58-8	10972-10977	onset	_	
58-9	10978-10986	differed	_	
58-10	10987-10994	between	_	
58-11	10995-11005	assessment	_	
58-12	11006-11013	periods	_	
58-13	11013-11014	,	_	
58-14	11015-11018	the	_	
58-15	11019-11027	cannabis	_	
58-16	11028-11031	age	_	
58-17	11032-11034	of	_	
58-18	11035-11040	onset	_	
58-19	11041-11045	from	_	
58-20	11046-11049	the	_	
58-21	11050-11058	earliest	_	
58-22	11059-11069	assessment	_	
58-23	11070-11076	period	_	
58-24	11077-11080	was	_	
58-25	11081-11085	used	_	
58-26	11085-11086	,	_	
58-27	11087-11089	as	_	
58-28	11090-11092	it	_	
58-29	11093-11096	was	_	
58-30	11097-11101	more	_	
58-31	11102-11110	proximal	_	
58-32	11111-11113	to	_	
58-33	11114-11117	the	_	
58-34	11118-11123	onset	_	
58-35	11124-11128	time	_	
58-36	11128-11129	.	_	

#Text=In statistical analysis, cannabis age of onset was examined as a continuous variable within both cannabis groups (EXP and REP).
59-1	11130-11132	In	_	
59-2	11133-11144	statistical	_	
59-3	11145-11153	analysis	_	
59-4	11153-11154	,	_	
59-5	11155-11163	cannabis	_	
59-6	11164-11167	age	_	
59-7	11168-11170	of	_	
59-8	11171-11176	onset	_	
59-9	11177-11180	was	_	
59-10	11181-11189	examined	_	
59-11	11190-11192	as	_	
59-12	11193-11194	a	_	
59-13	11195-11205	continuous	_	
59-14	11206-11214	variable	_	
59-15	11215-11221	within	_	
59-16	11222-11226	both	_	
59-17	11227-11235	cannabis	_	
59-18	11236-11242	groups	_	
59-19	11243-11244	(	_	
59-20	11244-11247	EXP	_	
59-21	11248-11251	and	_	
59-22	11252-11255	REP	_	
59-23	11255-11256	)	_	
59-24	11256-11257	.	_	

#Text=Total cannabis use, measured as the sum of joints per day across assessments (14-, 16-, 22-, 28-years-old) and conceptualized as a general measure of cannabis use severity, was examined only in those with a reported cannabis dose (REP).
60-1	11258-11263	Total	_	
60-2	11264-11272	cannabis	_	
60-3	11273-11276	use	_	
60-4	11276-11277	,	_	
60-5	11278-11286	measured	_	
60-6	11287-11289	as	_	
60-7	11290-11293	the	_	
60-8	11294-11297	sum	_	
60-9	11298-11300	of	_	
60-10	11301-11307	joints	_	
60-11	11308-11311	per	_	
60-12	11312-11315	day	_	
60-13	11316-11322	across	_	
60-14	11323-11334	assessments	_	
60-15	11335-11336	(	_	
60-16	11336-11338	14	_	
60-17	11338-11339	-	_	
60-18	11339-11340	,	_	
60-19	11341-11343	16	_	
60-20	11343-11344	-	_	
60-21	11344-11345	,	_	
60-22	11346-11348	22	_	
60-23	11348-11349	-	_	
60-24	11349-11350	,	_	
60-25	11351-11353	28	_	
60-26	11353-11354	-	_	
60-27	11354-11363	years-old	_	
60-28	11363-11364	)	_	
60-29	11365-11368	and	_	
60-30	11369-11383	conceptualized	_	
60-31	11384-11386	as	_	
60-32	11387-11388	a	_	
60-33	11389-11396	general	_	
60-34	11397-11404	measure	_	
60-35	11405-11407	of	_	
60-36	11408-11416	cannabis	_	
60-37	11417-11420	use	_	
60-38	11421-11429	severity	_	
60-39	11429-11430	,	_	
60-40	11431-11434	was	_	
60-41	11435-11443	examined	_	
60-42	11444-11448	only	_	
60-43	11449-11451	in	_	
60-44	11452-11457	those	_	
60-45	11458-11462	with	_	
60-46	11463-11464	a	_	
60-47	11465-11473	reported	_	
60-48	11474-11482	cannabis	_	
60-49	11483-11487	dose	_	
60-50	11488-11489	(	_	
60-51	11489-11492	REP	_	
60-52	11492-11493	)	_	
60-53	11493-11494	.	_	

#Text=Total cannabis use measures were log transformed to reduce the impact of the few high dose participants, evident in the strong positive skew of the total cannabis use distribution (Supplemental Fig.
61-1	11495-11500	Total	_	
61-2	11501-11509	cannabis	_	
61-3	11510-11513	use	_	
61-4	11514-11522	measures	_	
61-5	11523-11527	were	_	
61-6	11528-11531	log	_	
61-7	11532-11543	transformed	_	
61-8	11544-11546	to	_	
61-9	11547-11553	reduce	_	
61-10	11554-11557	the	_	
61-11	11558-11564	impact	_	
61-12	11565-11567	of	_	
61-13	11568-11571	the	_	
61-14	11572-11575	few	_	
61-15	11576-11580	high	_	
61-16	11581-11585	dose	_	
61-17	11586-11598	participants	_	
61-18	11598-11599	,	_	
61-19	11600-11607	evident	_	
61-20	11608-11610	in	_	
61-21	11611-11614	the	_	
61-22	11615-11621	strong	_	
61-23	11622-11630	positive	_	
61-24	11631-11635	skew	_	
61-25	11636-11638	of	_	
61-26	11639-11642	the	_	
61-27	11643-11648	total	_	
61-28	11649-11657	cannabis	_	
61-29	11658-11661	use	_	
61-30	11662-11674	distribution	_	
61-31	11675-11676	(	_	
61-32	11676-11688	Supplemental	_	
61-33	11689-11692	Fig	_	
61-34	11692-11693	.	_	

#Text=S1).
62-1	11694-11696	S1	_	
62-2	11696-11697	)	_	
62-3	11697-11698	.	_	

#Text=On the day of testing, all subjects included in the current analysis (N = 75) denied recreational drug use of any kind during the past week and had a negative multi-drug urine screen (Uritox Medical, Toledo, OH, THC Threshold 50 ng/ml).
63-1	11699-11701	On	_	
63-2	11702-11705	the	_	
63-3	11706-11709	day	_	
63-4	11710-11712	of	_	
63-5	11713-11720	testing	_	
63-6	11720-11721	,	_	
63-7	11722-11725	all	_	
63-8	11726-11734	subjects	_	
63-9	11735-11743	included	_	
63-10	11744-11746	in	_	
63-11	11747-11750	the	_	
63-12	11751-11758	current	_	
63-13	11759-11767	analysis	_	
63-14	11768-11769	(	_	
63-15	11769-11770	N	_	
63-16	11771-11772	=	_	
63-17	11773-11775	75	_	
63-18	11775-11776	)	_	
63-19	11777-11783	denied	_	
63-20	11784-11796	recreational	_	
63-21	11797-11801	drug	_	
63-22	11802-11805	use	_	
63-23	11806-11808	of	_	
63-24	11809-11812	any	_	
63-25	11813-11817	kind	_	
63-26	11818-11824	during	_	
63-27	11825-11828	the	_	
63-28	11829-11833	past	_	
63-29	11834-11838	week	_	
63-30	11839-11842	and	_	
63-31	11843-11846	had	_	
63-32	11847-11848	a	_	
63-33	11849-11857	negative	_	
63-34	11858-11868	multi-drug	_	
63-35	11869-11874	urine	_	
63-36	11875-11881	screen	_	
63-37	11882-11883	(	_	
63-38	11883-11889	Uritox	_	
63-39	11890-11897	Medical	_	
63-40	11897-11898	,	_	
63-41	11899-11905	Toledo	_	
63-42	11905-11906	,	_	
63-43	11907-11909	OH	_	
63-44	11909-11910	,	_	
63-45	11911-11914	THC	_	
63-46	11915-11924	Threshold	_	
63-47	11925-11927	50	_	
63-48	11928-11930	ng	_	
63-49	11930-11931	/	_	
63-50	11931-11933	ml	_	
63-51	11933-11934	)	_	
63-52	11934-11935	.	_	

#Text=Accordingly, we consider all subjects abstinent at testing (no recent use).
64-1	11936-11947	Accordingly	_	
64-2	11947-11948	,	_	
64-3	11949-11951	we	_	
64-4	11952-11960	consider	_	
64-5	11961-11964	all	_	
64-6	11965-11973	subjects	_	
64-7	11974-11983	abstinent	_	
64-8	11984-11986	at	_	
64-9	11987-11994	testing	_	
64-10	11995-11996	(	_	
64-11	11996-11998	no	_	
64-12	11999-12005	recent	_	
64-13	12006-12009	use	_	
64-14	12009-12010	)	_	
64-15	12010-12011	.	_	

#Text=Demographics and participant characteristics
#Text=As detailed in previous work, extensive participant demographics and characteristics were collected as part of MHCPD assessments.
65-1	12012-12024	Demographics	_	
65-2	12025-12028	and	_	
65-3	12029-12040	participant	_	
65-4	12041-12056	characteristics	_	
65-5	12057-12059	As	_	
65-6	12060-12068	detailed	_	
65-7	12069-12071	in	_	
65-8	12072-12080	previous	_	
65-9	12081-12085	work	_	
65-10	12085-12086	,	_	
65-11	12087-12096	extensive	_	
65-12	12097-12108	participant	_	
65-13	12109-12121	demographics	_	
65-14	12122-12125	and	_	
65-15	12126-12141	characteristics	_	
65-16	12142-12146	were	_	
65-17	12147-12156	collected	_	
65-18	12157-12159	as	_	
65-19	12160-12164	part	_	
65-20	12165-12167	of	_	
65-21	12168-12173	MHCPD	_	
65-22	12174-12185	assessments	_	
65-23	12185-12186	.	_	

#Text=In the current work, we included measures associated with cannabis use risk in previous work in the MHCPD (e.g.,) and other studies of adolescent cannabis use (e.g.,) (see Table 1).
66-1	12187-12189	In	_	
66-2	12190-12193	the	_	
66-3	12194-12201	current	_	
66-4	12202-12206	work	_	
66-5	12206-12207	,	_	
66-6	12208-12210	we	_	
66-7	12211-12219	included	_	
66-8	12220-12228	measures	_	
66-9	12229-12239	associated	_	
66-10	12240-12244	with	_	
66-11	12245-12253	cannabis	_	
66-12	12254-12257	use	_	
66-13	12258-12262	risk	_	
66-14	12263-12265	in	_	
66-15	12266-12274	previous	_	
66-16	12275-12279	work	_	
66-17	12280-12282	in	_	
66-18	12283-12286	the	_	
66-19	12287-12292	MHCPD	_	
66-20	12293-12294	(	_	
66-21	12294-12297	e.g	_	
66-22	12297-12298	.	_	
66-23	12298-12299	,	_	
66-24	12299-12300	)	_	
66-25	12301-12304	and	_	
66-26	12305-12310	other	_	
66-27	12311-12318	studies	_	
66-28	12319-12321	of	_	
66-29	12322-12332	adolescent	_	
66-30	12333-12341	cannabis	_	
66-31	12342-12345	use	_	
66-32	12346-12347	(	_	
66-33	12347-12350	e.g	_	
66-34	12350-12351	.	_	
66-35	12351-12352	,	_	
66-36	12352-12353	)	_	
66-37	12354-12355	(	_	
66-38	12355-12358	see	_	
66-39	12359-12364	Table	_	
66-40	12365-12366	1	_	
66-41	12366-12367	)	_	
66-42	12367-12368	.	_	

#Text=Measures examined as potential covariates included socioeconomic status (highest level of education, family income), IQ (WISC-III Full Scale), other substance use (alcohol and cigarette use), and prenatal drug exposure (cannabis, alcohol, and cigarette).
67-1	12369-12377	Measures	_	
67-2	12378-12386	examined	_	
67-3	12387-12389	as	_	
67-4	12390-12399	potential	_	
67-5	12400-12410	covariates	_	
67-6	12411-12419	included	_	
67-7	12420-12433	socioeconomic	http://www.case.edu/ProvCaRe/provcare#SocialStatusQuestionnaire[31]	
67-8	12434-12440	status	http://www.case.edu/ProvCaRe/provcare#SocialStatusQuestionnaire[31]	
67-9	12441-12442	(	_	
67-10	12442-12449	highest	_	
67-11	12450-12455	level	_	
67-12	12456-12458	of	_	
67-13	12459-12468	education	_	
67-14	12468-12469	,	_	
67-15	12470-12476	family	_	
67-16	12477-12483	income	_	
67-17	12483-12484	)	_	
67-18	12484-12485	,	_	
67-19	12486-12488	IQ	_	
67-20	12489-12490	(	_	
67-21	12490-12498	WISC-III	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
67-22	12499-12503	Full	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
67-23	12504-12509	Scale	http://www.case.edu/ProvCaRe/provcare#NeurocognitiveTest[32]	
67-24	12509-12510	)	_	
67-25	12510-12511	,	_	
67-26	12512-12517	other	_	
67-27	12518-12527	substance	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[33]	
67-28	12528-12531	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceUseScale[33]	
67-29	12532-12533	(	_	
67-30	12533-12540	alcohol	_	
67-31	12541-12544	and	_	
67-32	12545-12554	cigarette	_	
67-33	12555-12558	use	_	
67-34	12558-12559	)	_	
67-35	12559-12560	,	_	
67-36	12561-12564	and	_	
67-37	12565-12573	prenatal	_	
67-38	12574-12578	drug	_	
67-39	12579-12587	exposure	_	
67-40	12588-12589	(	_	
67-41	12589-12597	cannabis	_	
67-42	12597-12598	,	_	
67-43	12599-12606	alcohol	_	
67-44	12606-12607	,	_	
67-45	12608-12611	and	_	
67-46	12612-12621	cigarette	_	
67-47	12621-12622	)	_	
67-48	12622-12623	.	_	

#Text=In cases where measures were available from multiple assessment phases (e.g., IQ, family income), we selected the measure that was closest to the year of neuroimaging testing (age 28).
68-1	12624-12626	In	_	
68-2	12627-12632	cases	_	
68-3	12633-12638	where	_	
68-4	12639-12647	measures	_	
68-5	12648-12652	were	_	
68-6	12653-12662	available	_	
68-7	12663-12667	from	_	
68-8	12668-12676	multiple	_	
68-9	12677-12687	assessment	_	
68-10	12688-12694	phases	_	
68-11	12695-12696	(	_	
68-12	12696-12699	e.g	_	
68-13	12699-12700	.	_	
68-14	12700-12701	,	_	
68-15	12702-12704	IQ	_	
68-16	12704-12705	,	_	
68-17	12706-12712	family	_	
68-18	12713-12719	income	_	
68-19	12719-12720	)	_	
68-20	12720-12721	,	_	
68-21	12722-12724	we	_	
68-22	12725-12733	selected	_	
68-23	12734-12737	the	_	
68-24	12738-12745	measure	_	
68-25	12746-12750	that	_	
68-26	12751-12754	was	_	
68-27	12755-12762	closest	_	
68-28	12763-12765	to	_	
68-29	12766-12769	the	_	
68-30	12770-12774	year	_	
68-31	12775-12777	of	_	
68-32	12778-12790	neuroimaging	_	
68-33	12791-12798	testing	_	
68-34	12799-12800	(	_	
68-35	12800-12803	age	_	
68-36	12804-12806	28	_	
68-37	12806-12807	)	_	
68-38	12807-12808	.	_	

#Text=For five subjects, the most recent IQ measurement (age 14) was missing but age 10 IQ scores were available for these subjects.
69-1	12809-12812	For	_	
69-2	12813-12817	five	_	
69-3	12818-12826	subjects	_	
69-4	12826-12827	,	_	
69-5	12828-12831	the	_	
69-6	12832-12836	most	_	
69-7	12837-12843	recent	_	
69-8	12844-12846	IQ	_	
69-9	12847-12858	measurement	_	
69-10	12859-12860	(	_	
69-11	12860-12863	age	_	
69-12	12864-12866	14	_	
69-13	12866-12867	)	_	
69-14	12868-12871	was	_	
69-15	12872-12879	missing	_	
69-16	12880-12883	but	_	
69-17	12884-12887	age	_	
69-18	12888-12890	10	_	
69-19	12891-12893	IQ	_	
69-20	12894-12900	scores	_	
69-21	12901-12905	were	_	
69-22	12906-12915	available	_	
69-23	12916-12919	for	_	
69-24	12920-12925	these	_	
69-25	12926-12934	subjects	_	
69-26	12934-12935	.	_	

#Text=Similarly, for seven subjects, the most recent family income data (age 16) were missing but age 10 family income data was available for these subjects.
70-1	12936-12945	Similarly	_	
70-2	12945-12946	,	_	
70-3	12947-12950	for	_	
70-4	12951-12956	seven	_	
70-5	12957-12965	subjects	_	
70-6	12965-12966	,	_	
70-7	12967-12970	the	_	
70-8	12971-12975	most	_	
70-9	12976-12982	recent	_	
70-10	12983-12989	family	_	
70-11	12990-12996	income	_	
70-12	12997-13001	data	_	
70-13	13002-13003	(	_	
70-14	13003-13006	age	_	
70-15	13007-13009	16	_	
70-16	13009-13010	)	_	
70-17	13011-13015	were	_	
70-18	13016-13023	missing	_	
70-19	13024-13027	but	_	
70-20	13028-13031	age	_	
70-21	13032-13034	10	_	
70-22	13035-13041	family	_	
70-23	13042-13048	income	_	
70-24	13049-13053	data	_	
70-25	13054-13057	was	_	
70-26	13058-13067	available	_	
70-27	13068-13071	for	_	
70-28	13072-13077	these	_	
70-29	13078-13086	subjects	_	
70-30	13086-13087	.	_	

#Text=In both cases, data from these earlier assessments were included and adjusted based on regression models predicting the most recent assessment from the rest of the cohort and used in covariate models (IQ, Standford-Binet Intelligence Scale 4th Edition age 10 predicting WISC at age 14, B = .986, t = 8.87, p < .0001; family income at age 10 predicting family income at age 16 (n = 7), B = .848, t = 8.68, p < .0001).
#Text=fMRI task design
#Text=Across four fMRI runs, participants performed 96 full trials of a Sternberg type spatial working memory task (see Fig. 1) with a 2 (load) x 2 (delay length) x 2 (cue validity) factorial design.
71-1	13088-13090	In	_	
71-2	13091-13095	both	_	
71-3	13096-13101	cases	_	
71-4	13101-13102	,	_	
71-5	13103-13107	data	_	
71-6	13108-13112	from	_	
71-7	13113-13118	these	_	
71-8	13119-13126	earlier	_	
71-9	13127-13138	assessments	_	
71-10	13139-13143	were	_	
71-11	13144-13152	included	_	
71-12	13153-13156	and	_	
71-13	13157-13165	adjusted	_	
71-14	13166-13171	based	_	
71-15	13172-13174	on	_	
71-16	13175-13185	regression	_	
71-17	13186-13192	models	_	
71-18	13193-13203	predicting	_	
71-19	13204-13207	the	_	
71-20	13208-13212	most	_	
71-21	13213-13219	recent	_	
71-22	13220-13230	assessment	_	
71-23	13231-13235	from	_	
71-24	13236-13239	the	_	
71-25	13240-13244	rest	_	
71-26	13245-13247	of	_	
71-27	13248-13251	the	_	
71-28	13252-13258	cohort	_	
71-29	13259-13262	and	_	
71-30	13263-13267	used	_	
71-31	13268-13270	in	_	
71-32	13271-13280	covariate	_	
71-33	13281-13287	models	_	
71-34	13288-13289	(	_	
71-35	13289-13291	IQ	_	
71-36	13291-13292	,	_	
71-37	13293-13308	Standford-Binet	_	
71-38	13309-13321	Intelligence	_	
71-39	13322-13327	Scale	_	
71-40	13328-13331	4th	_	
71-41	13332-13339	Edition	_	
71-42	13340-13343	age	_	
71-43	13344-13346	10	_	
71-44	13347-13357	predicting	_	
71-45	13358-13362	WISC	_	
71-46	13363-13365	at	_	
71-47	13366-13369	age	_	
71-48	13370-13372	14	_	
71-49	13372-13373	,	_	
71-50	13374-13375	B	_	
71-51	13376-13377	=	_	
71-52	13378-13382	.986	_	
71-53	13382-13383	,	_	
71-54	13384-13385	t	_	
71-55	13386-13387	=	_	
71-56	13388-13392	8.87	_	
71-57	13392-13393	,	_	
71-58	13394-13395	p	_	
71-59	13396-13397	<	_	
71-60	13398-13403	.0001	_	
71-61	13403-13404	;	_	
71-62	13405-13411	family	_	
71-63	13412-13418	income	_	
71-64	13419-13421	at	_	
71-65	13422-13425	age	_	
71-66	13426-13428	10	_	
71-67	13429-13439	predicting	_	
71-68	13440-13446	family	_	
71-69	13447-13453	income	_	
71-70	13454-13456	at	_	
71-71	13457-13460	age	_	
71-72	13461-13463	16	_	
71-73	13464-13465	(	_	
71-74	13465-13466	n	_	
71-75	13467-13468	=	_	
71-76	13469-13470	7	_	
71-77	13470-13471	)	_	
71-78	13471-13472	,	_	
71-79	13473-13474	B	_	
71-80	13475-13476	=	_	
71-81	13477-13481	.848	_	
71-82	13481-13482	,	_	
71-83	13483-13484	t	_	
71-84	13485-13486	=	_	
71-85	13487-13491	8.68	_	
71-86	13491-13492	,	_	
71-87	13493-13494	p	_	
71-88	13495-13496	<	_	
71-89	13497-13502	.0001	_	
71-90	13502-13503	)	_	
71-91	13503-13504	.	_	
71-92	13505-13509	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[34]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[35]	
71-93	13510-13514	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[34]	
71-94	13515-13521	design	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[34]	
71-95	13522-13528	Across	_	
71-96	13529-13533	four	_	
71-97	13534-13538	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
71-98	13539-13543	runs	_	
71-99	13543-13544	,	_	
71-100	13545-13557	participants	_	
71-101	13558-13567	performed	_	
71-102	13568-13570	96	_	
71-103	13571-13575	full	_	
71-104	13576-13582	trials	_	
71-105	13583-13585	of	_	
71-106	13586-13587	a	_	
71-107	13588-13597	Sternberg	http://maven.renci.org/NeuroBridge/neurobridge#SternbergItemRecognitionParadigmTask[36]	
71-108	13598-13602	type	http://maven.renci.org/NeuroBridge/neurobridge#SternbergItemRecognitionParadigmTask[36]	
71-109	13603-13610	spatial	http://maven.renci.org/NeuroBridge/neurobridge#SternbergItemRecognitionParadigmTask[36]	
71-110	13611-13618	working	http://maven.renci.org/NeuroBridge/neurobridge#SternbergItemRecognitionParadigmTask[36]	
71-111	13619-13625	memory	http://maven.renci.org/NeuroBridge/neurobridge#SternbergItemRecognitionParadigmTask[36]	
71-112	13626-13630	task	http://maven.renci.org/NeuroBridge/neurobridge#SternbergItemRecognitionParadigmTask[36]	
71-113	13631-13632	(	_	
71-114	13632-13635	see	_	
71-115	13636-13639	Fig	_	
71-116	13639-13640	.	_	
71-117	13641-13642	1	_	
71-118	13642-13643	)	_	
71-119	13644-13648	with	_	
71-120	13649-13650	a	_	
71-121	13651-13652	2	_	
71-122	13653-13654	(	_	
71-123	13654-13658	load	_	
71-124	13658-13659	)	_	
71-125	13660-13661	x	_	
71-126	13662-13663	2	_	
71-127	13664-13665	(	_	
71-128	13665-13670	delay	_	
71-129	13671-13677	length	_	
71-130	13677-13678	)	_	
71-131	13679-13680	x	_	
71-132	13681-13682	2	_	
71-133	13683-13684	(	_	
71-134	13684-13687	cue	_	
71-135	13688-13696	validity	_	
71-136	13696-13697	)	_	
71-137	13698-13707	factorial	_	
71-138	13708-13714	design	_	
71-139	13714-13715	.	_	

#Text=The task included three epochs: a cue (encoding) epoch (1.5s) where subjects were shown to-be-remembered stimuli (one or three spatial locations), a delay (maintenance) epoch, where subjects maintained information (1.5 or 6s), and a target (retrieval) epoch, where subjects had to retrieve information and respond to whether a probe (four spatial locations) matched any of the cued information (<3s).
72-1	13716-13719	The	_	
72-2	13720-13724	task	_	
72-3	13725-13733	included	_	
72-4	13734-13739	three	_	
72-5	13740-13746	epochs	_	
72-6	13746-13747	:	_	
72-7	13748-13749	a	_	
72-8	13750-13753	cue	_	
72-9	13754-13755	(	_	
72-10	13755-13763	encoding	_	
72-11	13763-13764	)	_	
72-12	13765-13770	epoch	_	
72-13	13771-13772	(	_	
72-14	13772-13776	1.5s	_	
72-15	13776-13777	)	_	
72-16	13778-13783	where	_	
72-17	13784-13792	subjects	_	
72-18	13793-13797	were	_	
72-19	13798-13803	shown	_	
72-20	13804-13820	to-be-remembered	_	
72-21	13821-13828	stimuli	_	
72-22	13829-13830	(	_	
72-23	13830-13833	one	_	
72-24	13834-13836	or	_	
72-25	13837-13842	three	_	
72-26	13843-13850	spatial	_	
72-27	13851-13860	locations	_	
72-28	13860-13861	)	_	
72-29	13861-13862	,	_	
72-30	13863-13864	a	_	
72-31	13865-13870	delay	_	
72-32	13871-13872	(	_	
72-33	13872-13883	maintenance	_	
72-34	13883-13884	)	_	
72-35	13885-13890	epoch	_	
72-36	13890-13891	,	_	
72-37	13892-13897	where	_	
72-38	13898-13906	subjects	_	
72-39	13907-13917	maintained	_	
72-40	13918-13929	information	_	
72-41	13930-13931	(	_	
72-42	13931-13934	1.5	_	
72-43	13935-13937	or	_	
72-44	13938-13940	6s	_	
72-45	13940-13941	)	_	
72-46	13941-13942	,	_	
72-47	13943-13946	and	_	
72-48	13947-13948	a	_	
72-49	13949-13955	target	_	
72-50	13956-13957	(	_	
72-51	13957-13966	retrieval	_	
72-52	13966-13967	)	_	
72-53	13968-13973	epoch	_	
72-54	13973-13974	,	_	
72-55	13975-13980	where	_	
72-56	13981-13989	subjects	_	
72-57	13990-13993	had	_	
72-58	13994-13996	to	_	
72-59	13997-14005	retrieve	_	
72-60	14006-14017	information	_	
72-61	14018-14021	and	_	
72-62	14022-14029	respond	_	
72-63	14030-14032	to	_	
72-64	14033-14040	whether	_	
72-65	14041-14042	a	_	
72-66	14043-14048	probe	_	
72-67	14049-14050	(	_	
72-68	14050-14054	four	_	
72-69	14055-14062	spatial	_	
72-70	14063-14072	locations	_	
72-71	14072-14073	)	_	
72-72	14074-14081	matched	_	
72-73	14082-14085	any	_	
72-74	14086-14088	of	_	
72-75	14089-14092	the	_	
72-76	14093-14097	cued	_	
72-77	14098-14109	information	_	
72-78	14110-14111	(	_	
72-79	14111-14112	<	_	
72-80	14112-14114	3s	_	
72-81	14114-14115	)	_	
72-82	14115-14116	.	_	

#Text=An additional 48 partial trials with either the cue epoch alone (n = 24) or the cue and delay epochs but not the target epoch (n = 24) were included in order to estimate the hemodynamic response for each epoch.
73-1	14117-14119	An	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-2	14120-14130	additional	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-3	14131-14133	48	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-4	14134-14141	partial	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-5	14142-14148	trials	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-6	14149-14153	with	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-7	14154-14160	either	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-8	14161-14164	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-9	14165-14168	cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-10	14169-14174	epoch	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-11	14175-14180	alone	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-12	14181-14182	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-13	14182-14183	n	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-14	14184-14185	=	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-15	14186-14188	24	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-16	14188-14189	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-17	14190-14192	or	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-18	14193-14196	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-19	14197-14200	cue	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-20	14201-14204	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-21	14205-14210	delay	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-22	14211-14217	epochs	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-23	14218-14221	but	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-24	14222-14225	not	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-25	14226-14229	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-26	14230-14236	target	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-27	14237-14242	epoch	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-28	14243-14244	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-29	14244-14245	n	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-30	14246-14247	=	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-31	14248-14250	24	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-32	14250-14251	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-33	14252-14256	were	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-34	14257-14265	included	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-35	14266-14268	in	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-36	14269-14274	order	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-37	14275-14277	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-38	14278-14286	estimate	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-39	14287-14290	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-40	14291-14302	hemodynamic	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-41	14303-14311	response	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-42	14312-14315	for	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-43	14316-14320	each	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-44	14321-14326	epoch	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[37]	
73-45	14326-14327	.	_	

#Text=The task utilized a mixed block/event-related fMRI design with interleaved task blocks (102s) and fixation only periods (12s).
74-1	14328-14331	The	_	
74-2	14332-14336	task	_	
74-3	14337-14345	utilized	_	
74-4	14346-14347	a	_	
74-5	14348-14353	mixed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[38]	
74-6	14354-14359	block	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[38]	
74-7	14359-14360	/	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[38]	
74-8	14360-14373	event-related	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[38]	
74-9	14374-14378	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[38]	
74-10	14379-14385	design	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[38]	
74-11	14386-14390	with	_	
74-12	14391-14402	interleaved	_	
74-13	14403-14407	task	_	
74-14	14408-14414	blocks	_	
74-15	14415-14416	(	_	
74-16	14416-14420	102s	_	
74-17	14420-14421	)	_	
74-18	14422-14425	and	_	
74-19	14426-14434	fixation	_	
74-20	14435-14439	only	_	
74-21	14440-14447	periods	_	
74-22	14448-14449	(	_	
74-23	14449-14452	12s	_	
74-24	14452-14453	)	_	
74-25	14453-14454	.	_	

#Text=Inter-trial intervals within task blocks were pseudo-randomized and ranged from 1.5s to 5.5s.
#Text=fMRI data acquisition
#Text=Stimuli were presented onto a screen behind the scanner using E- Prime software (Psychology Software Tools, Inc., Pittsburgh, PA) and were visible to the subject through a mirror mounted to the head coil.
75-1	14455-14466	Inter-trial	_	
75-2	14467-14476	intervals	_	
75-3	14477-14483	within	_	
75-4	14484-14488	task	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[39]	
75-5	14489-14495	blocks	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[39]	
75-6	14496-14500	were	_	
75-7	14501-14518	pseudo-randomized	_	
75-8	14519-14522	and	_	
75-9	14523-14529	ranged	_	
75-10	14530-14534	from	_	
75-11	14535-14539	1.5s	_	
75-12	14540-14542	to	_	
75-13	14543-14547	5.5s	_	
75-14	14547-14548	.	_	
75-15	14549-14553	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[40]|http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[41]	
75-16	14554-14558	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[40]	
75-17	14559-14570	acquisition	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[40]	
75-18	14571-14578	Stimuli	_	
75-19	14579-14583	were	_	
75-20	14584-14593	presented	_	
75-21	14594-14598	onto	_	
75-22	14599-14600	a	_	
75-23	14601-14607	screen	_	
75-24	14608-14614	behind	_	
75-25	14615-14618	the	_	
75-26	14619-14626	scanner	_	
75-27	14627-14632	using	_	
75-28	14633-14634	E	_	
75-29	14634-14635	-	_	
75-30	14636-14641	Prime	_	
75-31	14642-14650	software	_	
75-32	14651-14652	(	_	
75-33	14652-14662	Psychology	_	
75-34	14663-14671	Software	_	
75-35	14672-14677	Tools	_	
75-36	14677-14678	,	_	
75-37	14679-14682	Inc	_	
75-38	14682-14683	.	_	
75-39	14683-14684	,	_	
75-40	14685-14695	Pittsburgh	_	
75-41	14695-14696	,	_	
75-42	14697-14699	PA	_	
75-43	14699-14700	)	_	
75-44	14701-14704	and	_	
75-45	14705-14709	were	_	
75-46	14710-14717	visible	_	
75-47	14718-14720	to	_	
75-48	14721-14724	the	_	
75-49	14725-14732	subject	_	
75-50	14733-14740	through	_	
75-51	14741-14742	a	_	
75-52	14743-14749	mirror	_	
75-53	14750-14757	mounted	_	
75-54	14758-14760	to	_	
75-55	14761-14764	the	_	
75-56	14765-14769	head	_	
75-57	14770-14774	coil	_	
75-58	14774-14775	.	_	

#Text=Reaction time in the working memory task was recorded as the time in milliseconds from the probe display (four yellow circles) to response (button press on MRI safe button box).
76-1	14776-14784	Reaction	_	
76-2	14785-14789	time	_	
76-3	14790-14792	in	_	
76-4	14793-14796	the	_	
76-5	14797-14804	working	_	
76-6	14805-14811	memory	_	
76-7	14812-14816	task	_	
76-8	14817-14820	was	_	
76-9	14821-14829	recorded	_	
76-10	14830-14832	as	_	
76-11	14833-14836	the	_	
76-12	14837-14841	time	_	
76-13	14842-14844	in	_	
76-14	14845-14857	milliseconds	_	
76-15	14858-14862	from	_	
76-16	14863-14866	the	_	
76-17	14867-14872	probe	_	
76-18	14873-14880	display	_	
76-19	14881-14882	(	_	
76-20	14882-14886	four	_	
76-21	14887-14893	yellow	_	
76-22	14894-14901	circles	_	
76-23	14901-14902	)	_	
76-24	14903-14905	to	_	
76-25	14906-14914	response	_	
76-26	14915-14916	(	_	
76-27	14916-14922	button	_	
76-28	14923-14928	press	_	
76-29	14929-14931	on	_	
76-30	14932-14935	MRI	_	
76-31	14936-14940	safe	_	
76-32	14941-14947	button	_	
76-33	14948-14951	box	_	
76-34	14951-14952	)	_	
76-35	14952-14953	.	_	

#Text=Trials were marked correct if the button response (Pointer Finger = yes/match; Middle Finger = no/no match; right hand glove) correctly indicated whether or not one of the probes occupied a previously cued location.
77-1	14954-14960	Trials	_	
77-2	14961-14965	were	_	
77-3	14966-14972	marked	_	
77-4	14973-14980	correct	_	
77-5	14981-14983	if	_	
77-6	14984-14987	the	_	
77-7	14988-14994	button	_	
77-8	14995-15003	response	_	
77-9	15004-15005	(	_	
77-10	15005-15012	Pointer	_	
77-11	15013-15019	Finger	_	
77-12	15020-15021	=	_	
77-13	15022-15025	yes	_	
77-14	15025-15026	/	_	
77-15	15026-15031	match	_	
77-16	15031-15032	;	_	
77-17	15033-15039	Middle	_	
77-18	15040-15046	Finger	_	
77-19	15047-15048	=	_	
77-20	15049-15051	no	_	
77-21	15051-15052	/	_	
77-22	15052-15054	no	_	
77-23	15055-15060	match	_	
77-24	15060-15061	;	_	
77-25	15062-15067	right	_	
77-26	15068-15072	hand	_	
77-27	15073-15078	glove	_	
77-28	15078-15079	)	_	
77-29	15080-15089	correctly	_	
77-30	15090-15099	indicated	_	
77-31	15100-15107	whether	_	
77-32	15108-15110	or	_	
77-33	15111-15114	not	_	
77-34	15115-15118	one	_	
77-35	15119-15121	of	_	
77-36	15122-15125	the	_	
77-37	15126-15132	probes	_	
77-38	15133-15141	occupied	_	
77-39	15142-15143	a	_	
77-40	15144-15154	previously	_	
77-41	15155-15159	cued	_	
77-42	15160-15168	location	_	
77-43	15168-15169	.	_	

#Text=If no response was given after 3000 ms, the trial was “timed-out” and marked as an omission error.
78-1	15170-15172	If	_	
78-2	15173-15175	no	_	
78-3	15176-15184	response	_	
78-4	15185-15188	was	_	
78-5	15189-15194	given	_	
78-6	15195-15200	after	_	
78-7	15201-15205	3000	_	
78-8	15206-15208	ms	_	
78-9	15208-15209	,	_	
78-10	15210-15213	the	_	
78-11	15214-15219	trial	_	
78-12	15220-15223	was	_	
78-13	15224-15225	“	_	
78-14	15225-15234	timed-out	_	
78-15	15234-15235	”	_	
78-16	15236-15239	and	_	
78-17	15240-15246	marked	_	
78-18	15247-15249	as	_	
78-19	15250-15252	an	_	
78-20	15253-15261	omission	_	
78-21	15262-15267	error	_	
78-22	15267-15268	.	_	

#Text=Imaging data were collected using a 3.0-T Siemens Magnetom TIM Trio (Erlangen, Germany) at the Magnetic Resonance Research Center at the University of Pittsburgh.
79-1	15269-15276	Imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[42]	
79-2	15277-15281	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[42]	
79-3	15282-15286	were	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[42]	
79-4	15287-15296	collected	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[42]	
79-5	15297-15302	using	_	
79-6	15303-15304	a	_	
79-7	15305-15308	3.0	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[43]	
79-8	15308-15309	-	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[43]	
79-9	15309-15310	T	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[43]	
79-10	15311-15318	Siemens	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[43]	
79-11	15319-15327	Magnetom	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[43]	
79-12	15328-15331	TIM	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[43]	
79-13	15332-15336	Trio	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[43]	
79-14	15337-15338	(	_	
79-15	15338-15346	Erlangen	_	
79-16	15346-15347	,	_	
79-17	15348-15355	Germany	_	
79-18	15355-15356	)	_	
79-19	15357-15359	at	_	
79-20	15360-15363	the	_	
79-21	15364-15372	Magnetic	_	
79-22	15373-15382	Resonance	_	
79-23	15383-15391	Research	_	
79-24	15392-15398	Center	_	
79-25	15399-15401	at	_	
79-26	15402-15405	the	_	
79-27	15406-15416	University	_	
79-28	15417-15419	of	_	
79-29	15420-15430	Pittsburgh	_	
79-30	15430-15431	.	_	

#Text=Structural images were collected using a magnetization prepared rapid acquistion gradient-echo (MP-rage) pulse sequence with a 192 slices (1 mm slice thickness; 1 mm isotropic voxels).
80-1	15432-15442	Structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[44]	
80-2	15443-15449	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[44]	
80-3	15450-15454	were	_	
80-4	15455-15464	collected	_	
80-5	15465-15470	using	_	
80-6	15471-15472	a	_	
80-7	15473-15486	magnetization	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[45]	
80-8	15487-15495	prepared	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[45]	
80-9	15496-15501	rapid	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[45]	
80-10	15502-15512	acquistion	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[45]	
80-11	15513-15526	gradient-echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[45]	
80-12	15527-15528	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[45]	
80-13	15528-15535	MP-rage	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[45]	
80-14	15535-15536	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[45]	
80-15	15537-15542	pulse	_	
80-16	15543-15551	sequence	_	
80-17	15552-15556	with	_	
80-18	15557-15558	a	_	
80-19	15559-15562	192	_	
80-20	15563-15569	slices	_	
80-21	15570-15571	(	_	
80-22	15571-15572	1	_	
80-23	15573-15575	mm	_	
80-24	15576-15581	slice	_	
80-25	15582-15591	thickness	_	
80-26	15591-15592	;	_	
80-27	15593-15594	1	_	
80-28	15595-15597	mm	_	
80-29	15598-15607	isotropic	_	
80-30	15608-15614	voxels	_	
80-31	15614-15615	)	_	
80-32	15615-15616	.	_	

#Text=Functional data were collected using an echo-planar imaging (EPI) sequence with the following parameters: TR = 2.0s,TE = 20ms, Flip Angle = 80°, and 128 × 120 acquisition matrix with a field of view of 220 mm.
81-1	15617-15627	Functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[46]	
81-2	15628-15632	data	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[46]	
81-3	15633-15637	were	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[46]	
81-4	15638-15647	collected	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[46]	
81-5	15648-15653	using	_	
81-6	15654-15656	an	_	
81-7	15657-15668	echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[47]	
81-8	15669-15676	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[47]	
81-9	15677-15678	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[47]	
81-10	15678-15681	EPI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[47]	
81-11	15681-15682	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[47]	
81-12	15683-15691	sequence	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[47]	
81-13	15692-15696	with	_	
81-14	15697-15700	the	_	
81-15	15701-15710	following	_	
81-16	15711-15721	parameters	_	
81-17	15721-15722	:	_	
81-18	15723-15725	TR	_	
81-19	15726-15727	=	_	
81-20	15728-15732	2.0s	_	
81-21	15732-15733	,	_	
81-22	15733-15735	TE	_	
81-23	15736-15737	=	_	
81-24	15738-15742	20ms	_	
81-25	15742-15743	,	_	
81-26	15744-15748	Flip	_	
81-27	15749-15754	Angle	_	
81-28	15755-15756	=	_	
81-29	15757-15759	80	_	
81-30	15759-15760	°	_	
81-31	15760-15761	,	_	
81-32	15762-15765	and	_	
81-33	15766-15769	128	_	
81-34	15770-15771	×	_	
81-35	15772-15775	120	_	
81-36	15776-15787	acquisition	_	
81-37	15788-15794	matrix	_	
81-38	15795-15799	with	_	
81-39	15800-15801	a	_	
81-40	15802-15807	field	_	
81-41	15808-15810	of	_	
81-42	15811-15815	view	_	
81-43	15816-15818	of	_	
81-44	15819-15822	220	_	
81-45	15823-15825	mm	_	
81-46	15825-15826	.	_	

#Text=Thirty-three slices were collected in the axial plane with an anisotropic voxel size of 1.72 mm × 1.72 mm × 3 mm and a .75 mm gap between slices.
82-1	15827-15839	Thirty-three	_	
82-2	15840-15846	slices	_	
82-3	15847-15851	were	_	
82-4	15852-15861	collected	_	
82-5	15862-15864	in	_	
82-6	15865-15868	the	_	
82-7	15869-15874	axial	_	
82-8	15875-15880	plane	_	
82-9	15881-15885	with	_	
82-10	15886-15888	an	_	
82-11	15889-15900	anisotropic	_	
82-12	15901-15906	voxel	_	
82-13	15907-15911	size	_	
82-14	15912-15914	of	_	
82-15	15915-15919	1.72	_	
82-16	15920-15922	mm	_	
82-17	15923-15924	×	_	
82-18	15925-15929	1.72	_	
82-19	15930-15932	mm	_	
82-20	15933-15934	×	_	
82-21	15935-15936	3	_	
82-22	15937-15939	mm	_	
82-23	15940-15943	and	_	
82-24	15944-15945	a	_	
82-25	15946-15949	.75	_	
82-26	15950-15952	mm	_	
82-27	15953-15956	gap	_	
82-28	15957-15964	between	_	
82-29	15965-15971	slices	_	
82-30	15971-15972	.	_	

#Text=Standard techniques were used to preprocess the functional data and used the same pipeline as previous work from our group (cf.,).
83-1	15973-15981	Standard	_	
83-2	15982-15992	techniques	_	
83-3	15993-15997	were	_	
83-4	15998-16002	used	_	
83-5	16003-16005	to	_	
83-6	16006-16016	preprocess	_	
83-7	16017-16020	the	_	
83-8	16021-16031	functional	_	
83-9	16032-16036	data	_	
83-10	16037-16040	and	_	
83-11	16041-16045	used	_	
83-12	16046-16049	the	_	
83-13	16050-16054	same	_	
83-14	16055-16063	pipeline	_	
83-15	16064-16066	as	_	
83-16	16067-16075	previous	_	
83-17	16076-16080	work	_	
83-18	16081-16085	from	_	
83-19	16086-16089	our	_	
83-20	16090-16095	group	_	
83-21	16096-16097	(	_	
83-22	16097-16099	cf	_	
83-23	16099-16100	.	_	
83-24	16100-16101	,	_	
83-25	16101-16102	)	_	
83-26	16102-16103	.	_	

#Text=This included wavelet despiking, slice timing correction, motion correction (mcflirt), brain extraction, non-linear registration of functional data to a standardized anatomical brain (MNI-152 template), spatial smoothing with FWHM of 4.25 mm (SUSAN), high pass filtering at 0.008 Hz, and rescaling to a 10,000 unit global median.
84-1	16104-16108	This	_	
84-2	16109-16117	included	_	
84-3	16118-16125	wavelet	_	
84-4	16126-16135	despiking	_	
84-5	16135-16136	,	_	
84-6	16137-16142	slice	_	
84-7	16143-16149	timing	_	
84-8	16150-16160	correction	_	
84-9	16160-16161	,	_	
84-10	16162-16168	motion	_	
84-11	16169-16179	correction	_	
84-12	16180-16181	(	_	
84-13	16181-16188	mcflirt	_	
84-14	16188-16189	)	_	
84-15	16189-16190	,	_	
84-16	16191-16196	brain	_	
84-17	16197-16207	extraction	_	
84-18	16207-16208	,	_	
84-19	16209-16219	non-linear	_	
84-20	16220-16232	registration	_	
84-21	16233-16235	of	_	
84-22	16236-16246	functional	_	
84-23	16247-16251	data	_	
84-24	16252-16254	to	_	
84-25	16255-16256	a	_	
84-26	16257-16269	standardized	_	
84-27	16270-16280	anatomical	_	
84-28	16281-16286	brain	_	
84-29	16287-16288	(	_	
84-30	16288-16291	MNI	_	
84-31	16291-16292	-	_	
84-32	16292-16295	152	_	
84-33	16296-16304	template	_	
84-34	16304-16305	)	_	
84-35	16305-16306	,	_	
84-36	16307-16314	spatial	_	
84-37	16315-16324	smoothing	_	
84-38	16325-16329	with	_	
84-39	16330-16334	FWHM	_	
84-40	16335-16337	of	_	
84-41	16338-16342	4.25	_	
84-42	16343-16345	mm	_	
84-43	16346-16347	(	_	
84-44	16347-16352	SUSAN	_	
84-45	16352-16353	)	_	
84-46	16353-16354	,	_	
84-47	16355-16359	high	_	
84-48	16360-16364	pass	_	
84-49	16365-16374	filtering	_	
84-50	16375-16377	at	_	
84-51	16378-16383	0.008	_	
84-52	16384-16386	Hz	_	
84-53	16386-16387	,	_	
84-54	16388-16391	and	_	
84-55	16392-16401	rescaling	_	
84-56	16402-16404	to	_	
84-57	16405-16406	a	_	
84-58	16407-16413	10,000	_	
84-59	16414-16418	unit	_	
84-60	16419-16425	global	_	
84-61	16426-16432	median	_	
84-62	16432-16433	.	_	

#Text=Statistical analysis
#Text=Selection of covariates
#Text=We tested bivariate associations between usage groups (NU, EXP, REP) and our primary variables of interest (cannabis age of onset, total cannabis use) and participant demographics and characteristics as reported in Tables 1 and 2.
85-1	16434-16445	Statistical	_	
85-2	16446-16454	analysis	_	
85-3	16455-16464	Selection	_	
85-4	16465-16467	of	_	
85-5	16468-16478	covariates	_	
85-6	16479-16481	We	_	
85-7	16482-16488	tested	_	
85-8	16489-16498	bivariate	_	
85-9	16499-16511	associations	_	
85-10	16512-16519	between	_	
85-11	16520-16525	usage	_	
85-12	16526-16532	groups	_	
85-13	16533-16534	(	_	
85-14	16534-16536	NU	_	
85-15	16536-16537	,	_	
85-16	16538-16541	EXP	_	
85-17	16541-16542	,	_	
85-18	16543-16546	REP	_	
85-19	16546-16547	)	_	
85-20	16548-16551	and	_	
85-21	16552-16555	our	_	
85-22	16556-16563	primary	_	
85-23	16564-16573	variables	_	
85-24	16574-16576	of	_	
85-25	16577-16585	interest	_	
85-26	16586-16587	(	_	
85-27	16587-16595	cannabis	_	
85-28	16596-16599	age	_	
85-29	16600-16602	of	_	
85-30	16603-16608	onset	_	
85-31	16608-16609	,	_	
85-32	16610-16615	total	_	
85-33	16616-16624	cannabis	_	
85-34	16625-16628	use	_	
85-35	16628-16629	)	_	
85-36	16630-16633	and	_	
85-37	16634-16645	participant	_	
85-38	16646-16658	demographics	_	
85-39	16659-16662	and	_	
85-40	16663-16678	characteristics	_	
85-41	16679-16681	as	_	
85-42	16682-16690	reported	_	
85-43	16691-16693	in	_	
85-44	16694-16700	Tables	_	
85-45	16701-16702	1	_	
85-46	16703-16706	and	_	
85-47	16707-16708	2	_	
85-48	16708-16709	.	_	

#Text=For associations with categorical usage groups (NU, EXP, REP), statistical testing utilized Welch’s unequal variance t-test (continuous variables), Mann-Whitney U (substance use measures), or Fisher’s exact test (categorical variables).
86-1	16710-16713	For	_	
86-2	16714-16726	associations	_	
86-3	16727-16731	with	_	
86-4	16732-16743	categorical	_	
86-5	16744-16749	usage	_	
86-6	16750-16756	groups	_	
86-7	16757-16758	(	_	
86-8	16758-16760	NU	_	
86-9	16760-16761	,	_	
86-10	16762-16765	EXP	_	
86-11	16765-16766	,	_	
86-12	16767-16770	REP	_	
86-13	16770-16771	)	_	
86-14	16771-16772	,	_	
86-15	16773-16784	statistical	_	
86-16	16785-16792	testing	_	
86-17	16793-16801	utilized	_	
86-18	16802-16807	Welch	_	
86-19	16807-16808	’	_	
86-20	16808-16809	s	_	
86-21	16810-16817	unequal	_	
86-22	16818-16826	variance	_	
86-23	16827-16833	t-test	_	
86-24	16834-16835	(	_	
86-25	16835-16845	continuous	_	
86-26	16846-16855	variables	_	
86-27	16855-16856	)	_	
86-28	16856-16857	,	_	
86-29	16858-16870	Mann-Whitney	_	
86-30	16871-16872	U	_	
86-31	16873-16874	(	_	
86-32	16874-16883	substance	_	
86-33	16884-16887	use	_	
86-34	16888-16896	measures	_	
86-35	16896-16897	)	_	
86-36	16897-16898	,	_	
86-37	16899-16901	or	_	
86-38	16902-16908	Fisher	_	
86-39	16908-16909	’	_	
86-40	16909-16910	s	_	
86-41	16911-16916	exact	_	
86-42	16917-16921	test	_	
86-43	16922-16923	(	_	
86-44	16923-16934	categorical	_	
86-45	16935-16944	variables	_	
86-46	16944-16945	)	_	
86-47	16945-16946	.	_	

#Text=For bivariate associations with continuous cannabis use measures (cannabis age of onset, total cannabis), statistical testing utilized Pearson correlation (continuous variables) and Welch’s unequal variance t-test (categorical variables).
87-1	16947-16950	For	_	
87-2	16951-16960	bivariate	_	
87-3	16961-16973	associations	_	
87-4	16974-16978	with	_	
87-5	16979-16989	continuous	_	
87-6	16990-16998	cannabis	_	
87-7	16999-17002	use	_	
87-8	17003-17011	measures	_	
87-9	17012-17013	(	_	
87-10	17013-17021	cannabis	_	
87-11	17022-17025	age	_	
87-12	17026-17028	of	_	
87-13	17029-17034	onset	_	
87-14	17034-17035	,	_	
87-15	17036-17041	total	_	
87-16	17042-17050	cannabis	_	
87-17	17050-17051	)	_	
87-18	17051-17052	,	_	
87-19	17053-17064	statistical	_	
87-20	17065-17072	testing	_	
87-21	17073-17081	utilized	_	
87-22	17082-17089	Pearson	_	
87-23	17090-17101	correlation	_	
87-24	17102-17103	(	_	
87-25	17103-17113	continuous	_	
87-26	17114-17123	variables	_	
87-27	17123-17124	)	_	
87-28	17125-17128	and	_	
87-29	17129-17134	Welch	_	
87-30	17134-17135	’	_	
87-31	17135-17136	s	_	
87-32	17137-17144	unequal	_	
87-33	17145-17153	variance	_	
87-34	17154-17160	t-test	_	
87-35	17161-17162	(	_	
87-36	17162-17173	categorical	_	
87-37	17174-17183	variables	_	
87-38	17183-17184	)	_	
87-39	17184-17185	.	_	

#Text=Any measures that had a significant or trending association (p < .10, uncorrected) to cannabis age of onset or total cannabis use and/or distinguished usage groups (Tables 1 and 2) were used as covariates in behavior and neuroimaging analysis according to the procedures outlined below.
88-1	17186-17189	Any	_	
88-2	17190-17198	measures	_	
88-3	17199-17203	that	_	
88-4	17204-17207	had	_	
88-5	17208-17209	a	_	
88-6	17210-17221	significant	_	
88-7	17222-17224	or	_	
88-8	17225-17233	trending	_	
88-9	17234-17245	association	_	
88-10	17246-17247	(	_	
88-11	17247-17248	p	_	
88-12	17249-17250	<	_	
88-13	17251-17254	.10	_	
88-14	17254-17255	,	_	
88-15	17256-17267	uncorrected	_	
88-16	17267-17268	)	_	
88-17	17269-17271	to	_	
88-18	17272-17280	cannabis	_	
88-19	17281-17284	age	_	
88-20	17285-17287	of	_	
88-21	17288-17293	onset	_	
88-22	17294-17296	or	_	
88-23	17297-17302	total	_	
88-24	17303-17311	cannabis	_	
88-25	17312-17315	use	_	
88-26	17316-17319	and	_	
88-27	17319-17320	/	_	
88-28	17320-17322	or	_	
88-29	17323-17336	distinguished	_	
88-30	17337-17342	usage	_	
88-31	17343-17349	groups	_	
88-32	17350-17351	(	_	
88-33	17351-17357	Tables	_	
88-34	17358-17359	1	_	
88-35	17360-17363	and	_	
88-36	17364-17365	2	_	
88-37	17365-17366	)	_	
88-38	17367-17371	were	_	
88-39	17372-17376	used	_	
88-40	17377-17379	as	_	
88-41	17380-17390	covariates	_	
88-42	17391-17393	in	_	
88-43	17394-17402	behavior	_	
88-44	17403-17406	and	_	
88-45	17407-17419	neuroimaging	_	
88-46	17420-17428	analysis	_	
88-47	17429-17438	according	_	
88-48	17439-17441	to	_	
88-49	17442-17445	the	_	
88-50	17446-17456	procedures	_	
88-51	17457-17465	outlined	_	
88-52	17466-17471	below	_	
88-53	17471-17472	.	_	

#Text=Based on this covariate testing procedure, for cannabis age of onset analyses, highest level of education, total cigarette use, cigarette use within the last year, other drug use, and cannabis group (EXP/REP) were used as covariates (covariate set A).
89-1	17473-17478	Based	_	
89-2	17479-17481	on	_	
89-3	17482-17486	this	_	
89-4	17487-17496	covariate	_	
89-5	17497-17504	testing	_	
89-6	17505-17514	procedure	_	
89-7	17514-17515	,	_	
89-8	17516-17519	for	_	
89-9	17520-17528	cannabis	_	
89-10	17529-17532	age	_	
89-11	17533-17535	of	_	
89-12	17536-17541	onset	_	
89-13	17542-17550	analyses	_	
89-14	17550-17551	,	_	
89-15	17552-17559	highest	_	
89-16	17560-17565	level	_	
89-17	17566-17568	of	_	
89-18	17569-17578	education	_	
89-19	17578-17579	,	_	
89-20	17580-17585	total	_	
89-21	17586-17595	cigarette	_	
89-22	17596-17599	use	_	
89-23	17599-17600	,	_	
89-24	17601-17610	cigarette	_	
89-25	17611-17614	use	_	
89-26	17615-17621	within	_	
89-27	17622-17625	the	_	
89-28	17626-17630	last	_	
89-29	17631-17635	year	_	
89-30	17635-17636	,	_	
89-31	17637-17642	other	_	
89-32	17643-17647	drug	_	
89-33	17648-17651	use	_	
89-34	17651-17652	,	_	
89-35	17653-17656	and	_	
89-36	17657-17665	cannabis	_	
89-37	17666-17671	group	_	
89-38	17672-17673	(	_	
89-39	17673-17676	EXP	_	
89-40	17676-17677	/	_	
89-41	17677-17680	REP	_	
89-42	17680-17681	)	_	
89-43	17682-17686	were	_	
89-44	17687-17691	used	_	
89-45	17692-17694	as	_	
89-46	17695-17705	covariates	_	
89-47	17706-17707	(	_	
89-48	17707-17716	covariate	_	
89-49	17717-17720	set	_	
89-50	17721-17722	A	_	
89-51	17722-17723	)	_	
89-52	17723-17724	.	_	

#Text=For total cannabis use analysis, highest level of education, family income, cannabis age of onset (see below), cannabis use within the last year, total alcohol use, total cigarette use, cigarette use within the last year, and other drug used were used as covariates (covariate set B).
90-1	17725-17728	For	_	
90-2	17729-17734	total	_	
90-3	17735-17743	cannabis	_	
90-4	17744-17747	use	_	
90-5	17748-17756	analysis	_	
90-6	17756-17757	,	_	
90-7	17758-17765	highest	_	
90-8	17766-17771	level	_	
90-9	17772-17774	of	_	
90-10	17775-17784	education	_	
90-11	17784-17785	,	_	
90-12	17786-17792	family	_	
90-13	17793-17799	income	_	
90-14	17799-17800	,	_	
90-15	17801-17809	cannabis	_	
90-16	17810-17813	age	_	
90-17	17814-17816	of	_	
90-18	17817-17822	onset	_	
90-19	17823-17824	(	_	
90-20	17824-17827	see	_	
90-21	17828-17833	below	_	
90-22	17833-17834	)	_	
90-23	17834-17835	,	_	
90-24	17836-17844	cannabis	_	
90-25	17845-17848	use	_	
90-26	17849-17855	within	_	
90-27	17856-17859	the	_	
90-28	17860-17864	last	_	
90-29	17865-17869	year	_	
90-30	17869-17870	,	_	
90-31	17871-17876	total	_	
90-32	17877-17884	alcohol	_	
90-33	17885-17888	use	_	
90-34	17888-17889	,	_	
90-35	17890-17895	total	_	
90-36	17896-17905	cigarette	_	
90-37	17906-17909	use	_	
90-38	17909-17910	,	_	
90-39	17911-17920	cigarette	_	
90-40	17921-17924	use	_	
90-41	17925-17931	within	_	
90-42	17932-17935	the	_	
90-43	17936-17940	last	_	
90-44	17941-17945	year	_	
90-45	17945-17946	,	_	
90-46	17947-17950	and	_	
90-47	17951-17956	other	_	
90-48	17957-17961	drug	_	
90-49	17962-17966	used	_	
90-50	17967-17971	were	_	
90-51	17972-17976	used	_	
90-52	17977-17979	as	_	
90-53	17980-17990	covariates	_	
90-54	17991-17992	(	_	
90-55	17992-18001	covariate	_	
90-56	18002-18005	set	_	
90-57	18006-18007	B	_	
90-58	18007-18008	)	_	
90-59	18008-18009	.	_	

#Text=One subject (cannabis age of onset = 12.33, REP) was missing highest level of education data and was therefore not included in covariate models with this measure.
91-1	18010-18013	One	_	
91-2	18014-18021	subject	_	
91-3	18022-18023	(	_	
91-4	18023-18031	cannabis	_	
91-5	18032-18035	age	_	
91-6	18036-18038	of	_	
91-7	18039-18044	onset	_	
91-8	18045-18046	=	_	
91-9	18047-18052	12.33	_	
91-10	18052-18053	,	_	
91-11	18054-18057	REP	_	
91-12	18057-18058	)	_	
91-13	18059-18062	was	_	
91-14	18063-18070	missing	_	
91-15	18071-18078	highest	_	
91-16	18079-18084	level	_	
91-17	18085-18087	of	_	
91-18	18088-18097	education	_	
91-19	18098-18102	data	_	
91-20	18103-18106	and	_	
91-21	18107-18110	was	_	
91-22	18111-18120	therefore	_	
91-23	18121-18124	not	_	
91-24	18125-18133	included	_	
91-25	18134-18136	in	_	
91-26	18137-18146	covariate	_	
91-27	18147-18153	models	_	
91-28	18154-18158	with	_	
91-29	18159-18163	this	_	
91-30	18164-18171	measure	_	
91-31	18171-18172	.	_	

#Text=See Supplemental Table 1:4 for significance of covariates in primary cannabis age of onset and total cannabis use analyses.
92-1	18173-18176	See	_	
92-2	18177-18189	Supplemental	_	
92-3	18190-18195	Table	_	
92-4	18196-18197	1	_	
92-5	18197-18198	:	_	
92-6	18198-18199	4	_	
92-7	18200-18203	for	_	
92-8	18204-18216	significance	_	
92-9	18217-18219	of	_	
92-10	18220-18230	covariates	_	
92-11	18231-18233	in	_	
92-12	18234-18241	primary	_	
92-13	18242-18250	cannabis	_	
92-14	18251-18254	age	_	
92-15	18255-18257	of	_	
92-16	18258-18263	onset	_	
92-17	18264-18267	and	_	
92-18	18268-18273	total	_	
92-19	18274-18282	cannabis	_	
92-20	18283-18286	use	_	
92-21	18287-18295	analyses	_	
92-22	18295-18296	.	_	

#Text=For comparison between usage groups (NU, EXP, REP), total alcohol use, alcohol use within the last year, total cigarette use, and cigarette use within the last year were used as covariates (covariate set C).
93-1	18297-18300	For	_	
93-2	18301-18311	comparison	_	
93-3	18312-18319	between	_	
93-4	18320-18325	usage	_	
93-5	18326-18332	groups	_	
93-6	18333-18334	(	_	
93-7	18334-18336	NU	_	
93-8	18336-18337	,	_	
93-9	18338-18341	EXP	_	
93-10	18341-18342	,	_	
93-11	18343-18346	REP	_	
93-12	18346-18347	)	_	
93-13	18347-18348	,	_	
93-14	18349-18354	total	_	
93-15	18355-18362	alcohol	_	
93-16	18363-18366	use	_	
93-17	18366-18367	,	_	
93-18	18368-18375	alcohol	_	
93-19	18376-18379	use	_	
93-20	18380-18386	within	_	
93-21	18387-18390	the	_	
93-22	18391-18395	last	_	
93-23	18396-18400	year	_	
93-24	18400-18401	,	_	
93-25	18402-18407	total	_	
93-26	18408-18417	cigarette	_	
93-27	18418-18421	use	_	
93-28	18421-18422	,	_	
93-29	18423-18426	and	_	
93-30	18427-18436	cigarette	_	
93-31	18437-18440	use	_	
93-32	18441-18447	within	_	
93-33	18448-18451	the	_	
93-34	18452-18456	last	_	
93-35	18457-18461	year	_	
93-36	18462-18466	were	_	
93-37	18467-18471	used	_	
93-38	18472-18474	as	_	
93-39	18475-18485	covariates	_	
93-40	18486-18487	(	_	
93-41	18487-18496	covariate	_	
93-42	18497-18500	set	_	
93-43	18501-18502	C	_	
93-44	18502-18503	)	_	
93-45	18503-18504	.	_	

#Text=Of note, the NU group contained a small proportion of men (2 out of 15).
94-1	18505-18507	Of	_	
94-2	18508-18512	note	_	
94-3	18512-18513	,	_	
94-4	18514-18517	the	_	
94-5	18518-18520	NU	_	
94-6	18521-18526	group	_	
94-7	18527-18536	contained	_	
94-8	18537-18538	a	_	
94-9	18539-18544	small	_	
94-10	18545-18555	proportion	_	
94-11	18556-18558	of	_	
94-12	18559-18562	men	_	
94-13	18563-18564	(	_	
94-14	18564-18565	2	_	
94-15	18566-18569	out	_	
94-16	18570-18572	of	_	
94-17	18573-18575	15	_	
94-18	18575-18576	)	_	
94-19	18576-18577	.	_	

#Text=Therefore, instead of model adjustment, secondary analyses were run including only women when comparing NU, REP, and EXP.
95-1	18578-18587	Therefore	_	
95-2	18587-18588	,	_	
95-3	18589-18596	instead	_	
95-4	18597-18599	of	_	
95-5	18600-18605	model	_	
95-6	18606-18616	adjustment	_	
95-7	18616-18617	,	_	
95-8	18618-18627	secondary	_	
95-9	18628-18636	analyses	_	
95-10	18637-18641	were	_	
95-11	18642-18645	run	_	
95-12	18646-18655	including	_	
95-13	18656-18660	only	_	
95-14	18661-18666	women	_	
95-15	18667-18671	when	_	
95-16	18672-18681	comparing	_	
95-17	18682-18684	NU	_	
95-18	18684-18685	,	_	
95-19	18686-18689	REP	_	
95-20	18689-18690	,	_	
95-21	18691-18694	and	_	
95-22	18695-18698	EXP	_	
95-23	18698-18699	.	_	

#Text=Additionally, given the MHCPD assessment of prenatal exposure, which has been associated with IQ and WM, secondary analyses were also run with prenatal cannabis, alcohol, and cigarette exposure as covariates and moderators when examining both cannabis age of onset and total cannabis use (Supplemental Fig.
96-1	18700-18712	Additionally	_	
96-2	18712-18713	,	_	
96-3	18714-18719	given	_	
96-4	18720-18723	the	_	
96-5	18724-18729	MHCPD	_	
96-6	18730-18740	assessment	_	
96-7	18741-18743	of	_	
96-8	18744-18752	prenatal	_	
96-9	18753-18761	exposure	_	
96-10	18761-18762	,	_	
96-11	18763-18768	which	_	
96-12	18769-18772	has	_	
96-13	18773-18777	been	_	
96-14	18778-18788	associated	_	
96-15	18789-18793	with	_	
96-16	18794-18796	IQ	_	
96-17	18797-18800	and	_	
96-18	18801-18803	WM	_	
96-19	18803-18804	,	_	
96-20	18805-18814	secondary	_	
96-21	18815-18823	analyses	_	
96-22	18824-18828	were	_	
96-23	18829-18833	also	_	
96-24	18834-18837	run	_	
96-25	18838-18842	with	_	
96-26	18843-18851	prenatal	_	
96-27	18852-18860	cannabis	_	
96-28	18860-18861	,	_	
96-29	18862-18869	alcohol	_	
96-30	18869-18870	,	_	
96-31	18871-18874	and	_	
96-32	18875-18884	cigarette	_	
96-33	18885-18893	exposure	_	
96-34	18894-18896	as	_	
96-35	18897-18907	covariates	_	
96-36	18908-18911	and	_	
96-37	18912-18922	moderators	_	
96-38	18923-18927	when	_	
96-39	18928-18937	examining	_	
96-40	18938-18942	both	_	
96-41	18943-18951	cannabis	_	
96-42	18952-18955	age	_	
96-43	18956-18958	of	_	
96-44	18959-18964	onset	_	
96-45	18965-18968	and	_	
96-46	18969-18974	total	_	
96-47	18975-18983	cannabis	_	
96-48	18984-18987	use	_	
96-49	18988-18989	(	_	
96-50	18989-19001	Supplemental	_	
96-51	19002-19005	Fig	_	
96-52	19005-19006	.	_	

#Text=S2).
97-1	19007-19009	S2	_	
97-2	19009-19010	)	_	
97-3	19010-19011	.	_	

#Text=Furthermore, based on the reviewed literature (cf.,) and the differences in cannabis age of onset between EXP and REP (Table 1), we performed secondary analysis examining cannabis age of onset associations in the REP group while covarying total cannabis use.
98-1	19012-19023	Furthermore	_	
98-2	19023-19024	,	_	
98-3	19025-19030	based	_	
98-4	19031-19033	on	_	
98-5	19034-19037	the	_	
98-6	19038-19046	reviewed	_	
98-7	19047-19057	literature	_	
98-8	19058-19059	(	_	
98-9	19059-19061	cf	_	
98-10	19061-19062	.	_	
98-11	19062-19063	,	_	
98-12	19063-19064	)	_	
98-13	19065-19068	and	_	
98-14	19069-19072	the	_	
98-15	19073-19084	differences	_	
98-16	19085-19087	in	_	
98-17	19088-19096	cannabis	_	
98-18	19097-19100	age	_	
98-19	19101-19103	of	_	
98-20	19104-19109	onset	_	
98-21	19110-19117	between	_	
98-22	19118-19121	EXP	_	
98-23	19122-19125	and	_	
98-24	19126-19129	REP	_	
98-25	19130-19131	(	_	
98-26	19131-19136	Table	_	
98-27	19137-19138	1	_	
98-28	19138-19139	)	_	
98-29	19139-19140	,	_	
98-30	19141-19143	we	_	
98-31	19144-19153	performed	_	
98-32	19154-19163	secondary	_	
98-33	19164-19172	analysis	_	
98-34	19173-19182	examining	_	
98-35	19183-19191	cannabis	_	
98-36	19192-19195	age	_	
98-37	19196-19198	of	_	
98-38	19199-19204	onset	_	
98-39	19205-19217	associations	_	
98-40	19218-19220	in	_	
98-41	19221-19224	the	_	
98-42	19225-19228	REP	_	
98-43	19229-19234	group	_	
98-44	19235-19240	while	_	
98-45	19241-19250	covarying	_	
98-46	19251-19256	total	_	
98-47	19257-19265	cannabis	_	
98-48	19266-19269	use	_	
98-49	19269-19270	.	_	

#Text=Finally, one subject (cannabis age of onset =13.75, REP) reported use of a drug other than cannabis, alcohol, or cigarettes during the year prior to testing (recreational use of opioid pain medication).
99-1	19271-19278	Finally	_	
99-2	19278-19279	,	_	
99-3	19280-19283	one	_	
99-4	19284-19291	subject	_	
99-5	19292-19293	(	_	
99-6	19293-19301	cannabis	_	
99-7	19302-19305	age	_	
99-8	19306-19308	of	_	
99-9	19309-19314	onset	_	
99-10	19315-19316	=	_	
99-11	19316-19321	13.75	_	
99-12	19321-19322	,	_	
99-13	19323-19326	REP	_	
99-14	19326-19327	)	_	
99-15	19328-19336	reported	_	
99-16	19337-19340	use	_	
99-17	19341-19343	of	_	
99-18	19344-19345	a	_	
99-19	19346-19350	drug	_	
99-20	19351-19356	other	_	
99-21	19357-19361	than	_	
99-22	19362-19370	cannabis	_	
99-23	19370-19371	,	_	
99-24	19372-19379	alcohol	_	
99-25	19379-19380	,	_	
99-26	19381-19383	or	_	
99-27	19384-19394	cigarettes	_	
99-28	19395-19401	during	_	
99-29	19402-19405	the	_	
99-30	19406-19410	year	_	
99-31	19411-19416	prior	_	
99-32	19417-19419	to	_	
99-33	19420-19427	testing	_	
99-34	19428-19429	(	_	
99-35	19429-19441	recreational	_	
99-36	19442-19445	use	_	
99-37	19446-19448	of	_	
99-38	19449-19455	opioid	_	
99-39	19456-19460	pain	_	
99-40	19461-19471	medication	_	
99-41	19471-19472	)	_	
99-42	19472-19473	.	_	

#Text=The pattern of significant results was unchanged when excluding this subject.
100-1	19474-19477	The	_	
100-2	19478-19485	pattern	_	
100-3	19486-19488	of	_	
100-4	19489-19500	significant	_	
100-5	19501-19508	results	_	
100-6	19509-19512	was	_	
100-7	19513-19522	unchanged	_	
100-8	19523-19527	when	_	
100-9	19528-19537	excluding	_	
100-10	19538-19542	this	_	
100-11	19543-19550	subject	_	
100-12	19550-19551	.	_	

#Text=WM behavior
#Text=Primary behavioral analysis was performed in R 3.1.2.
101-1	19552-19554	WM	_	
101-2	19555-19563	behavior	_	
101-3	19564-19571	Primary	_	
101-4	19572-19582	behavioral	_	
101-5	19583-19591	analysis	_	
101-6	19592-19595	was	_	
101-7	19596-19605	performed	_	
101-8	19606-19608	in	_	
101-9	19609-19610	R	_	
101-10	19611-19616	3.1.2	_	
101-11	19616-19617	.	_	

#Text=Mixed-effects models (lme4 package) were used to examine main effects and interactions between task conditions and categorical (NU, EXP, REP) and continuous (age of onset, total cannabis use) cannabis measures.
102-1	19618-19631	Mixed-effects	_	
102-2	19632-19638	models	_	
102-3	19639-19640	(	_	
102-4	19640-19644	lme4	_	
102-5	19645-19652	package	_	
102-6	19652-19653	)	_	
102-7	19654-19658	were	_	
102-8	19659-19663	used	_	
102-9	19664-19666	to	_	
102-10	19667-19674	examine	_	
102-11	19675-19679	main	_	
102-12	19680-19687	effects	_	
102-13	19688-19691	and	_	
102-14	19692-19704	interactions	_	
102-15	19705-19712	between	_	
102-16	19713-19717	task	_	
102-17	19718-19728	conditions	_	
102-18	19729-19732	and	_	
102-19	19733-19744	categorical	_	
102-20	19745-19746	(	_	
102-21	19746-19748	NU	_	
102-22	19748-19749	,	_	
102-23	19750-19753	EXP	_	
102-24	19753-19754	,	_	
102-25	19755-19758	REP	_	
102-26	19758-19759	)	_	
102-27	19760-19763	and	_	
102-28	19764-19774	continuous	_	
102-29	19775-19776	(	_	
102-30	19776-19779	age	_	
102-31	19780-19782	of	_	
102-32	19783-19788	onset	_	
102-33	19788-19789	,	_	
102-34	19790-19795	total	_	
102-35	19796-19804	cannabis	_	
102-36	19805-19808	use	_	
102-37	19808-19809	)	_	
102-38	19810-19818	cannabis	_	
102-39	19819-19827	measures	_	
102-40	19827-19828	.	_	

#Text=Accuracy data were analyzed using a generalized-linear mixed-effects model with a logit link function since trial level data were binomially distributed (correct vs. incorrect).
103-1	19829-19837	Accuracy	_	
103-2	19838-19842	data	_	
103-3	19843-19847	were	_	
103-4	19848-19856	analyzed	_	
103-5	19857-19862	using	_	
103-6	19863-19864	a	_	
103-7	19865-19883	generalized-linear	_	
103-8	19884-19897	mixed-effects	_	
103-9	19898-19903	model	_	
103-10	19904-19908	with	_	
103-11	19909-19910	a	_	
103-12	19911-19916	logit	_	
103-13	19917-19921	link	_	
103-14	19922-19930	function	_	
103-15	19931-19936	since	_	
103-16	19937-19942	trial	_	
103-17	19943-19948	level	_	
103-18	19949-19953	data	_	
103-19	19954-19958	were	_	
103-20	19959-19969	binomially	_	
103-21	19970-19981	distributed	_	
103-22	19982-19983	(	_	
103-23	19983-19990	correct	_	
103-24	19991-19993	vs	_	
103-25	19993-19994	.	_	
103-26	19995-20004	incorrect	_	
103-27	20004-20005	)	_	
103-28	20005-20006	.	_	

#Text=Trials with omission errors (4.02% of all trials) were excluded from the accuracy analysis, where omissions were not counted toward the trial count (see Supplemental Tables 5 and 6 for omission error analysis).
104-1	20007-20013	Trials	_	
104-2	20014-20018	with	_	
104-3	20019-20027	omission	_	
104-4	20028-20034	errors	_	
104-5	20035-20036	(	_	
104-6	20036-20041	4.02%	_	
104-7	20042-20044	of	_	
104-8	20045-20048	all	_	
104-9	20049-20055	trials	_	
104-10	20055-20056	)	_	
104-11	20057-20061	were	_	
104-12	20062-20070	excluded	_	
104-13	20071-20075	from	_	
104-14	20076-20079	the	_	
104-15	20080-20088	accuracy	_	
104-16	20089-20097	analysis	_	
104-17	20097-20098	,	_	
104-18	20099-20104	where	_	
104-19	20105-20114	omissions	_	
104-20	20115-20119	were	_	
104-21	20120-20123	not	_	
104-22	20124-20131	counted	_	
104-23	20132-20138	toward	_	
104-24	20139-20142	the	_	
104-25	20143-20148	trial	_	
104-26	20149-20154	count	_	
104-27	20155-20156	(	_	
104-28	20156-20159	see	_	
104-29	20160-20172	Supplemental	_	
104-30	20173-20179	Tables	_	
104-31	20180-20181	5	_	
104-32	20182-20185	and	_	
104-33	20186-20187	6	_	
104-34	20188-20191	for	_	
104-35	20192-20200	omission	_	
104-36	20201-20206	error	_	
104-37	20207-20215	analysis	_	
104-38	20215-20216	)	_	
104-39	20216-20217	.	_	

#Text=Reaction time data were log transformed to reduce heteroscedasticity of residuals and analyzed using a linear mixed-effects model including only correct trials.
105-1	20218-20226	Reaction	_	
105-2	20227-20231	time	_	
105-3	20232-20236	data	_	
105-4	20237-20241	were	_	
105-5	20242-20245	log	_	
105-6	20246-20257	transformed	_	
105-7	20258-20260	to	_	
105-8	20261-20267	reduce	_	
105-9	20268-20286	heteroscedasticity	_	
105-10	20287-20289	of	_	
105-11	20290-20299	residuals	_	
105-12	20300-20303	and	_	
105-13	20304-20312	analyzed	_	
105-14	20313-20318	using	_	
105-15	20319-20320	a	_	
105-16	20321-20327	linear	_	
105-17	20328-20341	mixed-effects	_	
105-18	20342-20347	model	_	
105-19	20348-20357	including	_	
105-20	20358-20362	only	_	
105-21	20363-20370	correct	_	
105-22	20371-20377	trials	_	
105-23	20377-20378	.	_	

#Text=Both linear- and generalized-linear mixed-effects models were estimated with maximum likelihood.
106-1	20379-20383	Both	_	
106-2	20384-20390	linear	_	
106-3	20390-20391	-	_	
106-4	20392-20395	and	_	
106-5	20396-20414	generalized-linear	_	
106-6	20415-20428	mixed-effects	_	
106-7	20429-20435	models	_	
106-8	20436-20440	were	_	
106-9	20441-20450	estimated	_	
106-10	20451-20455	with	_	
106-11	20456-20463	maximum	_	
106-12	20464-20474	likelihood	_	
106-13	20474-20475	.	_	

#Text=Random intercepts were estimated for each subject.
107-1	20476-20482	Random	_	
107-2	20483-20493	intercepts	_	
107-3	20494-20498	were	_	
107-4	20499-20508	estimated	_	
107-5	20509-20512	for	_	
107-6	20513-20517	each	_	
107-7	20518-20525	subject	_	
107-8	20525-20526	.	_	

#Text=Task conditions (load, delay length, cue validity), cannabis measures, and covariates were included as fixed effects in two phases: a baseline model, with only the task conditions and cannabis measure in question, and a full model with all potential confounding variables as covariates (see Tables 1 and 2).
108-1	20527-20531	Task	_	
108-2	20532-20542	conditions	_	
108-3	20543-20544	(	_	
108-4	20544-20548	load	_	
108-5	20548-20549	,	_	
108-6	20550-20555	delay	_	
108-7	20556-20562	length	_	
108-8	20562-20563	,	_	
108-9	20564-20567	cue	_	
108-10	20568-20576	validity	_	
108-11	20576-20577	)	_	
108-12	20577-20578	,	_	
108-13	20579-20587	cannabis	_	
108-14	20588-20596	measures	_	
108-15	20596-20597	,	_	
108-16	20598-20601	and	_	
108-17	20602-20612	covariates	_	
108-18	20613-20617	were	_	
108-19	20618-20626	included	_	
108-20	20627-20629	as	_	
108-21	20630-20635	fixed	_	
108-22	20636-20643	effects	_	
108-23	20644-20646	in	_	
108-24	20647-20650	two	_	
108-25	20651-20657	phases	_	
108-26	20657-20658	:	_	
108-27	20659-20660	a	_	
108-28	20661-20669	baseline	_	
108-29	20670-20675	model	_	
108-30	20675-20676	,	_	
108-31	20677-20681	with	_	
108-32	20682-20686	only	_	
108-33	20687-20690	the	_	
108-34	20691-20695	task	_	
108-35	20696-20706	conditions	_	
108-36	20707-20710	and	_	
108-37	20711-20719	cannabis	_	
108-38	20720-20727	measure	_	
108-39	20728-20730	in	_	
108-40	20731-20739	question	_	
108-41	20739-20740	,	_	
108-42	20741-20744	and	_	
108-43	20745-20746	a	_	
108-44	20747-20751	full	_	
108-45	20752-20757	model	_	
108-46	20758-20762	with	_	
108-47	20763-20766	all	_	
108-48	20767-20776	potential	_	
108-49	20777-20788	confounding	_	
108-50	20789-20798	variables	_	
108-51	20799-20801	as	_	
108-52	20802-20812	covariates	_	
108-53	20813-20814	(	_	
108-54	20814-20817	see	_	
108-55	20818-20824	Tables	_	
108-56	20825-20826	1	_	
108-57	20827-20830	and	_	
108-58	20831-20832	2	_	
108-59	20832-20833	)	_	
108-60	20833-20834	.	_	

#Text=Significance values for fixed effects were obtained through the car package (chi-square test).
109-1	20835-20847	Significance	_	
109-2	20848-20854	values	_	
109-3	20855-20858	for	_	
109-4	20859-20864	fixed	_	
109-5	20865-20872	effects	_	
109-6	20873-20877	were	_	
109-7	20878-20886	obtained	_	
109-8	20887-20894	through	_	
109-9	20895-20898	the	_	
109-10	20899-20902	car	_	
109-11	20903-20910	package	_	
109-12	20911-20912	(	_	
109-13	20912-20922	chi-square	_	
109-14	20923-20927	test	_	
109-15	20927-20928	)	_	
109-16	20928-20929	.	_	

#Text=Simple effects were obtained through the lsmeans package.
110-1	20930-20936	Simple	_	
110-2	20937-20944	effects	_	
110-3	20945-20949	were	_	
110-4	20950-20958	obtained	_	
110-5	20959-20966	through	_	
110-6	20967-20970	the	_	
110-7	20971-20978	lsmeans	_	
110-8	20979-20986	package	_	
110-9	20986-20987	.	_	

#Text=Potential influential observations were examined using Cook’s distance and dfbetas (both cutoffs > 1) on mean performance measures.
111-1	20988-20997	Potential	_	
111-2	20998-21009	influential	_	
111-3	21010-21022	observations	_	
111-4	21023-21027	were	_	
111-5	21028-21036	examined	_	
111-6	21037-21042	using	_	
111-7	21043-21047	Cook	_	
111-8	21047-21048	’	_	
111-9	21048-21049	s	_	
111-10	21050-21058	distance	_	
111-11	21059-21062	and	_	
111-12	21063-21070	dfbetas	_	
111-13	21071-21072	(	_	
111-14	21072-21076	both	_	
111-15	21077-21084	cutoffs	_	
111-16	21085-21086	>	_	
111-17	21087-21088	1	_	
111-18	21088-21089	)	_	
111-19	21090-21092	on	_	
111-20	21093-21097	mean	_	
111-21	21098-21109	performance	_	
111-22	21110-21118	measures	_	
111-23	21118-21119	.	_	

#Text=No subjects exceeded these thresholds.
112-1	21120-21122	No	_	
112-2	21123-21131	subjects	_	
112-3	21132-21140	exceeded	_	
112-4	21141-21146	these	_	
112-5	21147-21157	thresholds	_	
112-6	21157-21158	.	_	

#Text=WMfMRI
#Text=All imaging analysis was performed with Analysis and Visualization of Functional Neuroimages (AFNI, Bethesda, MD) software.
113-1	21159-21165	WMfMRI	_	
113-2	21166-21169	All	_	
113-3	21170-21177	imaging	_	
113-4	21178-21186	analysis	_	
113-5	21187-21190	was	_	
113-6	21191-21200	performed	_	
113-7	21201-21205	with	_	
113-8	21206-21214	Analysis	_	
113-9	21215-21218	and	_	
113-10	21219-21232	Visualization	_	
113-11	21233-21235	of	_	
113-12	21236-21246	Functional	_	
113-13	21247-21258	Neuroimages	_	
113-14	21259-21260	(	_	
113-15	21260-21264	AFNI	_	
113-16	21264-21265	,	_	
113-17	21266-21274	Bethesda	_	
113-18	21274-21275	,	_	
113-19	21276-21278	MD	_	
113-20	21278-21279	)	_	
113-21	21280-21288	software	_	
113-22	21288-21289	.	_	

#Text=In order to estimate the BOLD response at both the trial- and WM epoch-level (cue, delay, target), two level-1 GLM analyses were run for every subject using AFNI’s 3dDeconvolve tool.
114-1	21290-21292	In	_	
114-2	21293-21298	order	_	
114-3	21299-21301	to	_	
114-4	21302-21310	estimate	_	
114-5	21311-21314	the	_	
114-6	21315-21319	BOLD	_	
114-7	21320-21328	response	_	
114-8	21329-21331	at	_	
114-9	21332-21336	both	_	
114-10	21337-21340	the	_	
114-11	21341-21346	trial	_	
114-12	21346-21347	-	_	
114-13	21348-21351	and	_	
114-14	21352-21354	WM	_	
114-15	21355-21366	epoch-level	_	
114-16	21367-21368	(	_	
114-17	21368-21371	cue	_	
114-18	21371-21372	,	_	
114-19	21373-21378	delay	_	
114-20	21378-21379	,	_	
114-21	21380-21386	target	_	
114-22	21386-21387	)	_	
114-23	21387-21388	,	_	
114-24	21389-21392	two	_	
114-25	21393-21398	level	_	
114-26	21398-21399	-	_	
114-27	21399-21400	1	_	
114-28	21401-21404	GLM	_	
114-29	21405-21413	analyses	_	
114-30	21414-21418	were	_	
114-31	21419-21422	run	_	
114-32	21423-21426	for	_	
114-33	21427-21432	every	_	
114-34	21433-21440	subject	_	
114-35	21441-21446	using	_	
114-36	21447-21451	AFNI	_	
114-37	21451-21452	’	_	
114-38	21452-21453	s	_	
114-39	21454-21466	3dDeconvolve	_	
114-40	21467-21471	tool	_	
114-41	21471-21472	.	_	

#Text=GLM-1.
115-1	21473-21476	GLM	_	
115-2	21476-21477	-	_	
115-3	21477-21478	1	_	
115-4	21478-21479	.	_	

#Text=To estimate the average HRF response to the task, trial time courses for correct, incorrect, and partial trials were modeled using TENT basis functions spanning 28 s with 15 time steps.
116-1	21480-21482	To	_	
116-2	21483-21491	estimate	_	
116-3	21492-21495	the	_	
116-4	21496-21503	average	_	
116-5	21504-21507	HRF	_	
116-6	21508-21516	response	_	
116-7	21517-21519	to	_	
116-8	21520-21523	the	_	
116-9	21524-21528	task	_	
116-10	21528-21529	,	_	
116-11	21530-21535	trial	_	
116-12	21536-21540	time	_	
116-13	21541-21548	courses	_	
116-14	21549-21552	for	_	
116-15	21553-21560	correct	_	
116-16	21560-21561	,	_	
116-17	21562-21571	incorrect	_	
116-18	21571-21572	,	_	
116-19	21573-21576	and	_	
116-20	21577-21584	partial	_	
116-21	21585-21591	trials	_	
116-22	21592-21596	were	_	
116-23	21597-21604	modeled	_	
116-24	21605-21610	using	_	
116-25	21611-21615	TENT	_	
116-26	21616-21621	basis	_	
116-27	21622-21631	functions	_	
116-28	21632-21640	spanning	_	
116-29	21641-21643	28	_	
116-30	21644-21645	s	_	
116-31	21646-21650	with	_	
116-32	21651-21653	15	_	
116-33	21654-21658	time	_	
116-34	21659-21664	steps	_	
116-35	21664-21665	.	_	

#Text=Due to the temporal properties of the HRF, conditions with different durations were modeled separately (1500 ms and 6000 ms delay trials).
117-1	21666-21669	Due	_	
117-2	21670-21672	to	_	
117-3	21673-21676	the	_	
117-4	21677-21685	temporal	_	
117-5	21686-21696	properties	_	
117-6	21697-21699	of	_	
117-7	21700-21703	the	_	
117-8	21704-21707	HRF	_	
117-9	21707-21708	,	_	
117-10	21709-21719	conditions	_	
117-11	21720-21724	with	_	
117-12	21725-21734	different	_	
117-13	21735-21744	durations	_	
117-14	21745-21749	were	_	
117-15	21750-21757	modeled	_	
117-16	21758-21768	separately	_	
117-17	21769-21770	(	_	
117-18	21770-21774	1500	_	
117-19	21775-21777	ms	_	
117-20	21778-21781	and	_	
117-21	21782-21786	6000	_	
117-22	21787-21789	ms	_	
117-23	21790-21795	delay	_	
117-24	21796-21802	trials	_	
117-25	21802-21803	)	_	
117-26	21803-21804	.	_	

#Text=Six rigid-body head motion parameters and their derivatives, as well as run-wise 0 through 3rd order polynomials, were used as nuisance regressors.
118-1	21805-21808	Six	_	
118-2	21809-21819	rigid-body	_	
118-3	21820-21824	head	_	
118-4	21825-21831	motion	_	
118-5	21832-21842	parameters	_	
118-6	21843-21846	and	_	
118-7	21847-21852	their	_	
118-8	21853-21864	derivatives	_	
118-9	21864-21865	,	_	
118-10	21866-21868	as	_	
118-11	21869-21873	well	_	
118-12	21874-21876	as	_	
118-13	21877-21885	run-wise	_	
118-14	21886-21887	0	_	
118-15	21888-21895	through	_	
118-16	21896-21899	3rd	_	
118-17	21900-21905	order	_	
118-18	21906-21917	polynomials	_	
118-19	21917-21918	,	_	
118-20	21919-21923	were	_	
118-21	21924-21928	used	_	
118-22	21929-21931	as	_	
118-23	21932-21940	nuisance	_	
118-24	21941-21951	regressors	_	
118-25	21951-21952	.	_	

#Text=The current and preceding TR were censored if the Euclidean norm head motion distance surpassed 0.9 mm.
119-1	21953-21956	The	_	
119-2	21957-21964	current	_	
119-3	21965-21968	and	_	
119-4	21969-21978	preceding	_	
119-5	21979-21981	TR	_	
119-6	21982-21986	were	_	
119-7	21987-21995	censored	_	
119-8	21996-21998	if	_	
119-9	21999-22002	the	_	
119-10	22003-22012	Euclidean	_	
119-11	22013-22017	norm	_	
119-12	22018-22022	head	_	
119-13	22023-22029	motion	_	
119-14	22030-22038	distance	_	
119-15	22039-22048	surpassed	_	
119-16	22049-22052	0.9	_	
119-17	22053-22055	mm	_	
119-18	22055-22056	.	_	

#Text=This choice of censoring threshold was guided by work examining motion outliers in task-based fMRI.
120-1	22057-22061	This	_	
120-2	22062-22068	choice	_	
120-3	22069-22071	of	_	
120-4	22072-22081	censoring	_	
120-5	22082-22091	threshold	_	
120-6	22092-22095	was	_	
120-7	22096-22102	guided	_	
120-8	22103-22105	by	_	
120-9	22106-22110	work	_	
120-10	22111-22120	examining	_	
120-11	22121-22127	motion	_	
120-12	22128-22136	outliers	_	
120-13	22137-22139	in	_	
120-14	22140-22150	task-based	_	
120-15	22151-22155	fMRI	_	
120-16	22155-22156	.	_	

#Text=GLM-2.
121-1	22157-22160	GLM	_	
121-2	22160-22161	-	_	
121-3	22161-22162	2	_	
121-4	22162-22163	.	_	

#Text=To estimate the HRF to individual epochs of the task, a second model was run with individual regressors for cue, delay, and target epochs.
122-1	22164-22166	To	_	
122-2	22167-22175	estimate	_	
122-3	22176-22179	the	_	
122-4	22180-22183	HRF	_	
122-5	22184-22186	to	_	
122-6	22187-22197	individual	_	
122-7	22198-22204	epochs	_	
122-8	22205-22207	of	_	
122-9	22208-22211	the	_	
122-10	22212-22216	task	_	
122-11	22216-22217	,	_	
122-12	22218-22219	a	_	
122-13	22220-22226	second	_	
122-14	22227-22232	model	_	
122-15	22233-22236	was	_	
122-16	22237-22240	run	_	
122-17	22241-22245	with	_	
122-18	22246-22256	individual	_	
122-19	22257-22267	regressors	_	
122-20	22268-22271	for	_	
122-21	22272-22275	cue	_	
122-22	22275-22276	,	_	
122-23	22277-22282	delay	_	
122-24	22282-22283	,	_	
122-25	22284-22287	and	_	
122-26	22288-22294	target	_	
122-27	22295-22301	epochs	_	
122-28	22301-22302	.	_	

#Text=Relevant partial trials were included as examples of the epoch in question to aid in epoch-specific HRF estimation.
123-1	22303-22311	Relevant	_	
123-2	22312-22319	partial	_	
123-3	22320-22326	trials	_	
123-4	22327-22331	were	_	
123-5	22332-22340	included	_	
123-6	22341-22343	as	_	
123-7	22344-22352	examples	_	
123-8	22353-22355	of	_	
123-9	22356-22359	the	_	
123-10	22360-22365	epoch	_	
123-11	22366-22368	in	_	
123-12	22369-22377	question	_	
123-13	22378-22380	to	_	
123-14	22381-22384	aid	_	
123-15	22385-22387	in	_	
123-16	22388-22402	epoch-specific	_	
123-17	22403-22406	HRF	_	
123-18	22407-22417	estimation	_	
123-19	22417-22418	.	_	

#Text=Cue epochs were modeled with a 1500 ms boxcar convolved with a gamma function (AFNI’s block 4) and scaled to have an amplitude of 1.
124-1	22419-22422	Cue	_	
124-2	22423-22429	epochs	_	
124-3	22430-22434	were	_	
124-4	22435-22442	modeled	_	
124-5	22443-22447	with	_	
124-6	22448-22449	a	_	
124-7	22450-22454	1500	_	
124-8	22455-22457	ms	_	
124-9	22458-22464	boxcar	_	
124-10	22465-22474	convolved	_	
124-11	22475-22479	with	_	
124-12	22480-22481	a	_	
124-13	22482-22487	gamma	_	
124-14	22488-22496	function	_	
124-15	22497-22498	(	_	
124-16	22498-22502	AFNI	_	
124-17	22502-22503	’	_	
124-18	22503-22504	s	_	
124-19	22505-22510	block	_	
124-20	22511-22512	4	_	
124-21	22512-22513	)	_	
124-22	22514-22517	and	_	
124-23	22518-22524	scaled	_	
124-24	22525-22527	to	_	
124-25	22528-22532	have	_	
124-26	22533-22535	an	_	
124-27	22536-22545	amplitude	_	
124-28	22546-22548	of	_	
124-29	22549-22550	1	_	
124-30	22550-22551	.	_	

#Text=Delay epochs were modeled with a single regressor composed of a 1500 ms (short delay trials) or 6000 ms (long delay trials) boxcar convolved with a gamma function.
125-1	22552-22557	Delay	_	
125-2	22558-22564	epochs	_	
125-3	22565-22569	were	_	
125-4	22570-22577	modeled	_	
125-5	22578-22582	with	_	
125-6	22583-22584	a	_	
125-7	22585-22591	single	_	
125-8	22592-22601	regressor	_	
125-9	22602-22610	composed	_	
125-10	22611-22613	of	_	
125-11	22614-22615	a	_	
125-12	22616-22620	1500	_	
125-13	22621-22623	ms	_	
125-14	22624-22625	(	_	
125-15	22625-22630	short	_	
125-16	22631-22636	delay	_	
125-17	22637-22643	trials	_	
125-18	22643-22644	)	_	
125-19	22645-22647	or	_	
125-20	22648-22652	6000	_	
125-21	22653-22655	ms	_	
125-22	22656-22657	(	_	
125-23	22657-22661	long	_	
125-24	22662-22667	delay	_	
125-25	22668-22674	trials	_	
125-26	22674-22675	)	_	
125-27	22676-22682	boxcar	_	
125-28	22683-22692	convolved	_	
125-29	22693-22697	with	_	
125-30	22698-22699	a	_	
125-31	22700-22705	gamma	_	
125-32	22706-22714	function	_	
125-33	22714-22715	.	_	

#Text=Target epochs were modeled using constant and parametric terms, each convolved with a gamma function.
126-1	22716-22722	Target	_	
126-2	22723-22729	epochs	_	
126-3	22730-22734	were	_	
126-4	22735-22742	modeled	_	
126-5	22743-22748	using	_	
126-6	22749-22757	constant	_	
126-7	22758-22761	and	_	
126-8	22762-22772	parametric	_	
126-9	22773-22778	terms	_	
126-10	22778-22779	,	_	
126-11	22780-22784	each	_	
126-12	22785-22794	convolved	_	
126-13	22795-22799	with	_	
126-14	22800-22801	a	_	
126-15	22802-22807	gamma	_	
126-16	22808-22816	function	_	
126-17	22816-22817	.	_	

#Text=For each trial, reaction time determined the width of the constant term and the height of the parametric term.
127-1	22818-22821	For	_	
127-2	22822-22826	each	_	
127-3	22827-22832	trial	_	
127-4	22832-22833	,	_	
127-5	22834-22842	reaction	_	
127-6	22843-22847	time	_	
127-7	22848-22858	determined	_	
127-8	22859-22862	the	_	
127-9	22863-22868	width	_	
127-10	22869-22871	of	_	
127-11	22872-22875	the	_	
127-12	22876-22884	constant	_	
127-13	22885-22889	term	_	
127-14	22890-22893	and	_	
127-15	22894-22897	the	_	
127-16	22898-22904	height	_	
127-17	22905-22907	of	_	
127-18	22908-22911	the	_	
127-19	22912-22922	parametric	_	
127-20	22923-22927	term	_	
127-21	22927-22928	.	_	

#Text=The constant term was scaled to have an amplitude of 1.
128-1	22929-22932	The	_	
128-2	22933-22941	constant	_	
128-3	22942-22946	term	_	
128-4	22947-22950	was	_	
128-5	22951-22957	scaled	_	
128-6	22958-22960	to	_	
128-7	22961-22965	have	_	
128-8	22966-22968	an	_	
128-9	22969-22978	amplitude	_	
128-10	22979-22981	of	_	
128-11	22982-22983	1	_	
128-12	22983-22984	.	_	

#Text=The same nuisance regressors and motion censoring were used as in GLM-1.
129-1	22985-22988	The	_	
129-2	22989-22993	same	_	
129-3	22994-23002	nuisance	_	
129-4	23003-23013	regressors	_	
129-5	23014-23017	and	_	
129-6	23018-23024	motion	_	
129-7	23025-23034	censoring	_	
129-8	23035-23039	were	_	
129-9	23040-23044	used	_	
129-10	23045-23047	as	_	
129-11	23048-23050	in	_	
129-12	23051-23054	GLM	_	
129-13	23054-23055	-	_	
129-14	23055-23056	1	_	
129-15	23056-23057	.	_	

#Text=Comparison of a reconstructed time series from GLM-2 and the observed time series of GLM-1 (Supplemental Fig.
130-1	23058-23068	Comparison	_	
130-2	23069-23071	of	_	
130-3	23072-23073	a	_	
130-4	23074-23087	reconstructed	_	
130-5	23088-23092	time	_	
130-6	23093-23099	series	_	
130-7	23100-23104	from	_	
130-8	23105-23108	GLM	_	
130-9	23108-23109	-	_	
130-10	23109-23110	2	_	
130-11	23111-23114	and	_	
130-12	23115-23118	the	_	
130-13	23119-23127	observed	_	
130-14	23128-23132	time	_	
130-15	23133-23139	series	_	
130-16	23140-23142	of	_	
130-17	23143-23146	GLM	_	
130-18	23146-23147	-	_	
130-19	23147-23148	1	_	
130-20	23149-23150	(	_	
130-21	23150-23162	Supplemental	_	
130-22	23163-23166	Fig	_	
130-23	23166-23167	.	_	

#Text=S3) suggested the epoch-based analysis of GLM-2 adequately captured primary amplitude components of the piecewise time series in GLM-1.
131-1	23168-23170	S3	_	
131-2	23170-23171	)	_	
131-3	23172-23181	suggested	_	
131-4	23182-23185	the	_	
131-5	23186-23197	epoch-based	_	
131-6	23198-23206	analysis	_	
131-7	23207-23209	of	_	
131-8	23210-23213	GLM	_	
131-9	23213-23214	-	_	
131-10	23214-23215	2	_	
131-11	23216-23226	adequately	_	
131-12	23227-23235	captured	_	
131-13	23236-23243	primary	_	
131-14	23244-23253	amplitude	_	
131-15	23254-23264	components	_	
131-16	23265-23267	of	_	
131-17	23268-23271	the	_	
131-18	23272-23281	piecewise	_	
131-19	23282-23286	time	_	
131-20	23287-23293	series	_	
131-21	23294-23296	in	_	
131-22	23297-23300	GLM	_	
131-23	23300-23301	-	_	
131-24	23301-23302	1	_	
131-25	23302-23303	.	_	

#Text=Voxelwise testing.
132-1	23304-23313	Voxelwise	_	
132-2	23314-23321	testing	_	
132-3	23321-23322	.	_	

#Text=In order to detect potential subtle differences in the shape of the HRF as a function of cannabis measures, omnibus group effects were examined on correct trial time courses (GLM −1), entered into a voxel-wise multivariate model (3dMVM).
133-1	23323-23325	In	_	
133-2	23326-23331	order	_	
133-3	23332-23334	to	_	
133-4	23335-23341	detect	_	
133-5	23342-23351	potential	_	
133-6	23352-23358	subtle	_	
133-7	23359-23370	differences	_	
133-8	23371-23373	in	_	
133-9	23374-23377	the	_	
133-10	23378-23383	shape	_	
133-11	23384-23386	of	_	
133-12	23387-23390	the	_	
133-13	23391-23394	HRF	_	
133-14	23395-23397	as	_	
133-15	23398-23399	a	_	
133-16	23400-23408	function	_	
133-17	23409-23411	of	_	
133-18	23412-23420	cannabis	_	
133-19	23421-23429	measures	_	
133-20	23429-23430	,	_	
133-21	23431-23438	omnibus	_	
133-22	23439-23444	group	_	
133-23	23445-23452	effects	_	
133-24	23453-23457	were	_	
133-25	23458-23466	examined	_	
133-26	23467-23469	on	_	
133-27	23470-23477	correct	_	
133-28	23478-23483	trial	_	
133-29	23484-23488	time	_	
133-30	23489-23496	courses	_	
133-31	23497-23498	(	_	
133-32	23498-23501	GLM	_	
133-33	23502-23503	−	_	
133-34	23503-23504	1	_	
133-35	23504-23505	)	_	
133-36	23505-23506	,	_	
133-37	23507-23514	entered	_	
133-38	23515-23519	into	_	
133-39	23520-23521	a	_	
133-40	23522-23532	voxel-wise	_	
133-41	23533-23545	multivariate	_	
133-42	23546-23551	model	_	
133-43	23552-23553	(	_	
133-44	23553-23558	3dMVM	_	
133-45	23558-23559	)	_	
133-46	23559-23560	.	_	

#Text=TR (15 time points) and condition (1500 ms/6000 ms delay trials) were entered as within-subject effects and cannabis measures (age of onset or total use) were entered as between-subject effects.
134-1	23561-23563	TR	_	
134-2	23564-23565	(	_	
134-3	23565-23567	15	_	
134-4	23568-23572	time	_	
134-5	23573-23579	points	_	
134-6	23579-23580	)	_	
134-7	23581-23584	and	_	
134-8	23585-23594	condition	_	
134-9	23595-23596	(	_	
134-10	23596-23600	1500	_	
134-11	23601-23603	ms	_	
134-12	23603-23604	/	_	
134-13	23604-23608	6000	_	
134-14	23609-23611	ms	_	
134-15	23612-23617	delay	_	
134-16	23618-23624	trials	_	
134-17	23624-23625	)	_	
134-18	23626-23630	were	_	
134-19	23631-23638	entered	_	
134-20	23639-23641	as	_	
134-21	23642-23656	within-subject	_	
134-22	23657-23664	effects	_	
134-23	23665-23668	and	_	
134-24	23669-23677	cannabis	_	
134-25	23678-23686	measures	_	
134-26	23687-23688	(	_	
134-27	23688-23691	age	_	
134-28	23692-23694	of	_	
134-29	23695-23700	onset	_	
134-30	23701-23703	or	_	
134-31	23704-23709	total	_	
134-32	23710-23713	use	_	
134-33	23713-23714	)	_	
134-34	23715-23719	were	_	
134-35	23720-23727	entered	_	
134-36	23728-23730	as	_	
134-37	23731-23746	between-subject	_	
134-38	23747-23754	effects	_	
134-39	23754-23755	.	_	

#Text=An interaction term between TR and the cannabis measure was used to identify voxels whose correct, trial-wise HRF significantly varied as a function of age of onset or total use.
135-1	23756-23758	An	_	
135-2	23759-23770	interaction	_	
135-3	23771-23775	term	_	
135-4	23776-23783	between	_	
135-5	23784-23786	TR	_	
135-6	23787-23790	and	_	
135-7	23791-23794	the	_	
135-8	23795-23803	cannabis	_	
135-9	23804-23811	measure	_	
135-10	23812-23815	was	_	
135-11	23816-23820	used	_	
135-12	23821-23823	to	_	
135-13	23824-23832	identify	_	
135-14	23833-23839	voxels	_	
135-15	23840-23845	whose	_	
135-16	23846-23853	correct	_	
135-17	23853-23854	,	_	
135-18	23855-23865	trial-wise	_	
135-19	23866-23869	HRF	_	
135-20	23870-23883	significantly	_	
135-21	23884-23890	varied	_	
135-22	23891-23893	as	_	
135-23	23894-23895	a	_	
135-24	23896-23904	function	_	
135-25	23905-23907	of	_	
135-26	23908-23911	age	_	
135-27	23912-23914	of	_	
135-28	23915-23920	onset	_	
135-29	23921-23923	or	_	
135-30	23924-23929	total	_	
135-31	23930-23933	use	_	
135-32	23933-23934	.	_	

#Text=Importantly, this analysis was blind to the direction of the effect (F-test) and epoch amplitudes, such that differences as a function of a cannabis measure in any epoch could contribute to a trial-wise difference.
136-1	23935-23946	Importantly	_	
136-2	23946-23947	,	_	
136-3	23948-23952	this	_	
136-4	23953-23961	analysis	_	
136-5	23962-23965	was	_	
136-6	23966-23971	blind	_	
136-7	23972-23974	to	_	
136-8	23975-23978	the	_	
136-9	23979-23988	direction	_	
136-10	23989-23991	of	_	
136-11	23992-23995	the	_	
136-12	23996-24002	effect	_	
136-13	24003-24004	(	_	
136-14	24004-24010	F-test	_	
136-15	24010-24011	)	_	
136-16	24012-24015	and	_	
136-17	24016-24021	epoch	_	
136-18	24022-24032	amplitudes	_	
136-19	24032-24033	,	_	
136-20	24034-24038	such	_	
136-21	24039-24043	that	_	
136-22	24044-24055	differences	_	
136-23	24056-24058	as	_	
136-24	24059-24060	a	_	
136-25	24061-24069	function	_	
136-26	24070-24072	of	_	
136-27	24073-24074	a	_	
136-28	24075-24083	cannabis	_	
136-29	24084-24091	measure	_	
136-30	24092-24094	in	_	
136-31	24095-24098	any	_	
136-32	24099-24104	epoch	_	
136-33	24105-24110	could	_	
136-34	24111-24121	contribute	_	
136-35	24122-24124	to	_	
136-36	24125-24126	a	_	
136-37	24127-24137	trial-wise	_	
136-38	24138-24148	difference	_	
136-39	24148-24149	.	_	

#Text=Voxelwise testing was masked to only include voxels with a 50% or greater probability of being grey matter in the MNI-152 template and full EPI coverage in all subjects across all runs.
137-1	24150-24159	Voxelwise	_	
137-2	24160-24167	testing	_	
137-3	24168-24171	was	_	
137-4	24172-24178	masked	_	
137-5	24179-24181	to	_	
137-6	24182-24186	only	_	
137-7	24187-24194	include	_	
137-8	24195-24201	voxels	_	
137-9	24202-24206	with	_	
137-10	24207-24208	a	_	
137-11	24209-24212	50%	_	
137-12	24213-24215	or	_	
137-13	24216-24223	greater	_	
137-14	24224-24235	probability	_	
137-15	24236-24238	of	_	
137-16	24239-24244	being	_	
137-17	24245-24249	grey	_	
137-18	24250-24256	matter	_	
137-19	24257-24259	in	_	
137-20	24260-24263	the	_	
137-21	24264-24267	MNI	_	
137-22	24267-24268	-	_	
137-23	24268-24271	152	_	
137-24	24272-24280	template	_	
137-25	24281-24284	and	_	
137-26	24285-24289	full	_	
137-27	24290-24293	EPI	_	
137-28	24294-24302	coverage	_	
137-29	24303-24305	in	_	
137-30	24306-24309	all	_	
137-31	24310-24318	subjects	_	
137-32	24319-24325	across	_	
137-33	24326-24329	all	_	
137-34	24330-24334	runs	_	
137-35	24334-24335	.	_	

#Text=Voxels were further constrained such that each had a main effect of TR (F-test), suggesting activation to the WM task significantly differed (positively or negatively) from baseline.
138-1	24336-24342	Voxels	_	
138-2	24343-24347	were	_	
138-3	24348-24355	further	_	
138-4	24356-24367	constrained	_	
138-5	24368-24372	such	_	
138-6	24373-24377	that	_	
138-7	24378-24382	each	_	
138-8	24383-24386	had	_	
138-9	24387-24388	a	_	
138-10	24389-24393	main	_	
138-11	24394-24400	effect	_	
138-12	24401-24403	of	_	
138-13	24404-24406	TR	_	
138-14	24407-24408	(	_	
138-15	24408-24414	F-test	_	
138-16	24414-24415	)	_	
138-17	24415-24416	,	_	
138-18	24417-24427	suggesting	_	
138-19	24428-24438	activation	_	
138-20	24439-24441	to	_	
138-21	24442-24445	the	_	
138-22	24446-24448	WM	_	
138-23	24449-24453	task	_	
138-24	24454-24467	significantly	_	
138-25	24468-24476	differed	_	
138-26	24477-24478	(	_	
138-27	24478-24488	positively	_	
138-28	24489-24491	or	_	
138-29	24492-24502	negatively	_	
138-30	24502-24503	)	_	
138-31	24504-24508	from	_	
138-32	24509-24517	baseline	_	
138-33	24517-24518	.	_	

#Text=Results were corrected for multiple comparisons using the intersection of voxelwise FDR correction (q < .05) and cluster size within the voxelwise space as defined above.
139-1	24519-24526	Results	_	
139-2	24527-24531	were	_	
139-3	24532-24541	corrected	_	
139-4	24542-24545	for	_	
139-5	24546-24554	multiple	_	
139-6	24555-24566	comparisons	_	
139-7	24567-24572	using	_	
139-8	24573-24576	the	_	
139-9	24577-24589	intersection	_	
139-10	24590-24592	of	_	
139-11	24593-24602	voxelwise	_	
139-12	24603-24606	FDR	_	
139-13	24607-24617	correction	_	
139-14	24618-24619	(	_	
139-15	24619-24620	q	_	
139-16	24621-24622	<	_	
139-17	24623-24626	.05	_	
139-18	24626-24627	)	_	
139-19	24628-24631	and	_	
139-20	24632-24639	cluster	_	
139-21	24640-24644	size	_	
139-22	24645-24651	within	_	
139-23	24652-24655	the	_	
139-24	24656-24665	voxelwise	_	
139-25	24666-24671	space	_	
139-26	24672-24674	as	_	
139-27	24675-24682	defined	_	
139-28	24683-24688	above	_	
139-29	24688-24689	.	_	

#Text=Cluster size thresholds were determined through a Monte Carlo simulation using AFNI’s 3dClustSim program with mean spatial autocorrelation parameters estimated from GLM-1 residuals.
140-1	24690-24697	Cluster	_	
140-2	24698-24702	size	_	
140-3	24703-24713	thresholds	_	
140-4	24714-24718	were	_	
140-5	24719-24729	determined	_	
140-6	24730-24737	through	_	
140-7	24738-24739	a	_	
140-8	24740-24745	Monte	_	
140-9	24746-24751	Carlo	_	
140-10	24752-24762	simulation	_	
140-11	24763-24768	using	_	
140-12	24769-24773	AFNI	_	
140-13	24773-24774	’	_	
140-14	24774-24775	s	_	
140-15	24776-24786	3dClustSim	_	
140-16	24787-24794	program	_	
140-17	24795-24799	with	_	
140-18	24800-24804	mean	_	
140-19	24805-24812	spatial	_	
140-20	24813-24828	autocorrelation	_	
140-21	24829-24839	parameters	_	
140-22	24840-24849	estimated	_	
140-23	24850-24854	from	_	
140-24	24855-24858	GLM	_	
140-25	24858-24859	-	_	
140-26	24859-24860	1	_	
140-27	24861-24870	residuals	_	
140-28	24870-24871	.	_	

#Text=This analysis specified that 16 or more contiguous (faces touching) voxels with a single voxel threshold of p = .0018 (q < .05) for cannabis age of onset and p = .0023 (q < .05) for total cannabis use were required to achieve corrected, cluster-level alphas of less than .05.
141-1	24872-24876	This	_	
141-2	24877-24885	analysis	_	
141-3	24886-24895	specified	_	
141-4	24896-24900	that	_	
141-5	24901-24903	16	_	
141-6	24904-24906	or	_	
141-7	24907-24911	more	_	
141-8	24912-24922	contiguous	_	
141-9	24923-24924	(	_	
141-10	24924-24929	faces	_	
141-11	24930-24938	touching	_	
141-12	24938-24939	)	_	
141-13	24940-24946	voxels	_	
141-14	24947-24951	with	_	
141-15	24952-24953	a	_	
141-16	24954-24960	single	_	
141-17	24961-24966	voxel	_	
141-18	24967-24976	threshold	_	
141-19	24977-24979	of	_	
141-20	24980-24981	p	_	
141-21	24982-24983	=	_	
141-22	24984-24989	.0018	_	
141-23	24990-24991	(	_	
141-24	24991-24992	q	_	
141-25	24993-24994	<	_	
141-26	24995-24998	.05	_	
141-27	24998-24999	)	_	
141-28	25000-25003	for	_	
141-29	25004-25012	cannabis	_	
141-30	25013-25016	age	_	
141-31	25017-25019	of	_	
141-32	25020-25025	onset	_	
141-33	25026-25029	and	_	
141-34	25030-25031	p	_	
141-35	25032-25033	=	_	
141-36	25034-25039	.0023	_	
141-37	25040-25041	(	_	
141-38	25041-25042	q	_	
141-39	25043-25044	<	_	
141-40	25045-25048	.05	_	
141-41	25048-25049	)	_	
141-42	25050-25053	for	_	
141-43	25054-25059	total	_	
141-44	25060-25068	cannabis	_	
141-45	25069-25072	use	_	
141-46	25073-25077	were	_	
141-47	25078-25086	required	_	
141-48	25087-25089	to	_	
141-49	25090-25097	achieve	_	
141-50	25098-25107	corrected	_	
141-51	25107-25108	,	_	
141-52	25109-25122	cluster-level	_	
141-53	25123-25129	alphas	_	
141-54	25130-25132	of	_	
141-55	25133-25137	less	_	
141-56	25138-25142	than	_	
141-57	25143-25146	.05	_	
141-58	25146-25147	.	_	

#Text=Epoch testing.
142-1	25148-25153	Epoch	_	
142-2	25154-25161	testing	_	
142-3	25161-25162	.	_	

#Text=Post-hoc comparisons (using GLM-2) and brain-behavior analysis were performed on the mean activation within clusters with a significant cannabis by TR interaction (as defined above in GLM-1) for cue, delay, and target epochs.
143-1	25163-25171	Post-hoc	_	
143-2	25172-25183	comparisons	_	
143-3	25184-25185	(	_	
143-4	25185-25190	using	_	
143-5	25191-25194	GLM	_	
143-6	25194-25195	-	_	
143-7	25195-25196	2	_	
143-8	25196-25197	)	_	
143-9	25198-25201	and	_	
143-10	25202-25216	brain-behavior	_	
143-11	25217-25225	analysis	_	
143-12	25226-25230	were	_	
143-13	25231-25240	performed	_	
143-14	25241-25243	on	_	
143-15	25244-25247	the	_	
143-16	25248-25252	mean	_	
143-17	25253-25263	activation	_	
143-18	25264-25270	within	_	
143-19	25271-25279	clusters	_	
143-20	25280-25284	with	_	
143-21	25285-25286	a	_	
143-22	25287-25298	significant	_	
143-23	25299-25307	cannabis	_	
143-24	25308-25310	by	_	
143-25	25311-25313	TR	_	
143-26	25314-25325	interaction	_	
143-27	25326-25327	(	_	
143-28	25327-25329	as	_	
143-29	25330-25337	defined	_	
143-30	25338-25343	above	_	
143-31	25344-25346	in	_	
143-32	25347-25350	GLM	_	
143-33	25350-25351	-	_	
143-34	25351-25352	1	_	
143-35	25352-25353	)	_	
143-36	25354-25357	for	_	
143-37	25358-25361	cue	_	
143-38	25361-25362	,	_	
143-39	25363-25368	delay	_	
143-40	25368-25369	,	_	
143-41	25370-25373	and	_	
143-42	25374-25380	target	_	
143-43	25381-25387	epochs	_	
143-44	25387-25388	.	_	

#Text=Significance values were Bonferroni corrected across epochs within each cluster.
144-1	25389-25401	Significance	_	
144-2	25402-25408	values	_	
144-3	25409-25413	were	_	
144-4	25414-25424	Bonferroni	_	
144-5	25425-25434	corrected	_	
144-6	25435-25441	across	_	
144-7	25442-25448	epochs	_	
144-8	25449-25455	within	_	
144-9	25456-25460	each	_	
144-10	25461-25468	cluster	_	
144-11	25468-25469	.	_	

#Text=Covariates (Tables 1 and 2) were utilized in the same procedure as behavioral analysis (baseline and full models).
145-1	25470-25480	Covariates	_	
145-2	25481-25482	(	_	
145-3	25482-25488	Tables	_	
145-4	25489-25490	1	_	
145-5	25491-25494	and	_	
145-6	25495-25496	2	_	
145-7	25496-25497	)	_	
145-8	25498-25502	were	_	
145-9	25503-25511	utilized	_	
145-10	25512-25514	in	_	
145-11	25515-25518	the	_	
145-12	25519-25523	same	_	
145-13	25524-25533	procedure	_	
145-14	25534-25536	as	_	
145-15	25537-25547	behavioral	_	
145-16	25548-25556	analysis	_	
145-17	25557-25558	(	_	
145-18	25558-25566	baseline	_	
145-19	25567-25570	and	_	
145-20	25571-25575	full	_	
145-21	25576-25582	models	_	
145-22	25582-25583	)	_	
145-23	25583-25584	.	_	

#Text=Brain-behavior analyses were performed on mean performance measures (mean of log reaction time and mean accuracy).
146-1	25585-25599	Brain-behavior	_	
146-2	25600-25608	analyses	_	
146-3	25609-25613	were	_	
146-4	25614-25623	performed	_	
146-5	25624-25626	on	_	
146-6	25627-25631	mean	_	
146-7	25632-25643	performance	_	
146-8	25644-25652	measures	_	
146-9	25653-25654	(	_	
146-10	25654-25658	mean	_	
146-11	25659-25661	of	_	
146-12	25662-25665	log	_	
146-13	25666-25674	reaction	_	
146-14	25675-25679	time	_	
146-15	25680-25683	and	_	
146-16	25684-25688	mean	_	
146-17	25689-25697	accuracy	_	
146-18	25697-25698	)	_	
146-19	25698-25699	.	_	

#Text=Reaction time models used linear regression.
147-1	25700-25708	Reaction	_	
147-2	25709-25713	time	_	
147-3	25714-25720	models	_	
147-4	25721-25725	used	_	
147-5	25726-25732	linear	_	
147-6	25733-25743	regression	_	
147-7	25743-25744	.	_	

#Text=Accuracy models used beta regression in order to reduce the impact of mean accuracy distribution ceiling.
148-1	25745-25753	Accuracy	_	
148-2	25754-25760	models	_	
148-3	25761-25765	used	_	
148-4	25766-25770	beta	_	
148-5	25771-25781	regression	_	
148-6	25782-25784	in	_	
148-7	25785-25790	order	_	
148-8	25791-25793	to	_	
148-9	25794-25800	reduce	_	
148-10	25801-25804	the	_	
148-11	25805-25811	impact	_	
148-12	25812-25814	of	_	
148-13	25815-25819	mean	_	
148-14	25820-25828	accuracy	_	
148-15	25829-25841	distribution	_	
148-16	25842-25849	ceiling	_	
148-17	25849-25850	.	_	

#Text=For all epoch testing, potential influential observations were removed if Cook’s distance or dfbetas exceeded 1 in either the post-hoc epoch or brain-behavior model.
149-1	25851-25854	For	_	
149-2	25855-25858	all	_	
149-3	25859-25864	epoch	_	
149-4	25865-25872	testing	_	
149-5	25872-25873	,	_	
149-6	25874-25883	potential	_	
149-7	25884-25895	influential	_	
149-8	25896-25908	observations	_	
149-9	25909-25913	were	_	
149-10	25914-25921	removed	_	
149-11	25922-25924	if	_	
149-12	25925-25929	Cook	_	
149-13	25929-25930	’	_	
149-14	25930-25931	s	_	
149-15	25932-25940	distance	_	
149-16	25941-25943	or	_	
149-17	25944-25951	dfbetas	_	
149-18	25952-25960	exceeded	_	
149-19	25961-25962	1	_	
149-20	25963-25965	in	_	
149-21	25966-25972	either	_	
149-22	25973-25976	the	_	
149-23	25977-25985	post-hoc	_	
149-24	25986-25991	epoch	_	
149-25	25992-25994	or	_	
149-26	25995-26009	brain-behavior	_	
149-27	26010-26015	model	_	
149-28	26015-26016	.	_	

#Text=This never resulted in more than 2 subjects being removed.
150-1	26017-26021	This	_	
150-2	26022-26027	never	_	
150-3	26028-26036	resulted	_	
150-4	26037-26039	in	_	
150-5	26040-26044	more	_	
150-6	26045-26049	than	_	
150-7	26050-26051	2	_	
150-8	26052-26060	subjects	_	
150-9	26061-26066	being	_	
150-10	26067-26074	removed	_	
150-11	26074-26075	.	_	

#Text=Mediation analysis.
151-1	26076-26085	Mediation	_	
151-2	26086-26094	analysis	_	
151-3	26094-26095	.	_	

#Text=To examine whether differences in activation could account for behavioral differences, mediation analysis was performed on epoch amplitudes that had significant, corrected associations to 1) cannabis measures and 2) WM performance (while covarying the cannabis measure).
152-1	26096-26098	To	_	
152-2	26099-26106	examine	_	
152-3	26107-26114	whether	_	
152-4	26115-26126	differences	_	
152-5	26127-26129	in	_	
152-6	26130-26140	activation	_	
152-7	26141-26146	could	_	
152-8	26147-26154	account	_	
152-9	26155-26158	for	_	
152-10	26159-26169	behavioral	_	
152-11	26170-26181	differences	_	
152-12	26181-26182	,	_	
152-13	26183-26192	mediation	_	
152-14	26193-26201	analysis	_	
152-15	26202-26205	was	_	
152-16	26206-26215	performed	_	
152-17	26216-26218	on	_	
152-18	26219-26224	epoch	_	
152-19	26225-26235	amplitudes	_	
152-20	26236-26240	that	_	
152-21	26241-26244	had	_	
152-22	26245-26256	significant	_	
152-23	26256-26257	,	_	
152-24	26258-26267	corrected	_	
152-25	26268-26280	associations	_	
152-26	26281-26283	to	_	
152-27	26284-26285	1	_	
152-28	26285-26286	)	_	
152-29	26287-26295	cannabis	_	
152-30	26296-26304	measures	_	
152-31	26305-26308	and	_	
152-32	26309-26310	2	_	
152-33	26310-26311	)	_	
152-34	26312-26314	WM	_	
152-35	26315-26326	performance	_	
152-36	26327-26328	(	_	
152-37	26328-26333	while	_	
152-38	26334-26343	covarying	_	
152-39	26344-26347	the	_	
152-40	26348-26356	cannabis	_	
152-41	26357-26364	measure	_	
152-42	26364-26365	)	_	
152-43	26365-26366	.	_	

#Text=Significance values for indirect effects were obtained using 5000 draws in a bootstrap procedure (mediation package).
153-1	26367-26379	Significance	_	
153-2	26380-26386	values	_	
153-3	26387-26390	for	_	
153-4	26391-26399	indirect	_	
153-5	26400-26407	effects	_	
153-6	26408-26412	were	_	
153-7	26413-26421	obtained	_	
153-8	26422-26427	using	_	
153-9	26428-26432	5000	_	
153-10	26433-26438	draws	_	
153-11	26439-26441	in	_	
153-12	26442-26443	a	_	
153-13	26444-26453	bootstrap	_	
153-14	26454-26463	procedure	_	
153-15	26464-26465	(	_	
153-16	26465-26474	mediation	_	
153-17	26475-26482	package	_	
153-18	26482-26483	)	_	
153-19	26483-26484	.	_	

#Text=Results
#Text=WM behavior in cannabis users
#Text=Cannabis age of onset
#Text=In the groups that reported use (EXP, REP), cannabis age of onset was not a significant predictor of WM accuracy (baseline:  z = 1.30, p = .193; full model (covariate set A):  z = 0.52, p = .601) but showed a significant, negative relationship with WM RT in both baseline (, t = −2.99, p = .003) and full models ( t = −3.11, p = .002) (Fig. 2).
154-1	26485-26492	Results	_	
154-2	26493-26495	WM	_	
154-3	26496-26504	behavior	_	
154-4	26505-26507	in	_	
154-5	26508-26516	cannabis	_	
154-6	26517-26522	users	_	
154-7	26523-26531	Cannabis	_	
154-8	26532-26535	age	_	
154-9	26536-26538	of	_	
154-10	26539-26544	onset	_	
154-11	26545-26547	In	_	
154-12	26548-26551	the	_	
154-13	26552-26558	groups	_	
154-14	26559-26563	that	_	
154-15	26564-26572	reported	_	
154-16	26573-26576	use	_	
154-17	26577-26578	(	_	
154-18	26578-26581	EXP	_	
154-19	26581-26582	,	_	
154-20	26583-26586	REP	_	
154-21	26586-26587	)	_	
154-22	26587-26588	,	_	
154-23	26589-26597	cannabis	_	
154-24	26598-26601	age	_	
154-25	26602-26604	of	_	
154-26	26605-26610	onset	_	
154-27	26611-26614	was	_	
154-28	26615-26618	not	_	
154-29	26619-26620	a	_	
154-30	26621-26632	significant	_	
154-31	26633-26642	predictor	_	
154-32	26643-26645	of	_	
154-33	26646-26648	WM	_	
154-34	26649-26657	accuracy	_	
154-35	26658-26659	(	_	
154-36	26659-26667	baseline	_	
154-37	26667-26668	:	_	
154-38	26670-26671	z	_	
154-39	26672-26673	=	_	
154-40	26674-26678	1.30	_	
154-41	26678-26679	,	_	
154-42	26680-26681	p	_	
154-43	26682-26683	=	_	
154-44	26684-26688	.193	_	
154-45	26688-26689	;	_	
154-46	26690-26694	full	_	
154-47	26695-26700	model	_	
154-48	26701-26702	(	_	
154-49	26702-26711	covariate	_	
154-50	26712-26715	set	_	
154-51	26716-26717	A	_	
154-52	26717-26718	)	_	
154-53	26718-26719	:	_	
154-54	26721-26722	z	_	
154-55	26723-26724	=	_	
154-56	26725-26729	0.52	_	
154-57	26729-26730	,	_	
154-58	26731-26732	p	_	
154-59	26733-26734	=	_	
154-60	26735-26739	.601	_	
154-61	26739-26740	)	_	
154-62	26741-26744	but	_	
154-63	26745-26751	showed	_	
154-64	26752-26753	a	_	
154-65	26754-26765	significant	_	
154-66	26765-26766	,	_	
154-67	26767-26775	negative	_	
154-68	26776-26788	relationship	_	
154-69	26789-26793	with	_	
154-70	26794-26796	WM	_	
154-71	26797-26799	RT	_	
154-72	26800-26802	in	_	
154-73	26803-26807	both	_	
154-74	26808-26816	baseline	_	
154-75	26817-26818	(	_	
154-76	26818-26819	,	_	
154-77	26820-26821	t	_	
154-78	26822-26823	=	_	
154-79	26824-26825	−	_	
154-80	26825-26829	2.99	_	
154-81	26829-26830	,	_	
154-82	26831-26832	p	_	
154-83	26833-26834	=	_	
154-84	26835-26839	.003	_	
154-85	26839-26840	)	_	
154-86	26841-26844	and	_	
154-87	26845-26849	full	_	
154-88	26850-26856	models	_	
154-89	26857-26858	(	_	
154-90	26859-26860	t	_	
154-91	26861-26862	=	_	
154-92	26863-26864	−	_	
154-93	26864-26868	3.11	_	
154-94	26868-26869	,	_	
154-95	26870-26871	p	_	
154-96	26872-26873	=	_	
154-97	26874-26878	.002	_	
154-98	26878-26879	)	_	
154-99	26880-26881	(	_	
154-100	26881-26884	Fig	_	
154-101	26884-26885	.	_	
154-102	26886-26887	2	_	
154-103	26887-26888	)	_	
154-104	26888-26889	.	_	

#Text=Importantly, this relationship remained significant after adjusting for prenatal measures (full model + prenatal cannabis exposure:  t = - 3.10, p = .002) and the association between cannabis age of onset and RT did not differ in exposed vs. unexposed groups ( t = −0.54, p = .589, Supplemental Fig.
155-1	26890-26901	Importantly	_	
155-2	26901-26902	,	_	
155-3	26903-26907	this	_	
155-4	26908-26920	relationship	_	
155-5	26921-26929	remained	_	
155-6	26930-26941	significant	_	
155-7	26942-26947	after	_	
155-8	26948-26957	adjusting	_	
155-9	26958-26961	for	_	
155-10	26962-26970	prenatal	_	
155-11	26971-26979	measures	_	
155-12	26980-26981	(	_	
155-13	26981-26985	full	_	
155-14	26986-26991	model	_	
155-15	26992-26993	+	_	
155-16	26994-27002	prenatal	_	
155-17	27003-27011	cannabis	_	
155-18	27012-27020	exposure	_	
155-19	27020-27021	:	_	
155-20	27023-27024	t	_	
155-21	27025-27026	=	_	
155-22	27027-27028	-	_	
155-23	27029-27033	3.10	_	
155-24	27033-27034	,	_	
155-25	27035-27036	p	_	
155-26	27037-27038	=	_	
155-27	27039-27043	.002	_	
155-28	27043-27044	)	_	
155-29	27045-27048	and	_	
155-30	27049-27052	the	_	
155-31	27053-27064	association	_	
155-32	27065-27072	between	_	
155-33	27073-27081	cannabis	_	
155-34	27082-27085	age	_	
155-35	27086-27088	of	_	
155-36	27089-27094	onset	_	
155-37	27095-27098	and	_	
155-38	27099-27101	RT	_	
155-39	27102-27105	did	_	
155-40	27106-27109	not	_	
155-41	27110-27116	differ	_	
155-42	27117-27119	in	_	
155-43	27120-27127	exposed	_	
155-44	27128-27130	vs	_	
155-45	27130-27131	.	_	
155-46	27132-27141	unexposed	_	
155-47	27142-27148	groups	_	
155-48	27149-27150	(	_	
155-49	27151-27152	t	_	
155-50	27153-27154	=	_	
155-51	27155-27156	−	_	
155-52	27156-27160	0.54	_	
155-53	27160-27161	,	_	
155-54	27162-27163	p	_	
155-55	27164-27165	=	_	
155-56	27166-27170	.589	_	
155-57	27170-27171	,	_	
155-58	27172-27184	Supplemental	_	
155-59	27185-27188	Fig	_	
155-60	27188-27189	.	_	

#Text=S2).
156-1	27190-27192	S2	_	
156-2	27192-27193	)	_	
156-3	27193-27194	.	_	

#Text=Of the task conditions (load, delay length, cue validity), only WM load had a significant interaction with cannabis age of onset while predicting RT (full model:  t = −2.19, p = .028).
157-1	27195-27197	Of	_	
157-2	27198-27201	the	_	
157-3	27202-27206	task	_	
157-4	27207-27217	conditions	_	
157-5	27218-27219	(	_	
157-6	27219-27223	load	_	
157-7	27223-27224	,	_	
157-8	27225-27230	delay	_	
157-9	27231-27237	length	_	
157-10	27237-27238	,	_	
157-11	27239-27242	cue	_	
157-12	27243-27251	validity	_	
157-13	27251-27252	)	_	
157-14	27252-27253	,	_	
157-15	27254-27258	only	_	
157-16	27259-27261	WM	_	
157-17	27262-27266	load	_	
157-18	27267-27270	had	_	
157-19	27271-27272	a	_	
157-20	27273-27284	significant	_	
157-21	27285-27296	interaction	_	
157-22	27297-27301	with	_	
157-23	27302-27310	cannabis	_	
157-24	27311-27314	age	_	
157-25	27315-27317	of	_	
157-26	27318-27323	onset	_	
157-27	27324-27329	while	_	
157-28	27330-27340	predicting	_	
157-29	27341-27343	RT	_	
157-30	27344-27345	(	_	
157-31	27345-27349	full	_	
157-32	27350-27355	model	_	
157-33	27355-27356	:	_	
157-34	27358-27359	t	_	
157-35	27360-27361	=	_	
157-36	27362-27363	−	_	
157-37	27363-27367	2.19	_	
157-38	27367-27368	,	_	
157-39	27369-27370	p	_	
157-40	27371-27372	=	_	
157-41	27373-27377	.028	_	
157-42	27377-27378	)	_	
157-43	27378-27379	.	_	

#Text=Post hoc testing revealed the association between cannabis age of onset and RT was significantly greater in the low load condition (t(69.27) = −3.22, p = .002) compared to the high load condition (t(70.10) = −2.54, p = .013).
158-1	27380-27384	Post	_	
158-2	27385-27388	hoc	_	
158-3	27389-27396	testing	_	
158-4	27397-27405	revealed	_	
158-5	27406-27409	the	_	
158-6	27410-27421	association	_	
158-7	27422-27429	between	_	
158-8	27430-27438	cannabis	_	
158-9	27439-27442	age	_	
158-10	27443-27445	of	_	
158-11	27446-27451	onset	_	
158-12	27452-27455	and	_	
158-13	27456-27458	RT	_	
158-14	27459-27462	was	_	
158-15	27463-27476	significantly	_	
158-16	27477-27484	greater	_	
158-17	27485-27487	in	_	
158-18	27488-27491	the	_	
158-19	27492-27495	low	_	
158-20	27496-27500	load	_	
158-21	27501-27510	condition	_	
158-22	27511-27512	(	_	
158-23	27512-27513	t	_	
158-24	27513-27514	(	_	
158-25	27514-27519	69.27	_	
158-26	27519-27520	)	_	
158-27	27521-27522	=	_	
158-28	27523-27524	−	_	
158-29	27524-27528	3.22	_	
158-30	27528-27529	,	_	
158-31	27530-27531	p	_	
158-32	27532-27533	=	_	
158-33	27534-27538	.002	_	
158-34	27538-27539	)	_	
158-35	27540-27548	compared	_	
158-36	27549-27551	to	_	
158-37	27552-27555	the	_	
158-38	27556-27560	high	_	
158-39	27561-27565	load	_	
158-40	27566-27575	condition	_	
158-41	27576-27577	(	_	
158-42	27577-27578	t	_	
158-43	27578-27579	(	_	
158-44	27579-27584	70.10	_	
158-45	27584-27585	)	_	
158-46	27586-27587	=	_	
158-47	27588-27589	−	_	
158-48	27589-27593	2.54	_	
158-49	27593-27594	,	_	
158-50	27595-27596	p	_	
158-51	27597-27598	=	_	
158-52	27599-27603	.013	_	
158-53	27603-27604	)	_	
158-54	27604-27605	.	_	

#Text=An interaction between cannabis use group (EXP + REP) and cannabis age of onset in predicting WM RT did not reach significance (baseline:  t = 1.75, p = .079; full model:  t = 1.41, p = .160), suggesting the association between age of onset and WM RT did not differ in EXP and REP groups.
159-1	27606-27608	An	_	
159-2	27609-27620	interaction	_	
159-3	27621-27628	between	_	
159-4	27629-27637	cannabis	_	
159-5	27638-27641	use	_	
159-6	27642-27647	group	_	
159-7	27648-27649	(	_	
159-8	27649-27652	EXP	_	
159-9	27653-27654	+	_	
159-10	27655-27658	REP	_	
159-11	27658-27659	)	_	
159-12	27660-27663	and	_	
159-13	27664-27672	cannabis	_	
159-14	27673-27676	age	_	
159-15	27677-27679	of	_	
159-16	27680-27685	onset	_	
159-17	27686-27688	in	_	
159-18	27689-27699	predicting	_	
159-19	27700-27702	WM	_	
159-20	27703-27705	RT	_	
159-21	27706-27709	did	_	
159-22	27710-27713	not	_	
159-23	27714-27719	reach	_	
159-24	27720-27732	significance	_	
159-25	27733-27734	(	_	
159-26	27734-27742	baseline	_	
159-27	27742-27743	:	_	
159-28	27745-27746	t	_	
159-29	27747-27748	=	_	
159-30	27749-27753	1.75	_	
159-31	27753-27754	,	_	
159-32	27755-27756	p	_	
159-33	27757-27758	=	_	
159-34	27759-27763	.079	_	
159-35	27763-27764	;	_	
159-36	27765-27769	full	_	
159-37	27770-27775	model	_	
159-38	27775-27776	:	_	
159-39	27778-27779	t	_	
159-40	27780-27781	=	_	
159-41	27782-27786	1.41	_	
159-42	27786-27787	,	_	
159-43	27788-27789	p	_	
159-44	27790-27791	=	_	
159-45	27792-27796	.160	_	
159-46	27796-27797	)	_	
159-47	27797-27798	,	_	
159-48	27799-27809	suggesting	_	
159-49	27810-27813	the	_	
159-50	27814-27825	association	_	
159-51	27826-27833	between	_	
159-52	27834-27837	age	_	
159-53	27838-27840	of	_	
159-54	27841-27846	onset	_	
159-55	27847-27850	and	_	
159-56	27851-27853	WM	_	
159-57	27854-27856	RT	_	
159-58	27857-27860	did	_	
159-59	27861-27864	not	_	
159-60	27865-27871	differ	_	
159-61	27872-27874	in	_	
159-62	27875-27878	EXP	_	
159-63	27879-27882	and	_	
159-64	27883-27886	REP	_	
159-65	27887-27893	groups	_	
159-66	27893-27894	.	_	

#Text=However, the simple effect of age of onset predicting WM RT was significant in the EXP group (baseline: t(64.81) = −2.91, p = .005; full model: t(68.79) = −2.66, p = .010) and in the REP group in the full model (t(68.79) = −2.02, p = .048) but only a trend in the REP group in the baseline model (t(64.81) = −1.91, p = .060).
160-1	27895-27902	However	_	
160-2	27902-27903	,	_	
160-3	27904-27907	the	_	
160-4	27908-27914	simple	_	
160-5	27915-27921	effect	_	
160-6	27922-27924	of	_	
160-7	27925-27928	age	_	
160-8	27929-27931	of	_	
160-9	27932-27937	onset	_	
160-10	27938-27948	predicting	_	
160-11	27949-27951	WM	_	
160-12	27952-27954	RT	_	
160-13	27955-27958	was	_	
160-14	27959-27970	significant	_	
160-15	27971-27973	in	_	
160-16	27974-27977	the	_	
160-17	27978-27981	EXP	_	
160-18	27982-27987	group	_	
160-19	27988-27989	(	_	
160-20	27989-27997	baseline	_	
160-21	27997-27998	:	_	
160-22	27999-28000	t	_	
160-23	28000-28001	(	_	
160-24	28001-28006	64.81	_	
160-25	28006-28007	)	_	
160-26	28008-28009	=	_	
160-27	28010-28011	−	_	
160-28	28011-28015	2.91	_	
160-29	28015-28016	,	_	
160-30	28017-28018	p	_	
160-31	28019-28020	=	_	
160-32	28021-28025	.005	_	
160-33	28025-28026	;	_	
160-34	28027-28031	full	_	
160-35	28032-28037	model	_	
160-36	28037-28038	:	_	
160-37	28039-28040	t	_	
160-38	28040-28041	(	_	
160-39	28041-28046	68.79	_	
160-40	28046-28047	)	_	
160-41	28048-28049	=	_	
160-42	28050-28051	−	_	
160-43	28051-28055	2.66	_	
160-44	28055-28056	,	_	
160-45	28057-28058	p	_	
160-46	28059-28060	=	_	
160-47	28061-28065	.010	_	
160-48	28065-28066	)	_	
160-49	28067-28070	and	_	
160-50	28071-28073	in	_	
160-51	28074-28077	the	_	
160-52	28078-28081	REP	_	
160-53	28082-28087	group	_	
160-54	28088-28090	in	_	
160-55	28091-28094	the	_	
160-56	28095-28099	full	_	
160-57	28100-28105	model	_	
160-58	28106-28107	(	_	
160-59	28107-28108	t	_	
160-60	28108-28109	(	_	
160-61	28109-28114	68.79	_	
160-62	28114-28115	)	_	
160-63	28116-28117	=	_	
160-64	28118-28119	−	_	
160-65	28119-28123	2.02	_	
160-66	28123-28124	,	_	
160-67	28125-28126	p	_	
160-68	28127-28128	=	_	
160-69	28129-28133	.048	_	
160-70	28133-28134	)	_	
160-71	28135-28138	but	_	
160-72	28139-28143	only	_	
160-73	28144-28145	a	_	
160-74	28146-28151	trend	_	
160-75	28152-28154	in	_	
160-76	28155-28158	the	_	
160-77	28159-28162	REP	_	
160-78	28163-28168	group	_	
160-79	28169-28171	in	_	
160-80	28172-28175	the	_	
160-81	28176-28184	baseline	_	
160-82	28185-28190	model	_	
160-83	28191-28192	(	_	
160-84	28192-28193	t	_	
160-85	28193-28194	(	_	
160-86	28194-28199	64.81	_	
160-87	28199-28200	)	_	
160-88	28201-28202	=	_	
160-89	28203-28204	−	_	
160-90	28204-28208	1.91	_	
160-91	28208-28209	,	_	
160-92	28210-28211	p	_	
160-93	28212-28213	=	_	
160-94	28214-28218	.060	_	
160-95	28218-28219	)	_	
160-96	28219-28220	.	_	

#Text=Within the REP group, the association between cannabis age of onset and WM RT was relatively unchanged when additionally covarying total cannabis use (baseline model + total cannabis use (log):  t = −1.72, p = .085; full model (covariate set A) + total cannabis use (log):  t = −2.23, p = .025) and total cannabis use was not a significant predictor of WM RT (see below).
161-1	28221-28227	Within	_	
161-2	28228-28231	the	_	
161-3	28232-28235	REP	_	
161-4	28236-28241	group	_	
161-5	28241-28242	,	_	
161-6	28243-28246	the	_	
161-7	28247-28258	association	_	
161-8	28259-28266	between	_	
161-9	28267-28275	cannabis	_	
161-10	28276-28279	age	_	
161-11	28280-28282	of	_	
161-12	28283-28288	onset	_	
161-13	28289-28292	and	_	
161-14	28293-28295	WM	_	
161-15	28296-28298	RT	_	
161-16	28299-28302	was	_	
161-17	28303-28313	relatively	_	
161-18	28314-28323	unchanged	_	
161-19	28324-28328	when	_	
161-20	28329-28341	additionally	_	
161-21	28342-28351	covarying	_	
161-22	28352-28357	total	_	
161-23	28358-28366	cannabis	_	
161-24	28367-28370	use	_	
161-25	28371-28372	(	_	
161-26	28372-28380	baseline	_	
161-27	28381-28386	model	_	
161-28	28387-28388	+	_	
161-29	28389-28394	total	_	
161-30	28395-28403	cannabis	_	
161-31	28404-28407	use	_	
161-32	28408-28409	(	_	
161-33	28409-28412	log	_	
161-34	28412-28413	)	_	
161-35	28413-28414	:	_	
161-36	28416-28417	t	_	
161-37	28418-28419	=	_	
161-38	28420-28421	−	_	
161-39	28421-28425	1.72	_	
161-40	28425-28426	,	_	
161-41	28427-28428	p	_	
161-42	28429-28430	=	_	
161-43	28431-28435	.085	_	
161-44	28435-28436	;	_	
161-45	28437-28441	full	_	
161-46	28442-28447	model	_	
161-47	28448-28449	(	_	
161-48	28449-28458	covariate	_	
161-49	28459-28462	set	_	
161-50	28463-28464	A	_	
161-51	28464-28465	)	_	
161-52	28466-28467	+	_	
161-53	28468-28473	total	_	
161-54	28474-28482	cannabis	_	
161-55	28483-28486	use	_	
161-56	28487-28488	(	_	
161-57	28488-28491	log	_	
161-58	28491-28492	)	_	
161-59	28492-28493	:	_	
161-60	28495-28496	t	_	
161-61	28497-28498	=	_	
161-62	28499-28500	−	_	
161-63	28500-28504	2.23	_	
161-64	28504-28505	,	_	
161-65	28506-28507	p	_	
161-66	28508-28509	=	_	
161-67	28510-28514	.025	_	
161-68	28514-28515	)	_	
161-69	28516-28519	and	_	
161-70	28520-28525	total	_	
161-71	28526-28534	cannabis	_	
161-72	28535-28538	use	_	
161-73	28539-28542	was	_	
161-74	28543-28546	not	_	
161-75	28547-28548	a	_	
161-76	28549-28560	significant	_	
161-77	28561-28570	predictor	_	
161-78	28571-28573	of	_	
161-79	28574-28576	WM	_	
161-80	28577-28579	RT	_	
161-81	28580-28581	(	_	
161-82	28581-28584	see	_	
161-83	28585-28590	below	_	
161-84	28590-28591	)	_	
161-85	28591-28592	.	_	

#Text=Total cannabis use
#Text=In the REP group, total cannabis use (log) was not significantly related to WM RT (baseline: χ2(1) = 0.77, t = 0.88, p = .381; full model (covariate set B): χ2(1) = 2.10, t = 1.45, p = .147), but showed a near-significant, negative association with WM accuracy in the baseline model (baseline: χ2(1) = 3.72, z = −1.93, p = .054).
162-1	28593-28598	Total	_	
162-2	28599-28607	cannabis	_	
162-3	28608-28611	use	_	
162-4	28612-28614	In	_	
162-5	28615-28618	the	_	
162-6	28619-28622	REP	_	
162-7	28623-28628	group	_	
162-8	28628-28629	,	_	
162-9	28630-28635	total	_	
162-10	28636-28644	cannabis	_	
162-11	28645-28648	use	_	
162-12	28649-28650	(	_	
162-13	28650-28653	log	_	
162-14	28653-28654	)	_	
162-15	28655-28658	was	_	
162-16	28659-28662	not	_	
162-17	28663-28676	significantly	_	
162-18	28677-28684	related	_	
162-19	28685-28687	to	_	
162-20	28688-28690	WM	_	
162-21	28691-28693	RT	_	
162-22	28694-28695	(	_	
162-23	28695-28703	baseline	_	
162-24	28703-28704	:	_	
162-25	28705-28707	χ2	_	
162-26	28707-28708	(	_	
162-27	28708-28709	1	_	
162-28	28709-28710	)	_	
162-29	28711-28712	=	_	
162-30	28713-28717	0.77	_	
162-31	28717-28718	,	_	
162-32	28719-28720	t	_	
162-33	28721-28722	=	_	
162-34	28723-28727	0.88	_	
162-35	28727-28728	,	_	
162-36	28729-28730	p	_	
162-37	28731-28732	=	_	
162-38	28733-28737	.381	_	
162-39	28737-28738	;	_	
162-40	28739-28743	full	_	
162-41	28744-28749	model	_	
162-42	28750-28751	(	_	
162-43	28751-28760	covariate	_	
162-44	28761-28764	set	_	
162-45	28765-28766	B	_	
162-46	28766-28767	)	_	
162-47	28767-28768	:	_	
162-48	28769-28771	χ2	_	
162-49	28771-28772	(	_	
162-50	28772-28773	1	_	
162-51	28773-28774	)	_	
162-52	28775-28776	=	_	
162-53	28777-28781	2.10	_	
162-54	28781-28782	,	_	
162-55	28783-28784	t	_	
162-56	28785-28786	=	_	
162-57	28787-28791	1.45	_	
162-58	28791-28792	,	_	
162-59	28793-28794	p	_	
162-60	28795-28796	=	_	
162-61	28797-28801	.147	_	
162-62	28801-28802	)	_	
162-63	28802-28803	,	_	
162-64	28804-28807	but	_	
162-65	28808-28814	showed	_	
162-66	28815-28816	a	_	
162-67	28817-28833	near-significant	_	
162-68	28833-28834	,	_	
162-69	28835-28843	negative	_	
162-70	28844-28855	association	_	
162-71	28856-28860	with	_	
162-72	28861-28863	WM	_	
162-73	28864-28872	accuracy	_	
162-74	28873-28875	in	_	
162-75	28876-28879	the	_	
162-76	28880-28888	baseline	_	
162-77	28889-28894	model	_	
162-78	28895-28896	(	_	
162-79	28896-28904	baseline	_	
162-80	28904-28905	:	_	
162-81	28906-28908	χ2	_	
162-82	28908-28909	(	_	
162-83	28909-28910	1	_	
162-84	28910-28911	)	_	
162-85	28912-28913	=	_	
162-86	28914-28918	3.72	_	
162-87	28918-28919	,	_	
162-88	28920-28921	z	_	
162-89	28922-28923	=	_	
162-90	28924-28925	−	_	
162-91	28925-28929	1.93	_	
162-92	28929-28930	,	_	
162-93	28931-28932	p	_	
162-94	28933-28934	=	_	
162-95	28935-28939	.054	_	
162-96	28939-28940	)	_	
162-97	28940-28941	.	_	

#Text=However, this effect was no longer evident after adjusting for prenatal cannabis exposure (baseline + prenatal cannabis exposure: χ2(1) = 1.98, z = −1.41, p = .159).
163-1	28942-28949	However	_	
163-2	28949-28950	,	_	
163-3	28951-28955	this	_	
163-4	28956-28962	effect	_	
163-5	28963-28966	was	_	
163-6	28967-28969	no	_	
163-7	28970-28976	longer	_	
163-8	28977-28984	evident	_	
163-9	28985-28990	after	_	
163-10	28991-29000	adjusting	_	
163-11	29001-29004	for	_	
163-12	29005-29013	prenatal	_	
163-13	29014-29022	cannabis	_	
163-14	29023-29031	exposure	_	
163-15	29032-29033	(	_	
163-16	29033-29041	baseline	_	
163-17	29042-29043	+	_	
163-18	29044-29052	prenatal	_	
163-19	29053-29061	cannabis	_	
163-20	29062-29070	exposure	_	
163-21	29070-29071	:	_	
163-22	29072-29074	χ2	_	
163-23	29074-29075	(	_	
163-24	29075-29076	1	_	
163-25	29076-29077	)	_	
163-26	29078-29079	=	_	
163-27	29080-29084	1.98	_	
163-28	29084-29085	,	_	
163-29	29086-29087	z	_	
163-30	29088-29089	=	_	
163-31	29090-29091	−	_	
163-32	29091-29095	1.41	_	
163-33	29095-29096	,	_	
163-34	29097-29098	p	_	
163-35	29099-29100	=	_	
163-36	29101-29105	.159	_	
163-37	29105-29106	)	_	
163-38	29106-29107	.	_	

#Text=No significant task interactions were observed for total cannabis use.
164-1	29108-29110	No	_	
164-2	29111-29122	significant	_	
164-3	29123-29127	task	_	
164-4	29128-29140	interactions	_	
164-5	29141-29145	were	_	
164-6	29146-29154	observed	_	
164-7	29155-29158	for	_	
164-8	29159-29164	total	_	
164-9	29165-29173	cannabis	_	
164-10	29174-29177	use	_	
164-11	29177-29178	.	_	

#Text=See Fig. 2 for a summary of behavioral results.
#Text=interactions between cannabis age of onset and total cannabis use
#Text=Within the REP group, significant interactions were not observed between cannabis age of onset and total cannabis use for WM accuracy (baseline model: χ2(1) = 0.09, z = 0.29, p = .768; full model (covariate set B): χ2(1) = 0.10, z = 0.31, p = .753) or WM RT (baseline model: χ2(1) = 0.51, z = −0.72, p = .474; full model (covariate set B): χ2(1) = 0.29, z = −0.54, p = .592), suggesting there were no combined effects of cannabis age of onset and total cannabis use on WM behavior and age of onset associations were not dose-dependent.
165-1	29179-29182	See	_	
165-2	29183-29186	Fig	_	
165-3	29186-29187	.	_	
165-4	29188-29189	2	_	
165-5	29190-29193	for	_	
165-6	29194-29195	a	_	
165-7	29196-29203	summary	_	
165-8	29204-29206	of	_	
165-9	29207-29217	behavioral	_	
165-10	29218-29225	results	_	
165-11	29225-29226	.	_	
165-12	29227-29239	interactions	_	
165-13	29240-29247	between	_	
165-14	29248-29256	cannabis	_	
165-15	29257-29260	age	_	
165-16	29261-29263	of	_	
165-17	29264-29269	onset	_	
165-18	29270-29273	and	_	
165-19	29274-29279	total	_	
165-20	29280-29288	cannabis	_	
165-21	29289-29292	use	_	
165-22	29293-29299	Within	_	
165-23	29300-29303	the	_	
165-24	29304-29307	REP	_	
165-25	29308-29313	group	_	
165-26	29313-29314	,	_	
165-27	29315-29326	significant	_	
165-28	29327-29339	interactions	_	
165-29	29340-29344	were	_	
165-30	29345-29348	not	_	
165-31	29349-29357	observed	_	
165-32	29358-29365	between	_	
165-33	29366-29374	cannabis	_	
165-34	29375-29378	age	_	
165-35	29379-29381	of	_	
165-36	29382-29387	onset	_	
165-37	29388-29391	and	_	
165-38	29392-29397	total	_	
165-39	29398-29406	cannabis	_	
165-40	29407-29410	use	_	
165-41	29411-29414	for	_	
165-42	29415-29417	WM	_	
165-43	29418-29426	accuracy	_	
165-44	29427-29428	(	_	
165-45	29428-29436	baseline	_	
165-46	29437-29442	model	_	
165-47	29442-29443	:	_	
165-48	29444-29446	χ2	_	
165-49	29446-29447	(	_	
165-50	29447-29448	1	_	
165-51	29448-29449	)	_	
165-52	29450-29451	=	_	
165-53	29452-29456	0.09	_	
165-54	29456-29457	,	_	
165-55	29458-29459	z	_	
165-56	29460-29461	=	_	
165-57	29462-29466	0.29	_	
165-58	29466-29467	,	_	
165-59	29468-29469	p	_	
165-60	29470-29471	=	_	
165-61	29472-29476	.768	_	
165-62	29476-29477	;	_	
165-63	29478-29482	full	_	
165-64	29483-29488	model	_	
165-65	29489-29490	(	_	
165-66	29490-29499	covariate	_	
165-67	29500-29503	set	_	
165-68	29504-29505	B	_	
165-69	29505-29506	)	_	
165-70	29506-29507	:	_	
165-71	29508-29510	χ2	_	
165-72	29510-29511	(	_	
165-73	29511-29512	1	_	
165-74	29512-29513	)	_	
165-75	29514-29515	=	_	
165-76	29516-29520	0.10	_	
165-77	29520-29521	,	_	
165-78	29522-29523	z	_	
165-79	29524-29525	=	_	
165-80	29526-29530	0.31	_	
165-81	29530-29531	,	_	
165-82	29532-29533	p	_	
165-83	29534-29535	=	_	
165-84	29536-29540	.753	_	
165-85	29540-29541	)	_	
165-86	29542-29544	or	_	
165-87	29545-29547	WM	_	
165-88	29548-29550	RT	_	
165-89	29551-29552	(	_	
165-90	29552-29560	baseline	_	
165-91	29561-29566	model	_	
165-92	29566-29567	:	_	
165-93	29568-29570	χ2	_	
165-94	29570-29571	(	_	
165-95	29571-29572	1	_	
165-96	29572-29573	)	_	
165-97	29574-29575	=	_	
165-98	29576-29580	0.51	_	
165-99	29580-29581	,	_	
165-100	29582-29583	z	_	
165-101	29584-29585	=	_	
165-102	29586-29587	−	_	
165-103	29587-29591	0.72	_	
165-104	29591-29592	,	_	
165-105	29593-29594	p	_	
165-106	29595-29596	=	_	
165-107	29597-29601	.474	_	
165-108	29601-29602	;	_	
165-109	29603-29607	full	_	
165-110	29608-29613	model	_	
165-111	29614-29615	(	_	
165-112	29615-29624	covariate	_	
165-113	29625-29628	set	_	
165-114	29629-29630	B	_	
165-115	29630-29631	)	_	
165-116	29631-29632	:	_	
165-117	29633-29635	χ2	_	
165-118	29635-29636	(	_	
165-119	29636-29637	1	_	
165-120	29637-29638	)	_	
165-121	29639-29640	=	_	
165-122	29641-29645	0.29	_	
165-123	29645-29646	,	_	
165-124	29647-29648	z	_	
165-125	29649-29650	=	_	
165-126	29651-29652	−	_	
165-127	29652-29656	0.54	_	
165-128	29656-29657	,	_	
165-129	29658-29659	p	_	
165-130	29660-29661	=	_	
165-131	29662-29666	.592	_	
165-132	29666-29667	)	_	
165-133	29667-29668	,	_	
165-134	29669-29679	suggesting	_	
165-135	29680-29685	there	_	
165-136	29686-29690	were	_	
165-137	29691-29693	no	_	
165-138	29694-29702	combined	_	
165-139	29703-29710	effects	_	
165-140	29711-29713	of	_	
165-141	29714-29722	cannabis	_	
165-142	29723-29726	age	_	
165-143	29727-29729	of	_	
165-144	29730-29735	onset	_	
165-145	29736-29739	and	_	
165-146	29740-29745	total	_	
165-147	29746-29754	cannabis	_	
165-148	29755-29758	use	_	
165-149	29759-29761	on	_	
165-150	29762-29764	WM	_	
165-151	29765-29773	behavior	_	
165-152	29774-29777	and	_	
165-153	29778-29781	age	_	
165-154	29782-29784	of	_	
165-155	29785-29790	onset	_	
165-156	29791-29803	associations	_	
165-157	29804-29808	were	_	
165-158	29809-29812	not	_	
165-159	29813-29827	dose-dependent	_	
165-160	29827-29828	.	_	

#Text=Cannabis use in the last year
#Text=Cannabis use in the last year did not moderate the effects of cannabis age of onset or total cannabis use nor was it a significant predictor of WM accuracy or WM RT (Supplemental Fig.
166-1	29829-29837	Cannabis	_	
166-2	29838-29841	use	_	
166-3	29842-29844	in	_	
166-4	29845-29848	the	_	
166-5	29849-29853	last	_	
166-6	29854-29858	year	_	
166-7	29859-29867	Cannabis	_	
166-8	29868-29871	use	_	
166-9	29872-29874	in	_	
166-10	29875-29878	the	_	
166-11	29879-29883	last	_	
166-12	29884-29888	year	_	
166-13	29889-29892	did	_	
166-14	29893-29896	not	_	
166-15	29897-29905	moderate	_	
166-16	29906-29909	the	_	
166-17	29910-29917	effects	_	
166-18	29918-29920	of	_	
166-19	29921-29929	cannabis	_	
166-20	29930-29933	age	_	
166-21	29934-29936	of	_	
166-22	29937-29942	onset	_	
166-23	29943-29945	or	_	
166-24	29946-29951	total	_	
166-25	29952-29960	cannabis	_	
166-26	29961-29964	use	_	
166-27	29965-29968	nor	_	
166-28	29969-29972	was	_	
166-29	29973-29975	it	_	
166-30	29976-29977	a	_	
166-31	29978-29989	significant	_	
166-32	29990-29999	predictor	_	
166-33	30000-30002	of	_	
166-34	30003-30005	WM	_	
166-35	30006-30014	accuracy	_	
166-36	30015-30017	or	_	
166-37	30018-30020	WM	_	
166-38	30021-30023	RT	_	
166-39	30024-30025	(	_	
166-40	30025-30037	Supplemental	_	
166-41	30038-30041	Fig	_	
166-42	30041-30042	.	_	

#Text=S4).
167-1	30043-30045	S4	_	
167-2	30045-30046	)	_	
167-3	30046-30047	.	_	

#Text=Group differences in WM behavior
#Text=To examine whether cannabis use effects generalized to potential group differences with non-user participants (NU), we first compared a categorical model of cannabis use (EXP + REP) to NU (Fig. 3).
168-1	30048-30053	Group	_	
168-2	30054-30065	differences	_	
168-3	30066-30068	in	_	
168-4	30069-30071	WM	_	
168-5	30072-30080	behavior	_	
168-6	30081-30083	To	_	
168-7	30084-30091	examine	_	
168-8	30092-30099	whether	_	
168-9	30100-30108	cannabis	_	
168-10	30109-30112	use	_	
168-11	30113-30120	effects	_	
168-12	30121-30132	generalized	_	
168-13	30133-30135	to	_	
168-14	30136-30145	potential	_	
168-15	30146-30151	group	_	
168-16	30152-30163	differences	_	
168-17	30164-30168	with	_	
168-18	30169-30177	non-user	_	
168-19	30178-30190	participants	_	
168-20	30191-30192	(	_	
168-21	30192-30194	NU	_	
168-22	30194-30195	)	_	
168-23	30195-30196	,	_	
168-24	30197-30199	we	_	
168-25	30200-30205	first	_	
168-26	30206-30214	compared	_	
168-27	30215-30216	a	_	
168-28	30217-30228	categorical	_	
168-29	30229-30234	model	_	
168-30	30235-30237	of	_	
168-31	30238-30246	cannabis	_	
168-32	30247-30250	use	_	
168-33	30251-30252	(	_	
168-34	30252-30255	EXP	_	
168-35	30256-30257	+	_	
168-36	30258-30261	REP	_	
168-37	30261-30262	)	_	
168-38	30263-30265	to	_	
168-39	30266-30268	NU	_	
168-40	30269-30270	(	_	
168-41	30270-30273	Fig	_	
168-42	30273-30274	.	_	
168-43	30275-30276	3	_	
168-44	30276-30277	)	_	
168-45	30277-30278	.	_	

#Text=There was a trend for cannabis users to have higher accuracy than NU (baseline: χ2(1) = 3.79, z = 1.95, p = .052), which was relatively unchanged by the inclusion of distinguishing covariates (full model (covariate set C): χ2(1) = 4.78, z = 2.19, p = .029) and was significant when the analysis only included women (full model (w): χ2(1) = 5.71, z = 2.39, p = .017).
169-1	30279-30284	There	_	
169-2	30285-30288	was	_	
169-3	30289-30290	a	_	
169-4	30291-30296	trend	_	
169-5	30297-30300	for	_	
169-6	30301-30309	cannabis	_	
169-7	30310-30315	users	_	
169-8	30316-30318	to	_	
169-9	30319-30323	have	_	
169-10	30324-30330	higher	_	
169-11	30331-30339	accuracy	_	
169-12	30340-30344	than	_	
169-13	30345-30347	NU	_	
169-14	30348-30349	(	_	
169-15	30349-30357	baseline	_	
169-16	30357-30358	:	_	
169-17	30359-30361	χ2	_	
169-18	30361-30362	(	_	
169-19	30362-30363	1	_	
169-20	30363-30364	)	_	
169-21	30365-30366	=	_	
169-22	30367-30371	3.79	_	
169-23	30371-30372	,	_	
169-24	30373-30374	z	_	
169-25	30375-30376	=	_	
169-26	30377-30381	1.95	_	
169-27	30381-30382	,	_	
169-28	30383-30384	p	_	
169-29	30385-30386	=	_	
169-30	30387-30391	.052	_	
169-31	30391-30392	)	_	
169-32	30392-30393	,	_	
169-33	30394-30399	which	_	
169-34	30400-30403	was	_	
169-35	30404-30414	relatively	_	
169-36	30415-30424	unchanged	_	
169-37	30425-30427	by	_	
169-38	30428-30431	the	_	
169-39	30432-30441	inclusion	_	
169-40	30442-30444	of	_	
169-41	30445-30459	distinguishing	_	
169-42	30460-30470	covariates	_	
169-43	30471-30472	(	_	
169-44	30472-30476	full	_	
169-45	30477-30482	model	_	
169-46	30483-30484	(	_	
169-47	30484-30493	covariate	_	
169-48	30494-30497	set	_	
169-49	30498-30499	C	_	
169-50	30499-30500	)	_	
169-51	30500-30501	:	_	
169-52	30502-30504	χ2	_	
169-53	30504-30505	(	_	
169-54	30505-30506	1	_	
169-55	30506-30507	)	_	
169-56	30508-30509	=	_	
169-57	30510-30514	4.78	_	
169-58	30514-30515	,	_	
169-59	30516-30517	z	_	
169-60	30518-30519	=	_	
169-61	30520-30524	2.19	_	
169-62	30524-30525	,	_	
169-63	30526-30527	p	_	
169-64	30528-30529	=	_	
169-65	30530-30534	.029	_	
169-66	30534-30535	)	_	
169-67	30536-30539	and	_	
169-68	30540-30543	was	_	
169-69	30544-30555	significant	_	
169-70	30556-30560	when	_	
169-71	30561-30564	the	_	
169-72	30565-30573	analysis	_	
169-73	30574-30578	only	_	
169-74	30579-30587	included	_	
169-75	30588-30593	women	_	
169-76	30594-30595	(	_	
169-77	30595-30599	full	_	
169-78	30600-30605	model	_	
169-79	30606-30607	(	_	
169-80	30607-30608	w	_	
169-81	30608-30609	)	_	
169-82	30609-30610	:	_	
169-83	30611-30613	χ2	_	
169-84	30613-30614	(	_	
169-85	30614-30615	1	_	
169-86	30615-30616	)	_	
169-87	30617-30618	=	_	
169-88	30619-30623	5.71	_	
169-89	30623-30624	,	_	
169-90	30625-30626	z	_	
169-91	30627-30628	=	_	
169-92	30629-30633	2.39	_	
169-93	30633-30634	,	_	
169-94	30635-30636	p	_	
169-95	30637-30638	=	_	
169-96	30639-30643	.017	_	
169-97	30643-30644	)	_	
169-98	30644-30645	.	_	

#Text=A combined cannabis group also had significantly faster RT than NU in both a baseline (χ2(1) = 5.49, t = −2.34, p = .019) and full model (χ2(1) = 5.35, t = −2.31, p = .021).
170-1	30646-30647	A	_	
170-2	30648-30656	combined	_	
170-3	30657-30665	cannabis	_	
170-4	30666-30671	group	_	
170-5	30672-30676	also	_	
170-6	30677-30680	had	_	
170-7	30681-30694	significantly	_	
170-8	30695-30701	faster	_	
170-9	30702-30704	RT	_	
170-10	30705-30709	than	_	
170-11	30710-30712	NU	_	
170-12	30713-30715	in	_	
170-13	30716-30720	both	_	
170-14	30721-30722	a	_	
170-15	30723-30731	baseline	_	
170-16	30732-30733	(	_	
170-17	30733-30735	χ2	_	
170-18	30735-30736	(	_	
170-19	30736-30737	1	_	
170-20	30737-30738	)	_	
170-21	30739-30740	=	_	
170-22	30741-30745	5.49	_	
170-23	30745-30746	,	_	
170-24	30747-30748	t	_	
170-25	30749-30750	=	_	
170-26	30751-30752	−	_	
170-27	30752-30756	2.34	_	
170-28	30756-30757	,	_	
170-29	30758-30759	p	_	
170-30	30760-30761	=	_	
170-31	30762-30766	.019	_	
170-32	30766-30767	)	_	
170-33	30768-30771	and	_	
170-34	30772-30776	full	_	
170-35	30777-30782	model	_	
170-36	30783-30784	(	_	
170-37	30784-30786	χ2	_	
170-38	30786-30787	(	_	
170-39	30787-30788	1	_	
170-40	30788-30789	)	_	
170-41	30790-30791	=	_	
170-42	30792-30796	5.35	_	
170-43	30796-30797	,	_	
170-44	30798-30799	t	_	
170-45	30800-30801	=	_	
170-46	30802-30803	−	_	
170-47	30803-30807	2.31	_	
170-48	30807-30808	,	_	
170-49	30809-30810	p	_	
170-50	30811-30812	=	_	
170-51	30813-30817	.021	_	
170-52	30817-30818	)	_	
170-53	30818-30819	.	_	

#Text=However, this was not significant when the analysis only included women (full model (w): χ2(1) = 1.46, t = −1.21, p = .227).
171-1	30820-30827	However	_	
171-2	30827-30828	,	_	
171-3	30829-30833	this	_	
171-4	30834-30837	was	_	
171-5	30838-30841	not	_	
171-6	30842-30853	significant	_	
171-7	30854-30858	when	_	
171-8	30859-30862	the	_	
171-9	30863-30871	analysis	_	
171-10	30872-30876	only	_	
171-11	30877-30885	included	_	
171-12	30886-30891	women	_	
171-13	30892-30893	(	_	
171-14	30893-30897	full	_	
171-15	30898-30903	model	_	
171-16	30904-30905	(	_	
171-17	30905-30906	w	_	
171-18	30906-30907	)	_	
171-19	30907-30908	:	_	
171-20	30909-30911	χ2	_	
171-21	30911-30912	(	_	
171-22	30912-30913	1	_	
171-23	30913-30914	)	_	
171-24	30915-30916	=	_	
171-25	30917-30921	1.46	_	
171-26	30921-30922	,	_	
171-27	30923-30924	t	_	
171-28	30925-30926	=	_	
171-29	30927-30928	−	_	
171-30	30928-30932	1.21	_	
171-31	30932-30933	,	_	
171-32	30934-30935	p	_	
171-33	30936-30937	=	_	
171-34	30938-30942	.227	_	
171-35	30942-30943	)	_	
171-36	30943-30944	.	_	

#Text=In contrast, cannabis use groups (REP vs.
172-1	30945-30947	In	_	
172-2	30948-30956	contrast	_	
172-3	30956-30957	,	_	
172-4	30958-30966	cannabis	_	
172-5	30967-30970	use	_	
172-6	30971-30977	groups	_	
172-7	30978-30979	(	_	
172-8	30979-30982	REP	_	
172-9	30983-30985	vs	_	
172-10	30985-30986	.	_	

#Text=EXP) did not differ from one another in accuracy (baseline: χ2(1) = 1.40, z = −1.19, p = .237; full model: χ2(1) = 1.02, z = −1.01, p = .312) or RT (baseline: χ2(1) = 0.13, t = 0.36 p = .719; full model: χ2(1) = 0.47, t = −0.69, p = .492).
173-1	30987-30990	EXP	_	
173-2	30990-30991	)	_	
173-3	30992-30995	did	_	
173-4	30996-30999	not	_	
173-5	31000-31006	differ	_	
173-6	31007-31011	from	_	
173-7	31012-31015	one	_	
173-8	31016-31023	another	_	
173-9	31024-31026	in	_	
173-10	31027-31035	accuracy	_	
173-11	31036-31037	(	_	
173-12	31037-31045	baseline	_	
173-13	31045-31046	:	_	
173-14	31047-31049	χ2	_	
173-15	31049-31050	(	_	
173-16	31050-31051	1	_	
173-17	31051-31052	)	_	
173-18	31053-31054	=	_	
173-19	31055-31059	1.40	_	
173-20	31059-31060	,	_	
173-21	31061-31062	z	_	
173-22	31063-31064	=	_	
173-23	31065-31066	−	_	
173-24	31066-31070	1.19	_	
173-25	31070-31071	,	_	
173-26	31072-31073	p	_	
173-27	31074-31075	=	_	
173-28	31076-31080	.237	_	
173-29	31080-31081	;	_	
173-30	31082-31086	full	_	
173-31	31087-31092	model	_	
173-32	31092-31093	:	_	
173-33	31094-31096	χ2	_	
173-34	31096-31097	(	_	
173-35	31097-31098	1	_	
173-36	31098-31099	)	_	
173-37	31100-31101	=	_	
173-38	31102-31106	1.02	_	
173-39	31106-31107	,	_	
173-40	31108-31109	z	_	
173-41	31110-31111	=	_	
173-42	31112-31113	−	_	
173-43	31113-31117	1.01	_	
173-44	31117-31118	,	_	
173-45	31119-31120	p	_	
173-46	31121-31122	=	_	
173-47	31123-31127	.312	_	
173-48	31127-31128	)	_	
173-49	31129-31131	or	_	
173-50	31132-31134	RT	_	
173-51	31135-31136	(	_	
173-52	31136-31144	baseline	_	
173-53	31144-31145	:	_	
173-54	31146-31148	χ2	_	
173-55	31148-31149	(	_	
173-56	31149-31150	1	_	
173-57	31150-31151	)	_	
173-58	31152-31153	=	_	
173-59	31154-31158	0.13	_	
173-60	31158-31159	,	_	
173-61	31160-31161	t	_	
173-62	31162-31163	=	_	
173-63	31164-31168	0.36	_	
173-64	31169-31170	p	_	
173-65	31171-31172	=	_	
173-66	31173-31177	.719	_	
173-67	31177-31178	;	_	
173-68	31179-31183	full	_	
173-69	31184-31189	model	_	
173-70	31189-31190	:	_	
173-71	31191-31193	χ2	_	
173-72	31193-31194	(	_	
173-73	31194-31195	1	_	
173-74	31195-31196	)	_	
173-75	31197-31198	=	_	
173-76	31199-31203	0.47	_	
173-77	31203-31204	,	_	
173-78	31205-31206	t	_	
173-79	31207-31208	=	_	
173-80	31209-31210	−	_	
173-81	31210-31214	0.69	_	
173-82	31214-31215	,	_	
173-83	31216-31217	p	_	
173-84	31218-31219	=	_	
173-85	31220-31224	.492	_	
173-86	31224-31225	)	_	
173-87	31225-31226	.	_	

#Text=Follow up post-hoc comparisons were made between NU and EXP and REP separately to determine if the general pattern of users performing better than NU was held across the two cannabis groups (EXP, REP).
174-1	31227-31233	Follow	_	
174-2	31234-31236	up	_	
174-3	31237-31245	post-hoc	_	
174-4	31246-31257	comparisons	_	
174-5	31258-31262	were	_	
174-6	31263-31267	made	_	
174-7	31268-31275	between	_	
174-8	31276-31278	NU	_	
174-9	31279-31282	and	_	
174-10	31283-31286	EXP	_	
174-11	31287-31290	and	_	
174-12	31291-31294	REP	_	
174-13	31295-31305	separately	_	
174-14	31306-31308	to	_	
174-15	31309-31318	determine	_	
174-16	31319-31321	if	_	
174-17	31322-31325	the	_	
174-18	31326-31333	general	_	
174-19	31334-31341	pattern	_	
174-20	31342-31344	of	_	
174-21	31345-31350	users	_	
174-22	31351-31361	performing	_	
174-23	31362-31368	better	_	
174-24	31369-31373	than	_	
174-25	31374-31376	NU	_	
174-26	31377-31380	was	_	
174-27	31381-31385	held	_	
174-28	31386-31392	across	_	
174-29	31393-31396	the	_	
174-30	31397-31400	two	_	
174-31	31401-31409	cannabis	_	
174-32	31410-31416	groups	_	
174-33	31417-31418	(	_	
174-34	31418-31421	EXP	_	
174-35	31421-31422	,	_	
174-36	31423-31426	REP	_	
174-37	31426-31427	)	_	
174-38	31427-31428	.	_	

#Text=EXP had higher WM accuracy than NU in both baseline (z = 2.28, p = .023) and full models (covariate set C: z = 2.33, p = .020).
175-1	31429-31432	EXP	_	
175-2	31433-31436	had	_	
175-3	31437-31443	higher	_	
175-4	31444-31446	WM	_	
175-5	31447-31455	accuracy	_	
175-6	31456-31460	than	_	
175-7	31461-31463	NU	_	
175-8	31464-31466	in	_	
175-9	31467-31471	both	_	
175-10	31472-31480	baseline	_	
175-11	31481-31482	(	_	
175-12	31482-31483	z	_	
175-13	31484-31485	=	_	
175-14	31486-31490	2.28	_	
175-15	31490-31491	,	_	
175-16	31492-31493	p	_	
175-17	31494-31495	=	_	
175-18	31496-31500	.023	_	
175-19	31500-31501	)	_	
175-20	31502-31505	and	_	
175-21	31506-31510	full	_	
175-22	31511-31517	models	_	
175-23	31518-31519	(	_	
175-24	31519-31528	covariate	_	
175-25	31529-31532	set	_	
175-26	31533-31534	C	_	
175-27	31534-31535	:	_	
175-28	31536-31537	z	_	
175-29	31538-31539	=	_	
175-30	31540-31544	2.33	_	
175-31	31544-31545	,	_	
175-32	31546-31547	p	_	
175-33	31548-31549	=	_	
175-34	31550-31554	.020	_	
175-35	31554-31555	)	_	
175-36	31555-31556	.	_	

#Text=Furthermore, EXP still had higher WM accuracy when the analysis included only women (full model (w): z = 3.05, p = .002).
176-1	31557-31568	Furthermore	_	
176-2	31568-31569	,	_	
176-3	31570-31573	EXP	_	
176-4	31574-31579	still	_	
176-5	31580-31583	had	_	
176-6	31584-31590	higher	_	
176-7	31591-31593	WM	_	
176-8	31594-31602	accuracy	_	
176-9	31603-31607	when	_	
176-10	31608-31611	the	_	
176-11	31612-31620	analysis	_	
176-12	31621-31629	included	_	
176-13	31630-31634	only	_	
176-14	31635-31640	women	_	
176-15	31641-31642	(	_	
176-16	31642-31646	full	_	
176-17	31647-31652	model	_	
176-18	31653-31654	(	_	
176-19	31654-31655	w	_	
176-20	31655-31656	)	_	
176-21	31656-31657	:	_	
176-22	31658-31659	z	_	
176-23	31660-31661	=	_	
176-24	31662-31666	3.05	_	
176-25	31666-31667	,	_	
176-26	31668-31669	p	_	
176-27	31670-31671	=	_	
176-28	31672-31676	.002	_	
176-29	31676-31677	)	_	
176-30	31677-31678	.	_	

#Text=There was a trend for EXP to have faster WM RT than NU (baseline: t (78.24) = 1.96, p = .053; full model: t(84.02) = 1.89, p = .062).
177-1	31679-31684	There	_	
177-2	31685-31688	was	_	
177-3	31689-31690	a	_	
177-4	31691-31696	trend	_	
177-5	31697-31700	for	_	
177-6	31701-31704	EXP	_	
177-7	31705-31707	to	_	
177-8	31708-31712	have	_	
177-9	31713-31719	faster	_	
177-10	31720-31722	WM	_	
177-11	31723-31725	RT	_	
177-12	31726-31730	than	_	
177-13	31731-31733	NU	_	
177-14	31734-31735	(	_	
177-15	31735-31743	baseline	_	
177-16	31743-31744	:	_	
177-17	31745-31746	t	_	
177-18	31747-31748	(	_	
177-19	31748-31753	78.24	_	
177-20	31753-31754	)	_	
177-21	31755-31756	=	_	
177-22	31757-31761	1.96	_	
177-23	31761-31762	,	_	
177-24	31763-31764	p	_	
177-25	31765-31766	=	_	
177-26	31767-31771	.053	_	
177-27	31771-31772	;	_	
177-28	31773-31777	full	_	
177-29	31778-31783	model	_	
177-30	31783-31784	:	_	
177-31	31785-31786	t	_	
177-32	31786-31787	(	_	
177-33	31787-31792	84.02	_	
177-34	31792-31793	)	_	
177-35	31794-31795	=	_	
177-36	31796-31800	1.89	_	
177-37	31800-31801	,	_	
177-38	31802-31803	p	_	
177-39	31804-31805	=	_	
177-40	31806-31810	.062	_	
177-41	31810-31811	)	_	
177-42	31811-31812	.	_	

#Text=However, this was not significant when the analysis included women only (full model (w): t(57.60) = 1.39, p = .168).
178-1	31813-31820	However	_	
178-2	31820-31821	,	_	
178-3	31822-31826	this	_	
178-4	31827-31830	was	_	
178-5	31831-31834	not	_	
178-6	31835-31846	significant	_	
178-7	31847-31851	when	_	
178-8	31852-31855	the	_	
178-9	31856-31864	analysis	_	
178-10	31865-31873	included	_	
178-11	31874-31879	women	_	
178-12	31880-31884	only	_	
178-13	31885-31886	(	_	
178-14	31886-31890	full	_	
178-15	31891-31896	model	_	
178-16	31897-31898	(	_	
178-17	31898-31899	w	_	
178-18	31899-31900	)	_	
178-19	31900-31901	:	_	
178-20	31902-31903	t	_	
178-21	31903-31904	(	_	
178-22	31904-31909	57.60	_	
178-23	31909-31910	)	_	
178-24	31911-31912	=	_	
178-25	31913-31917	1.39	_	
178-26	31917-31918	,	_	
178-27	31919-31920	p	_	
178-28	31921-31922	=	_	
178-29	31923-31927	.168	_	
178-30	31927-31928	)	_	
178-31	31928-31929	.	_	

#Text=There was a trend for REP to have higher WM accuracy than NU (baseline: z = 1.61, p = .110; full model: z = 1.73, p = .083) and this was unchanged when the analysis included only women (full model (w): z = 1.68, p = .093).
179-1	31930-31935	There	_	
179-2	31936-31939	was	_	
179-3	31940-31941	a	_	
179-4	31942-31947	trend	_	
179-5	31948-31951	for	_	
179-6	31952-31955	REP	_	
179-7	31956-31958	to	_	
179-8	31959-31963	have	_	
179-9	31964-31970	higher	_	
179-10	31971-31973	WM	_	
179-11	31974-31982	accuracy	_	
179-12	31983-31987	than	_	
179-13	31988-31990	NU	_	
179-14	31991-31992	(	_	
179-15	31992-32000	baseline	_	
179-16	32000-32001	:	_	
179-17	32002-32003	z	_	
179-18	32004-32005	=	_	
179-19	32006-32010	1.61	_	
179-20	32010-32011	,	_	
179-21	32012-32013	p	_	
179-22	32014-32015	=	_	
179-23	32016-32020	.110	_	
179-24	32020-32021	;	_	
179-25	32022-32026	full	_	
179-26	32027-32032	model	_	
179-27	32032-32033	:	_	
179-28	32034-32035	z	_	
179-29	32036-32037	=	_	
179-30	32038-32042	1.73	_	
179-31	32042-32043	,	_	
179-32	32044-32045	p	_	
179-33	32046-32047	=	_	
179-34	32048-32052	.083	_	
179-35	32052-32053	)	_	
179-36	32054-32057	and	_	
179-37	32058-32062	this	_	
179-38	32063-32066	was	_	
179-39	32067-32076	unchanged	_	
179-40	32077-32081	when	_	
179-41	32082-32085	the	_	
179-42	32086-32094	analysis	_	
179-43	32095-32103	included	_	
179-44	32104-32108	only	_	
179-45	32109-32114	women	_	
179-46	32115-32116	(	_	
179-47	32116-32120	full	_	
179-48	32121-32126	model	_	
179-49	32127-32128	(	_	
179-50	32128-32129	w	_	
179-51	32129-32130	)	_	
179-52	32130-32131	:	_	
179-53	32132-32133	z	_	
179-54	32134-32135	=	_	
179-55	32136-32140	1.68	_	
179-56	32140-32141	,	_	
179-57	32142-32143	p	_	
179-58	32144-32145	=	_	
179-59	32146-32150	.093	_	
179-60	32150-32151	)	_	
179-61	32151-32152	.	_	

#Text=REP had faster WM RT than NU in the both the baseline (t (78.24) = −2.15, p = .034) and full models (t (84.11) = 2.00, p = .049).
180-1	32153-32156	REP	_	
180-2	32157-32160	had	_	
180-3	32161-32167	faster	_	
180-4	32168-32170	WM	_	
180-5	32171-32173	RT	_	
180-6	32174-32178	than	_	
180-7	32179-32181	NU	_	
180-8	32182-32184	in	_	
180-9	32185-32188	the	_	
180-10	32189-32193	both	_	
180-11	32194-32197	the	_	
180-12	32198-32206	baseline	_	
180-13	32207-32208	(	_	
180-14	32208-32209	t	_	
180-15	32210-32211	(	_	
180-16	32211-32216	78.24	_	
180-17	32216-32217	)	_	
180-18	32218-32219	=	_	
180-19	32220-32221	−	_	
180-20	32221-32225	2.15	_	
180-21	32225-32226	,	_	
180-22	32227-32228	p	_	
180-23	32229-32230	=	_	
180-24	32231-32235	.034	_	
180-25	32235-32236	)	_	
180-26	32237-32240	and	_	
180-27	32241-32245	full	_	
180-28	32246-32252	models	_	
180-29	32253-32254	(	_	
180-30	32254-32255	t	_	
180-31	32256-32257	(	_	
180-32	32257-32262	84.11	_	
180-33	32262-32263	)	_	
180-34	32264-32265	=	_	
180-35	32266-32270	2.00	_	
180-36	32270-32271	,	_	
180-37	32272-32273	p	_	
180-38	32274-32275	=	_	
180-39	32276-32280	.049	_	
180-40	32280-32281	)	_	
180-41	32281-32282	.	_	

#Text=However, this was not significant when the analysis included women only (full model (w): t(57.78) = 0.75, p = .459).
181-1	32283-32290	However	_	
181-2	32290-32291	,	_	
181-3	32292-32296	this	_	
181-4	32297-32300	was	_	
181-5	32301-32304	not	_	
181-6	32305-32316	significant	_	
181-7	32317-32321	when	_	
181-8	32322-32325	the	_	
181-9	32326-32334	analysis	_	
181-10	32335-32343	included	_	
181-11	32344-32349	women	_	
181-12	32350-32354	only	_	
181-13	32355-32356	(	_	
181-14	32356-32360	full	_	
181-15	32361-32366	model	_	
181-16	32367-32368	(	_	
181-17	32368-32369	w	_	
181-18	32369-32370	)	_	
181-19	32370-32371	:	_	
181-20	32372-32373	t	_	
181-21	32373-32374	(	_	
181-22	32374-32379	57.78	_	
181-23	32379-32380	)	_	
181-24	32381-32382	=	_	
181-25	32383-32387	0.75	_	
181-26	32387-32388	,	_	
181-27	32389-32390	p	_	
181-28	32391-32392	=	_	
181-29	32393-32397	.459	_	
181-30	32397-32398	)	_	
181-31	32398-32399	.	_	

#Text=Cannabis use and WM fMRI
#Text=Session-wise motion (mean Euclidean norm) was not associated with cannabis age of onset (r = .087, p = .511) or total cannabis use (log, r = - .226, p = .131) and did not differ between usage groups (p’s > .5).
182-1	32400-32408	Cannabis	_	
182-2	32409-32412	use	_	
182-3	32413-32416	and	_	
182-4	32417-32419	WM	_	
182-5	32420-32424	fMRI	_	
182-6	32425-32437	Session-wise	_	
182-7	32438-32444	motion	_	
182-8	32445-32446	(	_	
182-9	32446-32450	mean	_	
182-10	32451-32460	Euclidean	_	
182-11	32461-32465	norm	_	
182-12	32465-32466	)	_	
182-13	32467-32470	was	_	
182-14	32471-32474	not	_	
182-15	32475-32485	associated	_	
182-16	32486-32490	with	_	
182-17	32491-32499	cannabis	_	
182-18	32500-32503	age	_	
182-19	32504-32506	of	_	
182-20	32507-32512	onset	_	
182-21	32513-32514	(	_	
182-22	32514-32515	r	_	
182-23	32516-32517	=	_	
182-24	32518-32522	.087	_	
182-25	32522-32523	,	_	
182-26	32524-32525	p	_	
182-27	32526-32527	=	_	
182-28	32528-32532	.511	_	
182-29	32532-32533	)	_	
182-30	32534-32536	or	_	
182-31	32537-32542	total	_	
182-32	32543-32551	cannabis	_	
182-33	32552-32555	use	_	
182-34	32556-32557	(	_	
182-35	32557-32560	log	_	
182-36	32560-32561	,	_	
182-37	32562-32563	r	_	
182-38	32564-32565	=	_	
182-39	32566-32567	-	_	
182-40	32568-32572	.226	_	
182-41	32572-32573	,	_	
182-42	32574-32575	p	_	
182-43	32576-32577	=	_	
182-44	32578-32582	.131	_	
182-45	32582-32583	)	_	
182-46	32584-32587	and	_	
182-47	32588-32591	did	_	
182-48	32592-32595	not	_	
182-49	32596-32602	differ	_	
182-50	32603-32610	between	_	
182-51	32611-32616	usage	_	
182-52	32617-32623	groups	_	
182-53	32624-32625	(	_	
182-54	32625-32626	p	_	
182-55	32626-32627	’	_	
182-56	32627-32628	s	_	
182-57	32629-32630	>	_	
182-58	32631-32633	.5	_	
182-59	32633-32634	)	_	
182-60	32634-32635	.	_	

#Text=Likewise, the number of censored volumes was not associated with cannabis age of onset (r = .124, p = .339) or total cannabis use (log, r = .160, p = .287) and did not differ between usage groups (p’s > .5).
183-1	32636-32644	Likewise	_	
183-2	32644-32645	,	_	
183-3	32646-32649	the	_	
183-4	32650-32656	number	_	
183-5	32657-32659	of	_	
183-6	32660-32668	censored	_	
183-7	32669-32676	volumes	_	
183-8	32677-32680	was	_	
183-9	32681-32684	not	_	
183-10	32685-32695	associated	_	
183-11	32696-32700	with	_	
183-12	32701-32709	cannabis	_	
183-13	32710-32713	age	_	
183-14	32714-32716	of	_	
183-15	32717-32722	onset	_	
183-16	32723-32724	(	_	
183-17	32724-32725	r	_	
183-18	32726-32727	=	_	
183-19	32728-32732	.124	_	
183-20	32732-32733	,	_	
183-21	32734-32735	p	_	
183-22	32736-32737	=	_	
183-23	32738-32742	.339	_	
183-24	32742-32743	)	_	
183-25	32744-32746	or	_	
183-26	32747-32752	total	_	
183-27	32753-32761	cannabis	_	
183-28	32762-32765	use	_	
183-29	32766-32767	(	_	
183-30	32767-32770	log	_	
183-31	32770-32771	,	_	
183-32	32772-32773	r	_	
183-33	32774-32775	=	_	
183-34	32776-32780	.160	_	
183-35	32780-32781	,	_	
183-36	32782-32783	p	_	
183-37	32784-32785	=	_	
183-38	32786-32790	.287	_	
183-39	32790-32791	)	_	
183-40	32792-32795	and	_	
183-41	32796-32799	did	_	
183-42	32800-32803	not	_	
183-43	32804-32810	differ	_	
183-44	32811-32818	between	_	
183-45	32819-32824	usage	_	
183-46	32825-32831	groups	_	
183-47	32832-32833	(	_	
183-48	32833-32834	p	_	
183-49	32834-32835	’	_	
183-50	32835-32836	s	_	
183-51	32837-32838	>	_	
183-52	32839-32841	.5	_	
183-53	32841-32842	)	_	
183-54	32842-32843	.	_	

#Text=Robust, trail-wise BOLD activation was observed in canonical working memory regions during the task (Supplemental Fig.
184-1	32844-32850	Robust	_	
184-2	32850-32851	,	_	
184-3	32852-32862	trail-wise	_	
184-4	32863-32867	BOLD	_	
184-5	32868-32878	activation	_	
184-6	32879-32882	was	_	
184-7	32883-32891	observed	_	
184-8	32892-32894	in	_	
184-9	32895-32904	canonical	_	
184-10	32905-32912	working	_	
184-11	32913-32919	memory	_	
184-12	32920-32927	regions	_	
184-13	32928-32934	during	_	
184-14	32935-32938	the	_	
184-15	32939-32943	task	_	
184-16	32944-32945	(	_	
184-17	32945-32957	Supplemental	_	
184-18	32958-32961	Fig	_	
184-19	32961-32962	.	_	

#Text=S4).
185-1	32963-32965	S4	_	
185-2	32965-32966	)	_	
185-3	32966-32967	.	_	

#Text=Omnibus testing of the HRF time series revealed activation differences as a function of cannabis age of onset in the posterior parietal cortex (PPC) and the posterior cingulate (Table 3).
186-1	32968-32975	Omnibus	_	
186-2	32976-32983	testing	_	
186-3	32984-32986	of	_	
186-4	32987-32990	the	_	
186-5	32991-32994	HRF	_	
186-6	32995-32999	time	_	
186-7	33000-33006	series	_	
186-8	33007-33015	revealed	_	
186-9	33016-33026	activation	_	
186-10	33027-33038	differences	_	
186-11	33039-33041	as	_	
186-12	33042-33043	a	_	
186-13	33044-33052	function	_	
186-14	33053-33055	of	_	
186-15	33056-33064	cannabis	_	
186-16	33065-33068	age	_	
186-17	33069-33071	of	_	
186-18	33072-33077	onset	_	
186-19	33078-33080	in	_	
186-20	33081-33084	the	_	
186-21	33085-33094	posterior	_	
186-22	33095-33103	parietal	_	
186-23	33104-33110	cortex	_	
186-24	33111-33112	(	_	
186-25	33112-33115	PPC	_	
186-26	33115-33116	)	_	
186-27	33117-33120	and	_	
186-28	33121-33124	the	_	
186-29	33125-33134	posterior	_	
186-30	33135-33144	cingulate	_	
186-31	33145-33146	(	_	
186-32	33146-33151	Table	_	
186-33	33152-33153	3	_	
186-34	33153-33154	)	_	
186-35	33154-33155	.	_	

#Text=When considering total cannabis use, omnibus activation differences were observed in bilateral DLPFC and the inferior frontal gyrus (Table 3).
187-1	33156-33160	When	_	
187-2	33161-33172	considering	_	
187-3	33173-33178	total	_	
187-4	33179-33187	cannabis	_	
187-5	33188-33191	use	_	
187-6	33191-33192	,	_	
187-7	33193-33200	omnibus	_	
187-8	33201-33211	activation	_	
187-9	33212-33223	differences	_	
187-10	33224-33228	were	_	
187-11	33229-33237	observed	_	
187-12	33238-33240	in	_	
187-13	33241-33250	bilateral	_	
187-14	33251-33256	DLPFC	_	
187-15	33257-33260	and	_	
187-16	33261-33264	the	_	
187-17	33265-33273	inferior	_	
187-18	33274-33281	frontal	_	
187-19	33282-33287	gyrus	_	
187-20	33288-33289	(	_	
187-21	33289-33294	Table	_	
187-22	33295-33296	3	_	
187-23	33296-33297	)	_	
187-24	33297-33298	.	_	

#Text=WM epochs
#Text=Epoch specific comparisons revealed a significant (after Bonferonni correction) positive relationship between cue (encoding) epoch activation and cannabis age of onset in the PPC (cluster A), where those who began using earlier had reduced activation (standardized regression coefficient (β = .428, t(56) = 3.55, p = .002, corrected; Table 4; Fig. 4).
188-1	33299-33301	WM	_	
188-2	33302-33308	epochs	_	
188-3	33309-33314	Epoch	_	
188-4	33315-33323	specific	_	
188-5	33324-33335	comparisons	_	
188-6	33336-33344	revealed	_	
188-7	33345-33346	a	_	
188-8	33347-33358	significant	_	
188-9	33359-33360	(	_	
188-10	33360-33365	after	_	
188-11	33366-33376	Bonferonni	_	
188-12	33377-33387	correction	_	
188-13	33387-33388	)	_	
188-14	33389-33397	positive	_	
188-15	33398-33410	relationship	_	
188-16	33411-33418	between	_	
188-17	33419-33422	cue	_	
188-18	33423-33424	(	_	
188-19	33424-33432	encoding	_	
188-20	33432-33433	)	_	
188-21	33434-33439	epoch	_	
188-22	33440-33450	activation	_	
188-23	33451-33454	and	_	
188-24	33455-33463	cannabis	_	
188-25	33464-33467	age	_	
188-26	33468-33470	of	_	
188-27	33471-33476	onset	_	
188-28	33477-33479	in	_	
188-29	33480-33483	the	_	
188-30	33484-33487	PPC	_	
188-31	33488-33489	(	_	
188-32	33489-33496	cluster	_	
188-33	33497-33498	A	_	
188-34	33498-33499	)	_	
188-35	33499-33500	,	_	
188-36	33501-33506	where	_	
188-37	33507-33512	those	_	
188-38	33513-33516	who	_	
188-39	33517-33522	began	_	
188-40	33523-33528	using	_	
188-41	33529-33536	earlier	_	
188-42	33537-33540	had	_	
188-43	33541-33548	reduced	_	
188-44	33549-33559	activation	_	
188-45	33560-33561	(	_	
188-46	33561-33573	standardized	_	
188-47	33574-33584	regression	_	
188-48	33585-33596	coefficient	_	
188-49	33597-33598	(	_	
188-50	33598-33599	β	_	
188-51	33600-33601	=	_	
188-52	33602-33606	.428	_	
188-53	33606-33607	,	_	
188-54	33608-33609	t	_	
188-55	33609-33610	(	_	
188-56	33610-33612	56	_	
188-57	33612-33613	)	_	
188-58	33614-33615	=	_	
188-59	33616-33620	3.55	_	
188-60	33620-33621	,	_	
188-61	33622-33623	p	_	
188-62	33624-33625	=	_	
188-63	33626-33630	.002	_	
188-64	33630-33631	,	_	
188-65	33632-33641	corrected	_	
188-66	33641-33642	;	_	
188-67	33643-33648	Table	_	
188-68	33649-33650	4	_	
188-69	33650-33651	;	_	
188-70	33652-33655	Fig	_	
188-71	33655-33656	.	_	
188-72	33657-33658	4	_	
188-73	33658-33659	)	_	
188-74	33659-33660	.	_	

#Text=The association between cannabis age of onset and PPC cue BOLD activation did not differ between EXP and REP groups (t(54) = 0.43, p = .672), although the association was significant in the REP group (β = .423, t(44) = 3.10, p = .003, uncorrected, p = .010, corrected) but not the EXP group (β = .262, t(10) = 0.86, p = .410).
189-1	33661-33664	The	_	
189-2	33665-33676	association	_	
189-3	33677-33684	between	_	
189-4	33685-33693	cannabis	_	
189-5	33694-33697	age	_	
189-6	33698-33700	of	_	
189-7	33701-33706	onset	_	
189-8	33707-33710	and	_	
189-9	33711-33714	PPC	_	
189-10	33715-33718	cue	_	
189-11	33719-33723	BOLD	_	
189-12	33724-33734	activation	_	
189-13	33735-33738	did	_	
189-14	33739-33742	not	_	
189-15	33743-33749	differ	_	
189-16	33750-33757	between	_	
189-17	33758-33761	EXP	_	
189-18	33762-33765	and	_	
189-19	33766-33769	REP	_	
189-20	33770-33776	groups	_	
189-21	33777-33778	(	_	
189-22	33778-33779	t	_	
189-23	33779-33780	(	_	
189-24	33780-33782	54	_	
189-25	33782-33783	)	_	
189-26	33784-33785	=	_	
189-27	33786-33790	0.43	_	
189-28	33790-33791	,	_	
189-29	33792-33793	p	_	
189-30	33794-33795	=	_	
189-31	33796-33800	.672	_	
189-32	33800-33801	)	_	
189-33	33801-33802	,	_	
189-34	33803-33811	although	_	
189-35	33812-33815	the	_	
189-36	33816-33827	association	_	
189-37	33828-33831	was	_	
189-38	33832-33843	significant	_	
189-39	33844-33846	in	_	
189-40	33847-33850	the	_	
189-41	33851-33854	REP	_	
189-42	33855-33860	group	_	
189-43	33861-33862	(	_	
189-44	33862-33863	β	_	
189-45	33864-33865	=	_	
189-46	33866-33870	.423	_	
189-47	33870-33871	,	_	
189-48	33872-33873	t	_	
189-49	33873-33874	(	_	
189-50	33874-33876	44	_	
189-51	33876-33877	)	_	
189-52	33878-33879	=	_	
189-53	33880-33884	3.10	_	
189-54	33884-33885	,	_	
189-55	33886-33887	p	_	
189-56	33888-33889	=	_	
189-57	33890-33894	.003	_	
189-58	33894-33895	,	_	
189-59	33896-33907	uncorrected	_	
189-60	33907-33908	,	_	
189-61	33909-33910	p	_	
189-62	33911-33912	=	_	
189-63	33913-33917	.010	_	
189-64	33917-33918	,	_	
189-65	33919-33928	corrected	_	
189-66	33928-33929	)	_	
189-67	33930-33933	but	_	
189-68	33934-33937	not	_	
189-69	33938-33941	the	_	
189-70	33942-33945	EXP	_	
189-71	33946-33951	group	_	
189-72	33952-33953	(	_	
189-73	33953-33954	β	_	
189-74	33955-33956	=	_	
189-75	33957-33961	.262	_	
189-76	33961-33962	,	_	
189-77	33963-33964	t	_	
189-78	33964-33965	(	_	
189-79	33965-33967	10	_	
189-80	33967-33968	)	_	
189-81	33969-33970	=	_	
189-82	33971-33975	0.86	_	
189-83	33975-33976	,	_	
189-84	33977-33978	p	_	
189-85	33979-33980	=	_	
189-86	33981-33985	.410	_	
189-87	33985-33986	)	_	
189-88	33986-33987	.	_	

#Text=In the REP group, the association between cannabis age of onset and PPC (A) cue BOLD activation remained significant while covarying total cannabis use (β = .413, t(43) = 2.91, p = .006 uncorrected, p = .017, corrected) and total cannabis use was not a significant predictor of PPC cue BOLD activity (P = −.046, t(43) = −0.32, p = .749) nor did it moderate the effect of cannabis age of onset (age of onset by total cannabis use interaction: t(42) = −0.43, p = .673).
190-1	33988-33990	In	_	
190-2	33991-33994	the	_	
190-3	33995-33998	REP	_	
190-4	33999-34004	group	_	
190-5	34004-34005	,	_	
190-6	34006-34009	the	_	
190-7	34010-34021	association	_	
190-8	34022-34029	between	_	
190-9	34030-34038	cannabis	_	
190-10	34039-34042	age	_	
190-11	34043-34045	of	_	
190-12	34046-34051	onset	_	
190-13	34052-34055	and	_	
190-14	34056-34059	PPC	_	
190-15	34060-34061	(	_	
190-16	34061-34062	A	_	
190-17	34062-34063	)	_	
190-18	34064-34067	cue	_	
190-19	34068-34072	BOLD	_	
190-20	34073-34083	activation	_	
190-21	34084-34092	remained	_	
190-22	34093-34104	significant	_	
190-23	34105-34110	while	_	
190-24	34111-34120	covarying	_	
190-25	34121-34126	total	_	
190-26	34127-34135	cannabis	_	
190-27	34136-34139	use	_	
190-28	34140-34141	(	_	
190-29	34141-34142	β	_	
190-30	34143-34144	=	_	
190-31	34145-34149	.413	_	
190-32	34149-34150	,	_	
190-33	34151-34152	t	_	
190-34	34152-34153	(	_	
190-35	34153-34155	43	_	
190-36	34155-34156	)	_	
190-37	34157-34158	=	_	
190-38	34159-34163	2.91	_	
190-39	34163-34164	,	_	
190-40	34165-34166	p	_	
190-41	34167-34168	=	_	
190-42	34169-34173	.006	_	
190-43	34174-34185	uncorrected	_	
190-44	34185-34186	,	_	
190-45	34187-34188	p	_	
190-46	34189-34190	=	_	
190-47	34191-34195	.017	_	
190-48	34195-34196	,	_	
190-49	34197-34206	corrected	_	
190-50	34206-34207	)	_	
190-51	34208-34211	and	_	
190-52	34212-34217	total	_	
190-53	34218-34226	cannabis	_	
190-54	34227-34230	use	_	
190-55	34231-34234	was	_	
190-56	34235-34238	not	_	
190-57	34239-34240	a	_	
190-58	34241-34252	significant	_	
190-59	34253-34262	predictor	_	
190-60	34263-34265	of	_	
190-61	34266-34269	PPC	_	
190-62	34270-34273	cue	_	
190-63	34274-34278	BOLD	_	
190-64	34279-34287	activity	_	
190-65	34288-34289	(	_	
190-66	34289-34290	P	_	
190-67	34291-34292	=	_	
190-68	34293-34294	−	_	
190-69	34294-34298	.046	_	
190-70	34298-34299	,	_	
190-71	34300-34301	t	_	
190-72	34301-34302	(	_	
190-73	34302-34304	43	_	
190-74	34304-34305	)	_	
190-75	34306-34307	=	_	
190-76	34308-34309	−	_	
190-77	34309-34313	0.32	_	
190-78	34313-34314	,	_	
190-79	34315-34316	p	_	
190-80	34317-34318	=	_	
190-81	34319-34323	.749	_	
190-82	34323-34324	)	_	
190-83	34325-34328	nor	_	
190-84	34329-34332	did	_	
190-85	34333-34335	it	_	
190-86	34336-34344	moderate	_	
190-87	34345-34348	the	_	
190-88	34349-34355	effect	_	
190-89	34356-34358	of	_	
190-90	34359-34367	cannabis	_	
190-91	34368-34371	age	_	
190-92	34372-34374	of	_	
190-93	34375-34380	onset	_	
190-94	34381-34382	(	_	
190-95	34382-34385	age	_	
190-96	34386-34388	of	_	
190-97	34389-34394	onset	_	
190-98	34395-34397	by	_	
190-99	34398-34403	total	_	
190-100	34404-34412	cannabis	_	
190-101	34413-34416	use	_	
190-102	34417-34428	interaction	_	
190-103	34428-34429	:	_	
190-104	34430-34431	t	_	
190-105	34431-34432	(	_	
190-106	34432-34434	42	_	
190-107	34434-34435	)	_	
190-108	34436-34437	=	_	
190-109	34438-34439	−	_	
190-110	34439-34443	0.43	_	
190-111	34443-34444	,	_	
190-112	34445-34446	p	_	
190-113	34447-34448	=	_	
190-114	34449-34453	.673	_	
190-115	34453-34454	)	_	
190-116	34454-34455	.	_	

#Text=Epoch-specific BOLD associations with cannabis age of onset in other clusters (e.g., posterior cingulate) were not significant after multiple comparison correction (Table 4).
191-1	34456-34470	Epoch-specific	_	
191-2	34471-34475	BOLD	_	
191-3	34476-34488	associations	_	
191-4	34489-34493	with	_	
191-5	34494-34502	cannabis	_	
191-6	34503-34506	age	_	
191-7	34507-34509	of	_	
191-8	34510-34515	onset	_	
191-9	34516-34518	in	_	
191-10	34519-34524	other	_	
191-11	34525-34533	clusters	_	
191-12	34534-34535	(	_	
191-13	34535-34538	e.g	_	
191-14	34538-34539	.	_	
191-15	34539-34540	,	_	
191-16	34541-34550	posterior	_	
191-17	34551-34560	cingulate	_	
191-18	34560-34561	)	_	
191-19	34562-34566	were	_	
191-20	34567-34570	not	_	
191-21	34571-34582	significant	_	
191-22	34583-34588	after	_	
191-23	34589-34597	multiple	_	
191-24	34598-34608	comparison	_	
191-25	34609-34619	correction	_	
191-26	34620-34621	(	_	
191-27	34621-34626	Table	_	
191-28	34627-34628	4	_	
191-29	34628-34629	)	_	
191-30	34629-34630	.	_	

#Text=Higher levels of total cannabis use in the REP group were associated with increased activation in the R-DLPFC during the delay (maintenance) (β = .432, t(44) = 3.18, p = .008, corrected) and target (retrieval) (β = .478, t(44) = 3.61, p = .002, corrected) epochs (Table 5, Fig. 5).
192-1	34631-34637	Higher	_	
192-2	34638-34644	levels	_	
192-3	34645-34647	of	_	
192-4	34648-34653	total	_	
192-5	34654-34662	cannabis	_	
192-6	34663-34666	use	_	
192-7	34667-34669	in	_	
192-8	34670-34673	the	_	
192-9	34674-34677	REP	_	
192-10	34678-34683	group	_	
192-11	34684-34688	were	_	
192-12	34689-34699	associated	_	
192-13	34700-34704	with	_	
192-14	34705-34714	increased	_	
192-15	34715-34725	activation	_	
192-16	34726-34728	in	_	
192-17	34729-34732	the	_	
192-18	34733-34740	R-DLPFC	_	
192-19	34741-34747	during	_	
192-20	34748-34751	the	_	
192-21	34752-34757	delay	_	
192-22	34758-34759	(	_	
192-23	34759-34770	maintenance	_	
192-24	34770-34771	)	_	
192-25	34772-34773	(	_	
192-26	34773-34774	β	_	
192-27	34775-34776	=	_	
192-28	34777-34781	.432	_	
192-29	34781-34782	,	_	
192-30	34783-34784	t	_	
192-31	34784-34785	(	_	
192-32	34785-34787	44	_	
192-33	34787-34788	)	_	
192-34	34789-34790	=	_	
192-35	34791-34795	3.18	_	
192-36	34795-34796	,	_	
192-37	34797-34798	p	_	
192-38	34799-34800	=	_	
192-39	34801-34805	.008	_	
192-40	34805-34806	,	_	
192-41	34807-34816	corrected	_	
192-42	34816-34817	)	_	
192-43	34818-34821	and	_	
192-44	34822-34828	target	_	
192-45	34829-34830	(	_	
192-46	34830-34839	retrieval	_	
192-47	34839-34840	)	_	
192-48	34841-34842	(	_	
192-49	34842-34843	β	_	
192-50	34844-34845	=	_	
192-51	34846-34850	.478	_	
192-52	34850-34851	,	_	
192-53	34852-34853	t	_	
192-54	34853-34854	(	_	
192-55	34854-34856	44	_	
192-56	34856-34857	)	_	
192-57	34858-34859	=	_	
192-58	34860-34864	3.61	_	
192-59	34864-34865	,	_	
192-60	34866-34867	p	_	
192-61	34868-34869	=	_	
192-62	34870-34874	.002	_	
192-63	34874-34875	,	_	
192-64	34876-34885	corrected	_	
192-65	34885-34886	)	_	
192-66	34887-34893	epochs	_	
192-67	34894-34895	(	_	
192-68	34895-34900	Table	_	
192-69	34901-34902	5	_	
192-70	34902-34903	,	_	
192-71	34904-34907	Fig	_	
192-72	34907-34908	.	_	
192-73	34909-34910	5	_	
192-74	34910-34911	)	_	
192-75	34911-34912	.	_	

#Text=R- DLPFC delay and target BOLD activation remained significant while covarying cannabis age of onset (delay: β = .430, t(43) = 3.04, p = .012, corrected; target: β = .539, t(43) = 4.08, p = .0006, corrected).
193-1	34913-34914	R	_	
193-2	34914-34915	-	_	
193-3	34916-34921	DLPFC	_	
193-4	34922-34927	delay	_	
193-5	34928-34931	and	_	
193-6	34932-34938	target	_	
193-7	34939-34943	BOLD	_	
193-8	34944-34954	activation	_	
193-9	34955-34963	remained	_	
193-10	34964-34975	significant	_	
193-11	34976-34981	while	_	
193-12	34982-34991	covarying	_	
193-13	34992-35000	cannabis	_	
193-14	35001-35004	age	_	
193-15	35005-35007	of	_	
193-16	35008-35013	onset	_	
193-17	35014-35015	(	_	
193-18	35015-35020	delay	_	
193-19	35020-35021	:	_	
193-20	35022-35023	β	_	
193-21	35024-35025	=	_	
193-22	35026-35030	.430	_	
193-23	35030-35031	,	_	
193-24	35032-35033	t	_	
193-25	35033-35034	(	_	
193-26	35034-35036	43	_	
193-27	35036-35037	)	_	
193-28	35038-35039	=	_	
193-29	35040-35044	3.04	_	
193-30	35044-35045	,	_	
193-31	35046-35047	p	_	
193-32	35048-35049	=	_	
193-33	35050-35054	.012	_	
193-34	35054-35055	,	_	
193-35	35056-35065	corrected	_	
193-36	35065-35066	;	_	
193-37	35067-35073	target	_	
193-38	35073-35074	:	_	
193-39	35075-35076	β	_	
193-40	35077-35078	=	_	
193-41	35079-35083	.539	_	
193-42	35083-35084	,	_	
193-43	35085-35086	t	_	
193-44	35086-35087	(	_	
193-45	35087-35089	43	_	
193-46	35089-35090	)	_	
193-47	35091-35092	=	_	
193-48	35093-35097	4.08	_	
193-49	35097-35098	,	_	
193-50	35099-35100	p	_	
193-51	35101-35102	=	_	
193-52	35103-35108	.0006	_	
193-53	35108-35109	,	_	
193-54	35110-35119	corrected	_	
193-55	35119-35120	)	_	
193-56	35120-35121	.	_	

#Text=Further, cannabis age of onset was not a significant predictor of R-DLPFC delay BOLD activation in these models (delay: β = −.011, t(43) = −0.08, p = .940; target: β = .259, t(43) = 1.96, p = .057, corrected) nor did it moderate the effect of total cannabis use (delay: t(42) = −0.53, p = .600; target: t(42) = 0.68, p = .500).
194-1	35122-35129	Further	_	
194-2	35129-35130	,	_	
194-3	35131-35139	cannabis	_	
194-4	35140-35143	age	_	
194-5	35144-35146	of	_	
194-6	35147-35152	onset	_	
194-7	35153-35156	was	_	
194-8	35157-35160	not	_	
194-9	35161-35162	a	_	
194-10	35163-35174	significant	_	
194-11	35175-35184	predictor	_	
194-12	35185-35187	of	_	
194-13	35188-35195	R-DLPFC	_	
194-14	35196-35201	delay	_	
194-15	35202-35206	BOLD	_	
194-16	35207-35217	activation	_	
194-17	35218-35220	in	_	
194-18	35221-35226	these	_	
194-19	35227-35233	models	_	
194-20	35234-35235	(	_	
194-21	35235-35240	delay	_	
194-22	35240-35241	:	_	
194-23	35242-35243	β	_	
194-24	35244-35245	=	_	
194-25	35246-35247	−	_	
194-26	35247-35251	.011	_	
194-27	35251-35252	,	_	
194-28	35253-35254	t	_	
194-29	35254-35255	(	_	
194-30	35255-35257	43	_	
194-31	35257-35258	)	_	
194-32	35259-35260	=	_	
194-33	35261-35262	−	_	
194-34	35262-35266	0.08	_	
194-35	35266-35267	,	_	
194-36	35268-35269	p	_	
194-37	35270-35271	=	_	
194-38	35272-35276	.940	_	
194-39	35276-35277	;	_	
194-40	35278-35284	target	_	
194-41	35284-35285	:	_	
194-42	35286-35287	β	_	
194-43	35288-35289	=	_	
194-44	35290-35294	.259	_	
194-45	35294-35295	,	_	
194-46	35296-35297	t	_	
194-47	35297-35298	(	_	
194-48	35298-35300	43	_	
194-49	35300-35301	)	_	
194-50	35302-35303	=	_	
194-51	35304-35308	1.96	_	
194-52	35308-35309	,	_	
194-53	35310-35311	p	_	
194-54	35312-35313	=	_	
194-55	35314-35318	.057	_	
194-56	35318-35319	,	_	
194-57	35320-35329	corrected	_	
194-58	35329-35330	)	_	
194-59	35331-35334	nor	_	
194-60	35335-35338	did	_	
194-61	35339-35341	it	_	
194-62	35342-35350	moderate	_	
194-63	35351-35354	the	_	
194-64	35355-35361	effect	_	
194-65	35362-35364	of	_	
194-66	35365-35370	total	_	
194-67	35371-35379	cannabis	_	
194-68	35380-35383	use	_	
194-69	35384-35385	(	_	
194-70	35385-35390	delay	_	
194-71	35390-35391	:	_	
194-72	35392-35393	t	_	
194-73	35393-35394	(	_	
194-74	35394-35396	42	_	
194-75	35396-35397	)	_	
194-76	35398-35399	=	_	
194-77	35400-35401	−	_	
194-78	35401-35405	0.53	_	
194-79	35405-35406	,	_	
194-80	35407-35408	p	_	
194-81	35409-35410	=	_	
194-82	35411-35415	.600	_	
194-83	35415-35416	;	_	
194-84	35417-35423	target	_	
194-85	35423-35424	:	_	
194-86	35425-35426	t	_	
194-87	35426-35427	(	_	
194-88	35427-35429	42	_	
194-89	35429-35430	)	_	
194-90	35431-35432	=	_	
194-91	35433-35437	0.68	_	
194-92	35437-35438	,	_	
194-93	35439-35440	p	_	
194-94	35441-35442	=	_	
194-95	35443-35447	.500	_	
194-96	35447-35448	)	_	
194-97	35448-35449	.	_	

#Text=Epoch-specific BOLD associations with total cannabis use in other clusters (e.g., L-DLPFC, inferior frontal gyrus) were not significant after multiple comparison correction and adjusting for covariates (Table 5).
195-1	35450-35464	Epoch-specific	_	
195-2	35465-35469	BOLD	_	
195-3	35470-35482	associations	_	
195-4	35483-35487	with	_	
195-5	35488-35493	total	_	
195-6	35494-35502	cannabis	_	
195-7	35503-35506	use	_	
195-8	35507-35509	in	_	
195-9	35510-35515	other	_	
195-10	35516-35524	clusters	_	
195-11	35525-35526	(	_	
195-12	35526-35529	e.g	_	
195-13	35529-35530	.	_	
195-14	35530-35531	,	_	
195-15	35532-35539	L-DLPFC	_	
195-16	35539-35540	,	_	
195-17	35541-35549	inferior	_	
195-18	35550-35557	frontal	_	
195-19	35558-35563	gyrus	_	
195-20	35563-35564	)	_	
195-21	35565-35569	were	_	
195-22	35570-35573	not	_	
195-23	35574-35585	significant	_	
195-24	35586-35591	after	_	
195-25	35592-35600	multiple	_	
195-26	35601-35611	comparison	_	
195-27	35612-35622	correction	_	
195-28	35623-35626	and	_	
195-29	35627-35636	adjusting	_	
195-30	35637-35640	for	_	
195-31	35641-35651	covariates	_	
195-32	35652-35653	(	_	
195-33	35653-35658	Table	_	
195-34	35659-35660	5	_	
195-35	35660-35661	)	_	
195-36	35661-35662	.	_	

#Text=Brain-behavior relationships
#Text=Based on behavioral results, brain-behavior analyses were limited to RT for age of onset clusters, and accuracy for total use clusters.
196-1	35663-35677	Brain-behavior	_	
196-2	35678-35691	relationships	_	
196-3	35692-35697	Based	_	
196-4	35698-35700	on	_	
196-5	35701-35711	behavioral	_	
196-6	35712-35719	results	_	
196-7	35719-35720	,	_	
196-8	35721-35735	brain-behavior	_	
196-9	35736-35744	analyses	_	
196-10	35745-35749	were	_	
196-11	35750-35757	limited	_	
196-12	35758-35760	to	_	
196-13	35761-35763	RT	_	
196-14	35764-35767	for	_	
196-15	35768-35771	age	_	
196-16	35772-35774	of	_	
196-17	35775-35780	onset	_	
196-18	35781-35789	clusters	_	
196-19	35789-35790	,	_	
196-20	35791-35794	and	_	
196-21	35795-35803	accuracy	_	
196-22	35804-35807	for	_	
196-23	35808-35813	total	_	
196-24	35814-35817	use	_	
196-25	35818-35826	clusters	_	
196-26	35826-35827	.	_	

#Text=A significant (corrected) negative relationship was observed between cue epoch activation and RT (controlling for cannabis age of onset) in the PPC (cluster A), where those who had greater activation had faster RT’s (P = −.358, t (55) = −2.75, p = .024, corrected) (Fig. 6A; Table 4).
197-1	35828-35829	A	_	
197-2	35830-35841	significant	_	
197-3	35842-35843	(	_	
197-4	35843-35852	corrected	_	
197-5	35852-35853	)	_	
197-6	35854-35862	negative	_	
197-7	35863-35875	relationship	_	
197-8	35876-35879	was	_	
197-9	35880-35888	observed	_	
197-10	35889-35896	between	_	
197-11	35897-35900	cue	_	
197-12	35901-35906	epoch	_	
197-13	35907-35917	activation	_	
197-14	35918-35921	and	_	
197-15	35922-35924	RT	_	
197-16	35925-35926	(	_	
197-17	35926-35937	controlling	_	
197-18	35938-35941	for	_	
197-19	35942-35950	cannabis	_	
197-20	35951-35954	age	_	
197-21	35955-35957	of	_	
197-22	35958-35963	onset	_	
197-23	35963-35964	)	_	
197-24	35965-35967	in	_	
197-25	35968-35971	the	_	
197-26	35972-35975	PPC	_	
197-27	35976-35977	(	_	
197-28	35977-35984	cluster	_	
197-29	35985-35986	A	_	
197-30	35986-35987	)	_	
197-31	35987-35988	,	_	
197-32	35989-35994	where	_	
197-33	35995-36000	those	_	
197-34	36001-36004	who	_	
197-35	36005-36008	had	_	
197-36	36009-36016	greater	_	
197-37	36017-36027	activation	_	
197-38	36028-36031	had	_	
197-39	36032-36038	faster	_	
197-40	36039-36041	RT	_	
197-41	36041-36042	’	_	
197-42	36042-36043	s	_	
197-43	36044-36045	(	_	
197-44	36045-36046	P	_	
197-45	36047-36048	=	_	
197-46	36049-36050	−	_	
197-47	36050-36054	.358	_	
197-48	36054-36055	,	_	
197-49	36056-36057	t	_	
197-50	36058-36059	(	_	
197-51	36059-36061	55	_	
197-52	36061-36062	)	_	
197-53	36063-36064	=	_	
197-54	36065-36066	−	_	
197-55	36066-36070	2.75	_	
197-56	36070-36071	,	_	
197-57	36072-36073	p	_	
197-58	36074-36075	=	_	
197-59	36076-36080	.024	_	
197-60	36080-36081	,	_	
197-61	36082-36091	corrected	_	
197-62	36091-36092	)	_	
197-63	36093-36094	(	_	
197-64	36094-36097	Fig	_	
197-65	36097-36098	.	_	
197-66	36099-36101	6A	_	
197-67	36101-36102	;	_	
197-68	36103-36108	Table	_	
197-69	36109-36110	4	_	
197-70	36110-36111	)	_	
197-71	36111-36112	.	_	

#Text=Mediation analysis revealed that partialing out the variance of PPC (A) cue epoch activation significantly attenuated the relationship between cannabis age of onset and RT (baseline: average indirect pathway, β = −.153, 95% C.I., −.307: −.043, p = .003; full model (covariate set A): β = −.140,95% C.I., −.342: −.008, p = .029) (Fig. 6B).
198-1	36113-36122	Mediation	_	
198-2	36123-36131	analysis	_	
198-3	36132-36140	revealed	_	
198-4	36141-36145	that	_	
198-5	36146-36156	partialing	_	
198-6	36157-36160	out	_	
198-7	36161-36164	the	_	
198-8	36165-36173	variance	_	
198-9	36174-36176	of	_	
198-10	36177-36180	PPC	_	
198-11	36181-36182	(	_	
198-12	36182-36183	A	_	
198-13	36183-36184	)	_	
198-14	36185-36188	cue	_	
198-15	36189-36194	epoch	_	
198-16	36195-36205	activation	_	
198-17	36206-36219	significantly	_	
198-18	36220-36230	attenuated	_	
198-19	36231-36234	the	_	
198-20	36235-36247	relationship	_	
198-21	36248-36255	between	_	
198-22	36256-36264	cannabis	_	
198-23	36265-36268	age	_	
198-24	36269-36271	of	_	
198-25	36272-36277	onset	_	
198-26	36278-36281	and	_	
198-27	36282-36284	RT	_	
198-28	36285-36286	(	_	
198-29	36286-36294	baseline	_	
198-30	36294-36295	:	_	
198-31	36296-36303	average	_	
198-32	36304-36312	indirect	_	
198-33	36313-36320	pathway	_	
198-34	36320-36321	,	_	
198-35	36322-36323	β	_	
198-36	36324-36325	=	_	
198-37	36326-36327	−	_	
198-38	36327-36331	.153	_	
198-39	36331-36332	,	_	
198-40	36333-36336	95%	_	
198-41	36337-36340	C.I	_	
198-42	36340-36341	.	_	
198-43	36341-36342	,	_	
198-44	36343-36344	−	_	
198-45	36344-36348	.307	_	
198-46	36348-36349	:	_	
198-47	36350-36351	−	_	
198-48	36351-36355	.043	_	
198-49	36355-36356	,	_	
198-50	36357-36358	p	_	
198-51	36359-36360	=	_	
198-52	36361-36365	.003	_	
198-53	36365-36366	;	_	
198-54	36367-36371	full	_	
198-55	36372-36377	model	_	
198-56	36378-36379	(	_	
198-57	36379-36388	covariate	_	
198-58	36389-36392	set	_	
198-59	36393-36394	A	_	
198-60	36394-36395	)	_	
198-61	36395-36396	:	_	
198-62	36397-36398	β	_	
198-63	36399-36400	=	_	
198-64	36401-36402	−	_	
198-65	36402-36410	.140,95%	_	
198-66	36411-36414	C.I	_	
198-67	36414-36415	.	_	
198-68	36415-36416	,	_	
198-69	36417-36418	−	_	
198-70	36418-36422	.342	_	
198-71	36422-36423	:	_	
198-72	36424-36425	−	_	
198-73	36425-36429	.008	_	
198-74	36429-36430	,	_	
198-75	36431-36432	p	_	
198-76	36433-36434	=	_	
198-77	36435-36439	.029	_	
198-78	36439-36440	)	_	
198-79	36441-36442	(	_	
198-80	36442-36445	Fig	_	
198-81	36445-36446	.	_	
198-82	36447-36449	6B	_	
198-83	36449-36450	)	_	
198-84	36450-36451	.	_	

#Text=PPC cue epoch BOLD was also associated with WM RT in the REP group while covarying total cannabis use (β = −.459, t (42) = −3.01, p = .010, corrected) where mediation was also significant (average indirect pathway, P = −.189, 95% C.I., −.415: −.026, p = .017) (Fig. 6B).
199-1	36452-36455	PPC	_	
199-2	36456-36459	cue	_	
199-3	36460-36465	epoch	_	
199-4	36466-36470	BOLD	_	
199-5	36471-36474	was	_	
199-6	36475-36479	also	_	
199-7	36480-36490	associated	_	
199-8	36491-36495	with	_	
199-9	36496-36498	WM	_	
199-10	36499-36501	RT	_	
199-11	36502-36504	in	_	
199-12	36505-36508	the	_	
199-13	36509-36512	REP	_	
199-14	36513-36518	group	_	
199-15	36519-36524	while	_	
199-16	36525-36534	covarying	_	
199-17	36535-36540	total	_	
199-18	36541-36549	cannabis	_	
199-19	36550-36553	use	_	
199-20	36554-36555	(	_	
199-21	36555-36556	β	_	
199-22	36557-36558	=	_	
199-23	36559-36560	−	_	
199-24	36560-36564	.459	_	
199-25	36564-36565	,	_	
199-26	36566-36567	t	_	
199-27	36568-36569	(	_	
199-28	36569-36571	42	_	
199-29	36571-36572	)	_	
199-30	36573-36574	=	_	
199-31	36575-36576	−	_	
199-32	36576-36580	3.01	_	
199-33	36580-36581	,	_	
199-34	36582-36583	p	_	
199-35	36584-36585	=	_	
199-36	36586-36590	.010	_	
199-37	36590-36591	,	_	
199-38	36592-36601	corrected	_	
199-39	36601-36602	)	_	
199-40	36603-36608	where	_	
199-41	36609-36618	mediation	_	
199-42	36619-36622	was	_	
199-43	36623-36627	also	_	
199-44	36628-36639	significant	_	
199-45	36640-36641	(	_	
199-46	36641-36648	average	_	
199-47	36649-36657	indirect	_	
199-48	36658-36665	pathway	_	
199-49	36665-36666	,	_	
199-50	36667-36668	P	_	
199-51	36669-36670	=	_	
199-52	36671-36672	−	_	
199-53	36672-36676	.189	_	
199-54	36676-36677	,	_	
199-55	36678-36681	95%	_	
199-56	36682-36685	C.I	_	
199-57	36685-36686	.	_	
199-58	36686-36687	,	_	
199-59	36688-36689	−	_	
199-60	36689-36693	.415	_	
199-61	36693-36694	:	_	
199-62	36695-36696	−	_	
199-63	36696-36700	.026	_	
199-64	36700-36701	,	_	
199-65	36702-36703	p	_	
199-66	36704-36705	=	_	
199-67	36706-36710	.017	_	
199-68	36710-36711	)	_	
199-69	36712-36713	(	_	
199-70	36713-36716	Fig	_	
199-71	36716-36717	.	_	
199-72	36718-36720	6B	_	
199-73	36720-36721	)	_	
199-74	36721-36722	.	_	

#Text=In contrast, delay period R-DLPFC activation, which was positively associated with increased total cannabis use (Table 5), displayed a trend towards a negative relationship with accuracy (Odds Ratio (O.R.) = .978, z = −2.16, p = .032, uncorrected, p = .093, corrected) (Fig. 6C).
200-1	36723-36725	In	_	
200-2	36726-36734	contrast	_	
200-3	36734-36735	,	_	
200-4	36736-36741	delay	_	
200-5	36742-36748	period	_	
200-6	36749-36756	R-DLPFC	_	
200-7	36757-36767	activation	_	
200-8	36767-36768	,	_	
200-9	36769-36774	which	_	
200-10	36775-36778	was	_	
200-11	36779-36789	positively	_	
200-12	36790-36800	associated	_	
200-13	36801-36805	with	_	
200-14	36806-36815	increased	_	
200-15	36816-36821	total	_	
200-16	36822-36830	cannabis	_	
200-17	36831-36834	use	_	
200-18	36835-36836	(	_	
200-19	36836-36841	Table	_	
200-20	36842-36843	5	_	
200-21	36843-36844	)	_	
200-22	36844-36845	,	_	
200-23	36846-36855	displayed	_	
200-24	36856-36857	a	_	
200-25	36858-36863	trend	_	
200-26	36864-36871	towards	_	
200-27	36872-36873	a	_	
200-28	36874-36882	negative	_	
200-29	36883-36895	relationship	_	
200-30	36896-36900	with	_	
200-31	36901-36909	accuracy	_	
200-32	36910-36911	(	_	
200-33	36911-36915	Odds	_	
200-34	36916-36921	Ratio	_	
200-35	36922-36923	(	_	
200-36	36923-36926	O.R	_	
200-37	36926-36927	.	_	
200-38	36927-36928	)	_	
200-39	36929-36930	=	_	
200-40	36931-36935	.978	_	
200-41	36935-36936	,	_	
200-42	36937-36938	z	_	
200-43	36939-36940	=	_	
200-44	36941-36942	−	_	
200-45	36942-36946	2.16	_	
200-46	36946-36947	,	_	
200-47	36948-36949	p	_	
200-48	36950-36951	=	_	
200-49	36952-36956	.032	_	
200-50	36956-36957	,	_	
200-51	36958-36969	uncorrected	_	
200-52	36969-36970	,	_	
200-53	36971-36972	p	_	
200-54	36973-36974	=	_	
200-55	36975-36979	.093	_	
200-56	36979-36980	,	_	
200-57	36981-36990	corrected	_	
200-58	36990-36991	)	_	
200-59	36992-36993	(	_	
200-60	36993-36996	Fig	_	
200-61	36996-36997	.	_	
200-62	36998-37000	6C	_	
200-63	37000-37001	)	_	
200-64	37001-37002	.	_	

#Text=This relationship remained when including cannabis age of onset as a covariate (O.R. = .983, z = −2.09, p = .037, corrected, p = .110, corrected).
201-1	37003-37007	This	_	
201-2	37008-37020	relationship	_	
201-3	37021-37029	remained	_	
201-4	37030-37034	when	_	
201-5	37035-37044	including	_	
201-6	37045-37053	cannabis	_	
201-7	37054-37057	age	_	
201-8	37058-37060	of	_	
201-9	37061-37066	onset	_	
201-10	37067-37069	as	_	
201-11	37070-37071	a	_	
201-12	37072-37081	covariate	_	
201-13	37082-37083	(	_	
201-14	37083-37086	O.R	_	
201-15	37086-37087	.	_	
201-16	37088-37089	=	_	
201-17	37090-37094	.983	_	
201-18	37094-37095	,	_	
201-19	37096-37097	z	_	
201-20	37098-37099	=	_	
201-21	37100-37101	−	_	
201-22	37101-37105	2.09	_	
201-23	37105-37106	,	_	
201-24	37107-37108	p	_	
201-25	37109-37110	=	_	
201-26	37111-37115	.037	_	
201-27	37115-37116	,	_	
201-28	37117-37126	corrected	_	
201-29	37126-37127	,	_	
201-30	37128-37129	p	_	
201-31	37130-37131	=	_	
201-32	37132-37136	.110	_	
201-33	37136-37137	,	_	
201-34	37138-37147	corrected	_	
201-35	37147-37148	)	_	
201-36	37148-37149	.	_	

#Text=Group differences in fMRI
#Text=As in the behavioral analysis, we examined whether the epoch- specific brain-behavior BOLD relationships within user groups (EXP, REP) generalized to differences with non-user (NU) participants.
202-1	37150-37155	Group	_	
202-2	37156-37167	differences	_	
202-3	37168-37170	in	_	
202-4	37171-37175	fMRI	_	
202-5	37176-37178	As	_	
202-6	37179-37181	in	_	
202-7	37182-37185	the	_	
202-8	37186-37196	behavioral	_	
202-9	37197-37205	analysis	_	
202-10	37205-37206	,	_	
202-11	37207-37209	we	_	
202-12	37210-37218	examined	_	
202-13	37219-37226	whether	_	
202-14	37227-37230	the	_	
202-15	37231-37236	epoch	_	
202-16	37236-37237	-	_	
202-17	37238-37246	specific	_	
202-18	37247-37261	brain-behavior	_	
202-19	37262-37266	BOLD	_	
202-20	37267-37280	relationships	_	
202-21	37281-37287	within	_	
202-22	37288-37292	user	_	
202-23	37293-37299	groups	_	
202-24	37300-37301	(	_	
202-25	37301-37304	EXP	_	
202-26	37304-37305	,	_	
202-27	37306-37309	REP	_	
202-28	37309-37310	)	_	
202-29	37311-37322	generalized	_	
202-30	37323-37325	to	_	
202-31	37326-37337	differences	_	
202-32	37338-37342	with	_	
202-33	37343-37351	non-user	_	
202-34	37352-37353	(	_	
202-35	37353-37355	NU	_	
202-36	37355-37356	)	_	
202-37	37357-37369	participants	_	
202-38	37369-37370	.	_	

#Text=For PPC (A) cue BOLD activation (Fig. 7A), a combined user group (EXP + REP) did not differ from NU (welch’s t(24.35) = 1.56, p = .132).
203-1	37371-37374	For	_	
203-2	37375-37378	PPC	_	
203-3	37379-37380	(	_	
203-4	37380-37381	A	_	
203-5	37381-37382	)	_	
203-6	37383-37386	cue	_	
203-7	37387-37391	BOLD	_	
203-8	37392-37402	activation	_	
203-9	37403-37404	(	_	
203-10	37404-37407	Fig	_	
203-11	37407-37408	.	_	
203-12	37409-37411	7A	_	
203-13	37411-37412	)	_	
203-14	37412-37413	,	_	
203-15	37414-37415	a	_	
203-16	37416-37424	combined	_	
203-17	37425-37429	user	_	
203-18	37430-37435	group	_	
203-19	37436-37437	(	_	
203-20	37437-37440	EXP	_	
203-21	37441-37442	+	_	
203-22	37443-37446	REP	_	
203-23	37446-37447	)	_	
203-24	37448-37451	did	_	
203-25	37452-37455	not	_	
203-26	37456-37462	differ	_	
203-27	37463-37467	from	_	
203-28	37468-37470	NU	_	
203-29	37471-37472	(	_	
203-30	37472-37477	welch	_	
203-31	37477-37478	’	_	
203-32	37478-37479	s	_	
203-33	37480-37481	t	_	
203-34	37481-37482	(	_	
203-35	37482-37487	24.35	_	
203-36	37487-37488	)	_	
203-37	37489-37490	=	_	
203-38	37491-37495	1.56	_	
203-39	37495-37496	,	_	
203-40	37497-37498	p	_	
203-41	37499-37500	=	_	
203-42	37501-37505	.132	_	
203-43	37505-37506	)	_	
203-44	37506-37507	.	_	

#Text=Post-hoc testing examining EXP and REP separately demonstrated EXP had significantly greater PPC (A) cue BOLD activation compared to NU (t(22.08) = 2.10, p = .047), whereas EXP and REP (t(17.03) = 1.42, p = .176) and REP and NU (t(26.62) = 1.16, p = .255) did not differ.
204-1	37508-37516	Post-hoc	_	
204-2	37517-37524	testing	_	
204-3	37525-37534	examining	_	
204-4	37535-37538	EXP	_	
204-5	37539-37542	and	_	
204-6	37543-37546	REP	_	
204-7	37547-37557	separately	_	
204-8	37558-37570	demonstrated	_	
204-9	37571-37574	EXP	_	
204-10	37575-37578	had	_	
204-11	37579-37592	significantly	_	
204-12	37593-37600	greater	_	
204-13	37601-37604	PPC	_	
204-14	37605-37606	(	_	
204-15	37606-37607	A	_	
204-16	37607-37608	)	_	
204-17	37609-37612	cue	_	
204-18	37613-37617	BOLD	_	
204-19	37618-37628	activation	_	
204-20	37629-37637	compared	_	
204-21	37638-37640	to	_	
204-22	37641-37643	NU	_	
204-23	37644-37645	(	_	
204-24	37645-37646	t	_	
204-25	37646-37647	(	_	
204-26	37647-37652	22.08	_	
204-27	37652-37653	)	_	
204-28	37654-37655	=	_	
204-29	37656-37660	2.10	_	
204-30	37660-37661	,	_	
204-31	37662-37663	p	_	
204-32	37664-37665	=	_	
204-33	37666-37670	.047	_	
204-34	37670-37671	)	_	
204-35	37671-37672	,	_	
204-36	37673-37680	whereas	_	
204-37	37681-37684	EXP	_	
204-38	37685-37688	and	_	
204-39	37689-37692	REP	_	
204-40	37693-37694	(	_	
204-41	37694-37695	t	_	
204-42	37695-37696	(	_	
204-43	37696-37701	17.03	_	
204-44	37701-37702	)	_	
204-45	37703-37704	=	_	
204-46	37705-37709	1.42	_	
204-47	37709-37710	,	_	
204-48	37711-37712	p	_	
204-49	37713-37714	=	_	
204-50	37715-37719	.176	_	
204-51	37719-37720	)	_	
204-52	37721-37724	and	_	
204-53	37725-37728	REP	_	
204-54	37729-37732	and	_	
204-55	37733-37735	NU	_	
204-56	37736-37737	(	_	
204-57	37737-37738	t	_	
204-58	37738-37739	(	_	
204-59	37739-37744	26.62	_	
204-60	37744-37745	)	_	
204-61	37746-37747	=	_	
204-62	37748-37752	1.16	_	
204-63	37752-37753	,	_	
204-64	37754-37755	p	_	
204-65	37756-37757	=	_	
204-66	37758-37762	.255	_	
204-67	37762-37763	)	_	
204-68	37764-37767	did	_	
204-69	37768-37771	not	_	
204-70	37772-37778	differ	_	
204-71	37778-37779	.	_	

#Text=No significant group differences where observed for delay period R- DLPFC (EXP + REP vs.
205-1	37780-37782	No	_	
205-2	37783-37794	significant	_	
205-3	37795-37800	group	_	
205-4	37801-37812	differences	_	
205-5	37813-37818	where	_	
205-6	37819-37827	observed	_	
205-7	37828-37831	for	_	
205-8	37832-37837	delay	_	
205-9	37838-37844	period	_	
205-10	37845-37846	R	_	
205-11	37846-37847	-	_	
205-12	37848-37853	DLPFC	_	
205-13	37854-37855	(	_	
205-14	37855-37858	EXP	_	
205-15	37859-37860	+	_	
205-16	37861-37864	REP	_	
205-17	37865-37867	vs	_	
205-18	37867-37868	.	_	

#Text=NU: t(23.68) = −0.57, p = .572; EXP vs.
206-1	37869-37871	NU	_	
206-2	37871-37872	:	_	
206-3	37873-37874	t	_	
206-4	37874-37875	(	_	
206-5	37875-37880	23.68	_	
206-6	37880-37881	)	_	
206-7	37882-37883	=	_	
206-8	37884-37885	−	_	
206-9	37885-37889	0.57	_	
206-10	37889-37890	,	_	
206-11	37891-37892	p	_	
206-12	37893-37894	=	_	
206-13	37895-37899	.572	_	
206-14	37899-37900	;	_	
206-15	37901-37904	EXP	_	
206-16	37905-37907	vs	_	
206-17	37907-37908	.	_	

#Text=NU: t(26.62) = −0.64, p = .635; EXP vs.
207-1	37909-37911	NU	_	
207-2	37911-37912	:	_	
207-3	37913-37914	t	_	
207-4	37914-37915	(	_	
207-5	37915-37920	26.62	_	
207-6	37920-37921	)	_	
207-7	37922-37923	=	_	
207-8	37924-37925	−	_	
207-9	37925-37929	0.64	_	
207-10	37929-37930	,	_	
207-11	37931-37932	p	_	
207-12	37933-37934	=	_	
207-13	37935-37939	.635	_	
207-14	37939-37940	;	_	
207-15	37941-37944	EXP	_	
207-16	37945-37947	vs	_	
207-17	37947-37948	.	_	

#Text=REP: t(26.62) = −0.08, p = .930; REP vs.
208-1	37949-37952	REP	_	
208-2	37952-37953	:	_	
208-3	37954-37955	t	_	
208-4	37955-37956	(	_	
208-5	37956-37961	26.62	_	
208-6	37961-37962	)	_	
208-7	37963-37964	=	_	
208-8	37965-37966	−	_	
208-9	37966-37970	0.08	_	
208-10	37970-37971	,	_	
208-11	37972-37973	p	_	
208-12	37974-37975	=	_	
208-13	37976-37980	.930	_	
208-14	37980-37981	;	_	
208-15	37982-37985	REP	_	
208-16	37986-37988	vs	_	
208-17	37988-37989	.	_	

#Text=NU:t(26.62) = −0.53, p = .599).
209-1	37990-37992	NU	_	
209-2	37992-37993	:	_	
209-3	37993-37994	t	_	
209-4	37994-37995	(	_	
209-5	37995-38000	26.62	_	
209-6	38000-38001	)	_	
209-7	38002-38003	=	_	
209-8	38004-38005	−	_	
209-9	38005-38009	0.53	_	
209-10	38009-38010	,	_	
209-11	38011-38012	p	_	
209-12	38013-38014	=	_	
209-13	38015-38019	.599	_	
209-14	38019-38020	)	_	
209-15	38020-38021	.	_	

#Text=Combined, the lack of consistent differences between user groups (EXP, REP) and NU suggest the observed brain-behavior relationships in PPC and DLPFC within cannabis groups were distinct from performance differences in NU.
210-1	38022-38030	Combined	_	
210-2	38030-38031	,	_	
210-3	38032-38035	the	_	
210-4	38036-38040	lack	_	
210-5	38041-38043	of	_	
210-6	38044-38054	consistent	_	
210-7	38055-38066	differences	_	
210-8	38067-38074	between	_	
210-9	38075-38079	user	_	
210-10	38080-38086	groups	_	
210-11	38087-38088	(	_	
210-12	38088-38091	EXP	_	
210-13	38091-38092	,	_	
210-14	38093-38096	REP	_	
210-15	38096-38097	)	_	
210-16	38098-38101	and	_	
210-17	38102-38104	NU	_	
210-18	38105-38112	suggest	_	
210-19	38113-38116	the	_	
210-20	38117-38125	observed	_	
210-21	38126-38140	brain-behavior	_	
210-22	38141-38154	relationships	_	
210-23	38155-38157	in	_	
210-24	38158-38161	PPC	_	
210-25	38162-38165	and	_	
210-26	38166-38171	DLPFC	_	
210-27	38172-38178	within	_	
210-28	38179-38187	cannabis	_	
210-29	38188-38194	groups	_	
210-30	38195-38199	were	_	
210-31	38200-38208	distinct	_	
210-32	38209-38213	from	_	
210-33	38214-38225	performance	_	
210-34	38226-38237	differences	_	
210-35	38238-38240	in	_	
210-36	38241-38243	NU	_	
210-37	38243-38244	.	_	

#Text=Discussion
#Text=In this study, we aimed to identify brain processes that underlie the association between adolescent cannabis use and adult working memory (WM) performance.
211-1	38245-38255	Discussion	_	
211-2	38256-38258	In	_	
211-3	38259-38263	this	_	
211-4	38264-38269	study	_	
211-5	38269-38270	,	_	
211-6	38271-38273	we	_	
211-7	38274-38279	aimed	_	
211-8	38280-38282	to	_	
211-9	38283-38291	identify	_	
211-10	38292-38297	brain	_	
211-11	38298-38307	processes	_	
211-12	38308-38312	that	_	
211-13	38313-38321	underlie	_	
211-14	38322-38325	the	_	
211-15	38326-38337	association	_	
211-16	38338-38345	between	_	
211-17	38346-38356	adolescent	_	
211-18	38357-38365	cannabis	_	
211-19	38366-38369	use	_	
211-20	38370-38373	and	_	
211-21	38374-38379	adult	_	
211-22	38380-38387	working	_	
211-23	38388-38394	memory	_	
211-24	38395-38396	(	_	
211-25	38396-38398	WM	_	
211-26	38398-38399	)	_	
211-27	38400-38411	performance	_	
211-28	38411-38412	.	_	

#Text=Results indicated that early cannabis age of onset was associated with slower reaction times and this relationship was mediated by reduced BOLD activation of right posterior parietal cortex (PPC) during stimulus encoding.
212-1	38413-38420	Results	_	
212-2	38421-38430	indicated	_	
212-3	38431-38435	that	_	
212-4	38436-38441	early	_	
212-5	38442-38450	cannabis	_	
212-6	38451-38454	age	_	
212-7	38455-38457	of	_	
212-8	38458-38463	onset	_	
212-9	38464-38467	was	_	
212-10	38468-38478	associated	_	
212-11	38479-38483	with	_	
212-12	38484-38490	slower	_	
212-13	38491-38499	reaction	_	
212-14	38500-38505	times	_	
212-15	38506-38509	and	_	
212-16	38510-38514	this	_	
212-17	38515-38527	relationship	_	
212-18	38528-38531	was	_	
212-19	38532-38540	mediated	_	
212-20	38541-38543	by	_	
212-21	38544-38551	reduced	_	
212-22	38552-38556	BOLD	_	
212-23	38557-38567	activation	_	
212-24	38568-38570	of	_	
212-25	38571-38576	right	_	
212-26	38577-38586	posterior	_	
212-27	38587-38595	parietal	_	
212-28	38596-38602	cortex	_	
212-29	38603-38604	(	_	
212-30	38604-38607	PPC	_	
212-31	38607-38608	)	_	
212-32	38609-38615	during	_	
212-33	38616-38624	stimulus	_	
212-34	38625-38633	encoding	_	
212-35	38633-38634	.	_	

#Text=Independently of age of onset, higher levels of total cannabis use were associated with greater delay period DLPFC activation and a trend towards lower WM accuracy.
213-1	38635-38648	Independently	_	
213-2	38649-38651	of	_	
213-3	38652-38655	age	_	
213-4	38656-38658	of	_	
213-5	38659-38664	onset	_	
213-6	38664-38665	,	_	
213-7	38666-38672	higher	_	
213-8	38673-38679	levels	_	
213-9	38680-38682	of	_	
213-10	38683-38688	total	_	
213-11	38689-38697	cannabis	_	
213-12	38698-38701	use	_	
213-13	38702-38706	were	_	
213-14	38707-38717	associated	_	
213-15	38718-38722	with	_	
213-16	38723-38730	greater	_	
213-17	38731-38736	delay	_	
213-18	38737-38743	period	_	
213-19	38744-38749	DLPFC	_	
213-20	38750-38760	activation	_	
213-21	38761-38764	and	_	
213-22	38765-38766	a	_	
213-23	38767-38772	trend	_	
213-24	38773-38780	towards	_	
213-25	38781-38786	lower	_	
213-26	38787-38789	WM	_	
213-27	38790-38798	accuracy	_	
213-28	38798-38799	.	_	

#Text=Nevertheless, within this sample, cannabis users either had better WM performance or did not differ from non-user participants and no additive effects of cannabis age of onset and total cannabis use were observed, providing evidence against cognitive deficits induced by adolescent cannabis use.
214-1	38800-38812	Nevertheless	_	
214-2	38812-38813	,	_	
214-3	38814-38820	within	_	
214-4	38821-38825	this	_	
214-5	38826-38832	sample	_	
214-6	38832-38833	,	_	
214-7	38834-38842	cannabis	_	
214-8	38843-38848	users	_	
214-9	38849-38855	either	_	
214-10	38856-38859	had	_	
214-11	38860-38866	better	_	
214-12	38867-38869	WM	_	
214-13	38870-38881	performance	_	
214-14	38882-38884	or	_	
214-15	38885-38888	did	_	
214-16	38889-38892	not	_	
214-17	38893-38899	differ	_	
214-18	38900-38904	from	_	
214-19	38905-38913	non-user	_	
214-20	38914-38926	participants	_	
214-21	38927-38930	and	_	
214-22	38931-38933	no	_	
214-23	38934-38942	additive	_	
214-24	38943-38950	effects	_	
214-25	38951-38953	of	_	
214-26	38954-38962	cannabis	_	
214-27	38963-38966	age	_	
214-28	38967-38969	of	_	
214-29	38970-38975	onset	_	
214-30	38976-38979	and	_	
214-31	38980-38985	total	_	
214-32	38986-38994	cannabis	_	
214-33	38995-38998	use	_	
214-34	38999-39003	were	_	
214-35	39004-39012	observed	_	
214-36	39012-39013	,	_	
214-37	39014-39023	providing	_	
214-38	39024-39032	evidence	_	
214-39	39033-39040	against	_	
214-40	39041-39050	cognitive	_	
214-41	39051-39059	deficits	_	
214-42	39060-39067	induced	_	
214-43	39068-39070	by	_	
214-44	39071-39081	adolescent	_	
214-45	39082-39090	cannabis	_	
214-46	39091-39094	use	_	
214-47	39094-39095	.	_	

#Text=Cannabis age of onset
#Text=Our results indicating differential engagement of posterior parietal cortex in those with earlier age of onset cannabis during a spatial WM task are consistent with a prior study using a verbal WM task, supporting the hypothesis that cannabis age of onset is associated with BOLD activation in developmentally sensitive regions.
215-1	39096-39104	Cannabis	_	
215-2	39105-39108	age	_	
215-3	39109-39111	of	_	
215-4	39112-39117	onset	_	
215-5	39118-39121	Our	_	
215-6	39122-39129	results	_	
215-7	39130-39140	indicating	_	
215-8	39141-39153	differential	_	
215-9	39154-39164	engagement	_	
215-10	39165-39167	of	_	
215-11	39168-39177	posterior	_	
215-12	39178-39186	parietal	_	
215-13	39187-39193	cortex	_	
215-14	39194-39196	in	_	
215-15	39197-39202	those	_	
215-16	39203-39207	with	_	
215-17	39208-39215	earlier	_	
215-18	39216-39219	age	_	
215-19	39220-39222	of	_	
215-20	39223-39228	onset	_	
215-21	39229-39237	cannabis	_	
215-22	39238-39244	during	_	
215-23	39245-39246	a	_	
215-24	39247-39254	spatial	_	
215-25	39255-39257	WM	_	
215-26	39258-39262	task	_	
215-27	39263-39266	are	_	
215-28	39267-39277	consistent	_	
215-29	39278-39282	with	_	
215-30	39283-39284	a	_	
215-31	39285-39290	prior	_	
215-32	39291-39296	study	_	
215-33	39297-39302	using	_	
215-34	39303-39304	a	_	
215-35	39305-39311	verbal	_	
215-36	39312-39314	WM	_	
215-37	39315-39319	task	_	
215-38	39319-39320	,	_	
215-39	39321-39331	supporting	_	
215-40	39332-39335	the	_	
215-41	39336-39346	hypothesis	_	
215-42	39347-39351	that	_	
215-43	39352-39360	cannabis	_	
215-44	39361-39364	age	_	
215-45	39365-39367	of	_	
215-46	39368-39373	onset	_	
215-47	39374-39376	is	_	
215-48	39377-39387	associated	_	
215-49	39388-39392	with	_	
215-50	39393-39397	BOLD	_	
215-51	39398-39408	activation	_	
215-52	39409-39411	in	_	
215-53	39412-39427	developmentally	_	
215-54	39428-39437	sensitive	_	
215-55	39438-39445	regions	_	
215-56	39445-39446	.	_	

#Text=In addition, our study was able to further specify that association between cannabis age of onset and parietal activation are particularly evident during encoding processes of WM and that encoding PPC activation mediated the relationship between cannabis age of onset and working memory reaction time.
216-1	39447-39449	In	_	
216-2	39450-39458	addition	_	
216-3	39458-39459	,	_	
216-4	39460-39463	our	_	
216-5	39464-39469	study	_	
216-6	39470-39473	was	_	
216-7	39474-39478	able	_	
216-8	39479-39481	to	_	
216-9	39482-39489	further	_	
216-10	39490-39497	specify	_	
216-11	39498-39502	that	_	
216-12	39503-39514	association	_	
216-13	39515-39522	between	_	
216-14	39523-39531	cannabis	_	
216-15	39532-39535	age	_	
216-16	39536-39538	of	_	
216-17	39539-39544	onset	_	
216-18	39545-39548	and	_	
216-19	39549-39557	parietal	_	
216-20	39558-39568	activation	_	
216-21	39569-39572	are	_	
216-22	39573-39585	particularly	_	
216-23	39586-39593	evident	_	
216-24	39594-39600	during	_	
216-25	39601-39609	encoding	_	
216-26	39610-39619	processes	_	
216-27	39620-39622	of	_	
216-28	39623-39625	WM	_	
216-29	39626-39629	and	_	
216-30	39630-39634	that	_	
216-31	39635-39643	encoding	_	
216-32	39644-39647	PPC	_	
216-33	39648-39658	activation	_	
216-34	39659-39667	mediated	_	
216-35	39668-39671	the	_	
216-36	39672-39684	relationship	_	
216-37	39685-39692	between	_	
216-38	39693-39701	cannabis	_	
216-39	39702-39705	age	_	
216-40	39706-39708	of	_	
216-41	39709-39714	onset	_	
216-42	39715-39718	and	_	
216-43	39719-39726	working	_	
216-44	39727-39733	memory	_	
216-45	39734-39742	reaction	_	
216-46	39743-39747	time	_	
216-47	39747-39748	.	_	

#Text=Therefore, for the first time, we demonstrate brain-behavior relationships between cannabis age of onset and WM performance, adding specificity to the role of posterior parietal cortex activation in the association between adolescent cannabis age of onset, executive subprocesses, and WM performance.
217-1	39749-39758	Therefore	_	
217-2	39758-39759	,	_	
217-3	39760-39763	for	_	
217-4	39764-39767	the	_	
217-5	39768-39773	first	_	
217-6	39774-39778	time	_	
217-7	39778-39779	,	_	
217-8	39780-39782	we	_	
217-9	39783-39794	demonstrate	_	
217-10	39795-39809	brain-behavior	_	
217-11	39810-39823	relationships	_	
217-12	39824-39831	between	_	
217-13	39832-39840	cannabis	_	
217-14	39841-39844	age	_	
217-15	39845-39847	of	_	
217-16	39848-39853	onset	_	
217-17	39854-39857	and	_	
217-18	39858-39860	WM	_	
217-19	39861-39872	performance	_	
217-20	39872-39873	,	_	
217-21	39874-39880	adding	_	
217-22	39881-39892	specificity	_	
217-23	39893-39895	to	_	
217-24	39896-39899	the	_	
217-25	39900-39904	role	_	
217-26	39905-39907	of	_	
217-27	39908-39917	posterior	_	
217-28	39918-39926	parietal	_	
217-29	39927-39933	cortex	_	
217-30	39934-39944	activation	_	
217-31	39945-39947	in	_	
217-32	39948-39951	the	_	
217-33	39952-39963	association	_	
217-34	39964-39971	between	_	
217-35	39972-39982	adolescent	_	
217-36	39983-39991	cannabis	_	
217-37	39992-39995	age	_	
217-38	39996-39998	of	_	
217-39	39999-40004	onset	_	
217-40	40004-40005	,	_	
217-41	40006-40015	executive	_	
217-42	40016-40028	subprocesses	_	
217-43	40028-40029	,	_	
217-44	40030-40033	and	_	
217-45	40034-40036	WM	_	
217-46	40037-40048	performance	_	
217-47	40048-40049	.	_	

#Text=Interestingly, cannabis age of onset associations with WM reaction time and PPC encoding BOLD activation did not differ between users who only reported an age of onset (EXP) and those who reported repeated use (REP).
218-1	40050-40063	Interestingly	_	
218-2	40063-40064	,	_	
218-3	40065-40073	cannabis	_	
218-4	40074-40077	age	_	
218-5	40078-40080	of	_	
218-6	40081-40086	onset	_	
218-7	40087-40099	associations	_	
218-8	40100-40104	with	_	
218-9	40105-40107	WM	_	
218-10	40108-40116	reaction	_	
218-11	40117-40121	time	_	
218-12	40122-40125	and	_	
218-13	40126-40129	PPC	_	
218-14	40130-40138	encoding	_	
218-15	40139-40143	BOLD	_	
218-16	40144-40154	activation	_	
218-17	40155-40158	did	_	
218-18	40159-40162	not	_	
218-19	40163-40169	differ	_	
218-20	40170-40177	between	_	
218-21	40178-40183	users	_	
218-22	40184-40187	who	_	
218-23	40188-40192	only	_	
218-24	40193-40201	reported	_	
218-25	40202-40204	an	_	
218-26	40205-40208	age	_	
218-27	40209-40211	of	_	
218-28	40212-40217	onset	_	
218-29	40218-40219	(	_	
218-30	40219-40222	EXP	_	
218-31	40222-40223	)	_	
218-32	40224-40227	and	_	
218-33	40228-40233	those	_	
218-34	40234-40237	who	_	
218-35	40238-40246	reported	_	
218-36	40247-40255	repeated	_	
218-37	40256-40259	use	_	
218-38	40260-40261	(	_	
218-39	40261-40264	REP	_	
218-40	40264-40265	)	_	
218-41	40265-40266	.	_	

#Text=Furthermore, within the REP group, cannabis age of onset behavior associations were not moderated by total cannabis use and total cannabis use was not associated with WM reaction time or PPC encoding BOLD activation.
219-1	40267-40278	Furthermore	_	
219-2	40278-40279	,	_	
219-3	40280-40286	within	_	
219-4	40287-40290	the	_	
219-5	40291-40294	REP	_	
219-6	40295-40300	group	_	
219-7	40300-40301	,	_	
219-8	40302-40310	cannabis	_	
219-9	40311-40314	age	_	
219-10	40315-40317	of	_	
219-11	40318-40323	onset	_	
219-12	40324-40332	behavior	_	
219-13	40333-40345	associations	_	
219-14	40346-40350	were	_	
219-15	40351-40354	not	_	
219-16	40355-40364	moderated	_	
219-17	40365-40367	by	_	
219-18	40368-40373	total	_	
219-19	40374-40382	cannabis	_	
219-20	40383-40386	use	_	
219-21	40387-40390	and	_	
219-22	40391-40396	total	_	
219-23	40397-40405	cannabis	_	
219-24	40406-40409	use	_	
219-25	40410-40413	was	_	
219-26	40414-40417	not	_	
219-27	40418-40428	associated	_	
219-28	40429-40433	with	_	
219-29	40434-40436	WM	_	
219-30	40437-40445	reaction	_	
219-31	40446-40450	time	_	
219-32	40451-40453	or	_	
219-33	40454-40457	PPC	_	
219-34	40458-40466	encoding	_	
219-35	40467-40471	BOLD	_	
219-36	40472-40482	activation	_	
219-37	40482-40483	.	_	

#Text=Combined, these results suggest that, in the present high-risk cohort, cannabis age of onset associations were relatively independent of the severity of cannabis use.
220-1	40484-40492	Combined	_	
220-2	40492-40493	,	_	
220-3	40494-40499	these	_	
220-4	40500-40507	results	_	
220-5	40508-40515	suggest	_	
220-6	40516-40520	that	_	
220-7	40520-40521	,	_	
220-8	40522-40524	in	_	
220-9	40525-40528	the	_	
220-10	40529-40536	present	_	
220-11	40537-40546	high-risk	_	
220-12	40547-40553	cohort	_	
220-13	40553-40554	,	_	
220-14	40555-40563	cannabis	_	
220-15	40564-40567	age	_	
220-16	40568-40570	of	_	
220-17	40571-40576	onset	_	
220-18	40577-40589	associations	_	
220-19	40590-40594	were	_	
220-20	40595-40605	relatively	_	
220-21	40606-40617	independent	_	
220-22	40618-40620	of	_	
220-23	40621-40624	the	_	
220-24	40625-40633	severity	_	
220-25	40634-40636	of	_	
220-26	40637-40645	cannabis	_	
220-27	40646-40649	use	_	
220-28	40649-40650	.	_	

#Text=Accordingly, our results appear inconsistent with a developmentally timed cannabis exposure effect, which would predict cannabis age of onset effects to be dose-dependent.
221-1	40651-40662	Accordingly	_	
221-2	40662-40663	,	_	
221-3	40664-40667	our	_	
221-4	40668-40675	results	_	
221-5	40676-40682	appear	_	
221-6	40683-40695	inconsistent	_	
221-7	40696-40700	with	_	
221-8	40701-40702	a	_	
221-9	40703-40718	developmentally	_	
221-10	40719-40724	timed	_	
221-11	40725-40733	cannabis	_	
221-12	40734-40742	exposure	_	
221-13	40743-40749	effect	_	
221-14	40749-40750	,	_	
221-15	40751-40756	which	_	
221-16	40757-40762	would	_	
221-17	40763-40770	predict	_	
221-18	40771-40779	cannabis	_	
221-19	40780-40783	age	_	
221-20	40784-40786	of	_	
221-21	40787-40792	onset	_	
221-22	40793-40800	effects	_	
221-23	40801-40803	to	_	
221-24	40804-40806	be	_	
221-25	40807-40821	dose-dependent	_	
221-26	40821-40822	.	_	

#Text=From this perspective, the observed cannabis age of onset associations may reflect pre-onset characteristics that predict both brain-behavior development and substance use initiation.
222-1	40823-40827	From	_	
222-2	40828-40832	this	_	
222-3	40833-40844	perspective	_	
222-4	40844-40845	,	_	
222-5	40846-40849	the	_	
222-6	40850-40858	observed	_	
222-7	40859-40867	cannabis	_	
222-8	40868-40871	age	_	
222-9	40872-40874	of	_	
222-10	40875-40880	onset	_	
222-11	40881-40893	associations	_	
222-12	40894-40897	may	_	
222-13	40898-40905	reflect	_	
222-14	40906-40915	pre-onset	_	
222-15	40916-40931	characteristics	_	
222-16	40932-40936	that	_	
222-17	40937-40944	predict	_	
222-18	40945-40949	both	_	
222-19	40950-40964	brain-behavior	_	
222-20	40965-40976	development	_	
222-21	40977-40980	and	_	
222-22	40981-40990	substance	_	
222-23	40991-40994	use	_	
222-24	40995-41005	initiation	_	
222-25	41005-41006	.	_	

#Text=Based on the brain-behavior associations of cannabis age of onset, cognitive processing speed, or the efficiency in which information is integrated in complex cognitive tasks, may serve as mechanism for preonset characteristics distinguishing early and late cannabis users.
223-1	41007-41012	Based	_	
223-2	41013-41015	on	_	
223-3	41016-41019	the	_	
223-4	41020-41034	brain-behavior	_	
223-5	41035-41047	associations	_	
223-6	41048-41050	of	_	
223-7	41051-41059	cannabis	_	
223-8	41060-41063	age	_	
223-9	41064-41066	of	_	
223-10	41067-41072	onset	_	
223-11	41072-41073	,	_	
223-12	41074-41083	cognitive	_	
223-13	41084-41094	processing	_	
223-14	41095-41100	speed	_	
223-15	41100-41101	,	_	
223-16	41102-41104	or	_	
223-17	41105-41108	the	_	
223-18	41109-41119	efficiency	_	
223-19	41120-41122	in	_	
223-20	41123-41128	which	_	
223-21	41129-41140	information	_	
223-22	41141-41143	is	_	
223-23	41144-41154	integrated	_	
223-24	41155-41157	in	_	
223-25	41158-41165	complex	_	
223-26	41166-41175	cognitive	_	
223-27	41176-41181	tasks	_	
223-28	41181-41182	,	_	
223-29	41183-41186	may	_	
223-30	41187-41192	serve	_	
223-31	41193-41195	as	_	
223-32	41196-41205	mechanism	_	
223-33	41206-41209	for	_	
223-34	41210-41218	preonset	_	
223-35	41219-41234	characteristics	_	
223-36	41235-41249	distinguishing	_	
223-37	41250-41255	early	_	
223-38	41256-41259	and	_	
223-39	41260-41264	late	_	
223-40	41265-41273	cannabis	_	
223-41	41274-41279	users	_	
223-42	41279-41280	.	_	

#Text=Supporting this idea, cannabis age of onset was a significant predictor of working memory reaction time, but not working memory accuracy.
224-1	41281-41291	Supporting	_	
224-2	41292-41296	this	_	
224-3	41297-41301	idea	_	
224-4	41301-41302	,	_	
224-5	41303-41311	cannabis	_	
224-6	41312-41315	age	_	
224-7	41316-41318	of	_	
224-8	41319-41324	onset	_	
224-9	41325-41328	was	_	
224-10	41329-41330	a	_	
224-11	41331-41342	significant	_	
224-12	41343-41352	predictor	_	
224-13	41353-41355	of	_	
224-14	41356-41363	working	_	
224-15	41364-41370	memory	_	
224-16	41371-41379	reaction	_	
224-17	41380-41384	time	_	
224-18	41384-41385	,	_	
224-19	41386-41389	but	_	
224-20	41390-41393	not	_	
224-21	41394-41401	working	_	
224-22	41402-41408	memory	_	
224-23	41409-41417	accuracy	_	
224-24	41417-41418	.	_	

#Text=Age of onset and reaction time associations were significantly greater in low load trials, where individual differences are likely less influenced by working memory representation.
225-1	41419-41422	Age	_	
225-2	41423-41425	of	_	
225-3	41426-41431	onset	_	
225-4	41432-41435	and	_	
225-5	41436-41444	reaction	_	
225-6	41445-41449	time	_	
225-7	41450-41462	associations	_	
225-8	41463-41467	were	_	
225-9	41468-41481	significantly	_	
225-10	41482-41489	greater	_	
225-11	41490-41492	in	_	
225-12	41493-41496	low	_	
225-13	41497-41501	load	_	
225-14	41502-41508	trials	_	
225-15	41508-41509	,	_	
225-16	41510-41515	where	_	
225-17	41516-41526	individual	_	
225-18	41527-41538	differences	_	
225-19	41539-41542	are	_	
225-20	41543-41549	likely	_	
225-21	41550-41554	less	_	
225-22	41555-41565	influenced	_	
225-23	41566-41568	by	_	
225-24	41569-41576	working	_	
225-25	41577-41583	memory	_	
225-26	41584-41598	representation	_	
225-27	41598-41599	.	_	

#Text=Further, we observed performance- related differences in BOLD activation as a function of age of onset during the cue (encoding) epoch in the PPC.
226-1	41600-41607	Further	_	
226-2	41607-41608	,	_	
226-3	41609-41611	we	_	
226-4	41612-41620	observed	_	
226-5	41621-41632	performance	_	
226-6	41632-41633	-	_	
226-7	41634-41641	related	_	
226-8	41642-41653	differences	_	
226-9	41654-41656	in	_	
226-10	41657-41661	BOLD	_	
226-11	41662-41672	activation	_	
226-12	41673-41675	as	_	
226-13	41676-41677	a	_	
226-14	41678-41686	function	_	
226-15	41687-41689	of	_	
226-16	41690-41693	age	_	
226-17	41694-41696	of	_	
226-18	41697-41702	onset	_	
226-19	41703-41709	during	_	
226-20	41710-41713	the	_	
226-21	41714-41717	cue	_	
226-22	41718-41719	(	_	
226-23	41719-41727	encoding	_	
226-24	41727-41728	)	_	
226-25	41729-41734	epoch	_	
226-26	41735-41737	in	_	
226-27	41738-41741	the	_	
226-28	41742-41745	PPC	_	
226-29	41745-41746	.	_	

#Text=Individual differences in WM encoding may be more sensitive to how quickly the stimulus can be perceived, processed, and stored.
227-1	41747-41757	Individual	_	
227-2	41758-41769	differences	_	
227-3	41770-41772	in	_	
227-4	41773-41775	WM	_	
227-5	41776-41784	encoding	_	
227-6	41785-41788	may	_	
227-7	41789-41791	be	_	
227-8	41792-41796	more	_	
227-9	41797-41806	sensitive	_	
227-10	41807-41809	to	_	
227-11	41810-41813	how	_	
227-12	41814-41821	quickly	_	
227-13	41822-41825	the	_	
227-14	41826-41834	stimulus	_	
227-15	41835-41838	can	_	
227-16	41839-41841	be	_	
227-17	41842-41851	perceived	_	
227-18	41851-41852	,	_	
227-19	41853-41862	processed	_	
227-20	41862-41863	,	_	
227-21	41864-41867	and	_	
227-22	41868-41874	stored	_	
227-23	41874-41875	.	_	

#Text=Supporting this, previous research has demonstrated that BOLD activation in the parietal cortex and structural integrity of white matter tracks between parietal and frontal cortices (superior longitudinal fasciculus) are involved in cognitive processing speed.
228-1	41876-41886	Supporting	_	
228-2	41887-41891	this	_	
228-3	41891-41892	,	_	
228-4	41893-41901	previous	_	
228-5	41902-41910	research	_	
228-6	41911-41914	has	_	
228-7	41915-41927	demonstrated	_	
228-8	41928-41932	that	_	
228-9	41933-41937	BOLD	_	
228-10	41938-41948	activation	_	
228-11	41949-41951	in	_	
228-12	41952-41955	the	_	
228-13	41956-41964	parietal	_	
228-14	41965-41971	cortex	_	
228-15	41972-41975	and	_	
228-16	41976-41986	structural	_	
228-17	41987-41996	integrity	_	
228-18	41997-41999	of	_	
228-19	42000-42005	white	_	
228-20	42006-42012	matter	_	
228-21	42013-42019	tracks	_	
228-22	42020-42027	between	_	
228-23	42028-42036	parietal	_	
228-24	42037-42040	and	_	
228-25	42041-42048	frontal	_	
228-26	42049-42057	cortices	_	
228-27	42058-42059	(	_	
228-28	42059-42067	superior	_	
228-29	42068-42080	longitudinal	_	
228-30	42081-42091	fasciculus	_	
228-31	42091-42092	)	_	
228-32	42093-42096	are	_	
228-33	42097-42105	involved	_	
228-34	42106-42108	in	_	
228-35	42109-42118	cognitive	_	
228-36	42119-42129	processing	_	
228-37	42130-42135	speed	_	
228-38	42135-42136	.	_	

#Text=An additional explanation for the observed brain-behavior assocations may be that cannabis age of onset is associated with individual differences in visual attention, which has been shown to modulate WM RT and PPC BOLD activation.
229-1	42137-42139	An	_	
229-2	42140-42150	additional	_	
229-3	42151-42162	explanation	_	
229-4	42163-42166	for	_	
229-5	42167-42170	the	_	
229-6	42171-42179	observed	_	
229-7	42180-42194	brain-behavior	_	
229-8	42195-42206	assocations	_	
229-9	42207-42210	may	_	
229-10	42211-42213	be	_	
229-11	42214-42218	that	_	
229-12	42219-42227	cannabis	_	
229-13	42228-42231	age	_	
229-14	42232-42234	of	_	
229-15	42235-42240	onset	_	
229-16	42241-42243	is	_	
229-17	42244-42254	associated	_	
229-18	42255-42259	with	_	
229-19	42260-42270	individual	_	
229-20	42271-42282	differences	_	
229-21	42283-42285	in	_	
229-22	42286-42292	visual	_	
229-23	42293-42302	attention	_	
229-24	42302-42303	,	_	
229-25	42304-42309	which	_	
229-26	42310-42313	has	_	
229-27	42314-42318	been	_	
229-28	42319-42324	shown	_	
229-29	42325-42327	to	_	
229-30	42328-42336	modulate	_	
229-31	42337-42339	WM	_	
229-32	42340-42342	RT	_	
229-33	42343-42346	and	_	
229-34	42347-42350	PPC	_	
229-35	42351-42355	BOLD	_	
229-36	42356-42366	activation	_	
229-37	42366-42367	.	_	

#Text=Contrary to our hypothesis, we did not find significant activation differences as a function of cannabis age of onset in DLPFC.
230-1	42368-42376	Contrary	_	
230-2	42377-42379	to	_	
230-3	42380-42383	our	_	
230-4	42384-42394	hypothesis	_	
230-5	42394-42395	,	_	
230-6	42396-42398	we	_	
230-7	42399-42402	did	_	
230-8	42403-42406	not	_	
230-9	42407-42411	find	_	
230-10	42412-42423	significant	_	
230-11	42424-42434	activation	_	
230-12	42435-42446	differences	_	
230-13	42447-42449	as	_	
230-14	42450-42451	a	_	
230-15	42452-42460	function	_	
230-16	42461-42463	of	_	
230-17	42464-42472	cannabis	_	
230-18	42473-42476	age	_	
230-19	42477-42479	of	_	
230-20	42480-42485	onset	_	
230-21	42486-42488	in	_	
230-22	42489-42494	DLPFC	_	
230-23	42494-42495	.	_	

#Text=This is consistent with previous work examining cannabis age of onset during a WM task in adults (cf.,).
231-1	42496-42500	This	_	
231-2	42501-42503	is	_	
231-3	42504-42514	consistent	_	
231-4	42515-42519	with	_	
231-5	42520-42528	previous	_	
231-6	42529-42533	work	_	
231-7	42534-42543	examining	_	
231-8	42544-42552	cannabis	_	
231-9	42553-42556	age	_	
231-10	42557-42559	of	_	
231-11	42560-42565	onset	_	
231-12	42566-42572	during	_	
231-13	42573-42574	a	_	
231-14	42575-42577	WM	_	
231-15	42578-42582	task	_	
231-16	42583-42585	in	_	
231-17	42586-42592	adults	_	
231-18	42593-42594	(	_	
231-19	42594-42596	cf	_	
231-20	42596-42597	.	_	
231-21	42597-42598	,	_	
231-22	42598-42599	)	_	
231-23	42599-42600	.	_	

#Text=Previous work has shown DLPFC activation differences may be moderated by WM accuracy differences between groups (cf.,).
232-1	42601-42609	Previous	_	
232-2	42610-42614	work	_	
232-3	42615-42618	has	_	
232-4	42619-42624	shown	_	
232-5	42625-42630	DLPFC	_	
232-6	42631-42641	activation	_	
232-7	42642-42653	differences	_	
232-8	42654-42657	may	_	
232-9	42658-42660	be	_	
232-10	42661-42670	moderated	_	
232-11	42671-42673	by	_	
232-12	42674-42676	WM	_	
232-13	42677-42685	accuracy	_	
232-14	42686-42697	differences	_	
232-15	42698-42705	between	_	
232-16	42706-42712	groups	_	
232-17	42713-42714	(	_	
232-18	42714-42716	cf	_	
232-19	42716-42717	.	_	
232-20	42717-42718	,	_	
232-21	42718-42719	)	_	
232-22	42719-42720	.	_	

#Text=Accordingly, we may have not observed activation differences in DLPFC as cannabis age of onset was not associated with WM accuracy.
233-1	42721-42732	Accordingly	_	
233-2	42732-42733	,	_	
233-3	42734-42736	we	_	
233-4	42737-42740	may	_	
233-5	42741-42745	have	_	
233-6	42746-42749	not	_	
233-7	42750-42758	observed	_	
233-8	42759-42769	activation	_	
233-9	42770-42781	differences	_	
233-10	42782-42784	in	_	
233-11	42785-42790	DLPFC	_	
233-12	42791-42793	as	_	
233-13	42794-42802	cannabis	_	
233-14	42803-42806	age	_	
233-15	42807-42809	of	_	
233-16	42810-42815	onset	_	
233-17	42816-42819	was	_	
233-18	42820-42823	not	_	
233-19	42824-42834	associated	_	
233-20	42835-42839	with	_	
233-21	42840-42842	WM	_	
233-22	42843-42851	accuracy	_	
233-23	42851-42852	.	_	

#Text=This idea is supported by the association between total cannabis use and DLPFC activation (see 4.2).
234-1	42853-42857	This	_	
234-2	42858-42862	idea	_	
234-3	42863-42865	is	_	
234-4	42866-42875	supported	_	
234-5	42876-42878	by	_	
234-6	42879-42882	the	_	
234-7	42883-42894	association	_	
234-8	42895-42902	between	_	
234-9	42903-42908	total	_	
234-10	42909-42917	cannabis	_	
234-11	42918-42921	use	_	
234-12	42922-42925	and	_	
234-13	42926-42931	DLPFC	_	
234-14	42932-42942	activation	_	
234-15	42943-42944	(	_	
234-16	42944-42947	see	_	
234-17	42948-42951	4.2	_	
234-18	42951-42952	)	_	
234-19	42952-42953	.	_	

#Text=Another possibility is that WM maintenance and manpulation processes associated with DLPFC (cf.,) are not associated with cannabis age of onset.
235-1	42954-42961	Another	_	
235-2	42962-42973	possibility	_	
235-3	42974-42976	is	_	
235-4	42977-42981	that	_	
235-5	42982-42984	WM	_	
235-6	42985-42996	maintenance	_	
235-7	42997-43000	and	_	
235-8	43001-43012	manpulation	_	
235-9	43013-43022	processes	_	
235-10	43023-43033	associated	_	
235-11	43034-43038	with	_	
235-12	43039-43044	DLPFC	_	
235-13	43045-43046	(	_	
235-14	43046-43048	cf	_	
235-15	43048-43049	.	_	
235-16	43049-43050	,	_	
235-17	43050-43051	)	_	
235-18	43052-43055	are	_	
235-19	43056-43059	not	_	
235-20	43060-43070	associated	_	
235-21	43071-43075	with	_	
235-22	43076-43084	cannabis	_	
235-23	43085-43088	age	_	
235-24	43089-43091	of	_	
235-25	43092-43097	onset	_	
235-26	43097-43098	.	_	

#Text=Together, our results suggest that WM performance in early-onset cannabis users is particularly associated with processing speed or visual attention subserved by the integrity of PPC function.
236-1	43099-43107	Together	_	
236-2	43107-43108	,	_	
236-3	43109-43112	our	_	
236-4	43113-43120	results	_	
236-5	43121-43128	suggest	_	
236-6	43129-43133	that	_	
236-7	43134-43136	WM	_	
236-8	43137-43148	performance	_	
236-9	43149-43151	in	_	
236-10	43152-43163	early-onset	_	
236-11	43164-43172	cannabis	_	
236-12	43173-43178	users	_	
236-13	43179-43181	is	_	
236-14	43182-43194	particularly	_	
236-15	43195-43205	associated	_	
236-16	43206-43210	with	_	
236-17	43211-43221	processing	_	
236-18	43222-43227	speed	_	
236-19	43228-43230	or	_	
236-20	43231-43237	visual	_	
236-21	43238-43247	attention	_	
236-22	43248-43257	subserved	_	
236-23	43258-43260	by	_	
236-24	43261-43264	the	_	
236-25	43265-43274	integrity	_	
236-26	43275-43277	of	_	
236-27	43278-43281	PPC	_	
236-28	43282-43290	function	_	
236-29	43290-43291	.	_	

#Text=However, prospective, longitudinal studies are needed to test possible pre-cannabis use limitations in PPC that may contribute to WM differences and predict cannabis onset.
237-1	43292-43299	However	_	
237-2	43299-43300	,	_	
237-3	43301-43312	prospective	_	
237-4	43312-43313	,	_	
237-5	43314-43326	longitudinal	_	
237-6	43327-43334	studies	_	
237-7	43335-43338	are	_	
237-8	43339-43345	needed	_	
237-9	43346-43348	to	_	
237-10	43349-43353	test	_	
237-11	43354-43362	possible	_	
237-12	43363-43375	pre-cannabis	_	
237-13	43376-43379	use	_	
237-14	43380-43391	limitations	_	
237-15	43392-43394	in	_	
237-16	43395-43398	PPC	_	
237-17	43399-43403	that	_	
237-18	43404-43407	may	_	
237-19	43408-43418	contribute	_	
237-20	43419-43421	to	_	
237-21	43422-43424	WM	_	
237-22	43425-43436	differences	_	
237-23	43437-43440	and	_	
237-24	43441-43448	predict	_	
237-25	43449-43457	cannabis	_	
237-26	43458-43463	onset	_	
237-27	43463-43464	.	_	

#Text=Total cannabis use
#Text=Greater total cannabis use was associated with a trend toward lower working memory accuracy, providing some support for the hypothesis that cumulative cannabis use is associated with lower cognitive performance.
238-1	43465-43470	Total	_	
238-2	43471-43479	cannabis	_	
238-3	43480-43483	use	_	
238-4	43484-43491	Greater	_	
238-5	43492-43497	total	_	
238-6	43498-43506	cannabis	_	
238-7	43507-43510	use	_	
238-8	43511-43514	was	_	
238-9	43515-43525	associated	_	
238-10	43526-43530	with	_	
238-11	43531-43532	a	_	
238-12	43533-43538	trend	_	
238-13	43539-43545	toward	_	
238-14	43546-43551	lower	_	
238-15	43552-43559	working	_	
238-16	43560-43566	memory	_	
238-17	43567-43575	accuracy	_	
238-18	43575-43576	,	_	
238-19	43577-43586	providing	_	
238-20	43587-43591	some	_	
238-21	43592-43599	support	_	
238-22	43600-43603	for	_	
238-23	43604-43607	the	_	
238-24	43608-43618	hypothesis	_	
238-25	43619-43623	that	_	
238-26	43624-43634	cumulative	_	
238-27	43635-43643	cannabis	_	
238-28	43644-43647	use	_	
238-29	43648-43650	is	_	
238-30	43651-43661	associated	_	
238-31	43662-43666	with	_	
238-32	43667-43672	lower	_	
238-33	43673-43682	cognitive	_	
238-34	43683-43694	performance	_	
238-35	43694-43695	.	_	

#Text=Behavioral differences were accompanied by increased activation in bilateral DLPFC during multiple WM epochs.
239-1	43696-43706	Behavioral	_	
239-2	43707-43718	differences	_	
239-3	43719-43723	were	_	
239-4	43724-43735	accompanied	_	
239-5	43736-43738	by	_	
239-6	43739-43748	increased	_	
239-7	43749-43759	activation	_	
239-8	43760-43762	in	_	
239-9	43763-43772	bilateral	_	
239-10	43773-43778	DLPFC	_	
239-11	43779-43785	during	_	
239-12	43786-43794	multiple	_	
239-13	43795-43797	WM	_	
239-14	43798-43804	epochs	_	
239-15	43804-43805	.	_	

#Text=Given developmental patterns and network properties of CB1 receptors in the DLPFC (cf.,), activation differences may reflect long-term changes in task-evoked activity.
240-1	43806-43811	Given	_	
240-2	43812-43825	developmental	_	
240-3	43826-43834	patterns	_	
240-4	43835-43838	and	_	
240-5	43839-43846	network	_	
240-6	43847-43857	properties	_	
240-7	43858-43860	of	_	
240-8	43861-43864	CB1	_	
240-9	43865-43874	receptors	_	
240-10	43875-43877	in	_	
240-11	43878-43881	the	_	
240-12	43882-43887	DLPFC	_	
240-13	43888-43889	(	_	
240-14	43889-43891	cf	_	
240-15	43891-43892	.	_	
240-16	43892-43893	,	_	
240-17	43893-43894	)	_	
240-18	43894-43895	,	_	
240-19	43896-43906	activation	_	
240-20	43907-43918	differences	_	
240-21	43919-43922	may	_	
240-22	43923-43930	reflect	_	
240-23	43931-43940	long-term	_	
240-24	43941-43948	changes	_	
240-25	43949-43951	in	_	
240-26	43952-43963	task-evoked	_	
240-27	43964-43972	activity	_	
240-28	43972-43973	.	_	

#Text=Greater delay period activation in right DLPFC was associated with higher levels of total cannabis use and a corrected trend towards lower WM accuracy.
241-1	43974-43981	Greater	_	
241-2	43982-43987	delay	_	
241-3	43988-43994	period	_	
241-4	43995-44005	activation	_	
241-5	44006-44008	in	_	
241-6	44009-44014	right	_	
241-7	44015-44020	DLPFC	_	
241-8	44021-44024	was	_	
241-9	44025-44035	associated	_	
241-10	44036-44040	with	_	
241-11	44041-44047	higher	_	
241-12	44048-44054	levels	_	
241-13	44055-44057	of	_	
241-14	44058-44063	total	_	
241-15	44064-44072	cannabis	_	
241-16	44073-44076	use	_	
241-17	44077-44080	and	_	
241-18	44081-44082	a	_	
241-19	44083-44092	corrected	_	
241-20	44093-44098	trend	_	
241-21	44099-44106	towards	_	
241-22	44107-44112	lower	_	
241-23	44113-44115	WM	_	
241-24	44116-44124	accuracy	_	
241-25	44124-44125	.	_	

#Text=That higher levels of total cannabis use were associated with greater DLPFC BOLD is consistent with previous work suggesting compensatory-like DLPFC activation in groups with poorer executive function performance.
242-1	44126-44130	That	_	
242-2	44131-44137	higher	_	
242-3	44138-44144	levels	_	
242-4	44145-44147	of	_	
242-5	44148-44153	total	_	
242-6	44154-44162	cannabis	_	
242-7	44163-44166	use	_	
242-8	44167-44171	were	_	
242-9	44172-44182	associated	_	
242-10	44183-44187	with	_	
242-11	44188-44195	greater	_	
242-12	44196-44201	DLPFC	_	
242-13	44202-44206	BOLD	_	
242-14	44207-44209	is	_	
242-15	44210-44220	consistent	_	
242-16	44221-44225	with	_	
242-17	44226-44234	previous	_	
242-18	44235-44239	work	_	
242-19	44240-44250	suggesting	_	
242-20	44251-44268	compensatory-like	_	
242-21	44269-44274	DLPFC	_	
242-22	44275-44285	activation	_	
242-23	44286-44288	in	_	
242-24	44289-44295	groups	_	
242-25	44296-44300	with	_	
242-26	44301-44307	poorer	_	
242-27	44308-44317	executive	_	
242-28	44318-44326	function	_	
242-29	44327-44338	performance	_	
242-30	44338-44339	.	_	

#Text=Furthermore, our results are consistent with recent work demonstrating that DLPFC activation is positively associated with cannabis use frequency and negatively associated with WM performance.
243-1	44340-44351	Furthermore	_	
243-2	44351-44352	,	_	
243-3	44353-44356	our	_	
243-4	44357-44364	results	_	
243-5	44365-44368	are	_	
243-6	44369-44379	consistent	_	
243-7	44380-44384	with	_	
243-8	44385-44391	recent	_	
243-9	44392-44396	work	_	
243-10	44397-44410	demonstrating	_	
243-11	44411-44415	that	_	
243-12	44416-44421	DLPFC	_	
243-13	44422-44432	activation	_	
243-14	44433-44435	is	_	
243-15	44436-44446	positively	_	
243-16	44447-44457	associated	_	
243-17	44458-44462	with	_	
243-18	44463-44471	cannabis	_	
243-19	44472-44475	use	_	
243-20	44476-44485	frequency	_	
243-21	44486-44489	and	_	
243-22	44490-44500	negatively	_	
243-23	44501-44511	associated	_	
243-24	44512-44516	with	_	
243-25	44517-44519	WM	_	
243-26	44520-44531	performance	_	
243-27	44531-44532	.	_	

#Text=We extend this previous result by demonstrating brain-behavior relationships that are specific to the WM delay period.
244-1	44533-44535	We	_	
244-2	44536-44542	extend	_	
244-3	44543-44547	this	_	
244-4	44548-44556	previous	_	
244-5	44557-44563	result	_	
244-6	44564-44566	by	_	
244-7	44567-44580	demonstrating	_	
244-8	44581-44595	brain-behavior	_	
244-9	44596-44609	relationships	_	
244-10	44610-44614	that	_	
244-11	44615-44618	are	_	
244-12	44619-44627	specific	_	
244-13	44628-44630	to	_	
244-14	44631-44634	the	_	
244-15	44635-44637	WM	_	
244-16	44638-44643	delay	_	
244-17	44644-44650	period	_	
244-18	44650-44651	.	_	

#Text=Given the associations between total cannabis use and WM accuracy and delay period activation, our result appears more consistent with WM representational differences, as opposed to the processing speed effects of cannabis age of onset.
245-1	44652-44657	Given	_	
245-2	44658-44661	the	_	
245-3	44662-44674	associations	_	
245-4	44675-44682	between	_	
245-5	44683-44688	total	_	
245-6	44689-44697	cannabis	_	
245-7	44698-44701	use	_	
245-8	44702-44705	and	_	
245-9	44706-44708	WM	_	
245-10	44709-44717	accuracy	_	
245-11	44718-44721	and	_	
245-12	44722-44727	delay	_	
245-13	44728-44734	period	_	
245-14	44735-44745	activation	_	
245-15	44745-44746	,	_	
245-16	44747-44750	our	_	
245-17	44751-44757	result	_	
245-18	44758-44765	appears	_	
245-19	44766-44770	more	_	
245-20	44771-44781	consistent	_	
245-21	44782-44786	with	_	
245-22	44787-44789	WM	_	
245-23	44790-44806	representational	_	
245-24	44807-44818	differences	_	
245-25	44818-44819	,	_	
245-26	44820-44822	as	_	
245-27	44823-44830	opposed	_	
245-28	44831-44833	to	_	
245-29	44834-44837	the	_	
245-30	44838-44848	processing	_	
245-31	44849-44854	speed	_	
245-32	44855-44862	effects	_	
245-33	44863-44865	of	_	
245-34	44866-44874	cannabis	_	
245-35	44875-44878	age	_	
245-36	44879-44881	of	_	
245-37	44882-44887	onset	_	
245-38	44887-44888	.	_	

#Text=However, total cannabis use WM accuracy differences were no longer significant while adjusting for prenatal cannabis exposure and we did not find evidence supporting a brain-behavior mediation model.
246-1	44889-44896	However	_	
246-2	44896-44897	,	_	
246-3	44898-44903	total	_	
246-4	44904-44912	cannabis	_	
246-5	44913-44916	use	_	
246-6	44917-44919	WM	_	
246-7	44920-44928	accuracy	_	
246-8	44929-44940	differences	_	
246-9	44941-44945	were	_	
246-10	44946-44948	no	_	
246-11	44949-44955	longer	_	
246-12	44956-44967	significant	_	
246-13	44968-44973	while	_	
246-14	44974-44983	adjusting	_	
246-15	44984-44987	for	_	
246-16	44988-44996	prenatal	_	
246-17	44997-45005	cannabis	_	
246-18	45006-45014	exposure	_	
246-19	45015-45018	and	_	
246-20	45019-45021	we	_	
246-21	45022-45025	did	_	
246-22	45026-45029	not	_	
246-23	45030-45034	find	_	
246-24	45035-45043	evidence	_	
246-25	45044-45054	supporting	_	
246-26	45055-45056	a	_	
246-27	45057-45071	brain-behavior	_	
246-28	45072-45081	mediation	_	
246-29	45082-45087	model	_	
246-30	45087-45088	.	_	

#Text=Therefore, it is difficult to conclude whether these results represent neurocognitive deficits or pre-cannabis use cognitive differences and whether the identified circuits fully explain behavioral effects.
247-1	45089-45098	Therefore	_	
247-2	45098-45099	,	_	
247-3	45100-45102	it	_	
247-4	45103-45105	is	_	
247-5	45106-45115	difficult	_	
247-6	45116-45118	to	_	
247-7	45119-45127	conclude	_	
247-8	45128-45135	whether	_	
247-9	45136-45141	these	_	
247-10	45142-45149	results	_	
247-11	45150-45159	represent	_	
247-12	45160-45174	neurocognitive	_	
247-13	45175-45183	deficits	_	
247-14	45184-45186	or	_	
247-15	45187-45199	pre-cannabis	_	
247-16	45200-45203	use	_	
247-17	45204-45213	cognitive	_	
247-18	45214-45225	differences	_	
247-19	45226-45229	and	_	
247-20	45230-45237	whether	_	
247-21	45238-45241	the	_	
247-22	45242-45252	identified	_	
247-23	45253-45261	circuits	_	
247-24	45262-45267	fully	_	
247-25	45268-45275	explain	_	
247-26	45276-45286	behavioral	_	
247-27	45287-45294	effects	_	
247-28	45294-45295	.	_	

#Text=Cannabis users and non-users
#Text=Despite the specificity in brain-behavior relationships demonstrated for cannabis age of onset and total cannabis use, there was little evidence for general cannabis use differences in WM in the group comparisons.
248-1	45296-45304	Cannabis	_	
248-2	45305-45310	users	_	
248-3	45311-45314	and	_	
248-4	45315-45324	non-users	_	
248-5	45325-45332	Despite	_	
248-6	45333-45336	the	_	
248-7	45337-45348	specificity	_	
248-8	45349-45351	in	_	
248-9	45352-45366	brain-behavior	_	
248-10	45367-45380	relationships	_	
248-11	45381-45393	demonstrated	_	
248-12	45394-45397	for	_	
248-13	45398-45406	cannabis	_	
248-14	45407-45410	age	_	
248-15	45411-45413	of	_	
248-16	45414-45419	onset	_	
248-17	45420-45423	and	_	
248-18	45424-45429	total	_	
248-19	45430-45438	cannabis	_	
248-20	45439-45442	use	_	
248-21	45442-45443	,	_	
248-22	45444-45449	there	_	
248-23	45450-45453	was	_	
248-24	45454-45460	little	_	
248-25	45461-45469	evidence	_	
248-26	45470-45473	for	_	
248-27	45474-45481	general	_	
248-28	45482-45490	cannabis	_	
248-29	45491-45494	use	_	
248-30	45495-45506	differences	_	
248-31	45507-45509	in	_	
248-32	45510-45512	WM	_	
248-33	45513-45515	in	_	
248-34	45516-45519	the	_	
248-35	45520-45525	group	_	
248-36	45526-45537	comparisons	_	
248-37	45537-45538	.	_	

#Text=In particular, the cannabis group who only reported initiation, but no other use (EXP), had higher WM accuracy than non-users (NU), which is consistent with a recent large cross-sectional study of cannabis use and neurocognitive performance.
249-1	45539-45541	In	_	
249-2	45542-45552	particular	_	
249-3	45552-45553	,	_	
249-4	45554-45557	the	_	
249-5	45558-45566	cannabis	_	
249-6	45567-45572	group	_	
249-7	45573-45576	who	_	
249-8	45577-45581	only	_	
249-9	45582-45590	reported	_	
249-10	45591-45601	initiation	_	
249-11	45601-45602	,	_	
249-12	45603-45606	but	_	
249-13	45607-45609	no	_	
249-14	45610-45615	other	_	
249-15	45616-45619	use	_	
249-16	45620-45621	(	_	
249-17	45621-45624	EXP	_	
249-18	45624-45625	)	_	
249-19	45625-45626	,	_	
249-20	45627-45630	had	_	
249-21	45631-45637	higher	_	
249-22	45638-45640	WM	_	
249-23	45641-45649	accuracy	_	
249-24	45650-45654	than	_	
249-25	45655-45664	non-users	_	
249-26	45665-45666	(	_	
249-27	45666-45668	NU	_	
249-28	45668-45669	)	_	
249-29	45669-45670	,	_	
249-30	45671-45676	which	_	
249-31	45677-45679	is	_	
249-32	45680-45690	consistent	_	
249-33	45691-45695	with	_	
249-34	45696-45697	a	_	
249-35	45698-45704	recent	_	
249-36	45705-45710	large	_	
249-37	45711-45726	cross-sectional	_	
249-38	45727-45732	study	_	
249-39	45733-45735	of	_	
249-40	45736-45744	cannabis	_	
249-41	45745-45748	use	_	
249-42	45749-45752	and	_	
249-43	45753-45767	neurocognitive	_	
249-44	45768-45779	performance	_	
249-45	45779-45780	.	_	

#Text=Given the likelihood of very low cannabis use in the EXP group (recall a specific amount of cannabis use could not be established in the EXP group, as EXP only reported an age of initiation) its possible group differences between EXP and NU reflect alternative mechanisms that either precede or are independent of cannabis initiation.
250-1	45781-45786	Given	_	
250-2	45787-45790	the	_	
250-3	45791-45801	likelihood	_	
250-4	45802-45804	of	_	
250-5	45805-45809	very	_	
250-6	45810-45813	low	_	
250-7	45814-45822	cannabis	_	
250-8	45823-45826	use	_	
250-9	45827-45829	in	_	
250-10	45830-45833	the	_	
250-11	45834-45837	EXP	_	
250-12	45838-45843	group	_	
250-13	45844-45845	(	_	
250-14	45845-45851	recall	_	
250-15	45852-45853	a	_	
250-16	45854-45862	specific	_	
250-17	45863-45869	amount	_	
250-18	45870-45872	of	_	
250-19	45873-45881	cannabis	_	
250-20	45882-45885	use	_	
250-21	45886-45891	could	_	
250-22	45892-45895	not	_	
250-23	45896-45898	be	_	
250-24	45899-45910	established	_	
250-25	45911-45913	in	_	
250-26	45914-45917	the	_	
250-27	45918-45921	EXP	_	
250-28	45922-45927	group	_	
250-29	45927-45928	,	_	
250-30	45929-45931	as	_	
250-31	45932-45935	EXP	_	
250-32	45936-45940	only	_	
250-33	45941-45949	reported	_	
250-34	45950-45952	an	_	
250-35	45953-45956	age	_	
250-36	45957-45959	of	_	
250-37	45960-45970	initiation	_	
250-38	45970-45971	)	_	
250-39	45972-45975	its	_	
250-40	45976-45984	possible	_	
250-41	45985-45990	group	_	
250-42	45991-46002	differences	_	
250-43	46003-46010	between	_	
250-44	46011-46014	EXP	_	
250-45	46015-46018	and	_	
250-46	46019-46021	NU	_	
250-47	46022-46029	reflect	_	
250-48	46030-46041	alternative	_	
250-49	46042-46052	mechanisms	_	
250-50	46053-46057	that	_	
250-51	46058-46064	either	_	
250-52	46065-46072	precede	_	
250-53	46073-46075	or	_	
250-54	46076-46079	are	_	
250-55	46080-46091	independent	_	
250-56	46092-46094	of	_	
250-57	46095-46103	cannabis	_	
250-58	46104-46114	initiation	_	
250-59	46114-46115	.	_	

#Text=Again, however, prospective longitudinal studies are needed to better test this hypothesis.
251-1	46116-46121	Again	_	
251-2	46121-46122	,	_	
251-3	46123-46130	however	_	
251-4	46130-46131	,	_	
251-5	46132-46143	prospective	_	
251-6	46144-46156	longitudinal	_	
251-7	46157-46164	studies	_	
251-8	46165-46168	are	_	
251-9	46169-46175	needed	_	
251-10	46176-46178	to	_	
251-11	46179-46185	better	_	
251-12	46186-46190	test	_	
251-13	46191-46195	this	_	
251-14	46196-46206	hypothesis	_	
251-15	46206-46207	.	_	

#Text=Given the high-risk population of the study, it is possible group differences between NU and EXP reflect unique characteristics of substance use risk, rather than substance use itself.
252-1	46208-46213	Given	_	
252-2	46214-46217	the	_	
252-3	46218-46227	high-risk	_	
252-4	46228-46238	population	_	
252-5	46239-46241	of	_	
252-6	46242-46245	the	_	
252-7	46246-46251	study	_	
252-8	46251-46252	,	_	
252-9	46253-46255	it	_	
252-10	46256-46258	is	_	
252-11	46259-46267	possible	_	
252-12	46268-46273	group	_	
252-13	46274-46285	differences	_	
252-14	46286-46293	between	_	
252-15	46294-46296	NU	_	
252-16	46297-46300	and	_	
252-17	46301-46304	EXP	_	
252-18	46305-46312	reflect	_	
252-19	46313-46319	unique	_	
252-20	46320-46335	characteristics	_	
252-21	46336-46338	of	_	
252-22	46339-46348	substance	_	
252-23	46349-46352	use	_	
252-24	46353-46357	risk	_	
252-25	46357-46358	,	_	
252-26	46359-46365	rather	_	
252-27	46366-46370	than	_	
252-28	46371-46380	substance	_	
252-29	46381-46384	use	_	
252-30	46385-46391	itself	_	
252-31	46391-46392	.	_	

#Text=To this end, previous work has suggested executive function deficits in cannabis users compared to nonusers in more normative samples, without high-risk characteristics (see for a review).
253-1	46393-46395	To	_	
253-2	46396-46400	this	_	
253-3	46401-46404	end	_	
253-4	46404-46405	,	_	
253-5	46406-46414	previous	_	
253-6	46415-46419	work	_	
253-7	46420-46423	has	_	
253-8	46424-46433	suggested	_	
253-9	46434-46443	executive	_	
253-10	46444-46452	function	_	
253-11	46453-46461	deficits	_	
253-12	46462-46464	in	_	
253-13	46465-46473	cannabis	_	
253-14	46474-46479	users	_	
253-15	46480-46488	compared	_	
253-16	46489-46491	to	_	
253-17	46492-46500	nonusers	_	
253-18	46501-46503	in	_	
253-19	46504-46508	more	_	
253-20	46509-46518	normative	_	
253-21	46519-46526	samples	_	
253-22	46526-46527	,	_	
253-23	46528-46535	without	_	
253-24	46536-46545	high-risk	_	
253-25	46546-46561	characteristics	_	
253-26	46562-46563	(	_	
253-27	46563-46566	see	_	
253-28	46567-46570	for	_	
253-29	46571-46572	a	_	
253-30	46573-46579	review	_	
253-31	46579-46580	)	_	
253-32	46580-46581	.	_	

#Text=Within our high-risk cohort, most participants endorsed some level of cannabis use during adolescence.
254-1	46582-46588	Within	_	
254-2	46589-46592	our	_	
254-3	46593-46602	high-risk	_	
254-4	46603-46609	cohort	_	
254-5	46609-46610	,	_	
254-6	46611-46615	most	_	
254-7	46616-46628	participants	_	
254-8	46629-46637	endorsed	_	
254-9	46638-46642	some	_	
254-10	46643-46648	level	_	
254-11	46649-46651	of	_	
254-12	46652-46660	cannabis	_	
254-13	46661-46664	use	_	
254-14	46665-46671	during	_	
254-15	46672-46683	adolescence	_	
254-16	46683-46684	.	_	

#Text=Accordingly, the participants who did not endorse cannabis use at any time point (NU) may have unique cognitive characteristics that both protect against cannabis use during adolescence and predict differential WM performance in adulthood.
255-1	46685-46696	Accordingly	_	
255-2	46696-46697	,	_	
255-3	46698-46701	the	_	
255-4	46702-46714	participants	_	
255-5	46715-46718	who	_	
255-6	46719-46722	did	_	
255-7	46723-46726	not	_	
255-8	46727-46734	endorse	_	
255-9	46735-46743	cannabis	_	
255-10	46744-46747	use	_	
255-11	46748-46750	at	_	
255-12	46751-46754	any	_	
255-13	46755-46759	time	_	
255-14	46760-46765	point	_	
255-15	46766-46767	(	_	
255-16	46767-46769	NU	_	
255-17	46769-46770	)	_	
255-18	46771-46774	may	_	
255-19	46775-46779	have	_	
255-20	46780-46786	unique	_	
255-21	46787-46796	cognitive	_	
255-22	46797-46812	characteristics	_	
255-23	46813-46817	that	_	
255-24	46818-46822	both	_	
255-25	46823-46830	protect	_	
255-26	46831-46838	against	_	
255-27	46839-46847	cannabis	_	
255-28	46848-46851	use	_	
255-29	46852-46858	during	_	
255-30	46859-46870	adolescence	_	
255-31	46871-46874	and	_	
255-32	46875-46882	predict	_	
255-33	46883-46895	differential	_	
255-34	46896-46898	WM	_	
255-35	46899-46910	performance	_	
255-36	46911-46913	in	_	
255-37	46914-46923	adulthood	_	
255-38	46923-46924	.	_	

#Text=One possibility is anxiety and behavioral inhibition, which have been shown to predict poorer visuospatial WM performance and in social contexts may be protective against substance use involvement during adolescence.
256-1	46925-46928	One	_	
256-2	46929-46940	possibility	_	
256-3	46941-46943	is	_	
256-4	46944-46951	anxiety	_	
256-5	46952-46955	and	_	
256-6	46956-46966	behavioral	_	
256-7	46967-46977	inhibition	_	
256-8	46977-46978	,	_	
256-9	46979-46984	which	_	
256-10	46985-46989	have	_	
256-11	46990-46994	been	_	
256-12	46995-47000	shown	_	
256-13	47001-47003	to	_	
256-14	47004-47011	predict	_	
256-15	47012-47018	poorer	_	
256-16	47019-47031	visuospatial	_	
256-17	47032-47034	WM	_	
256-18	47035-47046	performance	_	
256-19	47047-47050	and	_	
256-20	47051-47053	in	_	
256-21	47054-47060	social	_	
256-22	47061-47069	contexts	_	
256-23	47070-47073	may	_	
256-24	47074-47076	be	_	
256-25	47077-47087	protective	_	
256-26	47088-47095	against	_	
256-27	47096-47105	substance	_	
256-28	47106-47109	use	_	
256-29	47110-47121	involvement	_	
256-30	47122-47128	during	_	
256-31	47129-47140	adolescence	_	
256-32	47140-47141	.	_	

#Text=Given the exclusion criteria for the current study included meeting criteria for a mental health disorder, the associations between cannabis use, WM, and anxiety, would have to function at subclinical levels.
257-1	47142-47147	Given	_	
257-2	47148-47151	the	_	
257-3	47152-47161	exclusion	_	
257-4	47162-47170	criteria	_	
257-5	47171-47174	for	_	
257-6	47175-47178	the	_	
257-7	47179-47186	current	_	
257-8	47187-47192	study	_	
257-9	47193-47201	included	_	
257-10	47202-47209	meeting	_	
257-11	47210-47218	criteria	_	
257-12	47219-47222	for	_	
257-13	47223-47224	a	_	
257-14	47225-47231	mental	_	
257-15	47232-47238	health	_	
257-16	47239-47247	disorder	_	
257-17	47247-47248	,	_	
257-18	47249-47252	the	_	
257-19	47253-47265	associations	_	
257-20	47266-47273	between	_	
257-21	47274-47282	cannabis	_	
257-22	47283-47286	use	_	
257-23	47286-47287	,	_	
257-24	47288-47290	WM	_	
257-25	47290-47291	,	_	
257-26	47292-47295	and	_	
257-27	47296-47303	anxiety	_	
257-28	47303-47304	,	_	
257-29	47305-47310	would	_	
257-30	47311-47315	have	_	
257-31	47316-47318	to	_	
257-32	47319-47327	function	_	
257-33	47328-47330	at	_	
257-34	47331-47342	subclinical	_	
257-35	47343-47349	levels	_	
257-36	47349-47350	.	_	

#Text=Accordingly, future research with dimensional assessments may examine anxiety as a moderating factor in cognitive differences between cannabis users and non-users in high-risk cohorts.
258-1	47351-47362	Accordingly	_	
258-2	47362-47363	,	_	
258-3	47364-47370	future	_	
258-4	47371-47379	research	_	
258-5	47380-47384	with	_	
258-6	47385-47396	dimensional	_	
258-7	47397-47408	assessments	_	
258-8	47409-47412	may	_	
258-9	47413-47420	examine	_	
258-10	47421-47428	anxiety	_	
258-11	47429-47431	as	_	
258-12	47432-47433	a	_	
258-13	47434-47444	moderating	_	
258-14	47445-47451	factor	_	
258-15	47452-47454	in	_	
258-16	47455-47464	cognitive	_	
258-17	47465-47476	differences	_	
258-18	47477-47484	between	_	
258-19	47485-47493	cannabis	_	
258-20	47494-47499	users	_	
258-21	47500-47503	and	_	
258-22	47504-47513	non-users	_	
258-23	47514-47516	in	_	
258-24	47517-47526	high-risk	_	
258-25	47527-47534	cohorts	_	
258-26	47534-47535	.	_	

#Text=Another explanation for the observed WM differences between EXP and NU could be gender, as the NU group was mostly women (13 out of 15).
259-1	47536-47543	Another	_	
259-2	47544-47555	explanation	_	
259-3	47556-47559	for	_	
259-4	47560-47563	the	_	
259-5	47564-47572	observed	_	
259-6	47573-47575	WM	_	
259-7	47576-47587	differences	_	
259-8	47588-47595	between	_	
259-9	47596-47599	EXP	_	
259-10	47600-47603	and	_	
259-11	47604-47606	NU	_	
259-12	47607-47612	could	_	
259-13	47613-47615	be	_	
259-14	47616-47622	gender	_	
259-15	47622-47623	,	_	
259-16	47624-47626	as	_	
259-17	47627-47630	the	_	
259-18	47631-47633	NU	_	
259-19	47634-47639	group	_	
259-20	47640-47643	was	_	
259-21	47644-47650	mostly	_	
259-22	47651-47656	women	_	
259-23	47657-47658	(	_	
259-24	47658-47660	13	_	
259-25	47661-47664	out	_	
259-26	47665-47667	of	_	
259-27	47668-47670	15	_	
259-28	47670-47671	)	_	
259-29	47671-47672	.	_	

#Text=Although we attempted to account for the specific discrepancy of male to female ratios among our groups by performing secondary behavior analysis with only the women from each group, future work with larger sample sizes of male and female users and non-users is justified.
260-1	47673-47681	Although	_	
260-2	47682-47684	we	_	
260-3	47685-47694	attempted	_	
260-4	47695-47697	to	_	
260-5	47698-47705	account	_	
260-6	47706-47709	for	_	
260-7	47710-47713	the	_	
260-8	47714-47722	specific	_	
260-9	47723-47734	discrepancy	_	
260-10	47735-47737	of	_	
260-11	47738-47742	male	_	
260-12	47743-47745	to	_	
260-13	47746-47752	female	_	
260-14	47753-47759	ratios	_	
260-15	47760-47765	among	_	
260-16	47766-47769	our	_	
260-17	47770-47776	groups	_	
260-18	47777-47779	by	_	
260-19	47780-47790	performing	_	
260-20	47791-47800	secondary	_	
260-21	47801-47809	behavior	_	
260-22	47810-47818	analysis	_	
260-23	47819-47823	with	_	
260-24	47824-47828	only	_	
260-25	47829-47832	the	_	
260-26	47833-47838	women	_	
260-27	47839-47843	from	_	
260-28	47844-47848	each	_	
260-29	47849-47854	group	_	
260-30	47854-47855	,	_	
260-31	47856-47862	future	_	
260-32	47863-47867	work	_	
260-33	47868-47872	with	_	
260-34	47873-47879	larger	_	
260-35	47880-47886	sample	_	
260-36	47887-47892	sizes	_	
260-37	47893-47895	of	_	
260-38	47896-47900	male	_	
260-39	47901-47904	and	_	
260-40	47905-47911	female	_	
260-41	47912-47917	users	_	
260-42	47918-47921	and	_	
260-43	47922-47931	non-users	_	
260-44	47932-47934	is	_	
260-45	47935-47944	justified	_	
260-46	47944-47945	.	_	

#Text=In sum, the reasons for worse performance in the non-user group (compared to the cannabis group) remain unclear.
261-1	47946-47948	In	_	
261-2	47949-47952	sum	_	
261-3	47952-47953	,	_	
261-4	47954-47957	the	_	
261-5	47958-47965	reasons	_	
261-6	47966-47969	for	_	
261-7	47970-47975	worse	_	
261-8	47976-47987	performance	_	
261-9	47988-47990	in	_	
261-10	47991-47994	the	_	
261-11	47995-48003	non-user	_	
261-12	48004-48009	group	_	
261-13	48010-48011	(	_	
261-14	48011-48019	compared	_	
261-15	48020-48022	to	_	
261-16	48023-48026	the	_	
261-17	48027-48035	cannabis	_	
261-18	48036-48041	group	_	
261-19	48041-48042	)	_	
261-20	48043-48049	remain	_	
261-21	48050-48057	unclear	_	
261-22	48057-48058	.	_	

#Text=The present study was designed to examine age-of-onset and cannabis severity brain-behavior associations within cannabis groups and not the precipitating factors and features associated with cannabis abstinence in high-risk cohorts, limiting our ability to make stronger conclusions.
262-1	48059-48062	The	_	
262-2	48063-48070	present	_	
262-3	48071-48076	study	_	
262-4	48077-48080	was	_	
262-5	48081-48089	designed	_	
262-6	48090-48092	to	_	
262-7	48093-48100	examine	_	
262-8	48101-48113	age-of-onset	_	
262-9	48114-48117	and	_	
262-10	48118-48126	cannabis	_	
262-11	48127-48135	severity	_	
262-12	48136-48150	brain-behavior	_	
262-13	48151-48163	associations	_	
262-14	48164-48170	within	_	
262-15	48171-48179	cannabis	_	
262-16	48180-48186	groups	_	
262-17	48187-48190	and	_	
262-18	48191-48194	not	_	
262-19	48195-48198	the	_	
262-20	48199-48212	precipitating	_	
262-21	48213-48220	factors	_	
262-22	48221-48224	and	_	
262-23	48225-48233	features	_	
262-24	48234-48244	associated	_	
262-25	48245-48249	with	_	
262-26	48250-48258	cannabis	_	
262-27	48259-48269	abstinence	_	
262-28	48270-48272	in	_	
262-29	48273-48282	high-risk	_	
262-30	48283-48290	cohorts	_	
262-31	48290-48291	,	_	
262-32	48292-48300	limiting	_	
262-33	48301-48304	our	_	
262-34	48305-48312	ability	_	
262-35	48313-48315	to	_	
262-36	48316-48320	make	_	
262-37	48321-48329	stronger	_	
262-38	48330-48341	conclusions	_	
262-39	48341-48342	.	_	

#Text=Further work is needed to determine whether this result replicates to other cohorts and whether more subtle, dimensional features of high-risk cohorts might explain group differences.
263-1	48343-48350	Further	_	
263-2	48351-48355	work	_	
263-3	48356-48358	is	_	
263-4	48359-48365	needed	_	
263-5	48366-48368	to	_	
263-6	48369-48378	determine	_	
263-7	48379-48386	whether	_	
263-8	48387-48391	this	_	
263-9	48392-48398	result	_	
263-10	48399-48409	replicates	_	
263-11	48410-48412	to	_	
263-12	48413-48418	other	_	
263-13	48419-48426	cohorts	_	
263-14	48427-48430	and	_	
263-15	48431-48438	whether	_	
263-16	48439-48443	more	_	
263-17	48444-48450	subtle	_	
263-18	48450-48451	,	_	
263-19	48452-48463	dimensional	_	
263-20	48464-48472	features	_	
263-21	48473-48475	of	_	
263-22	48476-48485	high-risk	_	
263-23	48486-48493	cohorts	_	
263-24	48494-48499	might	_	
263-25	48500-48507	explain	_	
263-26	48508-48513	group	_	
263-27	48514-48525	differences	_	
263-28	48525-48526	.	_	

#Text=Limitations
#Text=This study was designed to take advantage of the unique aspects of the population sample, including the prospective longitudinal assessment of cannabis use and prenatal cannabis exposure.
264-1	48527-48538	Limitations	_	
264-2	48539-48543	This	_	
264-3	48544-48549	study	_	
264-4	48550-48553	was	_	
264-5	48554-48562	designed	_	
264-6	48563-48565	to	_	
264-7	48566-48570	take	_	
264-8	48571-48580	advantage	_	
264-9	48581-48583	of	_	
264-10	48584-48587	the	_	
264-11	48588-48594	unique	_	
264-12	48595-48602	aspects	_	
264-13	48603-48605	of	_	
264-14	48606-48609	the	_	
264-15	48610-48620	population	_	
264-16	48621-48627	sample	_	
264-17	48627-48628	,	_	
264-18	48629-48638	including	_	
264-19	48639-48642	the	_	
264-20	48643-48654	prospective	_	
264-21	48655-48667	longitudinal	_	
264-22	48668-48678	assessment	_	
264-23	48679-48681	of	_	
264-24	48682-48690	cannabis	_	
264-25	48691-48694	use	_	
264-26	48695-48698	and	_	
264-27	48699-48707	prenatal	_	
264-28	48708-48716	cannabis	_	
264-29	48717-48725	exposure	_	
264-30	48725-48726	.	_	

#Text=We also utilized an approach to characterize specific epochs of the WM task to better identify which cognitive processes may be associated with age of onset and total cannabis use.
265-1	48727-48729	We	_	
265-2	48730-48734	also	_	
265-3	48735-48743	utilized	_	
265-4	48744-48746	an	_	
265-5	48747-48755	approach	_	
265-6	48756-48758	to	_	
265-7	48759-48771	characterize	_	
265-8	48772-48780	specific	_	
265-9	48781-48787	epochs	_	
265-10	48788-48790	of	_	
265-11	48791-48794	the	_	
265-12	48795-48797	WM	_	
265-13	48798-48802	task	_	
265-14	48803-48805	to	_	
265-15	48806-48812	better	_	
265-16	48813-48821	identify	_	
265-17	48822-48827	which	_	
265-18	48828-48837	cognitive	_	
265-19	48838-48847	processes	_	
265-20	48848-48851	may	_	
265-21	48852-48854	be	_	
265-22	48855-48865	associated	_	
265-23	48866-48870	with	_	
265-24	48871-48874	age	_	
265-25	48875-48877	of	_	
265-26	48878-48883	onset	_	
265-27	48884-48887	and	_	
265-28	48888-48893	total	_	
265-29	48894-48902	cannabis	_	
265-30	48903-48906	use	_	
265-31	48906-48907	.	_	

#Text=However, several limitations should also be noted.
266-1	48908-48915	However	_	
266-2	48915-48916	,	_	
266-3	48917-48924	several	_	
266-4	48925-48936	limitations	_	
266-5	48937-48943	should	_	
266-6	48944-48948	also	_	
266-7	48949-48951	be	_	
266-8	48952-48957	noted	_	
266-9	48957-48958	.	_	

#Text=First, this study utilized a high-risk prospective cohort sample with varying degrees of cannabis use throughout adolescence and adulthood.
267-1	48959-48964	First	_	
267-2	48964-48965	,	_	
267-3	48966-48970	this	_	
267-4	48971-48976	study	_	
267-5	48977-48985	utilized	_	
267-6	48986-48987	a	_	
267-7	48988-48997	high-risk	_	
267-8	48998-49009	prospective	_	
267-9	49010-49016	cohort	_	
267-10	49017-49023	sample	_	
267-11	49024-49028	with	_	
267-12	49029-49036	varying	_	
267-13	49037-49044	degrees	_	
267-14	49045-49047	of	_	
267-15	49048-49056	cannabis	_	
267-16	49057-49060	use	_	
267-17	49061-49071	throughout	_	
267-18	49072-49083	adolescence	_	
267-19	49084-49087	and	_	
267-20	49088-49097	adulthood	_	
267-21	49097-49098	.	_	

#Text=Accordingly, participants were not excluded from the study based on previous cannabis use, unless they had a positive urine screen on the day of testing or reported recreational drug use in the past week.
268-1	49099-49110	Accordingly	_	
268-2	49110-49111	,	_	
268-3	49112-49124	participants	_	
268-4	49125-49129	were	_	
268-5	49130-49133	not	_	
268-6	49134-49142	excluded	_	
268-7	49143-49147	from	_	
268-8	49148-49151	the	_	
268-9	49152-49157	study	_	
268-10	49158-49163	based	_	
268-11	49164-49166	on	_	
268-12	49167-49175	previous	_	
268-13	49176-49184	cannabis	_	
268-14	49185-49188	use	_	
268-15	49188-49189	,	_	
268-16	49190-49196	unless	_	
268-17	49197-49201	they	_	
268-18	49202-49205	had	_	
268-19	49206-49207	a	_	
268-20	49208-49216	positive	_	
268-21	49217-49222	urine	_	
268-22	49223-49229	screen	_	
268-23	49230-49232	on	_	
268-24	49233-49236	the	_	
268-25	49237-49240	day	_	
268-26	49241-49243	of	_	
268-27	49244-49251	testing	_	
268-28	49252-49254	or	_	
268-29	49255-49263	reported	_	
268-30	49264-49276	recreational	_	
268-31	49277-49281	drug	_	
268-32	49282-49285	use	_	
268-33	49286-49288	in	_	
268-34	49289-49292	the	_	
268-35	49293-49297	past	_	
268-36	49298-49302	week	_	
268-37	49302-49303	.	_	

#Text=In our analyses examining the REP group, in which fifteen subjects reported cannabis use in the last year, we covaried cannabis use within the last year.
269-1	49304-49306	In	_	
269-2	49307-49310	our	_	
269-3	49311-49319	analyses	_	
269-4	49320-49329	examining	_	
269-5	49330-49333	the	_	
269-6	49334-49337	REP	_	
269-7	49338-49343	group	_	
269-8	49343-49344	,	_	
269-9	49345-49347	in	_	
269-10	49348-49353	which	_	
269-11	49354-49361	fifteen	_	
269-12	49362-49370	subjects	_	
269-13	49371-49379	reported	_	
269-14	49380-49388	cannabis	_	
269-15	49389-49392	use	_	
269-16	49393-49395	in	_	
269-17	49396-49399	the	_	
269-18	49400-49404	last	_	
269-19	49405-49409	year	_	
269-20	49409-49410	,	_	
269-21	49411-49413	we	_	
269-22	49414-49422	covaried	_	
269-23	49423-49431	cannabis	_	
269-24	49432-49435	use	_	
269-25	49436-49442	within	_	
269-26	49443-49446	the	_	
269-27	49447-49451	last	_	
269-28	49452-49456	year	_	
269-29	49456-49457	.	_	

#Text=However, future investigations with larger samples should further investigate associations between cannabis use history, recent cannabis use, and neurocognitive function.
270-1	49458-49465	However	_	
270-2	49465-49466	,	_	
270-3	49467-49473	future	_	
270-4	49474-49488	investigations	_	
270-5	49489-49493	with	_	
270-6	49494-49500	larger	_	
270-7	49501-49508	samples	_	
270-8	49509-49515	should	_	
270-9	49516-49523	further	_	
270-10	49524-49535	investigate	_	
270-11	49536-49548	associations	_	
270-12	49549-49556	between	_	
270-13	49557-49565	cannabis	_	
270-14	49566-49569	use	_	
270-15	49570-49577	history	_	
270-16	49577-49578	,	_	
270-17	49579-49585	recent	_	
270-18	49586-49594	cannabis	_	
270-19	49595-49598	use	_	
270-20	49598-49599	,	_	
270-21	49600-49603	and	_	
270-22	49604-49618	neurocognitive	_	
270-23	49619-49627	function	_	
270-24	49627-49628	.	_	

#Text=An additional limitation of the study was the binary threshold (positive/negative) for the urine screen.
271-1	49629-49631	An	_	
271-2	49632-49642	additional	_	
271-3	49643-49653	limitation	_	
271-4	49654-49656	of	_	
271-5	49657-49660	the	_	
271-6	49661-49666	study	_	
271-7	49667-49670	was	_	
271-8	49671-49674	the	_	
271-9	49675-49681	binary	_	
271-10	49682-49691	threshold	_	
271-11	49692-49693	(	_	
271-12	49693-49701	positive	_	
271-13	49701-49702	/	_	
271-14	49702-49710	negative	_	
271-15	49710-49711	)	_	
271-16	49712-49715	for	_	
271-17	49716-49719	the	_	
271-18	49720-49725	urine	_	
271-19	49726-49732	screen	_	
271-20	49732-49733	.	_	

#Text=Future work may utilize drug screening procedures that provide a more dimensional biological measure of recent cannabis use and examine whether this moderates cannabis age of onset and cumulative cannabis use WM associations.
272-1	49734-49740	Future	_	
272-2	49741-49745	work	_	
272-3	49746-49749	may	_	
272-4	49750-49757	utilize	_	
272-5	49758-49762	drug	_	
272-6	49763-49772	screening	_	
272-7	49773-49783	procedures	_	
272-8	49784-49788	that	_	
272-9	49789-49796	provide	_	
272-10	49797-49798	a	_	
272-11	49799-49803	more	_	
272-12	49804-49815	dimensional	_	
272-13	49816-49826	biological	_	
272-14	49827-49834	measure	_	
272-15	49835-49837	of	_	
272-16	49838-49844	recent	_	
272-17	49845-49853	cannabis	_	
272-18	49854-49857	use	_	
272-19	49858-49861	and	_	
272-20	49862-49869	examine	_	
272-21	49870-49877	whether	_	
272-22	49878-49882	this	_	
272-23	49883-49892	moderates	_	
272-24	49893-49901	cannabis	_	
272-25	49902-49905	age	_	
272-26	49906-49908	of	_	
272-27	49909-49914	onset	_	
272-28	49915-49918	and	_	
272-29	49919-49929	cumulative	_	
272-30	49930-49938	cannabis	_	
272-31	49939-49942	use	_	
272-32	49943-49945	WM	_	
272-33	49946-49958	associations	_	
272-34	49958-49959	.	_	

#Text=Finally, although cannabis use was prospectively assessed (cohort years 14-, 16-, 22-, 28-years-old), the interview only asked about the previous year.
273-1	49960-49967	Finally	_	
273-2	49967-49968	,	_	
273-3	49969-49977	although	_	
273-4	49978-49986	cannabis	_	
273-5	49987-49990	use	_	
273-6	49991-49994	was	_	
273-7	49995-50008	prospectively	_	
273-8	50009-50017	assessed	_	
273-9	50018-50019	(	_	
273-10	50019-50025	cohort	_	
273-11	50026-50031	years	_	
273-12	50032-50034	14	_	
273-13	50034-50035	-	_	
273-14	50035-50036	,	_	
273-15	50037-50039	16	_	
273-16	50039-50040	-	_	
273-17	50040-50041	,	_	
273-18	50042-50044	22	_	
273-19	50044-50045	-	_	
273-20	50045-50046	,	_	
273-21	50047-50049	28	_	
273-22	50049-50050	-	_	
273-23	50050-50059	years-old	_	
273-24	50059-50060	)	_	
273-25	50060-50061	,	_	
273-26	50062-50065	the	_	
273-27	50066-50075	interview	_	
273-28	50076-50080	only	_	
273-29	50081-50086	asked	_	
273-30	50087-50092	about	_	
273-31	50093-50096	the	_	
273-32	50097-50105	previous	_	
273-33	50106-50110	year	_	
273-34	50110-50111	.	_	

#Text=Usage in the intervening years was not measured.
274-1	50112-50117	Usage	_	
274-2	50118-50120	in	_	
274-3	50121-50124	the	_	
274-4	50125-50136	intervening	_	
274-5	50137-50142	years	_	
274-6	50143-50146	was	_	
274-7	50147-50150	not	_	
274-8	50151-50159	measured	_	
274-9	50159-50160	.	_	

#Text=Accordingly, two participants who reported the same use at an assessment year (e.g., age 28) could have varied in their usage in the years between other assessment phases.
275-1	50161-50172	Accordingly	_	
275-2	50172-50173	,	_	
275-3	50174-50177	two	_	
275-4	50178-50190	participants	_	
275-5	50191-50194	who	_	
275-6	50195-50203	reported	_	
275-7	50204-50207	the	_	
275-8	50208-50212	same	_	
275-9	50213-50216	use	_	
275-10	50217-50219	at	_	
275-11	50220-50222	an	_	
275-12	50223-50233	assessment	_	
275-13	50234-50238	year	_	
275-14	50239-50240	(	_	
275-15	50240-50243	e.g	_	
275-16	50243-50244	.	_	
275-17	50244-50245	,	_	
275-18	50246-50249	age	_	
275-19	50250-50252	28	_	
275-20	50252-50253	)	_	
275-21	50254-50259	could	_	
275-22	50260-50264	have	_	
275-23	50265-50271	varied	_	
275-24	50272-50274	in	_	
275-25	50275-50280	their	_	
275-26	50281-50286	usage	_	
275-27	50287-50289	in	_	
275-28	50290-50293	the	_	
275-29	50294-50299	years	_	
275-30	50300-50307	between	_	
275-31	50308-50313	other	_	
275-32	50314-50324	assessment	_	
275-33	50325-50331	phases	_	
275-34	50331-50332	.	_	

#Text=Future work with prospective longitudinal assessment should incorporate more frequent assessments of cannabis use in order to better estimate total cannabis use trajectories.
276-1	50333-50339	Future	_	
276-2	50340-50344	work	_	
276-3	50345-50349	with	_	
276-4	50350-50361	prospective	_	
276-5	50362-50374	longitudinal	_	
276-6	50375-50385	assessment	_	
276-7	50386-50392	should	_	
276-8	50393-50404	incorporate	_	
276-9	50405-50409	more	_	
276-10	50410-50418	frequent	_	
276-11	50419-50430	assessments	_	
276-12	50431-50433	of	_	
276-13	50434-50442	cannabis	_	
276-14	50443-50446	use	_	
276-15	50447-50449	in	_	
276-16	50450-50455	order	_	
276-17	50456-50458	to	_	
276-18	50459-50465	better	_	
276-19	50466-50474	estimate	_	
276-20	50475-50480	total	_	
276-21	50481-50489	cannabis	_	
276-22	50490-50493	use	_	
276-23	50494-50506	trajectories	_	
276-24	50506-50507	.	_	

#Text=Despite these limitations, the current project highlights the value in examining associations between cannabis use and cognitive function in adults with longitudinal cannabis use history and prenatal substance exposure assessments.
277-1	50508-50515	Despite	_	
277-2	50516-50521	these	_	
277-3	50522-50533	limitations	_	
277-4	50533-50534	,	_	
277-5	50535-50538	the	_	
277-6	50539-50546	current	_	
277-7	50547-50554	project	_	
277-8	50555-50565	highlights	_	
277-9	50566-50569	the	_	
277-10	50570-50575	value	_	
277-11	50576-50578	in	_	
277-12	50579-50588	examining	_	
277-13	50589-50601	associations	_	
277-14	50602-50609	between	_	
277-15	50610-50618	cannabis	_	
277-16	50619-50622	use	_	
277-17	50623-50626	and	_	
277-18	50627-50636	cognitive	_	
277-19	50637-50645	function	_	
277-20	50646-50648	in	_	
277-21	50649-50655	adults	_	
277-22	50656-50660	with	_	
277-23	50661-50673	longitudinal	_	
277-24	50674-50682	cannabis	_	
277-25	50683-50686	use	_	
277-26	50687-50694	history	_	
277-27	50695-50698	and	_	
277-28	50699-50707	prenatal	_	
277-29	50708-50717	substance	_	
277-30	50718-50726	exposure	_	
277-31	50727-50738	assessments	_	
277-32	50738-50739	.	_	

#Text=Conclusion
#Text=Our results support evidence suggesting that reported early cannabis use in the adolescent period is associated with individual differences in the parietal cortex in adulthood.
278-1	50740-50750	Conclusion	_	
278-2	50751-50754	Our	_	
278-3	50755-50762	results	_	
278-4	50763-50770	support	_	
278-5	50771-50779	evidence	_	
278-6	50780-50790	suggesting	_	
278-7	50791-50795	that	_	
278-8	50796-50804	reported	_	
278-9	50805-50810	early	_	
278-10	50811-50819	cannabis	_	
278-11	50820-50823	use	_	
278-12	50824-50826	in	_	
278-13	50827-50830	the	_	
278-14	50831-50841	adolescent	_	
278-15	50842-50848	period	_	
278-16	50849-50851	is	_	
278-17	50852-50862	associated	_	
278-18	50863-50867	with	_	
278-19	50868-50878	individual	_	
278-20	50879-50890	differences	_	
278-21	50891-50893	in	_	
278-22	50894-50897	the	_	
278-23	50898-50906	parietal	_	
278-24	50907-50913	cortex	_	
278-25	50914-50916	in	_	
278-26	50917-50926	adulthood	_	
278-27	50926-50927	.	_	

#Text=We extend this line of inquiry by providing evidence that cannabis age of onset may be specifically associated with information processing speed and stimulus encoding.
279-1	50928-50930	We	_	
279-2	50931-50937	extend	_	
279-3	50938-50942	this	_	
279-4	50943-50947	line	_	
279-5	50948-50950	of	_	
279-6	50951-50958	inquiry	_	
279-7	50959-50961	by	_	
279-8	50962-50971	providing	_	
279-9	50972-50980	evidence	_	
279-10	50981-50985	that	_	
279-11	50986-50994	cannabis	_	
279-12	50995-50998	age	_	
279-13	50999-51001	of	_	
279-14	51002-51007	onset	_	
279-15	51008-51011	may	_	
279-16	51012-51014	be	_	
279-17	51015-51027	specifically	_	
279-18	51028-51038	associated	_	
279-19	51039-51043	with	_	
279-20	51044-51055	information	_	
279-21	51056-51066	processing	_	
279-22	51067-51072	speed	_	
279-23	51073-51076	and	_	
279-24	51077-51085	stimulus	_	
279-25	51086-51094	encoding	_	
279-26	51094-51095	.	_	

#Text=However, this pattern of results was evident in both those who reported a onetime use and those with repeated use, suggesting these effects may represent pre-onset substance use risk characteristics rather than cannabis exposure effects.
280-1	51096-51103	However	_	
280-2	51103-51104	,	_	
280-3	51105-51109	this	_	
280-4	51110-51117	pattern	_	
280-5	51118-51120	of	_	
280-6	51121-51128	results	_	
280-7	51129-51132	was	_	
280-8	51133-51140	evident	_	
280-9	51141-51143	in	_	
280-10	51144-51148	both	_	
280-11	51149-51154	those	_	
280-12	51155-51158	who	_	
280-13	51159-51167	reported	_	
280-14	51168-51169	a	_	
280-15	51170-51177	onetime	_	
280-16	51178-51181	use	_	
280-17	51182-51185	and	_	
280-18	51186-51191	those	_	
280-19	51192-51196	with	_	
280-20	51197-51205	repeated	_	
280-21	51206-51209	use	_	
280-22	51209-51210	,	_	
280-23	51211-51221	suggesting	_	
280-24	51222-51227	these	_	
280-25	51228-51235	effects	_	
280-26	51236-51239	may	_	
280-27	51240-51249	represent	_	
280-28	51250-51259	pre-onset	_	
280-29	51260-51269	substance	_	
280-30	51270-51273	use	_	
280-31	51274-51278	risk	_	
280-32	51279-51294	characteristics	_	
280-33	51295-51301	rather	_	
280-34	51302-51306	than	_	
280-35	51307-51315	cannabis	_	
280-36	51316-51324	exposure	_	
280-37	51325-51332	effects	_	
280-38	51332-51333	.	_	

#Text=In contrast, our results suggested total cannabis use may be specifically associated with processes underlying the ability to maintain information in WM through the DLPFC, independent of cannabis age of onset.
281-1	51334-51336	In	_	
281-2	51337-51345	contrast	_	
281-3	51345-51346	,	_	
281-4	51347-51350	our	_	
281-5	51351-51358	results	_	
281-6	51359-51368	suggested	_	
281-7	51369-51374	total	_	
281-8	51375-51383	cannabis	_	
281-9	51384-51387	use	_	
281-10	51388-51391	may	_	
281-11	51392-51394	be	_	
281-12	51395-51407	specifically	_	
281-13	51408-51418	associated	_	
281-14	51419-51423	with	_	
281-15	51424-51433	processes	_	
281-16	51434-51444	underlying	_	
281-17	51445-51448	the	_	
281-18	51449-51456	ability	_	
281-19	51457-51459	to	_	
281-20	51460-51468	maintain	_	
281-21	51469-51480	information	_	
281-22	51481-51483	in	_	
281-23	51484-51486	WM	_	
281-24	51487-51494	through	_	
281-25	51495-51498	the	_	
281-26	51499-51504	DLPFC	_	
281-27	51504-51505	,	_	
281-28	51506-51517	independent	_	
281-29	51518-51520	of	_	
281-30	51521-51529	cannabis	_	
281-31	51530-51533	age	_	
281-32	51534-51536	of	_	
281-33	51537-51542	onset	_	
281-34	51542-51543	.	_	

#Text=Together with previous reports, our data help refine distinct neurocognitive phenotypes of adolescent cannabis use.
282-1	51544-51552	Together	_	
282-2	51553-51557	with	_	
282-3	51558-51566	previous	_	
282-4	51567-51574	reports	_	
282-5	51574-51575	,	_	
282-6	51576-51579	our	_	
282-7	51580-51584	data	_	
282-8	51585-51589	help	_	
282-9	51590-51596	refine	_	
282-10	51597-51605	distinct	_	
282-11	51606-51620	neurocognitive	_	
282-12	51621-51631	phenotypes	_	
282-13	51632-51634	of	_	
282-14	51635-51645	adolescent	_	
282-15	51646-51654	cannabis	_	
282-16	51655-51658	use	_	
282-17	51658-51659	.	_	

#Text=However, this model necessitates future testing within prospective studies where neuroimaging and cognitive assessment are performed prior to cannabis use onset.
283-1	51660-51667	However	_	
283-2	51667-51668	,	_	
283-3	51669-51673	this	_	
283-4	51674-51679	model	_	
283-5	51680-51692	necessitates	_	
283-6	51693-51699	future	_	
283-7	51700-51707	testing	_	
283-8	51708-51714	within	_	
283-9	51715-51726	prospective	_	
283-10	51727-51734	studies	_	
283-11	51735-51740	where	_	
283-12	51741-51753	neuroimaging	_	
283-13	51754-51757	and	_	
283-14	51758-51767	cognitive	_	
283-15	51768-51778	assessment	_	
283-16	51779-51782	are	_	
283-17	51783-51792	performed	_	
283-18	51793-51798	prior	_	
283-19	51799-51801	to	_	
283-20	51802-51810	cannabis	_	
283-21	51811-51814	use	_	
283-22	51815-51820	onset	_	
283-23	51820-51821	.	_	

#Text=Supplementary Material
#Text=Financial disclosures
#Text=All authors report no financial interests or potential conflicts of interest.
284-1	51822-51835	Supplementary	_	
284-2	51836-51844	Material	_	
284-3	51845-51854	Financial	_	
284-4	51855-51866	disclosures	_	
284-5	51867-51870	All	_	
284-6	51871-51878	authors	_	
284-7	51879-51885	report	_	
284-8	51886-51888	no	_	
284-9	51889-51898	financial	_	
284-10	51899-51908	interests	_	
284-11	51909-51911	or	_	
284-12	51912-51921	potential	_	
284-13	51922-51931	conflicts	_	
284-14	51932-51934	of	_	
284-15	51935-51943	interest	_	
284-16	51943-51944	.	_	

#Text=Appendix A.
285-1	51945-51953	Appendix	_	
285-2	51954-51955	A	_	
285-3	51955-51956	.	_	

#Text=Supplementary data
#Text=Supplementary data related to this article can be found at https://doi.org/10.1016/j.neuroimage.2017.12.041.
286-1	51957-51970	Supplementary	_	
286-2	51971-51975	data	_	
286-3	51976-51989	Supplementary	_	
286-4	51990-51994	data	_	
286-5	51995-52002	related	_	
286-6	52003-52005	to	_	
286-7	52006-52010	this	_	
286-8	52011-52018	article	_	
286-9	52019-52022	can	_	
286-10	52023-52025	be	_	
286-11	52026-52031	found	_	
286-12	52032-52034	at	_	
286-13	52035-52040	https	_	
286-14	52040-52041	:	_	
286-15	52041-52042	/	_	
286-16	52042-52043	/	_	
286-17	52043-52050	doi.org	_	
286-18	52050-52051	/	_	
286-19	52051-52058	10.1016	_	
286-20	52058-52059	/	_	
286-21	52059-52071	j.neuroimage	_	
286-22	52071-52083	.2017.12.041	_	
286-23	52083-52084	.	_	

#Text=References
#Text=Overlapping mechanisms of attention and spatial working memory
#Text=
#Text=The impact of early-onset cannabis use on functional brain correlates of working memory
#Text=Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation
#Text=Detecting the subtle shape differences in hemodynamic responses at the group level
#Text=Voluntary orienting is dissociated from target detection in human posterior parietal cortex
#Text=AFNI: software for analysis and visualization of functional magnetic resonance neuroimages
#Text=An evidence based review of acute and longterm effects of cannabis use on executive cognitive functions
#Text=
#Text=Prenatal marijuana use and neonatal outcome
#Text=Effect of prenatal marijuana exposure on the cognitive development of offspring at age three
#Text=Prenatal marijuana exposure contributes to the prediction of marijuana use at age 14
#Text=Maintenance versus manipulation of information held in working memory: an event-related fMRI study
#Text=Development of cannabinoid 1 receptor protein and messenger RNA in monkey dorsolateral prefrontal cortex
#Text=Specific attentional dysfunction in adults following early start of cannabis use
#Text=Package “car.”
287-1	52085-52095	References	_	
287-2	52096-52107	Overlapping	_	
287-3	52108-52118	mechanisms	_	
287-4	52119-52121	of	_	
287-5	52122-52131	attention	_	
287-6	52132-52135	and	_	
287-7	52136-52143	spatial	_	
287-8	52144-52151	working	_	
287-9	52152-52158	memory	_	
287-10	52160-52163	The	_	
287-11	52164-52170	impact	_	
287-12	52171-52173	of	_	
287-13	52174-52185	early-onset	_	
287-14	52186-52194	cannabis	_	
287-15	52195-52198	use	_	
287-16	52199-52201	on	_	
287-17	52202-52212	functional	_	
287-18	52213-52218	brain	_	
287-19	52219-52229	correlates	_	
287-20	52230-52232	of	_	
287-21	52233-52240	working	_	
287-22	52241-52247	memory	_	
287-23	52248-52257	Marijuana	_	
287-24	52258-52261	use	_	
287-25	52262-52264	is	_	
287-26	52265-52275	associated	_	
287-27	52276-52280	with	_	
287-28	52281-52282	a	_	
287-29	52283-52294	reorganized	_	
287-30	52295-52311	visual-attention	_	
287-31	52312-52319	network	_	
287-32	52320-52323	and	_	
287-33	52324-52334	cerebellar	_	
287-34	52335-52349	hypoactivation	_	
287-35	52350-52359	Detecting	_	
287-36	52360-52363	the	_	
287-37	52364-52370	subtle	_	
287-38	52371-52376	shape	_	
287-39	52377-52388	differences	_	
287-40	52389-52391	in	_	
287-41	52392-52403	hemodynamic	_	
287-42	52404-52413	responses	_	
287-43	52414-52416	at	_	
287-44	52417-52420	the	_	
287-45	52421-52426	group	_	
287-46	52427-52432	level	_	
287-47	52433-52442	Voluntary	_	
287-48	52443-52452	orienting	_	
287-49	52453-52455	is	_	
287-50	52456-52467	dissociated	_	
287-51	52468-52472	from	_	
287-52	52473-52479	target	_	
287-53	52480-52489	detection	_	
287-54	52490-52492	in	_	
287-55	52493-52498	human	_	
287-56	52499-52508	posterior	_	
287-57	52509-52517	parietal	_	
287-58	52518-52524	cortex	_	
287-59	52525-52529	AFNI	_	
287-60	52529-52530	:	_	
287-61	52531-52539	software	_	
287-62	52540-52543	for	_	
287-63	52544-52552	analysis	_	
287-64	52553-52556	and	_	
287-65	52557-52570	visualization	_	
287-66	52571-52573	of	_	
287-67	52574-52584	functional	_	
287-68	52585-52593	magnetic	_	
287-69	52594-52603	resonance	_	
287-70	52604-52615	neuroimages	_	
287-71	52616-52618	An	_	
287-72	52619-52627	evidence	_	
287-73	52628-52633	based	_	
287-74	52634-52640	review	_	
287-75	52641-52643	of	_	
287-76	52644-52649	acute	_	
287-77	52650-52653	and	_	
287-78	52654-52662	longterm	_	
287-79	52663-52670	effects	_	
287-80	52671-52673	of	_	
287-81	52674-52682	cannabis	_	
287-82	52683-52686	use	_	
287-83	52687-52689	on	_	
287-84	52690-52699	executive	_	
287-85	52700-52709	cognitive	_	
287-86	52710-52719	functions	_	
287-87	52721-52729	Prenatal	_	
287-88	52730-52739	marijuana	_	
287-89	52740-52743	use	_	
287-90	52744-52747	and	_	
287-91	52748-52756	neonatal	_	
287-92	52757-52764	outcome	_	
287-93	52765-52771	Effect	_	
287-94	52772-52774	of	_	
287-95	52775-52783	prenatal	_	
287-96	52784-52793	marijuana	_	
287-97	52794-52802	exposure	_	
287-98	52803-52805	on	_	
287-99	52806-52809	the	_	
287-100	52810-52819	cognitive	_	
287-101	52820-52831	development	_	
287-102	52832-52834	of	_	
287-103	52835-52844	offspring	_	
287-104	52845-52847	at	_	
287-105	52848-52851	age	_	
287-106	52852-52857	three	_	
287-107	52858-52866	Prenatal	_	
287-108	52867-52876	marijuana	_	
287-109	52877-52885	exposure	_	
287-110	52886-52897	contributes	_	
287-111	52898-52900	to	_	
287-112	52901-52904	the	_	
287-113	52905-52915	prediction	_	
287-114	52916-52918	of	_	
287-115	52919-52928	marijuana	_	
287-116	52929-52932	use	_	
287-117	52933-52935	at	_	
287-118	52936-52939	age	_	
287-119	52940-52942	14	_	
287-120	52943-52954	Maintenance	_	
287-121	52955-52961	versus	_	
287-122	52962-52974	manipulation	_	
287-123	52975-52977	of	_	
287-124	52978-52989	information	_	
287-125	52990-52994	held	_	
287-126	52995-52997	in	_	
287-127	52998-53005	working	_	
287-128	53006-53012	memory	_	
287-129	53012-53013	:	_	
287-130	53014-53016	an	_	
287-131	53017-53030	event-related	_	
287-132	53031-53035	fMRI	_	
287-133	53036-53041	study	_	
287-134	53042-53053	Development	_	
287-135	53054-53056	of	_	
287-136	53057-53068	cannabinoid	_	
287-137	53069-53070	1	_	
287-138	53071-53079	receptor	_	
287-139	53080-53087	protein	_	
287-140	53088-53091	and	_	
287-141	53092-53101	messenger	_	
287-142	53102-53105	RNA	_	
287-143	53106-53108	in	_	
287-144	53109-53115	monkey	_	
287-145	53116-53128	dorsolateral	_	
287-146	53129-53139	prefrontal	_	
287-147	53140-53146	cortex	_	
287-148	53147-53155	Specific	_	
287-149	53156-53167	attentional	_	
287-150	53168-53179	dysfunction	_	
287-151	53180-53182	in	_	
287-152	53183-53189	adults	_	
287-153	53190-53199	following	_	
287-154	53200-53205	early	_	
287-155	53206-53211	start	_	
287-156	53212-53214	of	_	
287-157	53215-53223	cannabis	_	
287-158	53224-53227	use	_	
287-159	53228-53235	Package	_	
287-160	53236-53237	“	_	
287-161	53237-53240	car	_	
287-162	53240-53241	.	_	
287-163	53241-53242	”	_	

#Text=Companion to Applied Regression
#Text=Quantitative magnetic resonance imaging of human brain development: ages 4–18
#Text=
#Text=Prenatal marijuana exposure and intelligence test performance at age 6
#Text=Prenatal cigarette smoke exposure and early initiation of multiple substance use
#Text=Detection of time- varying signals in event-related fMRI designs
#Text=Age of onset of marijuana use impacts inhibitory processing
#Text=The relationship between non-acute adolescent cannabis use and cognition
#Text=Cannabinoid receptor localization in brain
#Text=Impact of adolescent marijuana use on intelligence: results from two longitudinal twin studies
#Text=Impact of cannabis use on brain function in adolescents
#Text=Improved optimization for the robust and accurate linear registration and motion correction of brain images
#Text=
#Text=Marijuana effects on human forgetting functions
#Text=Lsmeans: Least-squares Means
#Text=Maturation of cognitive processes from late childhood to adulthood
#Text=What has fMRI told us about the development of cognitive control through adolescence?
288-1	53243-53252	Companion	_	
288-2	53253-53255	to	_	
288-3	53256-53263	Applied	_	
288-4	53264-53274	Regression	_	
288-5	53275-53287	Quantitative	_	
288-6	53288-53296	magnetic	_	
288-7	53297-53306	resonance	_	
288-8	53307-53314	imaging	_	
288-9	53315-53317	of	_	
288-10	53318-53323	human	_	
288-11	53324-53329	brain	_	
288-12	53330-53341	development	_	
288-13	53341-53342	:	_	
288-14	53343-53347	ages	_	
288-15	53348-53349	4	_	
288-16	53349-53350	–	_	
288-17	53350-53352	18	_	
288-18	53354-53362	Prenatal	_	
288-19	53363-53372	marijuana	_	
288-20	53373-53381	exposure	_	
288-21	53382-53385	and	_	
288-22	53386-53398	intelligence	_	
288-23	53399-53403	test	_	
288-24	53404-53415	performance	_	
288-25	53416-53418	at	_	
288-26	53419-53422	age	_	
288-27	53423-53424	6	_	
288-28	53425-53433	Prenatal	_	
288-29	53434-53443	cigarette	_	
288-30	53444-53449	smoke	_	
288-31	53450-53458	exposure	_	
288-32	53459-53462	and	_	
288-33	53463-53468	early	_	
288-34	53469-53479	initiation	_	
288-35	53480-53482	of	_	
288-36	53483-53491	multiple	_	
288-37	53492-53501	substance	_	
288-38	53502-53505	use	_	
288-39	53506-53515	Detection	_	
288-40	53516-53518	of	_	
288-41	53519-53523	time	_	
288-42	53523-53524	-	_	
288-43	53525-53532	varying	_	
288-44	53533-53540	signals	_	
288-45	53541-53543	in	_	
288-46	53544-53557	event-related	_	
288-47	53558-53562	fMRI	_	
288-48	53563-53570	designs	_	
288-49	53571-53574	Age	_	
288-50	53575-53577	of	_	
288-51	53578-53583	onset	_	
288-52	53584-53586	of	_	
288-53	53587-53596	marijuana	_	
288-54	53597-53600	use	_	
288-55	53601-53608	impacts	_	
288-56	53609-53619	inhibitory	_	
288-57	53620-53630	processing	_	
288-58	53631-53634	The	_	
288-59	53635-53647	relationship	_	
288-60	53648-53655	between	_	
288-61	53656-53665	non-acute	_	
288-62	53666-53676	adolescent	_	
288-63	53677-53685	cannabis	_	
288-64	53686-53689	use	_	
288-65	53690-53693	and	_	
288-66	53694-53703	cognition	_	
288-67	53704-53715	Cannabinoid	_	
288-68	53716-53724	receptor	_	
288-69	53725-53737	localization	_	
288-70	53738-53740	in	_	
288-71	53741-53746	brain	_	
288-72	53747-53753	Impact	_	
288-73	53754-53756	of	_	
288-74	53757-53767	adolescent	_	
288-75	53768-53777	marijuana	_	
288-76	53778-53781	use	_	
288-77	53782-53784	on	_	
288-78	53785-53797	intelligence	_	
288-79	53797-53798	:	_	
288-80	53799-53806	results	_	
288-81	53807-53811	from	_	
288-82	53812-53815	two	_	
288-83	53816-53828	longitudinal	_	
288-84	53829-53833	twin	_	
288-85	53834-53841	studies	_	
288-86	53842-53848	Impact	_	
288-87	53849-53851	of	_	
288-88	53852-53860	cannabis	_	
288-89	53861-53864	use	_	
288-90	53865-53867	on	_	
288-91	53868-53873	brain	_	
288-92	53874-53882	function	_	
288-93	53883-53885	in	_	
288-94	53886-53897	adolescents	_	
288-95	53898-53906	Improved	_	
288-96	53907-53919	optimization	_	
288-97	53920-53923	for	_	
288-98	53924-53927	the	_	
288-99	53928-53934	robust	_	
288-100	53935-53938	and	_	
288-101	53939-53947	accurate	_	
288-102	53948-53954	linear	_	
288-103	53955-53967	registration	_	
288-104	53968-53971	and	_	
288-105	53972-53978	motion	_	
288-106	53979-53989	correction	_	
288-107	53990-53992	of	_	
288-108	53993-53998	brain	_	
288-109	53999-54005	images	_	
288-110	54007-54016	Marijuana	_	
288-111	54017-54024	effects	_	
288-112	54025-54027	on	_	
288-113	54028-54033	human	_	
288-114	54034-54044	forgetting	_	
288-115	54045-54054	functions	_	
288-116	54055-54062	Lsmeans	_	
288-117	54062-54063	:	_	
288-118	54064-54077	Least-squares	_	
288-119	54078-54083	Means	_	
288-120	54084-54094	Maturation	_	
288-121	54095-54097	of	_	
288-122	54098-54107	cognitive	_	
288-123	54108-54117	processes	_	
288-124	54118-54122	from	_	
288-125	54123-54127	late	_	
288-126	54128-54137	childhood	_	
288-127	54138-54140	to	_	
288-128	54141-54150	adulthood	_	
288-129	54151-54155	What	_	
288-130	54156-54159	has	_	
288-131	54160-54164	fMRI	_	
288-132	54165-54169	told	_	
288-133	54170-54172	us	_	
288-134	54173-54178	about	_	
288-135	54179-54182	the	_	
288-136	54183-54194	development	_	
288-137	54195-54197	of	_	
288-138	54198-54207	cognitive	_	
288-139	54208-54215	control	_	
288-140	54216-54223	through	_	
288-141	54224-54235	adolescence	_	
288-142	54235-54236	?	_	

#Text=The cannabinoid CB1 receptor antagonist SR141716A attenuates the memory impairment produced by Δ9-tetrahydrocannabinol or anandamide
#Text=Persistent cannabis users show neuropsychological decline from childhood to midlife
#Text=Social anxiety, negative affectivity, and substance use among high school students
#Text=Combined analysis of DTI and fMRI data reveals a joint maturation of white and grey matter in a fronto-parietal network
#Text=Separating processes within a trial in event-related functional MRI: I.
289-1	54237-54240	The	_	
289-2	54241-54252	cannabinoid	_	
289-3	54253-54256	CB1	_	
289-4	54257-54265	receptor	_	
289-5	54266-54276	antagonist	_	
289-6	54277-54286	SR141716A	_	
289-7	54287-54297	attenuates	_	
289-8	54298-54301	the	_	
289-9	54302-54308	memory	_	
289-10	54309-54319	impairment	_	
289-11	54320-54328	produced	_	
289-12	54329-54331	by	_	
289-13	54332-54334	Δ9	_	
289-14	54334-54335	-	_	
289-15	54335-54355	tetrahydrocannabinol	_	
289-16	54356-54358	or	_	
289-17	54359-54369	anandamide	_	
289-18	54370-54380	Persistent	_	
289-19	54381-54389	cannabis	_	
289-20	54390-54395	users	_	
289-21	54396-54400	show	_	
289-22	54401-54419	neuropsychological	_	
289-23	54420-54427	decline	_	
289-24	54428-54432	from	_	
289-25	54433-54442	childhood	_	
289-26	54443-54445	to	_	
289-27	54446-54453	midlife	_	
289-28	54454-54460	Social	_	
289-29	54461-54468	anxiety	_	
289-30	54468-54469	,	_	
289-31	54470-54478	negative	_	
289-32	54479-54490	affectivity	_	
289-33	54490-54491	,	_	
289-34	54492-54495	and	_	
289-35	54496-54505	substance	_	
289-36	54506-54509	use	_	
289-37	54510-54515	among	_	
289-38	54516-54520	high	_	
289-39	54521-54527	school	_	
289-40	54528-54536	students	_	
289-41	54537-54545	Combined	_	
289-42	54546-54554	analysis	_	
289-43	54555-54557	of	_	
289-44	54558-54561	DTI	_	
289-45	54562-54565	and	_	
289-46	54566-54570	fMRI	_	
289-47	54571-54575	data	_	
289-48	54576-54583	reveals	_	
289-49	54584-54585	a	_	
289-50	54586-54591	joint	_	
289-51	54592-54602	maturation	_	
289-52	54603-54605	of	_	
289-53	54606-54611	white	_	
289-54	54612-54615	and	_	
289-55	54616-54620	grey	_	
289-56	54621-54627	matter	_	
289-57	54628-54630	in	_	
289-58	54631-54632	a	_	
289-59	54633-54648	fronto-parietal	_	
289-60	54649-54656	network	_	
289-61	54657-54667	Separating	_	
289-62	54668-54677	processes	_	
289-63	54678-54684	within	_	
289-64	54685-54686	a	_	
289-65	54687-54692	trial	_	
289-66	54693-54695	in	_	
289-67	54696-54709	event-related	_	
289-68	54710-54720	functional	_	
289-69	54721-54724	MRI	_	
289-70	54724-54725	:	_	
289-71	54726-54727	I	_	
289-72	54727-54728	.	_	

#Text=The method
#Text=Longitudinal growth curves of brain function underlying inhibitory control through adolescence
#Text=Effects of incentives, age, and behavior on brain activation during inhibitory control: a longitudinal fMRI study
#Text=The residual cognitive effects of heavy marijuana use in college students
#Text=Early-onset cannabis use and cognitive deficits: what is the nature of the association?
290-1	54729-54732	The	_	
290-2	54733-54739	method	_	
290-3	54740-54752	Longitudinal	_	
290-4	54753-54759	growth	_	
290-5	54760-54766	curves	_	
290-6	54767-54769	of	_	
290-7	54770-54775	brain	_	
290-8	54776-54784	function	_	
290-9	54785-54795	underlying	_	
290-10	54796-54806	inhibitory	_	
290-11	54807-54814	control	_	
290-12	54815-54822	through	_	
290-13	54823-54834	adolescence	_	
290-14	54835-54842	Effects	_	
290-15	54843-54845	of	_	
290-16	54846-54856	incentives	_	
290-17	54856-54857	,	_	
290-18	54858-54861	age	_	
290-19	54861-54862	,	_	
290-20	54863-54866	and	_	
290-21	54867-54875	behavior	_	
290-22	54876-54878	on	_	
290-23	54879-54884	brain	_	
290-24	54885-54895	activation	_	
290-25	54896-54902	during	_	
290-26	54903-54913	inhibitory	_	
290-27	54914-54921	control	_	
290-28	54921-54922	:	_	
290-29	54923-54924	a	_	
290-30	54925-54937	longitudinal	_	
290-31	54938-54942	fMRI	_	
290-32	54943-54948	study	_	
290-33	54949-54952	The	_	
290-34	54953-54961	residual	_	
290-35	54962-54971	cognitive	_	
290-36	54972-54979	effects	_	
290-37	54980-54982	of	_	
290-38	54983-54988	heavy	_	
290-39	54989-54998	marijuana	_	
290-40	54999-55002	use	_	
290-41	55003-55005	in	_	
290-42	55006-55013	college	_	
290-43	55014-55022	students	_	
290-44	55023-55034	Early-onset	_	
290-45	55035-55043	cannabis	_	
290-46	55044-55047	use	_	
290-47	55048-55051	and	_	
290-48	55052-55061	cognitive	_	
290-49	55062-55070	deficits	_	
290-50	55070-55071	:	_	
290-51	55072-55076	what	_	
290-52	55077-55079	is	_	
290-53	55080-55083	the	_	
290-54	55084-55090	nature	_	
290-55	55091-55093	of	_	
290-56	55094-55097	the	_	
290-57	55098-55109	association	_	
290-58	55109-55110	?	_	

#Text=Prenatal alcohol and marijuana exposure: effects on neuropsychological outcomes at 10 years
#Text=Cambridge neuropsychological test automated battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers
#Text=Abstinent adolescent marijuana users show altered fMRI response during spatial working memory
#Text=Cognitive functioning of adolescent and young adult cannabis users in the Philadelphia Neurodevelopmental Cohort
#Text=Anxiety selectively disrupts visuospatial working memory
#Text=The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM- IV and ICD-10
#Text=Statistical improvements in functional magnetic resonance imaging analyses produced by censoring high-motion data points
#Text=SUSAN - a new approach to low level image processing
#Text=Functional neuroimaging of working memory in schizophrenia: task performance as a moderating variable
#Text=Mechanisms of working memory impairment in schizophrenia
#Text=Cognitive functioning of long-term heavy cannabis users seeking treatment
#Text=Prenatal marijuana exposure predicts marijuana use in young adulthood
#Text=Neural correlates of the difference between working memory speed and simple sensorimotor speed: an fMRI study
#Text=Functional MRI of inhibitory processing in abstinent adolescent marijuana users
#Text=Prefrontal activity during working memory is modulated by the interaction of variation in CB1 and COX2 coding genes and correlates with frequency of cannabis use
#Text=
#Text=
#Text=
#Text=Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system
#Text=Cognitive processing speed and the structure of white matter pathways: convergent evidence from normal variation and lesion studies
#Text=Cannabis and cognitive functions: a prospective study
#Text=Differential effects of Δ9-THC on spatial reference and working memory in mice
#Text=Maintenance versus manipulation in verbal working memory revisited: an fMRI study
#Text=
#Text=Working Memory Task.
291-1	55111-55119	Prenatal	_	
291-2	55120-55127	alcohol	_	
291-3	55128-55131	and	_	
291-4	55132-55141	marijuana	_	
291-5	55142-55150	exposure	_	
291-6	55150-55151	:	_	
291-7	55152-55159	effects	_	
291-8	55160-55162	on	_	
291-9	55163-55181	neuropsychological	_	
291-10	55182-55190	outcomes	_	
291-11	55191-55193	at	_	
291-12	55194-55196	10	_	
291-13	55197-55202	years	_	
291-14	55203-55212	Cambridge	_	
291-15	55213-55231	neuropsychological	_	
291-16	55232-55236	test	_	
291-17	55237-55246	automated	_	
291-18	55247-55254	battery	_	
291-19	55255-55256	(	_	
291-20	55256-55262	CANTAB	_	
291-21	55262-55263	)	_	
291-22	55263-55264	:	_	
291-23	55265-55266	a	_	
291-24	55267-55273	factor	_	
291-25	55274-55282	analytic	_	
291-26	55283-55288	study	_	
291-27	55289-55291	of	_	
291-28	55292-55293	a	_	
291-29	55294-55299	large	_	
291-30	55300-55306	sample	_	
291-31	55307-55309	of	_	
291-32	55310-55316	normal	_	
291-33	55317-55324	elderly	_	
291-34	55325-55335	volunteers	_	
291-35	55336-55345	Abstinent	_	
291-36	55346-55356	adolescent	_	
291-37	55357-55366	marijuana	_	
291-38	55367-55372	users	_	
291-39	55373-55377	show	_	
291-40	55378-55385	altered	_	
291-41	55386-55390	fMRI	_	
291-42	55391-55399	response	_	
291-43	55400-55406	during	_	
291-44	55407-55414	spatial	_	
291-45	55415-55422	working	_	
291-46	55423-55429	memory	_	
291-47	55430-55439	Cognitive	_	
291-48	55440-55451	functioning	_	
291-49	55452-55454	of	_	
291-50	55455-55465	adolescent	_	
291-51	55466-55469	and	_	
291-52	55470-55475	young	_	
291-53	55476-55481	adult	_	
291-54	55482-55490	cannabis	_	
291-55	55491-55496	users	_	
291-56	55497-55499	in	_	
291-57	55500-55503	the	_	
291-58	55504-55516	Philadelphia	_	
291-59	55517-55535	Neurodevelopmental	_	
291-60	55536-55542	Cohort	_	
291-61	55543-55550	Anxiety	_	
291-62	55551-55562	selectively	_	
291-63	55563-55571	disrupts	_	
291-64	55572-55584	visuospatial	_	
291-65	55585-55592	working	_	
291-66	55593-55599	memory	_	
291-67	55600-55603	The	_	
291-68	55604-55622	Mini-International	_	
291-69	55623-55639	Neuropsychiatric	_	
291-70	55640-55649	Interview	_	
291-71	55650-55651	(	_	
291-72	55651-55655	MINI	_	
291-73	55655-55656	)	_	
291-74	55656-55657	:	_	
291-75	55658-55661	the	_	
291-76	55662-55673	development	_	
291-77	55674-55677	and	_	
291-78	55678-55688	validation	_	
291-79	55689-55691	of	_	
291-80	55692-55693	a	_	
291-81	55694-55704	structured	_	
291-82	55705-55715	diagnostic	_	
291-83	55716-55727	psychiatric	_	
291-84	55728-55737	interview	_	
291-85	55738-55741	for	_	
291-86	55742-55745	DSM	_	
291-87	55745-55746	-	_	
291-88	55747-55749	IV	_	
291-89	55750-55753	and	_	
291-90	55754-55757	ICD	_	
291-91	55757-55758	-	_	
291-92	55758-55760	10	_	
291-93	55761-55772	Statistical	_	
291-94	55773-55785	improvements	_	
291-95	55786-55788	in	_	
291-96	55789-55799	functional	_	
291-97	55800-55808	magnetic	_	
291-98	55809-55818	resonance	_	
291-99	55819-55826	imaging	_	
291-100	55827-55835	analyses	_	
291-101	55836-55844	produced	_	
291-102	55845-55847	by	_	
291-103	55848-55857	censoring	_	
291-104	55858-55869	high-motion	_	
291-105	55870-55874	data	_	
291-106	55875-55881	points	_	
291-107	55882-55887	SUSAN	_	
291-108	55888-55889	-	_	
291-109	55890-55891	a	_	
291-110	55892-55895	new	_	
291-111	55896-55904	approach	_	
291-112	55905-55907	to	_	
291-113	55908-55911	low	_	
291-114	55912-55917	level	_	
291-115	55918-55923	image	_	
291-116	55924-55934	processing	_	
291-117	55935-55945	Functional	_	
291-118	55946-55958	neuroimaging	_	
291-119	55959-55961	of	_	
291-120	55962-55969	working	_	
291-121	55970-55976	memory	_	
291-122	55977-55979	in	_	
291-123	55980-55993	schizophrenia	_	
291-124	55993-55994	:	_	
291-125	55995-55999	task	_	
291-126	56000-56011	performance	_	
291-127	56012-56014	as	_	
291-128	56015-56016	a	_	
291-129	56017-56027	moderating	_	
291-130	56028-56036	variable	_	
291-131	56037-56047	Mechanisms	_	
291-132	56048-56050	of	_	
291-133	56051-56058	working	_	
291-134	56059-56065	memory	_	
291-135	56066-56076	impairment	_	
291-136	56077-56079	in	_	
291-137	56080-56093	schizophrenia	_	
291-138	56094-56103	Cognitive	_	
291-139	56104-56115	functioning	_	
291-140	56116-56118	of	_	
291-141	56119-56128	long-term	_	
291-142	56129-56134	heavy	_	
291-143	56135-56143	cannabis	_	
291-144	56144-56149	users	_	
291-145	56150-56157	seeking	_	
291-146	56158-56167	treatment	_	
291-147	56168-56176	Prenatal	_	
291-148	56177-56186	marijuana	_	
291-149	56187-56195	exposure	_	
291-150	56196-56204	predicts	_	
291-151	56205-56214	marijuana	_	
291-152	56215-56218	use	_	
291-153	56219-56221	in	_	
291-154	56222-56227	young	_	
291-155	56228-56237	adulthood	_	
291-156	56238-56244	Neural	_	
291-157	56245-56255	correlates	_	
291-158	56256-56258	of	_	
291-159	56259-56262	the	_	
291-160	56263-56273	difference	_	
291-161	56274-56281	between	_	
291-162	56282-56289	working	_	
291-163	56290-56296	memory	_	
291-164	56297-56302	speed	_	
291-165	56303-56306	and	_	
291-166	56307-56313	simple	_	
291-167	56314-56326	sensorimotor	_	
291-168	56327-56332	speed	_	
291-169	56332-56333	:	_	
291-170	56334-56336	an	_	
291-171	56337-56341	fMRI	_	
291-172	56342-56347	study	_	
291-173	56348-56358	Functional	_	
291-174	56359-56362	MRI	_	
291-175	56363-56365	of	_	
291-176	56366-56376	inhibitory	_	
291-177	56377-56387	processing	_	
291-178	56388-56390	in	_	
291-179	56391-56400	abstinent	_	
291-180	56401-56411	adolescent	_	
291-181	56412-56421	marijuana	_	
291-182	56422-56427	users	_	
291-183	56428-56438	Prefrontal	_	
291-184	56439-56447	activity	_	
291-185	56448-56454	during	_	
291-186	56455-56462	working	_	
291-187	56463-56469	memory	_	
291-188	56470-56472	is	_	
291-189	56473-56482	modulated	_	
291-190	56483-56485	by	_	
291-191	56486-56489	the	_	
291-192	56490-56501	interaction	_	
291-193	56502-56504	of	_	
291-194	56505-56514	variation	_	
291-195	56515-56517	in	_	
291-196	56518-56521	CB1	_	
291-197	56522-56525	and	_	
291-198	56526-56530	COX2	_	
291-199	56531-56537	coding	_	
291-200	56538-56543	genes	_	
291-201	56544-56547	and	_	
291-202	56548-56558	correlates	_	
291-203	56559-56563	with	_	
291-204	56564-56573	frequency	_	
291-205	56574-56576	of	_	
291-206	56577-56585	cannabis	_	
291-207	56586-56589	use	_	
291-208	56593-56612	Immunohistochemical	_	
291-209	56613-56625	distribution	_	
291-210	56626-56628	of	_	
291-211	56629-56640	cannabinoid	_	
291-212	56641-56644	CB1	_	
291-213	56645-56654	receptors	_	
291-214	56655-56657	in	_	
291-215	56658-56661	the	_	
291-216	56662-56665	rat	_	
291-217	56666-56673	central	_	
291-218	56674-56681	nervous	_	
291-219	56682-56688	system	_	
291-220	56689-56698	Cognitive	_	
291-221	56699-56709	processing	_	
291-222	56710-56715	speed	_	
291-223	56716-56719	and	_	
291-224	56720-56723	the	_	
291-225	56724-56733	structure	_	
291-226	56734-56736	of	_	
291-227	56737-56742	white	_	
291-228	56743-56749	matter	_	
291-229	56750-56758	pathways	_	
291-230	56758-56759	:	_	
291-231	56760-56770	convergent	_	
291-232	56771-56779	evidence	_	
291-233	56780-56784	from	_	
291-234	56785-56791	normal	_	
291-235	56792-56801	variation	_	
291-236	56802-56805	and	_	
291-237	56806-56812	lesion	_	
291-238	56813-56820	studies	_	
291-239	56821-56829	Cannabis	_	
291-240	56830-56833	and	_	
291-241	56834-56843	cognitive	_	
291-242	56844-56853	functions	_	
291-243	56853-56854	:	_	
291-244	56855-56856	a	_	
291-245	56857-56868	prospective	_	
291-246	56869-56874	study	_	
291-247	56875-56887	Differential	_	
291-248	56888-56895	effects	_	
291-249	56896-56898	of	_	
291-250	56899-56901	Δ9	_	
291-251	56901-56902	-	_	
291-252	56902-56905	THC	_	
291-253	56906-56908	on	_	
291-254	56909-56916	spatial	_	
291-255	56917-56926	reference	_	
291-256	56927-56930	and	_	
291-257	56931-56938	working	_	
291-258	56939-56945	memory	_	
291-259	56946-56948	in	_	
291-260	56949-56953	mice	_	
291-261	56954-56965	Maintenance	_	
291-262	56966-56972	versus	_	
291-263	56973-56985	manipulation	_	
291-264	56986-56988	in	_	
291-265	56989-56995	verbal	_	
291-266	56996-57003	working	_	
291-267	57004-57010	memory	_	
291-268	57011-57020	revisited	_	
291-269	57020-57021	:	_	
291-270	57022-57024	an	_	
291-271	57025-57029	fMRI	_	
291-272	57030-57035	study	_	
291-273	57037-57044	Working	_	
291-274	57045-57051	Memory	_	
291-275	57052-57056	Task	_	
291-276	57056-57057	.	_	

#Text=Three cues (yellow circles) were presented sequentially (300 ms presentation, 200 ms ISI) in one of eight possible locations (2 row X 4 column grid).
292-1	57058-57063	Three	_	
292-2	57064-57068	cues	_	
292-3	57069-57070	(	_	
292-4	57070-57076	yellow	_	
292-5	57077-57084	circles	_	
292-6	57084-57085	)	_	
292-7	57086-57090	were	_	
292-8	57091-57100	presented	_	
292-9	57101-57113	sequentially	_	
292-10	57114-57115	(	_	
292-11	57115-57118	300	_	
292-12	57119-57121	ms	_	
292-13	57122-57134	presentation	_	
292-14	57134-57135	,	_	
292-15	57136-57139	200	_	
292-16	57140-57142	ms	_	
292-17	57143-57146	ISI	_	
292-18	57146-57147	)	_	
292-19	57148-57150	in	_	
292-20	57151-57154	one	_	
292-21	57155-57157	of	_	
292-22	57158-57163	eight	_	
292-23	57164-57172	possible	_	
292-24	57173-57182	locations	_	
292-25	57183-57184	(	_	
292-26	57184-57185	2	_	
292-27	57186-57189	row	_	
292-28	57190-57191	X	_	
292-29	57192-57193	4	_	
292-30	57194-57200	column	_	
292-31	57201-57205	grid	_	
292-32	57205-57206	)	_	
292-33	57206-57207	.	_	

#Text=Behavioral Effects of Cannabis Age of Onset and Total Cannabis Use on Working Memory Performance.
293-1	57208-57218	Behavioral	_	
293-2	57219-57226	Effects	_	
293-3	57227-57229	of	_	
293-4	57230-57238	Cannabis	_	
293-5	57239-57242	Age	_	
293-6	57243-57245	of	_	
293-7	57246-57251	Onset	_	
293-8	57252-57255	and	_	
293-9	57256-57261	Total	_	
293-10	57262-57270	Cannabis	_	
293-11	57271-57274	Use	_	
293-12	57275-57277	on	_	
293-13	57278-57285	Working	_	
293-14	57286-57292	Memory	_	
293-15	57293-57304	Performance	_	
293-16	57304-57305	.	_	

#Text=N.S.
294-1	57306-57309	N.S	_	
294-2	57309-57310	.	_	

#Text=Non-significant, + p < .10, **p < .01.
295-1	57311-57326	Non-significant	_	
295-2	57326-57327	,	_	
295-3	57328-57329	+	_	
295-4	57330-57331	p	_	
295-5	57332-57333	<	_	
295-6	57334-57337	.10	_	
295-7	57337-57338	,	_	
295-8	57339-57340	*	_	
295-9	57340-57341	*	_	
295-10	57341-57342	p	_	
295-11	57343-57344	<	_	
295-12	57345-57348	.01	_	
295-13	57348-57349	.	_	

#Text=EXP, cannabis experimenters; REP, repeated cannabis users.
296-1	57350-57353	EXP	_	
296-2	57353-57354	,	_	
296-3	57355-57363	cannabis	_	
296-4	57364-57377	experimenters	_	
296-5	57377-57378	;	_	
296-6	57379-57382	REP	_	
296-7	57382-57383	,	_	
296-8	57384-57392	repeated	_	
296-9	57393-57401	cannabis	_	
296-10	57402-57407	users	_	
296-11	57407-57408	.	_	

#Text=Model estimates were back transformed from log (reaction time) and logit (accuracy) space for ease of interpretation.
297-1	57409-57414	Model	_	
297-2	57415-57424	estimates	_	
297-3	57425-57429	were	_	
297-4	57430-57434	back	_	
297-5	57435-57446	transformed	_	
297-6	57447-57451	from	_	
297-7	57452-57455	log	_	
297-8	57456-57457	(	_	
297-9	57457-57465	reaction	_	
297-10	57466-57470	time	_	
297-11	57470-57471	)	_	
297-12	57472-57475	and	_	
297-13	57476-57481	logit	_	
297-14	57482-57483	(	_	
297-15	57483-57491	accuracy	_	
297-16	57491-57492	)	_	
297-17	57493-57498	space	_	
297-18	57499-57502	for	_	
297-19	57503-57507	ease	_	
297-20	57508-57510	of	_	
297-21	57511-57525	interpretation	_	
297-22	57525-57526	.	_	

#Text=Visualized estimates are from intercept onlybaseline models.
298-1	57527-57537	Visualized	_	
298-2	57538-57547	estimates	_	
298-3	57548-57551	are	_	
298-4	57552-57556	from	_	
298-5	57557-57566	intercept	_	
298-6	57567-57579	onlybaseline	_	
298-7	57580-57586	models	_	
298-8	57586-57587	.	_	

#Text=(A), Cannabis age of onsetwas not a significant predictor of WM accuracy (baseline: z = 1.30, p = .193; full model: z = 0.52, p = .601), but had a significant, negative relationship with WM RT (C; baseline: t = −2.99, p = .003; full model: t = −3.11, p = .002).
299-1	57588-57589	(	_	
299-2	57589-57590	A	_	
299-3	57590-57591	)	_	
299-4	57591-57592	,	_	
299-5	57593-57601	Cannabis	_	
299-6	57602-57605	age	_	
299-7	57606-57608	of	_	
299-8	57609-57617	onsetwas	_	
299-9	57618-57621	not	_	
299-10	57622-57623	a	_	
299-11	57624-57635	significant	_	
299-12	57636-57645	predictor	_	
299-13	57646-57648	of	_	
299-14	57649-57651	WM	_	
299-15	57652-57660	accuracy	_	
299-16	57661-57662	(	_	
299-17	57662-57670	baseline	_	
299-18	57670-57671	:	_	
299-19	57672-57673	z	_	
299-20	57674-57675	=	_	
299-21	57676-57680	1.30	_	
299-22	57680-57681	,	_	
299-23	57682-57683	p	_	
299-24	57684-57685	=	_	
299-25	57686-57690	.193	_	
299-26	57690-57691	;	_	
299-27	57692-57696	full	_	
299-28	57697-57702	model	_	
299-29	57702-57703	:	_	
299-30	57704-57705	z	_	
299-31	57706-57707	=	_	
299-32	57708-57712	0.52	_	
299-33	57712-57713	,	_	
299-34	57714-57715	p	_	
299-35	57716-57717	=	_	
299-36	57718-57722	.601	_	
299-37	57722-57723	)	_	
299-38	57723-57724	,	_	
299-39	57725-57728	but	_	
299-40	57729-57732	had	_	
299-41	57733-57734	a	_	
299-42	57735-57746	significant	_	
299-43	57746-57747	,	_	
299-44	57748-57756	negative	_	
299-45	57757-57769	relationship	_	
299-46	57770-57774	with	_	
299-47	57775-57777	WM	_	
299-48	57778-57780	RT	_	
299-49	57781-57782	(	_	
299-50	57782-57783	C	_	
299-51	57783-57784	;	_	
299-52	57785-57793	baseline	_	
299-53	57793-57794	:	_	
299-54	57795-57796	t	_	
299-55	57797-57798	=	_	
299-56	57799-57800	−	_	
299-57	57800-57804	2.99	_	
299-58	57804-57805	,	_	
299-59	57806-57807	p	_	
299-60	57808-57809	=	_	
299-61	57810-57814	.003	_	
299-62	57814-57815	;	_	
299-63	57816-57820	full	_	
299-64	57821-57826	model	_	
299-65	57826-57827	:	_	
299-66	57828-57829	t	_	
299-67	57830-57831	=	_	
299-68	57832-57833	−	_	
299-69	57833-57837	3.11	_	
299-70	57837-57838	,	_	
299-71	57839-57840	p	_	
299-72	57841-57842	=	_	
299-73	57843-57847	.002	_	
299-74	57847-57848	)	_	
299-75	57848-57849	.	_	

#Text=In contrast, total cannabis use (log) was not a significant predictor of working memory RT (D; baseline: t = 0.88, p = .381; full model: t = 1.40, p = .162) but had a near significant, negative relationship with WM accuracy in the baseline model (B; z = −1.93, p = .054).
300-1	57850-57852	In	_	
300-2	57853-57861	contrast	_	
300-3	57861-57862	,	_	
300-4	57863-57868	total	_	
300-5	57869-57877	cannabis	_	
300-6	57878-57881	use	_	
300-7	57882-57883	(	_	
300-8	57883-57886	log	_	
300-9	57886-57887	)	_	
300-10	57888-57891	was	_	
300-11	57892-57895	not	_	
300-12	57896-57897	a	_	
300-13	57898-57909	significant	_	
300-14	57910-57919	predictor	_	
300-15	57920-57922	of	_	
300-16	57923-57930	working	_	
300-17	57931-57937	memory	_	
300-18	57938-57940	RT	_	
300-19	57941-57942	(	_	
300-20	57942-57943	D	_	
300-21	57943-57944	;	_	
300-22	57945-57953	baseline	_	
300-23	57953-57954	:	_	
300-24	57955-57956	t	_	
300-25	57957-57958	=	_	
300-26	57959-57963	0.88	_	
300-27	57963-57964	,	_	
300-28	57965-57966	p	_	
300-29	57967-57968	=	_	
300-30	57969-57973	.381	_	
300-31	57973-57974	;	_	
300-32	57975-57979	full	_	
300-33	57980-57985	model	_	
300-34	57985-57986	:	_	
300-35	57987-57988	t	_	
300-36	57989-57990	=	_	
300-37	57991-57995	1.40	_	
300-38	57995-57996	,	_	
300-39	57997-57998	p	_	
300-40	57999-58000	=	_	
300-41	58001-58005	.162	_	
300-42	58005-58006	)	_	
300-43	58007-58010	but	_	
300-44	58011-58014	had	_	
300-45	58015-58016	a	_	
300-46	58017-58021	near	_	
300-47	58022-58033	significant	_	
300-48	58033-58034	,	_	
300-49	58035-58043	negative	_	
300-50	58044-58056	relationship	_	
300-51	58057-58061	with	_	
300-52	58062-58064	WM	_	
300-53	58065-58073	accuracy	_	
300-54	58074-58076	in	_	
300-55	58077-58080	the	_	
300-56	58081-58089	baseline	_	
300-57	58090-58095	model	_	
300-58	58096-58097	(	_	
300-59	58097-58098	B	_	
300-60	58098-58099	;	_	
300-61	58100-58101	z	_	
300-62	58102-58103	=	_	
300-63	58104-58105	−	_	
300-64	58105-58109	1.93	_	
300-65	58109-58110	,	_	
300-66	58111-58112	p	_	
300-67	58113-58114	=	_	
300-68	58115-58119	.054	_	
300-69	58119-58120	)	_	
300-70	58120-58121	.	_	

#Text=However, this effect was no longer significant after adjusting for prenatal cannabis exposure (z = −1.41, p = .159).
301-1	58122-58129	However	_	
301-2	58129-58130	,	_	
301-3	58131-58135	this	_	
301-4	58136-58142	effect	_	
301-5	58143-58146	was	_	
301-6	58147-58149	no	_	
301-7	58150-58156	longer	_	
301-8	58157-58168	significant	_	
301-9	58169-58174	after	_	
301-10	58175-58184	adjusting	_	
301-11	58185-58188	for	_	
301-12	58189-58197	prenatal	_	
301-13	58198-58206	cannabis	_	
301-14	58207-58215	exposure	_	
301-15	58216-58217	(	_	
301-16	58217-58218	z	_	
301-17	58219-58220	=	_	
301-18	58221-58222	−	_	
301-19	58222-58226	1.41	_	
301-20	58226-58227	,	_	
301-21	58228-58229	p	_	
301-22	58230-58231	=	_	
301-23	58232-58236	.159	_	
301-24	58236-58237	)	_	
301-25	58237-58238	.	_	

#Text=Performance Differences in Usage Groups.
302-1	58239-58250	Performance	_	
302-2	58251-58262	Differences	_	
302-3	58263-58265	in	_	
302-4	58266-58271	Usage	_	
302-5	58272-58278	Groups	_	
302-6	58278-58279	.	_	

#Text=NU, non-user; EXP, cannabis experimenters; REP, repeated cannabis users.
303-1	58280-58282	NU	_	
303-2	58282-58283	,	_	
303-3	58284-58292	non-user	_	
303-4	58292-58293	;	_	
303-5	58294-58297	EXP	_	
303-6	58297-58298	,	_	
303-7	58299-58307	cannabis	_	
303-8	58308-58321	experimenters	_	
303-9	58321-58322	;	_	
303-10	58323-58326	REP	_	
303-11	58326-58327	,	_	
303-12	58328-58336	repeated	_	
303-13	58337-58345	cannabis	_	
303-14	58346-58351	users	_	
303-15	58351-58352	.	_	

#Text=N.S., Non-significant, + p < .10, *p < .05.
304-1	58353-58356	N.S	_	
304-2	58356-58357	.	_	
304-3	58357-58358	,	_	
304-4	58359-58374	Non-significant	_	
304-5	58374-58375	,	_	
304-6	58376-58377	+	_	
304-7	58378-58379	p	_	
304-8	58380-58381	<	_	
304-9	58382-58385	.10	_	
304-10	58385-58386	,	_	
304-11	58387-58388	*	_	
304-12	58388-58389	p	_	
304-13	58390-58391	<	_	
304-14	58392-58395	.05	_	
304-15	58395-58396	.	_	

#Text=Visualized estimates are from intercept only baseline models.
305-1	58397-58407	Visualized	_	
305-2	58408-58417	estimates	_	
305-3	58418-58421	are	_	
305-4	58422-58426	from	_	
305-5	58427-58436	intercept	_	
305-6	58437-58441	only	_	
305-7	58442-58450	baseline	_	
305-8	58451-58457	models	_	
305-9	58457-58458	.	_	

#Text=There was a trend (baseline: z = 1.95, p = .052) for a combined cannabis group (EXP + REP) to have higher WM accuracy than subjects that reported not using cannabis (NU).
306-1	58459-58464	There	_	
306-2	58465-58468	was	_	
306-3	58469-58470	a	_	
306-4	58471-58476	trend	_	
306-5	58477-58478	(	_	
306-6	58478-58486	baseline	_	
306-7	58486-58487	:	_	
306-8	58488-58489	z	_	
306-9	58490-58491	=	_	
306-10	58492-58496	1.95	_	
306-11	58496-58497	,	_	
306-12	58498-58499	p	_	
306-13	58500-58501	=	_	
306-14	58502-58506	.052	_	
306-15	58506-58507	)	_	
306-16	58508-58511	for	_	
306-17	58512-58513	a	_	
306-18	58514-58522	combined	_	
306-19	58523-58531	cannabis	_	
306-20	58532-58537	group	_	
306-21	58538-58539	(	_	
306-22	58539-58542	EXP	_	
306-23	58543-58544	+	_	
306-24	58545-58548	REP	_	
306-25	58548-58549	)	_	
306-26	58550-58552	to	_	
306-27	58553-58557	have	_	
306-28	58558-58564	higher	_	
306-29	58565-58567	WM	_	
306-30	58568-58576	accuracy	_	
306-31	58577-58581	than	_	
306-32	58582-58590	subjects	_	
306-33	58591-58595	that	_	
306-34	58596-58604	reported	_	
306-35	58605-58608	not	_	
306-36	58609-58614	using	_	
306-37	58615-58623	cannabis	_	
306-38	58624-58625	(	_	
306-39	58625-58627	NU	_	
306-40	58627-58628	)	_	
306-41	58628-58629	.	_	

#Text=Additionally, a combined cannabis group (EXP + REP) had significantly lower RT (baseline: t = −2.34, p = .019).
307-1	58630-58642	Additionally	_	
307-2	58642-58643	,	_	
307-3	58644-58645	a	_	
307-4	58646-58654	combined	_	
307-5	58655-58663	cannabis	_	
307-6	58664-58669	group	_	
307-7	58670-58671	(	_	
307-8	58671-58674	EXP	_	
307-9	58675-58676	+	_	
307-10	58677-58680	REP	_	
307-11	58680-58681	)	_	
307-12	58682-58685	had	_	
307-13	58686-58699	significantly	_	
307-14	58700-58705	lower	_	
307-15	58706-58708	RT	_	
307-16	58709-58710	(	_	
307-17	58710-58718	baseline	_	
307-18	58718-58719	:	_	
307-19	58720-58721	t	_	
307-20	58722-58723	=	_	
307-21	58724-58725	−	_	
307-22	58725-58729	2.34	_	
307-23	58729-58730	,	_	
307-24	58731-58732	p	_	
307-25	58733-58734	=	_	
307-26	58735-58739	.019	_	
307-27	58739-58740	)	_	
307-28	58740-58741	.	_	

#Text=In contrast, usage groups (REP vs.
308-1	58742-58744	In	_	
308-2	58745-58753	contrast	_	
308-3	58753-58754	,	_	
308-4	58755-58760	usage	_	
308-5	58761-58767	groups	_	
308-6	58768-58769	(	_	
308-7	58769-58772	REP	_	
308-8	58773-58775	vs	_	
308-9	58775-58776	.	_	

#Text=EXP) did not significantly differ on WM accuracy (baseline: z = −1.19, p = .237) or RT (baseline: t = 0.36 p = .719).
309-1	58777-58780	EXP	_	
309-2	58780-58781	)	_	
309-3	58782-58785	did	_	
309-4	58786-58789	not	_	
309-5	58790-58803	significantly	_	
309-6	58804-58810	differ	_	
309-7	58811-58813	on	_	
309-8	58814-58816	WM	_	
309-9	58817-58825	accuracy	_	
309-10	58826-58827	(	_	
309-11	58827-58835	baseline	_	
309-12	58835-58836	:	_	
309-13	58837-58838	z	_	
309-14	58839-58840	=	_	
309-15	58841-58842	−	_	
309-16	58842-58846	1.19	_	
309-17	58846-58847	,	_	
309-18	58848-58849	p	_	
309-19	58850-58851	=	_	
309-20	58852-58856	.237	_	
309-21	58856-58857	)	_	
309-22	58858-58860	or	_	
309-23	58861-58863	RT	_	
309-24	58864-58865	(	_	
309-25	58865-58873	baseline	_	
309-26	58873-58874	:	_	
309-27	58875-58876	t	_	
309-28	58877-58878	=	_	
309-29	58879-58883	0.36	_	
309-30	58884-58885	p	_	
309-31	58886-58887	=	_	
309-32	58888-58892	.719	_	
309-33	58892-58893	)	_	
309-34	58893-58894	.	_	

#Text=Clusters of Omnibus Activation Differences as a Function of Cannabis Age of Onset in the Right Posterior Parietal Cortex (cluster A, top; cluster b, bottom.
310-1	58895-58903	Clusters	_	
310-2	58904-58906	of	_	
310-3	58907-58914	Omnibus	_	
310-4	58915-58925	Activation	_	
310-5	58926-58937	Differences	_	
310-6	58938-58940	as	_	
310-7	58941-58942	a	_	
310-8	58943-58951	Function	_	
310-9	58952-58954	of	_	
310-10	58955-58963	Cannabis	_	
310-11	58964-58967	Age	_	
310-12	58968-58970	of	_	
310-13	58971-58976	Onset	_	
310-14	58977-58979	in	_	
310-15	58980-58983	the	_	
310-16	58984-58989	Right	_	
310-17	58990-58999	Posterior	_	
310-18	59000-59008	Parietal	_	
310-19	59009-59015	Cortex	_	
310-20	59016-59017	(	_	
310-21	59017-59024	cluster	_	
310-22	59025-59026	A	_	
310-23	59026-59027	,	_	
310-24	59028-59031	top	_	
310-25	59031-59032	;	_	
310-26	59033-59040	cluster	_	
310-27	59041-59042	b	_	
310-28	59042-59043	,	_	
310-29	59044-59050	bottom	_	
310-30	59050-59051	.	_	

#Text=**p < .01 (corrected); (A,C) Mean cluster time course with reference markers of cue (grey), delay (white), and target (black).
311-1	59052-59053	*	_	
311-2	59053-59054	*	_	
311-3	59054-59055	p	_	
311-4	59056-59057	<	_	
311-5	59058-59061	.01	_	
311-6	59062-59063	(	_	
311-7	59063-59072	corrected	_	
311-8	59072-59073	)	_	
311-9	59073-59074	;	_	
311-10	59075-59076	(	_	
311-11	59076-59077	A	_	
311-12	59077-59078	,	_	
311-13	59078-59079	C	_	
311-14	59079-59080	)	_	
311-15	59081-59085	Mean	_	
311-16	59086-59093	cluster	_	
311-17	59094-59098	time	_	
311-18	59099-59105	course	_	
311-19	59106-59110	with	_	
311-20	59111-59120	reference	_	
311-21	59121-59128	markers	_	
311-22	59129-59131	of	_	
311-23	59132-59135	cue	_	
311-24	59136-59137	(	_	
311-25	59137-59141	grey	_	
311-26	59141-59142	)	_	
311-27	59142-59143	,	_	
311-28	59144-59149	delay	_	
311-29	59150-59151	(	_	
311-30	59151-59156	white	_	
311-31	59156-59157	)	_	
311-32	59157-59158	,	_	
311-33	59159-59162	and	_	
311-34	59163-59169	target	_	
311-35	59170-59171	(	_	
311-36	59171-59176	black	_	
311-37	59176-59177	)	_	
311-38	59177-59178	.	_	

#Text=Model was run with a continuous age of onset function and data are median split for visualization only.
312-1	59179-59184	Model	_	
312-2	59185-59188	was	_	
312-3	59189-59192	run	_	
312-4	59193-59197	with	_	
312-5	59198-59199	a	_	
312-6	59200-59210	continuous	_	
312-7	59211-59214	age	_	
312-8	59215-59217	of	_	
312-9	59218-59223	onset	_	
312-10	59224-59232	function	_	
312-11	59233-59236	and	_	
312-12	59237-59241	data	_	
312-13	59242-59245	are	_	
312-14	59246-59252	median	_	
312-15	59253-59258	split	_	
312-16	59259-59262	for	_	
312-17	59263-59276	visualization	_	
312-18	59277-59281	only	_	
312-19	59281-59282	.	_	

#Text=(B,D) Epoch activation differences as a function of cannabis age of onset.
313-1	59283-59284	(	_	
313-2	59284-59285	B	_	
313-3	59285-59286	,	_	
313-4	59286-59287	D	_	
313-5	59287-59288	)	_	
313-6	59289-59294	Epoch	_	
313-7	59295-59305	activation	_	
313-8	59306-59317	differences	_	
313-9	59318-59320	as	_	
313-10	59321-59322	a	_	
313-11	59323-59331	function	_	
313-12	59332-59334	of	_	
313-13	59335-59343	cannabis	_	
313-14	59344-59347	age	_	
313-15	59348-59350	of	_	
313-16	59351-59356	onset	_	
313-17	59356-59357	.	_	

#Text=Clusters of Omnibus Activation Differences as a Function of Total Cannabis Use in Right (top) and Left (bottom) Dorsolateral Prefrontal Cortex (DLPFC).
314-1	59358-59366	Clusters	_	
314-2	59367-59369	of	_	
314-3	59370-59377	Omnibus	_	
314-4	59378-59388	Activation	_	
314-5	59389-59400	Differences	_	
314-6	59401-59403	as	_	
314-7	59404-59405	a	_	
314-8	59406-59414	Function	_	
314-9	59415-59417	of	_	
314-10	59418-59423	Total	_	
314-11	59424-59432	Cannabis	_	
314-12	59433-59436	Use	_	
314-13	59437-59439	in	_	
314-14	59440-59445	Right	_	
314-15	59446-59447	(	_	
314-16	59447-59450	top	_	
314-17	59450-59451	)	_	
314-18	59452-59455	and	_	
314-19	59456-59460	Left	_	
314-20	59461-59462	(	_	
314-21	59462-59468	bottom	_	
314-22	59468-59469	)	_	
314-23	59470-59482	Dorsolateral	_	
314-24	59483-59493	Prefrontal	_	
314-25	59494-59500	Cortex	_	
314-26	59501-59502	(	_	
314-27	59502-59507	DLPFC	_	
314-28	59507-59508	)	_	
314-29	59508-59509	.	_	

#Text=Left DLPFC cluster is represented as L-DLPFC (A) in tables.
315-1	59510-59514	Left	_	
315-2	59515-59520	DLPFC	_	
315-3	59521-59528	cluster	_	
315-4	59529-59531	is	_	
315-5	59532-59543	represented	_	
315-6	59544-59546	as	_	
315-7	59547-59554	L-DLPFC	_	
315-8	59555-59556	(	_	
315-9	59556-59557	A	_	
315-10	59557-59558	)	_	
315-11	59559-59561	in	_	
315-12	59562-59568	tables	_	
315-13	59568-59569	.	_	

#Text=(A,C) Mean cluster time course with reference markers for cue (grey), delay (white), and target (black).
316-1	59570-59571	(	_	
316-2	59571-59572	A	_	
316-3	59572-59573	,	_	
316-4	59573-59574	C	_	
316-5	59574-59575	)	_	
316-6	59576-59580	Mean	_	
316-7	59581-59588	cluster	_	
316-8	59589-59593	time	_	
316-9	59594-59600	course	_	
316-10	59601-59605	with	_	
316-11	59606-59615	reference	_	
316-12	59616-59623	markers	_	
316-13	59624-59627	for	_	
316-14	59628-59631	cue	_	
316-15	59632-59633	(	_	
316-16	59633-59637	grey	_	
316-17	59637-59638	)	_	
316-18	59638-59639	,	_	
316-19	59640-59645	delay	_	
316-20	59646-59647	(	_	
316-21	59647-59652	white	_	
316-22	59652-59653	)	_	
316-23	59653-59654	,	_	
316-24	59655-59658	and	_	
316-25	59659-59665	target	_	
316-26	59666-59667	(	_	
316-27	59667-59672	black	_	
316-28	59672-59673	)	_	
316-29	59673-59674	.	_	

#Text=Model was run with a continuous total cannabis use (log) function and data are median split for visualization only.
317-1	59675-59680	Model	_	
317-2	59681-59684	was	_	
317-3	59685-59688	run	_	
317-4	59689-59693	with	_	
317-5	59694-59695	a	_	
317-6	59696-59706	continuous	_	
317-7	59707-59712	total	_	
317-8	59713-59721	cannabis	_	
317-9	59722-59725	use	_	
317-10	59726-59727	(	_	
317-11	59727-59730	log	_	
317-12	59730-59731	)	_	
317-13	59732-59740	function	_	
317-14	59741-59744	and	_	
317-15	59745-59749	data	_	
317-16	59750-59753	are	_	
317-17	59754-59760	median	_	
317-18	59761-59766	split	_	
317-19	59767-59770	for	_	
317-20	59771-59784	visualization	_	
317-21	59785-59789	only	_	
317-22	59789-59790	.	_	

#Text=(B,D) Epoch activation differences as a function of total cannabis use (log).
318-1	59791-59792	(	_	
318-2	59792-59793	B	_	
318-3	59793-59794	,	_	
318-4	59794-59795	D	_	
318-5	59795-59796	)	_	
318-6	59797-59802	Epoch	_	
318-7	59803-59813	activation	_	
318-8	59814-59825	differences	_	
318-9	59826-59828	as	_	
318-10	59829-59830	a	_	
318-11	59831-59839	function	_	
318-12	59840-59842	of	_	
318-13	59843-59848	total	_	
318-14	59849-59857	cannabis	_	
318-15	59858-59861	use	_	
318-16	59862-59863	(	_	
318-17	59863-59866	log	_	
318-18	59866-59867	)	_	
318-19	59867-59868	.	_	

#Text=Brain Behavior Relationships for R-Posterior Parietal Cortex (A) (R-PPC(A)) and R-Dorsolateral Prefrontal Cortex (R-DLPFC). + p < .10, *p < .05, **p < .01.
319-1	59869-59874	Brain	_	
319-2	59875-59883	Behavior	_	
319-3	59884-59897	Relationships	_	
319-4	59898-59901	for	_	
319-5	59902-59913	R-Posterior	_	
319-6	59914-59922	Parietal	_	
319-7	59923-59929	Cortex	_	
319-8	59930-59931	(	_	
319-9	59931-59932	A	_	
319-10	59932-59933	)	_	
319-11	59934-59935	(	_	
319-12	59935-59940	R-PPC	_	
319-13	59940-59941	(	_	
319-14	59941-59942	A	_	
319-15	59942-59943	)	_	
319-16	59943-59944	)	_	
319-17	59945-59948	and	_	
319-18	59949-59963	R-Dorsolateral	_	
319-19	59964-59974	Prefrontal	_	
319-20	59975-59981	Cortex	_	
319-21	59982-59983	(	_	
319-22	59983-59990	R-DLPFC	_	
319-23	59990-59991	)	_	
319-24	59991-59992	.	_	
319-25	59993-59994	+	_	
319-26	59995-59996	p	_	
319-27	59997-59998	<	_	
319-28	59999-60002	.10	_	
319-29	60002-60003	,	_	
319-30	60004-60005	*	_	
319-31	60005-60006	p	_	
319-32	60007-60008	<	_	
319-33	60009-60012	.05	_	
319-34	60012-60013	,	_	
319-35	60014-60015	*	_	
319-36	60015-60016	*	_	
319-37	60016-60017	p	_	
319-38	60018-60019	<	_	
319-39	60020-60023	.01	_	
319-40	60023-60024	.	_	

#Text=(A) Cue epoch activation in the R-PPC (A) was a significant predictor of WM RT (β = −.358, t (55)) = −2.75, p= .024, corrected.
320-1	60024-60025	(	_	
320-2	60025-60026	A	_	
320-3	60026-60027	)	_	
320-4	60028-60031	Cue	_	
320-5	60032-60037	epoch	_	
320-6	60038-60048	activation	_	
320-7	60049-60051	in	_	
320-8	60052-60055	the	_	
320-9	60056-60061	R-PPC	_	
320-10	60062-60063	(	_	
320-11	60063-60064	A	_	
320-12	60064-60065	)	_	
320-13	60066-60069	was	_	
320-14	60070-60071	a	_	
320-15	60072-60083	significant	_	
320-16	60084-60093	predictor	_	
320-17	60094-60096	of	_	
320-18	60097-60099	WM	_	
320-19	60100-60102	RT	_	
320-20	60103-60104	(	_	
320-21	60104-60105	β	_	
320-22	60106-60107	=	_	
320-23	60108-60109	−	_	
320-24	60109-60113	.358	_	
320-25	60113-60114	,	_	
320-26	60115-60116	t	_	
320-27	60117-60118	(	_	
320-28	60118-60120	55	_	
320-29	60120-60121	)	_	
320-30	60121-60122	)	_	
320-31	60123-60124	=	_	
320-32	60125-60126	−	_	
320-33	60126-60130	2.75	_	
320-34	60130-60131	,	_	
320-35	60132-60133	p	_	
320-36	60133-60134	=	_	
320-37	60135-60139	.024	_	
320-38	60139-60140	,	_	
320-39	60141-60150	corrected	_	
320-40	60150-60151	.	_	

#Text=(B) Top panel, R-PPC (A) cue epoch activation significantly mediates the relationship between cannabis age of onset and reaction time (baseline: average indirect pathway, β= −.153, 95% C.I., −.307: −.043, p = .003; full model: β= −.140, 95% C.I., −.342: −.008, p = .029).
321-1	60152-60153	(	_	
321-2	60153-60154	B	_	
321-3	60154-60155	)	_	
321-4	60156-60159	Top	_	
321-5	60160-60165	panel	_	
321-6	60165-60166	,	_	
321-7	60167-60172	R-PPC	_	
321-8	60173-60174	(	_	
321-9	60174-60175	A	_	
321-10	60175-60176	)	_	
321-11	60177-60180	cue	_	
321-12	60181-60186	epoch	_	
321-13	60187-60197	activation	_	
321-14	60198-60211	significantly	_	
321-15	60212-60220	mediates	_	
321-16	60221-60224	the	_	
321-17	60225-60237	relationship	_	
321-18	60238-60245	between	_	
321-19	60246-60254	cannabis	_	
321-20	60255-60258	age	_	
321-21	60259-60261	of	_	
321-22	60262-60267	onset	_	
321-23	60268-60271	and	_	
321-24	60272-60280	reaction	_	
321-25	60281-60285	time	_	
321-26	60286-60287	(	_	
321-27	60287-60295	baseline	_	
321-28	60295-60296	:	_	
321-29	60297-60304	average	_	
321-30	60305-60313	indirect	_	
321-31	60314-60321	pathway	_	
321-32	60321-60322	,	_	
321-33	60323-60324	β	_	
321-34	60324-60325	=	_	
321-35	60326-60327	−	_	
321-36	60327-60331	.153	_	
321-37	60331-60332	,	_	
321-38	60333-60336	95%	_	
321-39	60337-60340	C.I	_	
321-40	60340-60341	.	_	
321-41	60341-60342	,	_	
321-42	60343-60344	−	_	
321-43	60344-60348	.307	_	
321-44	60348-60349	:	_	
321-45	60350-60351	−	_	
321-46	60351-60355	.043	_	
321-47	60355-60356	,	_	
321-48	60357-60358	p	_	
321-49	60359-60360	=	_	
321-50	60361-60365	.003	_	
321-51	60365-60366	;	_	
321-52	60367-60371	full	_	
321-53	60372-60377	model	_	
321-54	60377-60378	:	_	
321-55	60379-60380	β	_	
321-56	60380-60381	=	_	
321-57	60382-60383	−	_	
321-58	60383-60387	.140	_	
321-59	60387-60388	,	_	
321-60	60389-60392	95%	_	
321-61	60393-60396	C.I	_	
321-62	60396-60397	.	_	
321-63	60397-60398	,	_	
321-64	60399-60400	−	_	
321-65	60400-60404	.342	_	
321-66	60404-60405	:	_	
321-67	60406-60407	−	_	
321-68	60407-60411	.008	_	
321-69	60411-60412	,	_	
321-70	60413-60414	p	_	
321-71	60415-60416	=	_	
321-72	60417-60421	.029	_	
321-73	60421-60422	)	_	
321-74	60422-60423	.	_	

#Text=Bottom Panel, R-PPC (A) cue epoch activation significantly mediates the relationship between cannabis age of onset and reaction time in the REP only group while covarying total cannabis use (average indirect pathway, β= −.189, 95% C.I., −.415: −.026, p = .017).
322-1	60424-60430	Bottom	_	
322-2	60431-60436	Panel	_	
322-3	60436-60437	,	_	
322-4	60438-60443	R-PPC	_	
322-5	60444-60445	(	_	
322-6	60445-60446	A	_	
322-7	60446-60447	)	_	
322-8	60448-60451	cue	_	
322-9	60452-60457	epoch	_	
322-10	60458-60468	activation	_	
322-11	60469-60482	significantly	_	
322-12	60483-60491	mediates	_	
322-13	60492-60495	the	_	
322-14	60496-60508	relationship	_	
322-15	60509-60516	between	_	
322-16	60517-60525	cannabis	_	
322-17	60526-60529	age	_	
322-18	60530-60532	of	_	
322-19	60533-60538	onset	_	
322-20	60539-60542	and	_	
322-21	60543-60551	reaction	_	
322-22	60552-60556	time	_	
322-23	60557-60559	in	_	
322-24	60560-60563	the	_	
322-25	60564-60567	REP	_	
322-26	60568-60572	only	_	
322-27	60573-60578	group	_	
322-28	60579-60584	while	_	
322-29	60585-60594	covarying	_	
322-30	60595-60600	total	_	
322-31	60601-60609	cannabis	_	
322-32	60610-60613	use	_	
322-33	60614-60615	(	_	
322-34	60615-60622	average	_	
322-35	60623-60631	indirect	_	
322-36	60632-60639	pathway	_	
322-37	60639-60640	,	_	
322-38	60641-60642	β	_	
322-39	60642-60643	=	_	
322-40	60644-60645	−	_	
322-41	60645-60649	.189	_	
322-42	60649-60650	,	_	
322-43	60651-60654	95%	_	
322-44	60655-60658	C.I	_	
322-45	60658-60659	.	_	
322-46	60659-60660	,	_	
322-47	60661-60662	−	_	
322-48	60662-60666	.415	_	
322-49	60666-60667	:	_	
322-50	60668-60669	−	_	
322-51	60669-60673	.026	_	
322-52	60673-60674	,	_	
322-53	60675-60676	p	_	
322-54	60677-60678	=	_	
322-55	60679-60683	.017	_	
322-56	60683-60684	)	_	
322-57	60684-60685	.	_	

#Text=(C), Delay epoch activation in R-DLPFC had a negative trend with working memory accuracy (O.R. = .978, z = −2.16, p = .093, corrected).
323-1	60686-60687	(	_	
323-2	60687-60688	C	_	
323-3	60688-60689	)	_	
323-4	60689-60690	,	_	
323-5	60691-60696	Delay	_	
323-6	60697-60702	epoch	_	
323-7	60703-60713	activation	_	
323-8	60714-60716	in	_	
323-9	60717-60724	R-DLPFC	_	
323-10	60725-60728	had	_	
323-11	60729-60730	a	_	
323-12	60731-60739	negative	_	
323-13	60740-60745	trend	_	
323-14	60746-60750	with	_	
323-15	60751-60758	working	_	
323-16	60759-60765	memory	_	
323-17	60766-60774	accuracy	_	
323-18	60775-60776	(	_	
323-19	60776-60779	O.R	_	
323-20	60779-60780	.	_	
323-21	60781-60782	=	_	
323-22	60783-60787	.978	_	
323-23	60787-60788	,	_	
323-24	60789-60790	z	_	
323-25	60791-60792	=	_	
323-26	60793-60794	−	_	
323-27	60794-60798	2.16	_	
323-28	60798-60799	,	_	
323-29	60800-60801	p	_	
323-30	60802-60803	=	_	
323-31	60804-60808	.093	_	
323-32	60808-60809	,	_	
323-33	60810-60819	corrected	_	
323-34	60819-60820	)	_	
323-35	60820-60821	.	_	

#Text=*p < .05.
324-1	60822-60823	*	_	
324-2	60823-60824	p	_	
324-3	60825-60826	<	_	
324-4	60827-60830	.05	_	
324-5	60830-60831	.	_	

#Text=Usage groups (NU, non-user; EXP, cannabis experimenters; REP, repeated cannabis users) BOLD activation in performance-related fMRI regions from cannabis age of onset (A; R-PPC (A) cue epoch) and total cannabis use (B; R-DLPFC delay epoch) analyses.
325-1	60832-60837	Usage	_	
325-2	60838-60844	groups	_	
325-3	60845-60846	(	_	
325-4	60846-60848	NU	_	
325-5	60848-60849	,	_	
325-6	60850-60858	non-user	_	
325-7	60858-60859	;	_	
325-8	60860-60863	EXP	_	
325-9	60863-60864	,	_	
325-10	60865-60873	cannabis	_	
325-11	60874-60887	experimenters	_	
325-12	60887-60888	;	_	
325-13	60889-60892	REP	_	
325-14	60892-60893	,	_	
325-15	60894-60902	repeated	_	
325-16	60903-60911	cannabis	_	
325-17	60912-60917	users	_	
325-18	60917-60918	)	_	
325-19	60919-60923	BOLD	_	
325-20	60924-60934	activation	_	
325-21	60935-60937	in	_	
325-22	60938-60957	performance-related	_	
325-23	60958-60962	fMRI	_	
325-24	60963-60970	regions	_	
325-25	60971-60975	from	_	
325-26	60976-60984	cannabis	_	
325-27	60985-60988	age	_	
325-28	60989-60991	of	_	
325-29	60992-60997	onset	_	
325-30	60998-60999	(	_	
325-31	60999-61000	A	_	
325-32	61000-61001	;	_	
325-33	61002-61007	R-PPC	_	
325-34	61008-61009	(	_	
325-35	61009-61010	A	_	
325-36	61010-61011	)	_	
325-37	61012-61015	cue	_	
325-38	61016-61021	epoch	_	
325-39	61021-61022	)	_	
325-40	61023-61026	and	_	
325-41	61027-61032	total	_	
325-42	61033-61041	cannabis	_	
325-43	61042-61045	use	_	
325-44	61046-61047	(	_	
325-45	61047-61048	B	_	
325-46	61048-61049	;	_	
325-47	61050-61057	R-DLPFC	_	
325-48	61058-61063	delay	_	
325-49	61064-61069	epoch	_	
325-50	61069-61070	)	_	
325-51	61071-61079	analyses	_	
325-52	61079-61080	.	_	

#Text=Participant characteristics and bivariate relationships with cannabis usage groups.
326-1	61081-61092	Participant	_	
326-2	61093-61108	characteristics	_	
326-3	61109-61112	and	_	
326-4	61113-61122	bivariate	_	
326-5	61123-61136	relationships	_	
326-6	61137-61141	with	_	
326-7	61142-61150	cannabis	_	
326-8	61151-61156	usage	_	
326-9	61157-61163	groups	_	
326-10	61163-61164	.	_	

#Text=Variable\tNon-Users (NU)n = 15\tCannabisExperimenters(EXP)n = 14\tCannabisRepeated(REP)n = 46\tp-value\t \t\t \tAge (Years)\t28.16\t28.14\t28.22\tn.s
327-1	61165-61173	Variable	_	
327-2	61174-61183	Non-Users	_	
327-3	61184-61185	(	_	
327-4	61185-61187	NU	_	
327-5	61187-61188	)	_	
327-6	61188-61189	n	_	
327-7	61190-61191	=	_	
327-8	61192-61194	15	_	
327-9	61195-61216	CannabisExperimenters	_	
327-10	61216-61217	(	_	
327-11	61217-61220	EXP	_	
327-12	61220-61221	)	_	
327-13	61221-61222	n	_	
327-14	61223-61224	=	_	
327-15	61225-61227	14	_	
327-16	61228-61244	CannabisRepeated	_	
327-17	61244-61245	(	_	
327-18	61245-61248	REP	_	
327-19	61248-61249	)	_	
327-20	61249-61250	n	_	
327-21	61251-61252	=	_	
327-22	61253-61255	46	_	
327-23	61256-61263	p-value	_	
327-24	61269-61272	Age	_	
327-25	61273-61274	(	_	
327-26	61274-61279	Years	_	
327-27	61279-61280	)	_	
327-28	61281-61286	28.16	_	
327-29	61287-61292	28.14	_	
327-30	61293-61298	28.22	_	
327-31	61299-61302	n.s	_	

#Text=.
328-1	61302-61303	.	_	

#Text=(0.71)\t(0.66)\t(0.72)\t\t \tGender (n Female)\tn = 13\tn = 7\tn = 27\tNU by EXP = .050\t \t\t\t\t\tNU by REP = .067\t \tWISC-Full Scale IQ (Age 14)\t94.83\t99.12\t93.99\tn.s
329-1	61307-61308	(	_	
329-2	61308-61312	0.71	_	
329-3	61312-61313	)	_	
329-4	61314-61315	(	_	
329-5	61315-61319	0.66	_	
329-6	61319-61320	)	_	
329-7	61321-61322	(	_	
329-8	61322-61326	0.72	_	
329-9	61326-61327	)	_	
329-10	61331-61337	Gender	_	
329-11	61338-61339	(	_	
329-12	61339-61340	n	_	
329-13	61341-61347	Female	_	
329-14	61347-61348	)	_	
329-15	61349-61350	n	_	
329-16	61351-61352	=	_	
329-17	61353-61355	13	_	
329-18	61356-61357	n	_	
329-19	61358-61359	=	_	
329-20	61360-61361	7	_	
329-21	61362-61363	n	_	
329-22	61364-61365	=	_	
329-23	61366-61368	27	_	
329-24	61369-61371	NU	_	
329-25	61372-61374	by	_	
329-26	61375-61378	EXP	_	
329-27	61379-61380	=	_	
329-28	61381-61385	.050	_	
329-29	61392-61394	NU	_	
329-30	61395-61397	by	_	
329-31	61398-61401	REP	_	
329-32	61402-61403	=	_	
329-33	61404-61408	.067	_	
329-34	61411-61420	WISC-Full	_	
329-35	61421-61426	Scale	_	
329-36	61427-61429	IQ	_	
329-37	61430-61431	(	_	
329-38	61431-61434	Age	_	
329-39	61435-61437	14	_	
329-40	61437-61438	)	_	
329-41	61439-61444	94.83	_	
329-42	61445-61450	99.12	_	
329-43	61451-61456	93.99	_	
329-44	61457-61460	n.s	_	

#Text=.
330-1	61460-61461	.	_	

#Text=(12.05)\t(16.57)\t(13.32)\t\t \tHighest Level of Education (Years)\t14.73\t14.14\t13.76\tn.s
331-1	61465-61466	(	_	
331-2	61466-61471	12.05	_	
331-3	61471-61472	)	_	
331-4	61473-61474	(	_	
331-5	61474-61479	16.57	_	
331-6	61479-61480	)	_	
331-7	61481-61482	(	_	
331-8	61482-61487	13.32	_	
331-9	61487-61488	)	_	
331-10	61492-61499	Highest	_	
331-11	61500-61505	Level	_	
331-12	61506-61508	of	_	
331-13	61509-61518	Education	_	
331-14	61519-61520	(	_	
331-15	61520-61525	Years	_	
331-16	61525-61526	)	_	
331-17	61527-61532	14.73	_	
331-18	61533-61538	14.14	_	
331-19	61539-61544	13.76	_	
331-20	61545-61548	n.s	_	

#Text=.
332-1	61548-61549	.	_	

#Text=(2.40)\t(1.79)\t(1.58)\t\t \tFamily Income\t2185\t2320\t2216\tn.s.
333-1	61553-61554	(	_	
333-2	61554-61558	2.40	_	
333-3	61558-61559	)	_	
333-4	61560-61561	(	_	
333-5	61561-61565	1.79	_	
333-6	61565-61566	)	_	
333-7	61567-61568	(	_	
333-8	61568-61572	1.58	_	
333-9	61572-61573	)	_	
333-10	61577-61583	Family	_	
333-11	61584-61590	Income	_	
333-12	61591-61595	2185	_	
333-13	61596-61600	2320	_	
333-14	61601-61605	2216	_	
333-15	61606-61609	n.s	_	
333-16	61609-61610	.	_	

#Text=(Age 16; Dollars/Month)\t(1363)\t(1364)\t(1295)\t\t \tCannabis Age of Onset (Years)\t-\t17.18\t15.14\tEXP > REP = .006\t \t\t-\t(2.20)\t(2.27)\t\t \tTotal Cannabis Use\t-\t-\t1.45\t-\t \t(Total Joints Per Day)\t\t\t(2.67)\t\t \tPeak Cannabis Use\t\t\t1.14\t\t \t(Max joints per day 14-, 16-, 22-, 28-years-old)\t\t\t(2.14)\t\t \tMean Cannabis Use\t\t\t.367\t\t \t(Mean joints per day 14-, 16-, 22-, 28-years-old)\t\t\t(.683)\t\t \tCannabis Use within Last Year\t-\tn = 0\tn = 15\tREP > EXP = .013\t \t(Any Use in Last Year)\t\t\t\t\t \tTotal Alcohol Use\t0.58\t2.31\t3.30\tEXP > NU = .015\t \t(Total Drinks Per Day)\t(0.70)\t(2.63)\t(3.95)\tREP > NU = .0001\t \tAlcohol Use Within Last Year\t0.33\t0.81\t0.92\tEXP > NU = .037\t \t(Drinks Per Day)\t(0.56)\t(0.85)\t(1.14)\tREP > NU = .011\t \tTotal Cigarette Use\t1.21\t0.037\t14.82\tNU > EXP = .044\t \t(Total Cigarettes Per Day)\t(4.70)\t(0.11)\t(19.64)\tREP > NU < .0001\t \t\t\t\t\tREP > EXP = .001\t \tCigarette Use Within Last Year\tn = 1\tn = 0\tn = 21\tREP by NU = .001\t \t(Any Use in Last Year)\t\t\t\tREP by EXP = .011\t \tOther Drug Usea\tn = 0\tn = 2\tn = 12\tNU by REP = .027\t \t(Other Drug Use at Any Visit)\tn = 0\tn = 0\tn = 1\t\t \t(Other Drug Use in Last Year)\t\t\t\t\t \tPrenatal Cannabisb\t0.19\t0.16\t0.32\tn.s.
334-1	61613-61614	(	_	
334-2	61614-61617	Age	_	
334-3	61618-61620	16	_	
334-4	61620-61621	;	_	
334-5	61622-61629	Dollars	_	
334-6	61629-61630	/	_	
334-7	61630-61635	Month	_	
334-8	61635-61636	)	_	
334-9	61637-61638	(	_	
334-10	61638-61642	1363	_	
334-11	61642-61643	)	_	
334-12	61644-61645	(	_	
334-13	61645-61649	1364	_	
334-14	61649-61650	)	_	
334-15	61651-61652	(	_	
334-16	61652-61656	1295	_	
334-17	61656-61657	)	_	
334-18	61661-61669	Cannabis	_	
334-19	61670-61673	Age	_	
334-20	61674-61676	of	_	
334-21	61677-61682	Onset	_	
334-22	61683-61684	(	_	
334-23	61684-61689	Years	_	
334-24	61689-61690	)	_	
334-25	61691-61692	-	_	
334-26	61693-61698	17.18	_	
334-27	61699-61704	15.14	_	
334-28	61705-61708	EXP	_	
334-29	61709-61710	>	_	
334-30	61711-61714	REP	_	
334-31	61715-61716	=	_	
334-32	61717-61721	.006	_	
334-33	61725-61726	-	_	
334-34	61727-61728	(	_	
334-35	61728-61732	2.20	_	
334-36	61732-61733	)	_	
334-37	61734-61735	(	_	
334-38	61735-61739	2.27	_	
334-39	61739-61740	)	_	
334-40	61744-61749	Total	_	
334-41	61750-61758	Cannabis	_	
334-42	61759-61762	Use	_	
334-43	61763-61764	-	_	
334-44	61765-61766	-	_	
334-45	61767-61771	1.45	_	
334-46	61772-61773	-	_	
334-47	61776-61777	(	_	
334-48	61777-61782	Total	_	
334-49	61783-61789	Joints	_	
334-50	61790-61793	Per	_	
334-51	61794-61797	Day	_	
334-52	61797-61798	)	_	
334-53	61801-61802	(	_	
334-54	61802-61806	2.67	_	
334-55	61806-61807	)	_	
334-56	61811-61815	Peak	_	
334-57	61816-61824	Cannabis	_	
334-58	61825-61828	Use	_	
334-59	61831-61835	1.14	_	
334-60	61839-61840	(	_	
334-61	61840-61843	Max	_	
334-62	61844-61850	joints	_	
334-63	61851-61854	per	_	
334-64	61855-61858	day	_	
334-65	61859-61861	14	_	
334-66	61861-61862	-	_	
334-67	61862-61863	,	_	
334-68	61864-61866	16	_	
334-69	61866-61867	-	_	
334-70	61867-61868	,	_	
334-71	61869-61871	22	_	
334-72	61871-61872	-	_	
334-73	61872-61873	,	_	
334-74	61874-61876	28	_	
334-75	61876-61877	-	_	
334-76	61877-61886	years-old	_	
334-77	61886-61887	)	_	
334-78	61890-61891	(	_	
334-79	61891-61895	2.14	_	
334-80	61895-61896	)	_	
334-81	61900-61904	Mean	_	
334-82	61905-61913	Cannabis	_	
334-83	61914-61917	Use	_	
334-84	61920-61924	.367	_	
334-85	61928-61929	(	_	
334-86	61929-61933	Mean	_	
334-87	61934-61940	joints	_	
334-88	61941-61944	per	_	
334-89	61945-61948	day	_	
334-90	61949-61951	14	_	
334-91	61951-61952	-	_	
334-92	61952-61953	,	_	
334-93	61954-61956	16	_	
334-94	61956-61957	-	_	
334-95	61957-61958	,	_	
334-96	61959-61961	22	_	
334-97	61961-61962	-	_	
334-98	61962-61963	,	_	
334-99	61964-61966	28	_	
334-100	61966-61967	-	_	
334-101	61967-61976	years-old	_	
334-102	61976-61977	)	_	
334-103	61980-61981	(	_	
334-104	61981-61985	.683	_	
334-105	61985-61986	)	_	
334-106	61990-61998	Cannabis	_	
334-107	61999-62002	Use	_	
334-108	62003-62009	within	_	
334-109	62010-62014	Last	_	
334-110	62015-62019	Year	_	
334-111	62020-62021	-	_	
334-112	62022-62023	n	_	
334-113	62024-62025	=	_	
334-114	62026-62027	0	_	
334-115	62028-62029	n	_	
334-116	62030-62031	=	_	
334-117	62032-62034	15	_	
334-118	62035-62038	REP	_	
334-119	62039-62040	>	_	
334-120	62041-62044	EXP	_	
334-121	62045-62046	=	_	
334-122	62047-62051	.013	_	
334-123	62054-62055	(	_	
334-124	62055-62058	Any	_	
334-125	62059-62062	Use	_	
334-126	62063-62065	in	_	
334-127	62066-62070	Last	_	
334-128	62071-62075	Year	_	
334-129	62075-62076	)	_	
334-130	62083-62088	Total	_	
334-131	62089-62096	Alcohol	_	
334-132	62097-62100	Use	_	
334-133	62101-62105	0.58	_	
334-134	62106-62110	2.31	_	
334-135	62111-62115	3.30	_	
334-136	62116-62119	EXP	_	
334-137	62120-62121	>	_	
334-138	62122-62124	NU	_	
334-139	62125-62126	=	_	
334-140	62127-62131	.015	_	
334-141	62134-62135	(	_	
334-142	62135-62140	Total	_	
334-143	62141-62147	Drinks	_	
334-144	62148-62151	Per	_	
334-145	62152-62155	Day	_	
334-146	62155-62156	)	_	
334-147	62157-62158	(	_	
334-148	62158-62162	0.70	_	
334-149	62162-62163	)	_	
334-150	62164-62165	(	_	
334-151	62165-62169	2.63	_	
334-152	62169-62170	)	_	
334-153	62171-62172	(	_	
334-154	62172-62176	3.95	_	
334-155	62176-62177	)	_	
334-156	62178-62181	REP	_	
334-157	62182-62183	>	_	
334-158	62184-62186	NU	_	
334-159	62187-62188	=	_	
334-160	62189-62194	.0001	_	
334-161	62197-62204	Alcohol	_	
334-162	62205-62208	Use	_	
334-163	62209-62215	Within	_	
334-164	62216-62220	Last	_	
334-165	62221-62225	Year	_	
334-166	62226-62230	0.33	_	
334-167	62231-62235	0.81	_	
334-168	62236-62240	0.92	_	
334-169	62241-62244	EXP	_	
334-170	62245-62246	>	_	
334-171	62247-62249	NU	_	
334-172	62250-62251	=	_	
334-173	62252-62256	.037	_	
334-174	62259-62260	(	_	
334-175	62260-62266	Drinks	_	
334-176	62267-62270	Per	_	
334-177	62271-62274	Day	_	
334-178	62274-62275	)	_	
334-179	62276-62277	(	_	
334-180	62277-62281	0.56	_	
334-181	62281-62282	)	_	
334-182	62283-62284	(	_	
334-183	62284-62288	0.85	_	
334-184	62288-62289	)	_	
334-185	62290-62291	(	_	
334-186	62291-62295	1.14	_	
334-187	62295-62296	)	_	
334-188	62297-62300	REP	_	
334-189	62301-62302	>	_	
334-190	62303-62305	NU	_	
334-191	62306-62307	=	_	
334-192	62308-62312	.011	_	
334-193	62315-62320	Total	_	
334-194	62321-62330	Cigarette	_	
334-195	62331-62334	Use	_	
334-196	62335-62339	1.21	_	
334-197	62340-62345	0.037	_	
334-198	62346-62351	14.82	_	
334-199	62352-62354	NU	_	
334-200	62355-62356	>	_	
334-201	62357-62360	EXP	_	
334-202	62361-62362	=	_	
334-203	62363-62367	.044	_	
334-204	62370-62371	(	_	
334-205	62371-62376	Total	_	
334-206	62377-62387	Cigarettes	_	
334-207	62388-62391	Per	_	
334-208	62392-62395	Day	_	
334-209	62395-62396	)	_	
334-210	62397-62398	(	_	
334-211	62398-62402	4.70	_	
334-212	62402-62403	)	_	
334-213	62404-62405	(	_	
334-214	62405-62409	0.11	_	
334-215	62409-62410	)	_	
334-216	62411-62412	(	_	
334-217	62412-62417	19.64	_	
334-218	62417-62418	)	_	
334-219	62419-62422	REP	_	
334-220	62423-62424	>	_	
334-221	62425-62427	NU	_	
334-222	62428-62429	<	_	
334-223	62430-62435	.0001	_	
334-224	62442-62445	REP	_	
334-225	62446-62447	>	_	
334-226	62448-62451	EXP	_	
334-227	62452-62453	=	_	
334-228	62454-62458	.001	_	
334-229	62461-62470	Cigarette	_	
334-230	62471-62474	Use	_	
334-231	62475-62481	Within	_	
334-232	62482-62486	Last	_	
334-233	62487-62491	Year	_	
334-234	62492-62493	n	_	
334-235	62494-62495	=	_	
334-236	62496-62497	1	_	
334-237	62498-62499	n	_	
334-238	62500-62501	=	_	
334-239	62502-62503	0	_	
334-240	62504-62505	n	_	
334-241	62506-62507	=	_	
334-242	62508-62510	21	_	
334-243	62511-62514	REP	_	
334-244	62515-62517	by	_	
334-245	62518-62520	NU	_	
334-246	62521-62522	=	_	
334-247	62523-62527	.001	_	
334-248	62530-62531	(	_	
334-249	62531-62534	Any	_	
334-250	62535-62538	Use	_	
334-251	62539-62541	in	_	
334-252	62542-62546	Last	_	
334-253	62547-62551	Year	_	
334-254	62551-62552	)	_	
334-255	62556-62559	REP	_	
334-256	62560-62562	by	_	
334-257	62563-62566	EXP	_	
334-258	62567-62568	=	_	
334-259	62569-62573	.011	_	
334-260	62576-62581	Other	_	
334-261	62582-62586	Drug	_	
334-262	62587-62591	Usea	_	
334-263	62592-62593	n	_	
334-264	62594-62595	=	_	
334-265	62596-62597	0	_	
334-266	62598-62599	n	_	
334-267	62600-62601	=	_	
334-268	62602-62603	2	_	
334-269	62604-62605	n	_	
334-270	62606-62607	=	_	
334-271	62608-62610	12	_	
334-272	62611-62613	NU	_	
334-273	62614-62616	by	_	
334-274	62617-62620	REP	_	
334-275	62621-62622	=	_	
334-276	62623-62627	.027	_	
334-277	62630-62631	(	_	
334-278	62631-62636	Other	_	
334-279	62637-62641	Drug	_	
334-280	62642-62645	Use	_	
334-281	62646-62648	at	_	
334-282	62649-62652	Any	_	
334-283	62653-62658	Visit	_	
334-284	62658-62659	)	_	
334-285	62660-62661	n	_	
334-286	62662-62663	=	_	
334-287	62664-62665	0	_	
334-288	62666-62667	n	_	
334-289	62668-62669	=	_	
334-290	62670-62671	0	_	
334-291	62672-62673	n	_	
334-292	62674-62675	=	_	
334-293	62676-62677	1	_	
334-294	62681-62682	(	_	
334-295	62682-62687	Other	_	
334-296	62688-62692	Drug	_	
334-297	62693-62696	Use	_	
334-298	62697-62699	in	_	
334-299	62700-62704	Last	_	
334-300	62705-62709	Year	_	
334-301	62709-62710	)	_	
334-302	62717-62725	Prenatal	_	
334-303	62726-62735	Cannabisb	_	
334-304	62736-62740	0.19	_	
334-305	62741-62745	0.16	_	
334-306	62746-62750	0.32	_	
334-307	62751-62754	n.s	_	
334-308	62754-62755	.	_	

#Text=(Total Joints Per Day)\t(0.64)\t(0.33)\t(0.75)\tn.s.
335-1	62758-62759	(	_	
335-2	62759-62764	Total	_	
335-3	62765-62771	Joints	_	
335-4	62772-62775	Per	_	
335-5	62776-62779	Day	_	
335-6	62779-62780	)	_	
335-7	62781-62782	(	_	
335-8	62782-62786	0.64	_	
335-9	62786-62787	)	_	
335-10	62788-62789	(	_	
335-11	62789-62793	0.33	_	
335-12	62793-62794	)	_	
335-13	62795-62796	(	_	
335-14	62796-62800	0.75	_	
335-15	62800-62801	)	_	
335-16	62802-62805	n.s	_	
335-17	62805-62806	.	_	

#Text=(Any Exposure)\tn = 4\tn = 6\tn = 15\t\t \tPrenatal Alcoholb\t0.55\t0.67\t0.63\tn.s.
336-1	62809-62810	(	_	
336-2	62810-62813	Any	_	
336-3	62814-62822	Exposure	_	
336-4	62822-62823	)	_	
336-5	62824-62825	n	_	
336-6	62826-62827	=	_	
336-7	62828-62829	4	_	
336-8	62830-62831	n	_	
336-9	62832-62833	=	_	
336-10	62834-62835	6	_	
336-11	62836-62837	n	_	
336-12	62838-62839	=	_	
336-13	62840-62842	15	_	
336-14	62846-62854	Prenatal	_	
336-15	62855-62863	Alcoholb	_	
336-16	62864-62868	0.55	_	
336-17	62869-62873	0.67	_	
336-18	62874-62878	0.63	_	
336-19	62879-62882	n.s	_	
336-20	62882-62883	.	_	

#Text=(Total Drinks Per Day)\t(1.24)\t(1.06)\t(1.31)\tn.s.
337-1	62886-62887	(	_	
337-2	62887-62892	Total	_	
337-3	62893-62899	Drinks	_	
337-4	62900-62903	Per	_	
337-5	62904-62907	Day	_	
337-6	62907-62908	)	_	
337-7	62909-62910	(	_	
337-8	62910-62914	1.24	_	
337-9	62914-62915	)	_	
337-10	62916-62917	(	_	
337-11	62917-62921	1.06	_	
337-12	62921-62922	)	_	
337-13	62923-62924	(	_	
337-14	62924-62928	1.31	_	
337-15	62928-62929	)	_	
337-16	62930-62933	n.s	_	
337-17	62933-62934	.	_	

#Text=(Any Exposure)\tn = 9\tn = 8\tn = 36\t\t \tPrenatal Cigaretteb\t27.77\t25.71\t31.48\tn.s.
338-1	62937-62938	(	_	
338-2	62938-62941	Any	_	
338-3	62942-62950	Exposure	_	
338-4	62950-62951	)	_	
338-5	62952-62953	n	_	
338-6	62954-62955	=	_	
338-7	62956-62957	9	_	
338-8	62958-62959	n	_	
338-9	62960-62961	=	_	
338-10	62962-62963	8	_	
338-11	62964-62965	n	_	
338-12	62966-62967	=	_	
338-13	62968-62970	36	_	
338-14	62974-62982	Prenatal	_	
338-15	62983-62993	Cigaretteb	_	
338-16	62994-62999	27.77	_	
338-17	63000-63005	25.71	_	
338-18	63006-63011	31.48	_	
338-19	63012-63015	n.s	_	
338-20	63015-63016	.	_	

#Text=(Total Cigarettes Per Day)\t(39.14)\t(36.10)\t(36.79)\tn.s.
339-1	63019-63020	(	_	
339-2	63020-63025	Total	_	
339-3	63026-63036	Cigarettes	_	
339-4	63037-63040	Per	_	
339-5	63041-63044	Day	_	
339-6	63044-63045	)	_	
339-7	63046-63047	(	_	
339-8	63047-63052	39.14	_	
339-9	63052-63053	)	_	
339-10	63054-63055	(	_	
339-11	63055-63060	36.10	_	
339-12	63060-63061	)	_	
339-13	63062-63063	(	_	
339-14	63063-63068	36.79	_	
339-15	63068-63069	)	_	
339-16	63070-63073	n.s	_	
339-17	63073-63074	.	_	

#Text=(Any Exposure)\tn = 9\tn = 8\tn = 30\t\t \t
#Text=Note. p-value, pairwise significant and trending differences (p < .10) from Welch’s unequal variance t-test (continuous variables), Mann-Whitney U (substance use measures), or Fisher’s exact test (categorical variables).
340-1	63077-63078	(	_	
340-2	63078-63081	Any	_	
340-3	63082-63090	Exposure	_	
340-4	63090-63091	)	_	
340-5	63092-63093	n	_	
340-6	63094-63095	=	_	
340-7	63096-63097	9	_	
340-8	63098-63099	n	_	
340-9	63100-63101	=	_	
340-10	63102-63103	8	_	
340-11	63104-63105	n	_	
340-12	63106-63107	=	_	
340-13	63108-63110	30	_	
340-14	63115-63119	Note	_	
340-15	63119-63120	.	_	
340-16	63121-63128	p-value	_	
340-17	63128-63129	,	_	
340-18	63130-63138	pairwise	_	
340-19	63139-63150	significant	_	
340-20	63151-63154	and	_	
340-21	63155-63163	trending	_	
340-22	63164-63175	differences	_	
340-23	63176-63177	(	_	
340-24	63177-63178	p	_	
340-25	63179-63180	<	_	
340-26	63181-63184	.10	_	
340-27	63184-63185	)	_	
340-28	63186-63190	from	_	
340-29	63191-63196	Welch	_	
340-30	63196-63197	’	_	
340-31	63197-63198	s	_	
340-32	63199-63206	unequal	_	
340-33	63207-63215	variance	_	
340-34	63216-63222	t-test	_	
340-35	63223-63224	(	_	
340-36	63224-63234	continuous	_	
340-37	63235-63244	variables	_	
340-38	63244-63245	)	_	
340-39	63245-63246	,	_	
340-40	63247-63259	Mann-Whitney	_	
340-41	63260-63261	U	_	
340-42	63262-63263	(	_	
340-43	63263-63272	substance	_	
340-44	63273-63276	use	_	
340-45	63277-63285	measures	_	
340-46	63285-63286	)	_	
340-47	63286-63287	,	_	
340-48	63288-63290	or	_	
340-49	63291-63297	Fisher	_	
340-50	63297-63298	’	_	
340-51	63298-63299	s	_	
340-52	63300-63305	exact	_	
340-53	63306-63310	test	_	
340-54	63311-63312	(	_	
340-55	63312-63323	categorical	_	
340-56	63324-63333	variables	_	
340-57	63333-63334	)	_	
340-58	63334-63335	.	_	

#Text=Other drug use (at any visit) and cannabis and cigarette use within the year of testing were dichotomized into use and non-use groups, as they were relatively uncommon in the sample.
341-1	63336-63341	Other	_	
341-2	63342-63346	drug	_	
341-3	63347-63350	use	_	
341-4	63351-63352	(	_	
341-5	63352-63354	at	_	
341-6	63355-63358	any	_	
341-7	63359-63364	visit	_	
341-8	63364-63365	)	_	
341-9	63366-63369	and	_	
341-10	63370-63378	cannabis	_	
341-11	63379-63382	and	_	
341-12	63383-63392	cigarette	_	
341-13	63393-63396	use	_	
341-14	63397-63403	within	_	
341-15	63404-63407	the	_	
341-16	63408-63412	year	_	
341-17	63413-63415	of	_	
341-18	63416-63423	testing	_	
341-19	63424-63428	were	_	
341-20	63429-63441	dichotomized	_	
341-21	63442-63446	into	_	
341-22	63447-63450	use	_	
341-23	63451-63454	and	_	
341-24	63455-63462	non-use	_	
341-25	63463-63469	groups	_	
341-26	63469-63470	,	_	
341-27	63471-63473	as	_	
341-28	63474-63478	they	_	
341-29	63479-63483	were	_	
341-30	63484-63494	relatively	_	
341-31	63495-63503	uncommon	_	
341-32	63504-63506	in	_	
341-33	63507-63510	the	_	
341-34	63511-63517	sample	_	
341-35	63517-63518	.	_	

#Text=A total of 14 subjects reported drug use other than cannabis, alcohol, or cigarettes at any visit, including cocaine, LSD, and recreational use of prescription drugs.
342-1	63519-63520	A	_	
342-2	63521-63526	total	_	
342-3	63527-63529	of	_	
342-4	63530-63532	14	_	
342-5	63533-63541	subjects	_	
342-6	63542-63550	reported	_	
342-7	63551-63555	drug	_	
342-8	63556-63559	use	_	
342-9	63560-63565	other	_	
342-10	63566-63570	than	_	
342-11	63571-63579	cannabis	_	
342-12	63579-63580	,	_	
342-13	63581-63588	alcohol	_	
342-14	63588-63589	,	_	
342-15	63590-63592	or	_	
342-16	63593-63603	cigarettes	_	
342-17	63604-63606	at	_	
342-18	63607-63610	any	_	
342-19	63611-63616	visit	_	
342-20	63616-63617	,	_	
342-21	63618-63627	including	_	
342-22	63628-63635	cocaine	_	
342-23	63635-63636	,	_	
342-24	63637-63640	LSD	_	
342-25	63640-63641	,	_	
342-26	63642-63645	and	_	
342-27	63646-63658	recreational	_	
342-28	63659-63662	use	_	
342-29	63663-63665	of	_	
342-30	63666-63678	prescription	_	
342-31	63679-63684	drugs	_	
342-32	63684-63685	.	_	

#Text=One subject reported other drug use in the last year (recreational use of opioid pain medication).
343-1	63686-63689	One	_	
343-2	63690-63697	subject	_	
343-3	63698-63706	reported	_	
343-4	63707-63712	other	_	
343-5	63713-63717	drug	_	
343-6	63718-63721	use	_	
343-7	63722-63724	in	_	
343-8	63725-63728	the	_	
343-9	63729-63733	last	_	
343-10	63734-63738	year	_	
343-11	63739-63740	(	_	
343-12	63740-63752	recreational	_	
343-13	63753-63756	use	_	
343-14	63757-63759	of	_	
343-15	63760-63766	opioid	_	
343-16	63767-63771	pain	_	
343-17	63772-63782	medication	_	
343-18	63782-63783	)	_	
343-19	63783-63784	.	_	

#Text=Prenatal measures were collected longitudinally across three assessment periods (1 per trimester) and summed to create total exposure measures.
344-1	63785-63793	Prenatal	_	
344-2	63794-63802	measures	_	
344-3	63803-63807	were	_	
344-4	63808-63817	collected	_	
344-5	63818-63832	longitudinally	_	
344-6	63833-63839	across	_	
344-7	63840-63845	three	_	
344-8	63846-63856	assessment	_	
344-9	63857-63864	periods	_	
344-10	63865-63866	(	_	
344-11	63866-63867	1	_	
344-12	63868-63871	per	_	
344-13	63872-63881	trimester	_	
344-14	63881-63882	)	_	
344-15	63883-63886	and	_	
344-16	63887-63893	summed	_	
344-17	63894-63896	to	_	
344-18	63897-63903	create	_	
344-19	63904-63909	total	_	
344-20	63910-63918	exposure	_	
344-21	63919-63927	measures	_	
344-22	63927-63928	.	_	

#Text=Cannabis user (n = 60) characteristics and bivariate relationships with cannabis age of onset and total cannabis use.
345-1	63929-63937	Cannabis	_	
345-2	63938-63942	user	_	
345-3	63943-63944	(	_	
345-4	63944-63945	n	_	
345-5	63946-63947	=	_	
345-6	63948-63950	60	_	
345-7	63950-63951	)	_	
345-8	63952-63967	characteristics	_	
345-9	63968-63971	and	_	
345-10	63972-63981	bivariate	_	
345-11	63982-63995	relationships	_	
345-12	63996-64000	with	_	
345-13	64001-64009	cannabis	_	
345-14	64010-64013	age	_	
345-15	64014-64016	of	_	
345-16	64017-64022	onset	_	
345-17	64023-64026	and	_	
345-18	64027-64032	total	_	
345-19	64033-64041	cannabis	_	
345-20	64042-64045	use	_	
345-21	64045-64046	.	_	

#Text=Variable\tCannabis Age of Onset\tTotal Cannabis Use(log)\t \t\t \tAge (Years)\tr = .101\tr = .124\t \tSex\tt = 0.05\tt = −0.87,s\t \t(Male: 1 vs.
346-1	64047-64055	Variable	_	
346-2	64056-64064	Cannabis	_	
346-3	64065-64068	Age	_	
346-4	64069-64071	of	_	
346-5	64072-64077	Onset	_	
346-6	64078-64083	Total	_	
346-7	64084-64092	Cannabis	_	
346-8	64093-64096	Use	_	
346-9	64096-64097	(	_	
346-10	64097-64100	log	_	
346-11	64100-64101	)	_	
346-12	64107-64110	Age	_	
346-13	64111-64112	(	_	
346-14	64112-64117	Years	_	
346-15	64117-64118	)	_	
346-16	64119-64120	r	_	
346-17	64121-64122	=	_	
346-18	64123-64127	.101	_	
346-19	64128-64129	r	_	
346-20	64130-64131	=	_	
346-21	64132-64136	.124	_	
346-22	64139-64142	Sex	_	
346-23	64143-64144	t	_	
346-24	64145-64146	=	_	
346-25	64147-64151	0.05	_	
346-26	64152-64153	t	_	
346-27	64154-64155	=	_	
346-28	64156-64157	−	_	
346-29	64157-64161	0.87	_	
346-30	64161-64162	,	_	
346-31	64162-64163	s	_	
346-32	64166-64167	(	_	
346-33	64167-64171	Male	_	
346-34	64171-64172	:	_	
346-35	64173-64174	1	_	
346-36	64175-64177	vs	_	
346-37	64177-64178	.	_	

#Text=Female: 0)\t\t\t \tWISC-Full Scale IQ\tr = .091\tr = −.162\t \t(Age 14)\t\t\t \tHighest Level of Education (Years)\tr = .370**\tr = −.497**\t \tFamily Income\tr = −.0002\tr = −.265+\t \t(Age 16; Dollars/Month)\t\t\t \tCannabis Age of Onset (Years)\t-\tr = −.236°\t \tCannabis Use within Last Year\tt = 0.88\tt = 2.41*,s\t \t(Any Use in Last Year)\t\t\t \tTotal Alcohol Use\tr = −.057\tr = .323*\t \t(Total Drinks Per Day)\t\t\t \tAlcohol Use Within Last Year\tr = −.175\tr = .203\t \t(Drinks-Per-Day)\t\t\t \tTotal Cigarette Use\tr = −.432**\tr = .319*\t \t(Total Cigarettes Per Day)\t\t\t \tCigarette Use Within Last Year\tt = −2.00+\tt = 2.37*,s\t \t(Any Use in Last Year)\t\t\t \tOther Drug Use\tt = 4.17**\tt = 3.87**,s\t \t(Other Drug Use at Any Visit)\t\t\t \tPrenatal Cannabis\tr = −.110\tr = .162\t \t(Total Joints Per Day)\tt = −0.12\tt = 2.51*,s\t \t(Any Exposure)\t\t\t \tPrenatal Alcohol\tr = −.116\tr = 1.63s\t \t(Total Drinks Per Day)\tt = 1.04\tt=0.19s\t \t(Any Exposure)\t\t\t \tPrenatal Cigarette\tr = .079\tr = −.117\t \t(Total Cigarettes Per Day)\tt = 0.04\tt = −0.19s\t \t(Any Exposure)\t\t\t \t
#Text=Note. 0, p = .114,
#Text=p < .10,
#Text=p < .05.,
#Text=p < .01.
#Text=r - Pearson correlation. t - Welch’s unequal variance t-test.
#Text=sign flipped to represent higher values of total cannabis as positive value.
347-1	64179-64185	Female	_	
347-2	64185-64186	:	_	
347-3	64187-64188	0	_	
347-4	64188-64189	)	_	
347-5	64194-64203	WISC-Full	_	
347-6	64204-64209	Scale	_	
347-7	64210-64212	IQ	_	
347-8	64213-64214	r	_	
347-9	64215-64216	=	_	
347-10	64217-64221	.091	_	
347-11	64222-64223	r	_	
347-12	64224-64225	=	_	
347-13	64226-64227	−	_	
347-14	64227-64231	.162	_	
347-15	64234-64235	(	_	
347-16	64235-64238	Age	_	
347-17	64239-64241	14	_	
347-18	64241-64242	)	_	
347-19	64247-64254	Highest	_	
347-20	64255-64260	Level	_	
347-21	64261-64263	of	_	
347-22	64264-64273	Education	_	
347-23	64274-64275	(	_	
347-24	64275-64280	Years	_	
347-25	64280-64281	)	_	
347-26	64282-64283	r	_	
347-27	64284-64285	=	_	
347-28	64286-64290	.370	_	
347-29	64290-64291	*	_	
347-30	64291-64292	*	_	
347-31	64293-64294	r	_	
347-32	64295-64296	=	_	
347-33	64297-64298	−	_	
347-34	64298-64302	.497	_	
347-35	64302-64303	*	_	
347-36	64303-64304	*	_	
347-37	64307-64313	Family	_	
347-38	64314-64320	Income	_	
347-39	64321-64322	r	_	
347-40	64323-64324	=	_	
347-41	64325-64326	−	_	
347-42	64326-64331	.0002	_	
347-43	64332-64333	r	_	
347-44	64334-64335	=	_	
347-45	64336-64337	−	_	
347-46	64337-64341	.265	_	
347-47	64341-64342	+	_	
347-48	64345-64346	(	_	
347-49	64346-64349	Age	_	
347-50	64350-64352	16	_	
347-51	64352-64353	;	_	
347-52	64354-64361	Dollars	_	
347-53	64361-64362	/	_	
347-54	64362-64367	Month	_	
347-55	64367-64368	)	_	
347-56	64373-64381	Cannabis	_	
347-57	64382-64385	Age	_	
347-58	64386-64388	of	_	
347-59	64389-64394	Onset	_	
347-60	64395-64396	(	_	
347-61	64396-64401	Years	_	
347-62	64401-64402	)	_	
347-63	64403-64404	-	_	
347-64	64405-64406	r	_	
347-65	64407-64408	=	_	
347-66	64409-64410	−	_	
347-67	64410-64414	.236	_	
347-68	64414-64415	°	_	
347-69	64418-64426	Cannabis	_	
347-70	64427-64430	Use	_	
347-71	64431-64437	within	_	
347-72	64438-64442	Last	_	
347-73	64443-64447	Year	_	
347-74	64448-64449	t	_	
347-75	64450-64451	=	_	
347-76	64452-64456	0.88	_	
347-77	64457-64458	t	_	
347-78	64459-64460	=	_	
347-79	64461-64465	2.41	_	
347-80	64465-64466	*	_	
347-81	64466-64467	,	_	
347-82	64467-64468	s	_	
347-83	64471-64472	(	_	
347-84	64472-64475	Any	_	
347-85	64476-64479	Use	_	
347-86	64480-64482	in	_	
347-87	64483-64487	Last	_	
347-88	64488-64492	Year	_	
347-89	64492-64493	)	_	
347-90	64498-64503	Total	_	
347-91	64504-64511	Alcohol	_	
347-92	64512-64515	Use	_	
347-93	64516-64517	r	_	
347-94	64518-64519	=	_	
347-95	64520-64521	−	_	
347-96	64521-64525	.057	_	
347-97	64526-64527	r	_	
347-98	64528-64529	=	_	
347-99	64530-64534	.323	_	
347-100	64534-64535	*	_	
347-101	64538-64539	(	_	
347-102	64539-64544	Total	_	
347-103	64545-64551	Drinks	_	
347-104	64552-64555	Per	_	
347-105	64556-64559	Day	_	
347-106	64559-64560	)	_	
347-107	64565-64572	Alcohol	_	
347-108	64573-64576	Use	_	
347-109	64577-64583	Within	_	
347-110	64584-64588	Last	_	
347-111	64589-64593	Year	_	
347-112	64594-64595	r	_	
347-113	64596-64597	=	_	
347-114	64598-64599	−	_	
347-115	64599-64603	.175	_	
347-116	64604-64605	r	_	
347-117	64606-64607	=	_	
347-118	64608-64612	.203	_	
347-119	64615-64616	(	_	
347-120	64616-64630	Drinks-Per-Day	_	
347-121	64630-64631	)	_	
347-122	64636-64641	Total	_	
347-123	64642-64651	Cigarette	_	
347-124	64652-64655	Use	_	
347-125	64656-64657	r	_	
347-126	64658-64659	=	_	
347-127	64660-64661	−	_	
347-128	64661-64665	.432	_	
347-129	64665-64666	*	_	
347-130	64666-64667	*	_	
347-131	64668-64669	r	_	
347-132	64670-64671	=	_	
347-133	64672-64676	.319	_	
347-134	64676-64677	*	_	
347-135	64680-64681	(	_	
347-136	64681-64686	Total	_	
347-137	64687-64697	Cigarettes	_	
347-138	64698-64701	Per	_	
347-139	64702-64705	Day	_	
347-140	64705-64706	)	_	
347-141	64711-64720	Cigarette	_	
347-142	64721-64724	Use	_	
347-143	64725-64731	Within	_	
347-144	64732-64736	Last	_	
347-145	64737-64741	Year	_	
347-146	64742-64743	t	_	
347-147	64744-64745	=	_	
347-148	64746-64747	−	_	
347-149	64747-64751	2.00	_	
347-150	64751-64752	+	_	
347-151	64753-64754	t	_	
347-152	64755-64756	=	_	
347-153	64757-64761	2.37	_	
347-154	64761-64762	*	_	
347-155	64762-64763	,	_	
347-156	64763-64764	s	_	
347-157	64767-64768	(	_	
347-158	64768-64771	Any	_	
347-159	64772-64775	Use	_	
347-160	64776-64778	in	_	
347-161	64779-64783	Last	_	
347-162	64784-64788	Year	_	
347-163	64788-64789	)	_	
347-164	64794-64799	Other	_	
347-165	64800-64804	Drug	_	
347-166	64805-64808	Use	_	
347-167	64809-64810	t	_	
347-168	64811-64812	=	_	
347-169	64813-64817	4.17	_	
347-170	64817-64818	*	_	
347-171	64818-64819	*	_	
347-172	64820-64821	t	_	
347-173	64822-64823	=	_	
347-174	64824-64828	3.87	_	
347-175	64828-64829	*	_	
347-176	64829-64830	*	_	
347-177	64830-64831	,	_	
347-178	64831-64832	s	_	
347-179	64835-64836	(	_	
347-180	64836-64841	Other	_	
347-181	64842-64846	Drug	_	
347-182	64847-64850	Use	_	
347-183	64851-64853	at	_	
347-184	64854-64857	Any	_	
347-185	64858-64863	Visit	_	
347-186	64863-64864	)	_	
347-187	64869-64877	Prenatal	_	
347-188	64878-64886	Cannabis	_	
347-189	64887-64888	r	_	
347-190	64889-64890	=	_	
347-191	64891-64892	−	_	
347-192	64892-64896	.110	_	
347-193	64897-64898	r	_	
347-194	64899-64900	=	_	
347-195	64901-64905	.162	_	
347-196	64908-64909	(	_	
347-197	64909-64914	Total	_	
347-198	64915-64921	Joints	_	
347-199	64922-64925	Per	_	
347-200	64926-64929	Day	_	
347-201	64929-64930	)	_	
347-202	64931-64932	t	_	
347-203	64933-64934	=	_	
347-204	64935-64936	−	_	
347-205	64936-64940	0.12	_	
347-206	64941-64942	t	_	
347-207	64943-64944	=	_	
347-208	64945-64949	2.51	_	
347-209	64949-64950	*	_	
347-210	64950-64951	,	_	
347-211	64951-64952	s	_	
347-212	64955-64956	(	_	
347-213	64956-64959	Any	_	
347-214	64960-64968	Exposure	_	
347-215	64968-64969	)	_	
347-216	64974-64982	Prenatal	_	
347-217	64983-64990	Alcohol	_	
347-218	64991-64992	r	_	
347-219	64993-64994	=	_	
347-220	64995-64996	−	_	
347-221	64996-65000	.116	_	
347-222	65001-65002	r	_	
347-223	65003-65004	=	_	
347-224	65005-65010	1.63s	_	
347-225	65013-65014	(	_	
347-226	65014-65019	Total	_	
347-227	65020-65026	Drinks	_	
347-228	65027-65030	Per	_	
347-229	65031-65034	Day	_	
347-230	65034-65035	)	_	
347-231	65036-65037	t	_	
347-232	65038-65039	=	_	
347-233	65040-65044	1.04	_	
347-234	65045-65046	t	_	
347-235	65046-65047	=	_	
347-236	65047-65052	0.19s	_	
347-237	65055-65056	(	_	
347-238	65056-65059	Any	_	
347-239	65060-65068	Exposure	_	
347-240	65068-65069	)	_	
347-241	65074-65082	Prenatal	_	
347-242	65083-65092	Cigarette	_	
347-243	65093-65094	r	_	
347-244	65095-65096	=	_	
347-245	65097-65101	.079	_	
347-246	65102-65103	r	_	
347-247	65104-65105	=	_	
347-248	65106-65107	−	_	
347-249	65107-65111	.117	_	
347-250	65114-65115	(	_	
347-251	65115-65120	Total	_	
347-252	65121-65131	Cigarettes	_	
347-253	65132-65135	Per	_	
347-254	65136-65139	Day	_	
347-255	65139-65140	)	_	
347-256	65141-65142	t	_	
347-257	65143-65144	=	_	
347-258	65145-65149	0.04	_	
347-259	65150-65151	t	_	
347-260	65152-65153	=	_	
347-261	65154-65155	−	_	
347-262	65155-65160	0.19s	_	
347-263	65163-65164	(	_	
347-264	65164-65167	Any	_	
347-265	65168-65176	Exposure	_	
347-266	65176-65177	)	_	
347-267	65183-65187	Note	_	
347-268	65187-65188	.	_	
347-269	65189-65190	0	_	
347-270	65190-65191	,	_	
347-271	65192-65193	p	_	
347-272	65194-65195	=	_	
347-273	65196-65200	.114	_	
347-274	65200-65201	,	_	
347-275	65202-65203	p	_	
347-276	65204-65205	<	_	
347-277	65206-65209	.10	_	
347-278	65209-65210	,	_	
347-279	65211-65212	p	_	
347-280	65213-65214	<	_	
347-281	65215-65218	.05	_	
347-282	65218-65219	.	_	
347-283	65219-65220	,	_	
347-284	65221-65222	p	_	
347-285	65223-65224	<	_	
347-286	65225-65228	.01	_	
347-287	65228-65229	.	_	
347-288	65230-65231	r	_	
347-289	65232-65233	-	_	
347-290	65234-65241	Pearson	_	
347-291	65242-65253	correlation	_	
347-292	65253-65254	.	_	
347-293	65255-65256	t	_	
347-294	65257-65258	-	_	
347-295	65259-65264	Welch	_	
347-296	65264-65265	’	_	
347-297	65265-65266	s	_	
347-298	65267-65274	unequal	_	
347-299	65275-65283	variance	_	
347-300	65284-65290	t-test	_	
347-301	65290-65291	.	_	
347-302	65292-65296	sign	_	
347-303	65297-65304	flipped	_	
347-304	65305-65307	to	_	
347-305	65308-65317	represent	_	
347-306	65318-65324	higher	_	
347-307	65325-65331	values	_	
347-308	65332-65334	of	_	
347-309	65335-65340	total	_	
347-310	65341-65349	cannabis	_	
347-311	65350-65352	as	_	
347-312	65353-65361	positive	_	
347-313	65362-65367	value	_	
347-314	65367-65368	.	_	

#Text=Cannabis age of onset associations performed with full sample of cannabis users (EXP + REP, n = 60).
348-1	65369-65377	Cannabis	_	
348-2	65378-65381	age	_	
348-3	65382-65384	of	_	
348-4	65385-65390	onset	_	
348-5	65391-65403	associations	_	
348-6	65404-65413	performed	_	
348-7	65414-65418	with	_	
348-8	65419-65423	full	_	
348-9	65424-65430	sample	_	
348-10	65431-65433	of	_	
348-11	65434-65442	cannabis	_	
348-12	65443-65448	users	_	
348-13	65449-65450	(	_	
348-14	65450-65453	EXP	_	
348-15	65454-65455	+	_	
348-16	65456-65459	REP	_	
348-17	65459-65460	,	_	
348-18	65461-65462	n	_	
348-19	65463-65464	=	_	
348-20	65465-65467	60	_	
348-21	65467-65468	)	_	
348-22	65468-65469	.	_	

#Text=Total Cannabis use (log of total joints per day) associations performed with only users with repeated use (REP, n = 46).
#Text=fMRI time series activation interactions for cannabis age of onset and total cannabis use.
349-1	65470-65475	Total	_	
349-2	65476-65484	Cannabis	_	
349-3	65485-65488	use	_	
349-4	65489-65490	(	_	
349-5	65490-65493	log	_	
349-6	65494-65496	of	_	
349-7	65497-65502	total	_	
349-8	65503-65509	joints	_	
349-9	65510-65513	per	_	
349-10	65514-65517	day	_	
349-11	65517-65518	)	_	
349-12	65519-65531	associations	_	
349-13	65532-65541	performed	_	
349-14	65542-65546	with	_	
349-15	65547-65551	only	_	
349-16	65552-65557	users	_	
349-17	65558-65562	with	_	
349-18	65563-65571	repeated	_	
349-19	65572-65575	use	_	
349-20	65576-65577	(	_	
349-21	65577-65580	REP	_	
349-22	65580-65581	,	_	
349-23	65582-65583	n	_	
349-24	65584-65585	=	_	
349-25	65586-65588	46	_	
349-26	65588-65589	)	_	
349-27	65589-65590	.	_	
349-28	65591-65595	fMRI	_	
349-29	65596-65600	time	_	
349-30	65601-65607	series	_	
349-31	65608-65618	activation	_	
349-32	65619-65631	interactions	_	
349-33	65632-65635	for	_	
349-34	65636-65644	cannabis	_	
349-35	65645-65648	age	_	
349-36	65649-65651	of	_	
349-37	65652-65657	onset	_	
349-38	65658-65661	and	_	
349-39	65662-65667	total	_	
349-40	65668-65676	cannabis	_	
349-41	65677-65680	use	_	
349-42	65680-65681	.	_	

#Text=Region\tBA\tNumberofVoxels\tF-value(peak)\tMNI\t \tX\tY\tZ\t \t\t \tCannabis Age of Onset\t \tPosterior Cingulate\t30,31\t51\t5.15\t−8\t53\t11\t \tR-Posterior Parietal CortexA\t4,40\t23\t5.43\t−35\t32\t53\t \tR-Posterior Parietal CortexB\t7,40\t16\t6.72\t−38\t53\t62\t \tTotal Cannabis Use\t \tR-Dorsolateral Prefrontal Cortex\t46,10,9\t108\t5.49\t−47\t−38\t29\t \tL-Dorsolateral Prefrontal CortexA\t6,8,9\t49\t6.10\t44\t−5\t56\t \tL-Dorsolateral Prefrontal CortexB\t9,8\t44\t5.13\t50\t−11\t38\t \tR-Posterior Parietal CortexC\t40\t26\t5.34\t−59\t44\t41\t \tR-Posterior Parietal CortexD\t40\t22\t3.73\t−38\t47\t44\t \tR-Superior Frontal Gyrus\t10\t19\t5.15\t−35\t−62\t8\t \tL-Inferior Frontal Gyrus\t44, 45\t16\t3.68\t35\t−29\t5\t \t
#Text=Note.
350-1	65682-65688	Region	_	
350-2	65689-65691	BA	_	
350-3	65692-65706	NumberofVoxels	_	
350-4	65707-65714	F-value	_	
350-5	65714-65715	(	_	
350-6	65715-65719	peak	_	
350-7	65719-65720	)	_	
350-8	65721-65724	MNI	_	
350-9	65727-65728	X	_	
350-10	65729-65730	Y	_	
350-11	65731-65732	Z	_	
350-12	65738-65746	Cannabis	_	
350-13	65747-65750	Age	_	
350-14	65751-65753	of	_	
350-15	65754-65759	Onset	_	
350-16	65762-65771	Posterior	_	
350-17	65772-65781	Cingulate	_	
350-18	65782-65787	30,31	_	
350-19	65788-65790	51	_	
350-20	65791-65795	5.15	_	
350-21	65796-65797	−	_	
350-22	65797-65798	8	_	
350-23	65799-65801	53	_	
350-24	65802-65804	11	_	
350-25	65807-65818	R-Posterior	_	
350-26	65819-65827	Parietal	_	
350-27	65828-65835	CortexA	_	
350-28	65836-65840	4,40	_	
350-29	65841-65843	23	_	
350-30	65844-65848	5.43	_	
350-31	65849-65850	−	_	
350-32	65850-65852	35	_	
350-33	65853-65855	32	_	
350-34	65856-65858	53	_	
350-35	65861-65872	R-Posterior	_	
350-36	65873-65881	Parietal	_	
350-37	65882-65889	CortexB	_	
350-38	65890-65894	7,40	_	
350-39	65895-65897	16	_	
350-40	65898-65902	6.72	_	
350-41	65903-65904	−	_	
350-42	65904-65906	38	_	
350-43	65907-65909	53	_	
350-44	65910-65912	62	_	
350-45	65915-65920	Total	_	
350-46	65921-65929	Cannabis	_	
350-47	65930-65933	Use	_	
350-48	65936-65950	R-Dorsolateral	_	
350-49	65951-65961	Prefrontal	_	
350-50	65962-65968	Cortex	_	
350-51	65969-65976	46,10,9	_	
350-52	65977-65980	108	_	
350-53	65981-65985	5.49	_	
350-54	65986-65987	−	_	
350-55	65987-65989	47	_	
350-56	65990-65991	−	_	
350-57	65991-65993	38	_	
350-58	65994-65996	29	_	
350-59	65999-66013	L-Dorsolateral	_	
350-60	66014-66024	Prefrontal	_	
350-61	66025-66032	CortexA	_	
350-62	66033-66038	6,8,9	_	
350-63	66039-66041	49	_	
350-64	66042-66046	6.10	_	
350-65	66047-66049	44	_	
350-66	66050-66051	−	_	
350-67	66051-66052	5	_	
350-68	66053-66055	56	_	
350-69	66058-66072	L-Dorsolateral	_	
350-70	66073-66083	Prefrontal	_	
350-71	66084-66091	CortexB	_	
350-72	66092-66095	9,8	_	
350-73	66096-66098	44	_	
350-74	66099-66103	5.13	_	
350-75	66104-66106	50	_	
350-76	66107-66108	−	_	
350-77	66108-66110	11	_	
350-78	66111-66113	38	_	
350-79	66116-66127	R-Posterior	_	
350-80	66128-66136	Parietal	_	
350-81	66137-66144	CortexC	_	
350-82	66145-66147	40	_	
350-83	66148-66150	26	_	
350-84	66151-66155	5.34	_	
350-85	66156-66157	−	_	
350-86	66157-66159	59	_	
350-87	66160-66162	44	_	
350-88	66163-66165	41	_	
350-89	66168-66179	R-Posterior	_	
350-90	66180-66188	Parietal	_	
350-91	66189-66196	CortexD	_	
350-92	66197-66199	40	_	
350-93	66200-66202	22	_	
350-94	66203-66207	3.73	_	
350-95	66208-66209	−	_	
350-96	66209-66211	38	_	
350-97	66212-66214	47	_	
350-98	66215-66217	44	_	
350-99	66220-66230	R-Superior	_	
350-100	66231-66238	Frontal	_	
350-101	66239-66244	Gyrus	_	
350-102	66245-66247	10	_	
350-103	66248-66250	19	_	
350-104	66251-66255	5.15	_	
350-105	66256-66257	−	_	
350-106	66257-66259	35	_	
350-107	66260-66261	−	_	
350-108	66261-66263	62	_	
350-109	66264-66265	8	_	
350-110	66268-66278	L-Inferior	_	
350-111	66279-66286	Frontal	_	
350-112	66287-66292	Gyrus	_	
350-113	66293-66295	44	_	
350-114	66295-66296	,	_	
350-115	66297-66299	45	_	
350-116	66300-66302	16	_	
350-117	66303-66307	3.68	_	
350-118	66308-66310	35	_	
350-119	66311-66312	−	_	
350-120	66312-66314	29	_	
350-121	66315-66316	5	_	
350-122	66320-66324	Note	_	
350-123	66324-66325	.	_	

#Text=BA, Brodmann areas; F-value, cluster peak test statistic for cannabis age of onset, F(14,714), or total cannabis use (log), F(14,616); MNI, MNI-152 coordinates at peak.
#Text=designations used to distinguish clusters within the same region.
351-1	66326-66328	BA	_	
351-2	66328-66329	,	_	
351-3	66330-66338	Brodmann	_	
351-4	66339-66344	areas	_	
351-5	66344-66345	;	_	
351-6	66346-66353	F-value	_	
351-7	66353-66354	,	_	
351-8	66355-66362	cluster	_	
351-9	66363-66367	peak	_	
351-10	66368-66372	test	_	
351-11	66373-66382	statistic	_	
351-12	66383-66386	for	_	
351-13	66387-66395	cannabis	_	
351-14	66396-66399	age	_	
351-15	66400-66402	of	_	
351-16	66403-66408	onset	_	
351-17	66408-66409	,	_	
351-18	66410-66411	F	_	
351-19	66411-66412	(	_	
351-20	66412-66418	14,714	_	
351-21	66418-66419	)	_	
351-22	66419-66420	,	_	
351-23	66421-66423	or	_	
351-24	66424-66429	total	_	
351-25	66430-66438	cannabis	_	
351-26	66439-66442	use	_	
351-27	66443-66444	(	_	
351-28	66444-66447	log	_	
351-29	66447-66448	)	_	
351-30	66448-66449	,	_	
351-31	66450-66451	F	_	
351-32	66451-66452	(	_	
351-33	66452-66458	14,616	_	
351-34	66458-66459	)	_	
351-35	66459-66460	;	_	
351-36	66461-66464	MNI	_	
351-37	66464-66465	,	_	
351-38	66466-66469	MNI	_	
351-39	66469-66470	-	_	
351-40	66470-66473	152	_	
351-41	66474-66485	coordinates	_	
351-42	66486-66488	at	_	
351-43	66489-66493	peak	_	
351-44	66493-66494	.	_	
351-45	66495-66507	designations	_	
351-46	66508-66512	used	_	
351-47	66513-66515	to	_	
351-48	66516-66527	distinguish	_	
351-49	66528-66536	clusters	_	
351-50	66537-66543	within	_	
351-51	66544-66547	the	_	
351-52	66548-66552	same	_	
351-53	66553-66559	region	_	
351-54	66559-66560	.	_	

#Text=Epoch amplitudes and relationships with cannabis age of onset and working memory reaction time.
352-1	66561-66566	Epoch	_	
352-2	66567-66577	amplitudes	_	
352-3	66578-66581	and	_	
352-4	66582-66595	relationships	_	
352-5	66596-66600	with	_	
352-6	66601-66609	cannabis	_	
352-7	66610-66613	age	_	
352-8	66614-66616	of	_	
352-9	66617-66622	onset	_	
352-10	66623-66626	and	_	
352-11	66627-66634	working	_	
352-12	66635-66641	memory	_	
352-13	66642-66650	reaction	_	
352-14	66651-66655	time	_	
352-15	66655-66656	.	_	

#Text=Cluster\tM\tSD\tCannabis Age of Onsetβ\tWorking MemoryReaction Timeβ\t \t\t \tPosterior Cingulate\t \tCue\t−5.50\t11.18\t.070\t−.270+C,P\t \tDelay\t−9.73\t14.19\t.009\t.102\t \tTarget\t18.74\t18.55\t−.079\t−.204\t \tR-Posterior Parietal Cortex (A)\t \tCue\t3.24\t9.22\t.428**C,P\t−.358*C,P\t \tDelay\t1.56\t11.09\t.004\t.098\t \tTarget\t5.76\t11.33\t.138\t.090\t \tR-Posterior Parietal Cortex (B)\t \tCue\t20.64\t15.05\t.253\t−.153\t \tDelay\t11.18\t14.08\t.232\t.105\t \tTarget\t20.38\t15.89\t.164\t−.174\t \t
#Text=Note.
#Text=p < .10,
#Text=p < .05.,
#Text=p < .01 (corrected);
#Text=p < .05 with full model covariates (set A);
#Text=p < .05 with full model + prenatal measures.
353-1	66657-66664	Cluster	_	
353-2	66665-66666	M	_	
353-3	66667-66669	SD	_	
353-4	66670-66678	Cannabis	_	
353-5	66679-66682	Age	_	
353-6	66683-66685	of	_	
353-7	66686-66692	Onsetβ	_	
353-8	66693-66700	Working	_	
353-9	66701-66715	MemoryReaction	_	
353-10	66716-66721	Timeβ	_	
353-11	66727-66736	Posterior	_	
353-12	66737-66746	Cingulate	_	
353-13	66749-66752	Cue	_	
353-14	66753-66754	−	_	
353-15	66754-66758	5.50	_	
353-16	66759-66764	11.18	_	
353-17	66765-66769	.070	_	
353-18	66770-66771	−	_	
353-19	66771-66775	.270	_	
353-20	66775-66776	+	_	
353-21	66776-66777	C	_	
353-22	66777-66778	,	_	
353-23	66778-66779	P	_	
353-24	66782-66787	Delay	_	
353-25	66788-66789	−	_	
353-26	66789-66793	9.73	_	
353-27	66794-66799	14.19	_	
353-28	66800-66804	.009	_	
353-29	66805-66809	.102	_	
353-30	66812-66818	Target	_	
353-31	66819-66824	18.74	_	
353-32	66825-66830	18.55	_	
353-33	66831-66832	−	_	
353-34	66832-66836	.079	_	
353-35	66837-66838	−	_	
353-36	66838-66842	.204	_	
353-37	66845-66856	R-Posterior	_	
353-38	66857-66865	Parietal	_	
353-39	66866-66872	Cortex	_	
353-40	66873-66874	(	_	
353-41	66874-66875	A	_	
353-42	66875-66876	)	_	
353-43	66879-66882	Cue	_	
353-44	66883-66887	3.24	_	
353-45	66888-66892	9.22	_	
353-46	66893-66897	.428	_	
353-47	66897-66898	*	_	
353-48	66898-66899	*	_	
353-49	66899-66900	C	_	
353-50	66900-66901	,	_	
353-51	66901-66902	P	_	
353-52	66903-66904	−	_	
353-53	66904-66908	.358	_	
353-54	66908-66909	*	_	
353-55	66909-66910	C	_	
353-56	66910-66911	,	_	
353-57	66911-66912	P	_	
353-58	66915-66920	Delay	_	
353-59	66921-66925	1.56	_	
353-60	66926-66931	11.09	_	
353-61	66932-66936	.004	_	
353-62	66937-66941	.098	_	
353-63	66944-66950	Target	_	
353-64	66951-66955	5.76	_	
353-65	66956-66961	11.33	_	
353-66	66962-66966	.138	_	
353-67	66967-66971	.090	_	
353-68	66974-66985	R-Posterior	_	
353-69	66986-66994	Parietal	_	
353-70	66995-67001	Cortex	_	
353-71	67002-67003	(	_	
353-72	67003-67004	B	_	
353-73	67004-67005	)	_	
353-74	67008-67011	Cue	_	
353-75	67012-67017	20.64	_	
353-76	67018-67023	15.05	_	
353-77	67024-67028	.253	_	
353-78	67029-67030	−	_	
353-79	67030-67034	.153	_	
353-80	67037-67042	Delay	_	
353-81	67043-67048	11.18	_	
353-82	67049-67054	14.08	_	
353-83	67055-67059	.232	_	
353-84	67060-67064	.105	_	
353-85	67067-67073	Target	_	
353-86	67074-67079	20.38	_	
353-87	67080-67085	15.89	_	
353-88	67086-67090	.164	_	
353-89	67091-67092	−	_	
353-90	67092-67096	.174	_	
353-91	67100-67104	Note	_	
353-92	67104-67105	.	_	
353-93	67106-67107	p	_	
353-94	67108-67109	<	_	
353-95	67110-67113	.10	_	
353-96	67113-67114	,	_	
353-97	67115-67116	p	_	
353-98	67117-67118	<	_	
353-99	67119-67122	.05	_	
353-100	67122-67123	.	_	
353-101	67123-67124	,	_	
353-102	67125-67126	p	_	
353-103	67127-67128	<	_	
353-104	67129-67132	.01	_	
353-105	67133-67134	(	_	
353-106	67134-67143	corrected	_	
353-107	67143-67144	)	_	
353-108	67144-67145	;	_	
353-109	67146-67147	p	_	
353-110	67148-67149	<	_	
353-111	67150-67153	.05	_	
353-112	67154-67158	with	_	
353-113	67159-67163	full	_	
353-114	67164-67169	model	_	
353-115	67170-67180	covariates	_	
353-116	67181-67182	(	_	
353-117	67182-67185	set	_	
353-118	67186-67187	A	_	
353-119	67187-67188	)	_	
353-120	67188-67189	;	_	
353-121	67190-67191	p	_	
353-122	67192-67193	<	_	
353-123	67194-67197	.05	_	
353-124	67198-67202	with	_	
353-125	67203-67207	full	_	
353-126	67208-67213	model	_	
353-127	67214-67215	+	_	
353-128	67216-67224	prenatal	_	
353-129	67225-67233	measures	_	
353-130	67233-67234	.	_	

#Text=Epoch means and standard deviations of clusters with an omnibus cannabis age of onset effect. β, standardized regression coefficients for cannabis age of onset and reaction time (mean of log reaction time).
354-1	67235-67240	Epoch	_	
354-2	67241-67246	means	_	
354-3	67247-67250	and	_	
354-4	67251-67259	standard	_	
354-5	67260-67270	deviations	_	
354-6	67271-67273	of	_	
354-7	67274-67282	clusters	_	
354-8	67283-67287	with	_	
354-9	67288-67290	an	_	
354-10	67291-67298	omnibus	_	
354-11	67299-67307	cannabis	_	
354-12	67308-67311	age	_	
354-13	67312-67314	of	_	
354-14	67315-67320	onset	_	
354-15	67321-67327	effect	_	
354-16	67327-67328	.	_	
354-17	67329-67330	β	_	
354-18	67330-67331	,	_	
354-19	67332-67344	standardized	_	
354-20	67345-67355	regression	_	
354-21	67356-67368	coefficients	_	
354-22	67369-67372	for	_	
354-23	67373-67381	cannabis	_	
354-24	67382-67385	age	_	
354-25	67386-67388	of	_	
354-26	67389-67394	onset	_	
354-27	67395-67398	and	_	
354-28	67399-67407	reaction	_	
354-29	67408-67412	time	_	
354-30	67413-67414	(	_	
354-31	67414-67418	mean	_	
354-32	67419-67421	of	_	
354-33	67422-67425	log	_	
354-34	67426-67434	reaction	_	
354-35	67435-67439	time	_	
354-36	67439-67440	)	_	
354-37	67440-67441	.	_	

#Text=Significant and trending effects (p < .10, corrected) are bolded.
355-1	67442-67453	Significant	_	
355-2	67454-67457	and	_	
355-3	67458-67466	trending	_	
355-4	67467-67474	effects	_	
355-5	67475-67476	(	_	
355-6	67476-67477	p	_	
355-7	67478-67479	<	_	
355-8	67480-67483	.10	_	
355-9	67483-67484	,	_	
355-10	67485-67494	corrected	_	
355-11	67494-67495	)	_	
355-12	67496-67499	are	_	
355-13	67500-67506	bolded	_	
355-14	67506-67507	.	_	

#Text=Epoch amplitudes and relationships with total cannabis use and working memory Accuracy.
356-1	67508-67513	Epoch	_	
356-2	67514-67524	amplitudes	_	
356-3	67525-67528	and	_	
356-4	67529-67542	relationships	_	
356-5	67543-67547	with	_	
356-6	67548-67553	total	_	
356-7	67554-67562	cannabis	_	
356-8	67563-67566	use	_	
356-9	67567-67570	and	_	
356-10	67571-67578	working	_	
356-11	67579-67585	memory	_	
356-12	67586-67594	Accuracy	_	
356-13	67594-67595	.	_	

#Text=Cluster\tM\tSD\tTotal Cannabis Use(log)P\tWorking MemoryAccuracyO.R.
357-1	67596-67603	Cluster	_	
357-2	67604-67605	M	_	
357-3	67606-67608	SD	_	
357-4	67609-67614	Total	_	
357-5	67615-67623	Cannabis	_	
357-6	67624-67627	Use	_	
357-7	67627-67628	(	_	
357-8	67628-67631	log	_	
357-9	67631-67632	)	_	
357-10	67632-67633	P	_	
357-11	67634-67641	Working	_	
357-12	67642-67659	MemoryAccuracyO.R	_	
357-13	67659-67660	.	_	

#Text=R-Dorsolateral Prefrontal Cortex\t \tCue\t1.69\t7.05\t.293\t.997\t \tDelay\t3.80\t10.21\t.432**C‘P\t.978+C,P\t \tTarget\t13.04\t10.35\t.478**C,P\t.997\t \tL-Dorsolateral Prefrontal Cortex (A)\t \tCue\t6.41\t12.08\t.468**\t1.007\t \tDelay\t3.58\t11.44\t.303\t1.010\t \tTarget\t8.55\t12.40\t.498**\t1.018\t \tL-Dorsolateral Prefrontal Cortex (B)\t \tCue\t8.22\t11.20\t.227\t1.005\t \tDelay\t7.07\t11.87\t.309\t.990\t \tTarget\t15.54\t12.77\t.464**\t.988\t \tL-Inferior Frontal Gyrus\t \tCue\t0.69\t8.57\t.005\t1.015\t \tDelay\t14.19\t12.50\t.255\t.998\t \tTarget\t19.15\t12.96\t.420*\t.995\t \t
#Text=Note.
#Text=p < .10,
#Text=p < .05.,
#Text=p < .01 (corrected).
#Text=p < .05 with full model covariates (set B);
#Text=p < .05 with full model + prenatal measures.
358-1	67666-67680	R-Dorsolateral	_	
358-2	67681-67691	Prefrontal	_	
358-3	67692-67698	Cortex	_	
358-4	67701-67704	Cue	_	
358-5	67705-67709	1.69	_	
358-6	67710-67714	7.05	_	
358-7	67715-67719	.293	_	
358-8	67720-67724	.997	_	
358-9	67727-67732	Delay	_	
358-10	67733-67737	3.80	_	
358-11	67738-67743	10.21	_	
358-12	67744-67748	.432	_	
358-13	67748-67749	*	_	
358-14	67749-67750	*	_	
358-15	67750-67751	C	_	
358-16	67751-67752	‘	_	
358-17	67752-67753	P	_	
358-18	67754-67758	.978	_	
358-19	67758-67759	+	_	
358-20	67759-67760	C	_	
358-21	67760-67761	,	_	
358-22	67761-67762	P	_	
358-23	67765-67771	Target	_	
358-24	67772-67777	13.04	_	
358-25	67778-67783	10.35	_	
358-26	67784-67788	.478	_	
358-27	67788-67789	*	_	
358-28	67789-67790	*	_	
358-29	67790-67791	C	_	
358-30	67791-67792	,	_	
358-31	67792-67793	P	_	
358-32	67794-67798	.997	_	
358-33	67801-67815	L-Dorsolateral	_	
358-34	67816-67826	Prefrontal	_	
358-35	67827-67833	Cortex	_	
358-36	67834-67835	(	_	
358-37	67835-67836	A	_	
358-38	67836-67837	)	_	
358-39	67840-67843	Cue	_	
358-40	67844-67848	6.41	_	
358-41	67849-67854	12.08	_	
358-42	67855-67859	.468	_	
358-43	67859-67860	*	_	
358-44	67860-67861	*	_	
358-45	67862-67867	1.007	_	
358-46	67870-67875	Delay	_	
358-47	67876-67880	3.58	_	
358-48	67881-67886	11.44	_	
358-49	67887-67891	.303	_	
358-50	67892-67897	1.010	_	
358-51	67900-67906	Target	_	
358-52	67907-67911	8.55	_	
358-53	67912-67917	12.40	_	
358-54	67918-67922	.498	_	
358-55	67922-67923	*	_	
358-56	67923-67924	*	_	
358-57	67925-67930	1.018	_	
358-58	67933-67947	L-Dorsolateral	_	
358-59	67948-67958	Prefrontal	_	
358-60	67959-67965	Cortex	_	
358-61	67966-67967	(	_	
358-62	67967-67968	B	_	
358-63	67968-67969	)	_	
358-64	67972-67975	Cue	_	
358-65	67976-67980	8.22	_	
358-66	67981-67986	11.20	_	
358-67	67987-67991	.227	_	
358-68	67992-67997	1.005	_	
358-69	68000-68005	Delay	_	
358-70	68006-68010	7.07	_	
358-71	68011-68016	11.87	_	
358-72	68017-68021	.309	_	
358-73	68022-68026	.990	_	
358-74	68029-68035	Target	_	
358-75	68036-68041	15.54	_	
358-76	68042-68047	12.77	_	
358-77	68048-68052	.464	_	
358-78	68052-68053	*	_	
358-79	68053-68054	*	_	
358-80	68055-68059	.988	_	
358-81	68062-68072	L-Inferior	_	
358-82	68073-68080	Frontal	_	
358-83	68081-68086	Gyrus	_	
358-84	68089-68092	Cue	_	
358-85	68093-68097	0.69	_	
358-86	68098-68102	8.57	_	
358-87	68103-68107	.005	_	
358-88	68108-68113	1.015	_	
358-89	68116-68121	Delay	_	
358-90	68122-68127	14.19	_	
358-91	68128-68133	12.50	_	
358-92	68134-68138	.255	_	
358-93	68139-68143	.998	_	
358-94	68146-68152	Target	_	
358-95	68153-68158	19.15	_	
358-96	68159-68164	12.96	_	
358-97	68165-68169	.420	_	
358-98	68169-68170	*	_	
358-99	68171-68175	.995	_	
358-100	68179-68183	Note	_	
358-101	68183-68184	.	_	
358-102	68185-68186	p	_	
358-103	68187-68188	<	_	
358-104	68189-68192	.10	_	
358-105	68192-68193	,	_	
358-106	68194-68195	p	_	
358-107	68196-68197	<	_	
358-108	68198-68201	.05	_	
358-109	68201-68202	.	_	
358-110	68202-68203	,	_	
358-111	68204-68205	p	_	
358-112	68206-68207	<	_	
358-113	68208-68211	.01	_	
358-114	68212-68213	(	_	
358-115	68213-68222	corrected	_	
358-116	68222-68223	)	_	
358-117	68223-68224	.	_	
358-118	68225-68226	p	_	
358-119	68227-68228	<	_	
358-120	68229-68232	.05	_	
358-121	68233-68237	with	_	
358-122	68238-68242	full	_	
358-123	68243-68248	model	_	
358-124	68249-68259	covariates	_	
358-125	68260-68261	(	_	
358-126	68261-68264	set	_	
358-127	68265-68266	B	_	
358-128	68266-68267	)	_	
358-129	68267-68268	;	_	
358-130	68269-68270	p	_	
358-131	68271-68272	<	_	
358-132	68273-68276	.05	_	
358-133	68277-68281	with	_	
358-134	68282-68286	full	_	
358-135	68287-68292	model	_	
358-136	68293-68294	+	_	
358-137	68295-68303	prenatal	_	
358-138	68304-68312	measures	_	
358-139	68312-68313	.	_	

#Text=Epoch means and standard deviations of clusters with an omnibus total cannabis use effect and a significant (corrected) associations with epoch amplitudes. β, standardized regression coefficients for total cannabis use (log).
359-1	68314-68319	Epoch	_	
359-2	68320-68325	means	_	
359-3	68326-68329	and	_	
359-4	68330-68338	standard	_	
359-5	68339-68349	deviations	_	
359-6	68350-68352	of	_	
359-7	68353-68361	clusters	_	
359-8	68362-68366	with	_	
359-9	68367-68369	an	_	
359-10	68370-68377	omnibus	_	
359-11	68378-68383	total	_	
359-12	68384-68392	cannabis	_	
359-13	68393-68396	use	_	
359-14	68397-68403	effect	_	
359-15	68404-68407	and	_	
359-16	68408-68409	a	_	
359-17	68410-68421	significant	_	
359-18	68422-68423	(	_	
359-19	68423-68432	corrected	_	
359-20	68432-68433	)	_	
359-21	68434-68446	associations	_	
359-22	68447-68451	with	_	
359-23	68452-68457	epoch	_	
359-24	68458-68468	amplitudes	_	
359-25	68468-68469	.	_	
359-26	68470-68471	β	_	
359-27	68471-68472	,	_	
359-28	68473-68485	standardized	_	
359-29	68486-68496	regression	_	
359-30	68497-68509	coefficients	_	
359-31	68510-68513	for	_	
359-32	68514-68519	total	_	
359-33	68520-68528	cannabis	_	
359-34	68529-68532	use	_	
359-35	68533-68534	(	_	
359-36	68534-68537	log	_	
359-37	68537-68538	)	_	
359-38	68538-68539	.	_	

#Text=O.R., odds ratio (based on one unit of BOLD amplitude) from beta regression model performed on mean accuracy data with logit link function.
360-1	68540-68543	O.R	_	
360-2	68543-68544	.	_	
360-3	68544-68545	,	_	
360-4	68546-68550	odds	_	
360-5	68551-68556	ratio	_	
360-6	68557-68558	(	_	
360-7	68558-68563	based	_	
360-8	68564-68566	on	_	
360-9	68567-68570	one	_	
360-10	68571-68575	unit	_	
360-11	68576-68578	of	_	
360-12	68579-68583	BOLD	_	
360-13	68584-68593	amplitude	_	
360-14	68593-68594	)	_	
360-15	68595-68599	from	_	
360-16	68600-68604	beta	_	
360-17	68605-68615	regression	_	
360-18	68616-68621	model	_	
360-19	68622-68631	performed	_	
360-20	68632-68634	on	_	
360-21	68635-68639	mean	_	
360-22	68640-68648	accuracy	_	
360-23	68649-68653	data	_	
360-24	68654-68658	with	_	
360-25	68659-68664	logit	_	
360-26	68665-68669	link	_	
360-27	68670-68678	function	_	
360-28	68678-68679	.	_	

#Text=Significant and trending effects (p < .10, corrected) are bolded.
361-1	68680-68691	Significant	_	
361-2	68692-68695	and	_	
361-3	68696-68704	trending	_	
361-4	68705-68712	effects	_	
361-5	68713-68714	(	_	
361-6	68714-68715	p	_	
361-7	68716-68717	<	_	
361-8	68718-68721	.10	_	
361-9	68721-68722	,	_	
361-10	68723-68732	corrected	_	
361-11	68732-68733	)	_	
361-12	68734-68737	are	_	
361-13	68738-68744	bolded	_	
361-14	68744-68745	.	_	
